<!DOCTYPE html><html lang="en"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=0"/><link rel="preload" href="../fonts/Inter-Regular.woff2" as="font" type="font/woff2"/><link rel="preload" href="../fonts/Inter-SemiBold.woff2" as="font" type="font/woff2"/><script type="text/javascript">
window.dataLayer = window.dataLayer || [];
window.authRequired = false;
window.serverAuthenticated = false;
              </script><title>Invest in biotechnology &amp; genetic engineering companies | Public.com</title><meta name="description" content="Invest in biotechnology &amp; genetic engineering companies.  Public offers commission-free trading and much more."/><meta name="apple-itunes-app" content="app-id=1204112719, app-argument=https%3A%2F%2Fapp.public.com%2Fthemes%2F2a206e44-2387-4810-807d-8d10034a186a"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="article"/><meta property="og:title" content="Invest in biotechnology &amp; genetic engineering companies"/><meta property="og:description" content="Invest in biotechnology &amp; genetic engineering companies.  Public offers commission-free trading and much more."/><meta property="og:image" content="https://public.com/images/og/themes/2a206e44-2387-4810-807d-8d10034a186a-og.jpg"/><meta property="og:image:width" content="1200"/><meta property="og:image:height" content="630"/><meta property="og:url" content="https://public.com/themes/genetic-engineering"/><meta property="og:site_name" content="Public"/><meta name="twitter:card" content="summary_large_image"/><meta name="twitter:description" content="Invest in biotechnology &amp; genetic engineering companies.  Public offers commission-free trading and much more."/><meta name="twitter:title" content="Invest in biotechnology &amp; genetic engineering companies"/><meta name="twitter:site" content="@public"/><meta name="twitter:image" content="https://public.com/images/og/themes/2a206e44-2387-4810-807d-8d10034a186a-og.jpg"/><meta name="twitter:creator" content="@public"/><meta name="next-head-count" content="23"/><link rel="shortcut icon" href="../images/icon.png" type="image/png"/><link rel="preconnect" href="https://universal.hellopublic.com"/><link rel="preload" href="../_next/static/css/c43ab53f090cc2ae.css" as="style"/><link rel="stylesheet" href="../_next/static/css/c43ab53f090cc2ae.css" data-n-g=""/><link rel="preload" href="../_next/static/css/40884651acce11a5.css" as="style"/><link rel="stylesheet" href="../_next/static/css/40884651acce11a5.css" data-n-p=""/><noscript data-n-css=""></noscript><script defer="" nomodule="" src="../_next/static/chunks/polyfills-c67a75d1b6f99dc8.js"></script><script src="../_next/static/chunks/webpack-d84e9e85696641b3.js" defer=""></script><script src="../_next/static/chunks/framework-663f14bc8ac481eb.js" defer=""></script><script src="../_next/static/chunks/main-0d98400d7b2443d6.js" defer=""></script><script src="../_next/static/chunks/pages/_app-5a93c16e44bac4d4.js" defer=""></script><script src="../_next/static/chunks/1664-402522dac0871a46.js" defer=""></script><script src="../_next/static/chunks/1454-e3bbb12c4afed291.js" defer=""></script><script src="../_next/static/chunks/6406-3c6ef6a539e8b36f.js" defer=""></script><script src="../_next/static/chunks/920-5a7e04ac7f09af58.js" defer=""></script><script src="../_next/static/chunks/3707-b59547e02bc13bd5.js" defer=""></script><script src="../_next/static/chunks/6840-c8dd281ccea41814.js" defer=""></script><script src="../_next/static/chunks/1078-fe444151edabcc74.js" defer=""></script><script src="../_next/static/chunks/1852-bf14fe5709c35c21.js" defer=""></script><script src="../_next/static/chunks/8594-1ae4967cb2d6f0bc.js" defer=""></script><script src="../_next/static/chunks/7921-ecd3d82cfbc6d484.js" defer=""></script><script src="../_next/static/chunks/1483-5bc66fa4289689c2.js" defer=""></script><script src="../_next/static/chunks/356-8f95f9f2befef946.js" defer=""></script><script src="../_next/static/chunks/5156-bde4371170e2a121.js" defer=""></script><script src="../_next/static/chunks/pages/themes/%5Bname%5D-71dfba377ecd2729.js" defer=""></script><script src="../_next/static/vtCYKp0Ai9E1UhSXnGgkP/_buildManifest.js" defer=""></script><script src="../_next/static/vtCYKp0Ai9E1UhSXnGgkP/_ssgManifest.js" defer=""></script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-PCBFC3K" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript><div id="__next"><style data-emotion="css agw2bd">.css-agw2bd{background:linear-gradient(
            180deg,rgba(0,0,0,0.25) 0%,rgba(0,0,0,0.02) 100%
          );background-image:url(https://prod-api.154310543964.hellopublic.com/static/themes/images/kWMrmJmBx5mZN9TnbZEO5eSl5IR1Ovzl.jpg);-webkit-background-position:center;background-position:center;background-repeat:repeat-x;-webkit-background-size:cover;background-size:cover;height:400px;}@media (min-width:760px){.css-agw2bd{height:548px;}}</style><div class="css-agw2bd"><style data-emotion="css 1v2pizs">.css-1v2pizs{background:transparent;}.css-1v2pizs a{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;}.css-1v2pizs a >svg path{fill:var(--pw-core-color-greyscale-100);}</style><header class="css-1v2pizs"><style data-emotion="css 1kwkp96">.css-1kwkp96{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;box-sizing:border-box;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;margin:0 auto;padding:12px 16px;position:relative;-webkit-box-pack:justify;-webkit-justify-content:space-between;justify-content:space-between;width:100%;}.css-1kwkp96 a{display:inline-block;outline:none;}</style><div class="css-1kwkp96"><a role="button" href="../index.html" aria-label="home"><svg width="147" height="28" viewBox="0 0 126 24" fill="none"><path d="M83.5876 18.5712C83.9239 18.5731 84.2531 18.4756 84.5338 18.2908C84.8145 18.1061 85.034 17.8424 85.1646 17.5332C85.2952 17.224 85.331 16.8831 85.2676 16.5536C85.2041 16.2241 85.0442 15.9207 84.808 15.6819C84.5719 15.4431 84.2701 15.2794 83.9407 15.2117C83.6114 15.144 83.2694 15.1752 82.9579 15.3014C82.6463 15.4276 82.3793 15.6432 82.1904 15.9208C82.0016 16.1984 81.8995 16.5257 81.8969 16.8612C81.8952 17.0843 81.9377 17.3056 82.0218 17.5123C82.1058 17.7191 82.23 17.9073 82.387 18.0661C82.544 18.2249 82.7309 18.3512 82.9369 18.4379C83.1429 18.5246 83.3641 18.5699 83.5876 18.5712Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M92.2184 18.6362C94.2124 18.6362 96.0122 17.6193 97.0964 15.758L95.3404 14.6761C95.0469 15.246 94.5992 15.7225 94.0481 16.0515C93.497 16.3805 92.8646 16.5488 92.2226 16.5373C90.4228 16.5373 88.9262 15.3465 88.9262 12.9874C88.9262 10.5434 90.5305 9.39635 92.2878 9.39635C93.4797 9.39635 94.4986 9.96209 95.3447 10.9762L96.9036 9.63396C95.9286 8.3356 94.2109 7.29748 92.2864 7.29748C89.5101 7.29748 86.7593 9.39635 86.7593 12.9874C86.7537 16.5373 89.4421 18.6362 92.2184 18.6362Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M112.795 9.15309L113.403 9.28321V7.36112H111.299V18.3109H113.533V11.5575C113.533 10.2365 114.356 9.28462 115.571 9.28462C116.763 9.28462 117.609 10.2365 117.609 11.5575V18.3081H119.756V11.5575C119.756 10.2365 120.606 9.28462 121.75 9.28462C122.894 9.28462 123.68 10.1502 123.68 11.5575V18.3081H126V11.4302C126 8.8985 124.441 7.18716 122.293 7.18716C120.926 7.18716 119.821 7.85755 119.033 8.93952C118.448 7.85755 117.364 7.18716 116.019 7.18716C115.351 7.18154 114.695 7.36273 114.125 7.7102C113.555 8.05767 113.094 8.55753 112.795 9.15309Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M103.559 7.18857C100.328 7.18857 97.856 9.5689 97.856 12.8799C97.856 16.1908 100.328 18.5712 103.559 18.5712C106.875 18.5712 109.152 16.1668 109.152 12.8799C109.152 9.59294 106.875 7.18857 103.559 7.18857ZM103.623 16.4723C101.585 16.4723 100.024 14.9165 100.024 12.8148C100.024 10.7131 101.583 9.28745 103.623 9.28745C105.531 9.28745 106.984 10.7159 106.984 12.8148C106.984 14.9137 105.531 16.4723 103.623 16.4723Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M74.828 18.5712C75.8186 18.5553 76.7879 18.2814 77.6398 17.7765C78.4917 17.2717 79.1966 16.5534 79.6847 15.693L78.0223 14.611C77.7188 15.1879 77.2592 15.6681 76.6958 15.9972C76.1323 16.3262 75.4876 16.4908 74.835 16.4723C73.1443 16.4723 71.6038 15.2163 71.6038 12.8799C71.6038 10.4133 73.1443 9.28745 74.835 9.28745C76.0935 9.28745 77.1125 9.80651 78.0223 10.8885L79.4976 9.5689C78.9838 8.8385 78.3025 8.24133 77.5103 7.82725C76.7182 7.41317 75.8384 7.19418 74.9442 7.18857C72.1254 7.18857 69.3491 9.28744 69.3491 12.8799C69.3491 16.4723 72.0531 18.5712 74.828 18.5712Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M66.1987 5.43622C66.5357 5.43789 66.8657 5.33957 67.1467 5.15372C67.4276 4.96788 67.6469 4.7029 67.7767 4.39243C67.9065 4.08197 67.9409 3.74001 67.8755 3.41C67.8102 3.07998 67.648 2.77679 67.4097 2.53892C67.1713 2.30106 66.8675 2.13924 66.5368 2.07403C66.2062 2.00881 65.8635 2.04313 65.5524 2.17264C65.2413 2.30215 64.9758 2.521 64.7896 2.8014C64.6034 3.0818 64.5048 3.4111 64.5065 3.7475C64.5037 3.97005 64.5455 4.19093 64.6295 4.3971C64.7135 4.60327 64.8381 4.79057 64.9958 4.94795C65.1535 5.10534 65.3412 5.22962 65.5477 5.31348C65.7543 5.39733 65.9757 5.43907 66.1987 5.43622Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M67.2389 7.53508H65.0918V18.3109H67.2389V7.53508Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M62.2291 1.865H59.8879V18.3109H62.2291V1.865Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M52.5596 7.18857C50.934 7.18857 49.7408 7.85897 49.069 8.94094V1.86925H46.6839V18.3109H49.069V16.9475C49.7408 17.9644 50.934 18.5712 52.5596 18.5712C55.6774 18.5712 57.85 16.1668 57.85 12.8799C57.85 9.76408 55.5513 7.18857 52.5596 7.18857ZM52.3711 16.3662C50.2254 16.3662 48.7728 14.9165 48.7728 12.8827C48.7728 10.8913 50.2254 9.39918 52.3711 9.39918C54.3013 9.39918 55.6887 10.7838 55.6887 12.8827C55.6816 14.9137 54.2942 16.3662 52.3711 16.3662Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M38.878 18.4623C40.0273 18.4623 40.9811 17.9644 41.6968 16.9475V18.3109H43.9303V7.53508H41.6316V13.7667C41.6316 15.3465 40.6778 16.3634 39.1161 16.3634C37.7938 16.3634 37.0781 15.2164 37.0781 13.7667V7.53508H34.7355V14.1344C34.7355 16.6491 36.2973 18.4623 38.878 18.4623Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M27.6028 7.18857C26.0438 7.18857 24.8491 7.85897 23.8727 8.94094V7.53508H21.5967V22.165H23.8727V16.9475C24.8491 17.9644 26.041 18.5712 27.6028 18.5712C30.7036 18.5712 32.9371 15.9957 32.9371 12.8799C32.9371 9.5689 30.7036 7.18857 27.6028 7.18857ZM27.2995 16.3662C25.0872 16.3662 23.765 14.9165 23.765 12.8827C23.765 10.8913 25.0872 9.39918 27.2995 9.39918C29.4026 9.39918 30.7007 10.8913 30.7007 12.8827C30.7036 14.9137 29.4026 16.3662 27.2995 16.3662Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M7.19935 14.396C11.1754 14.396 14.3987 11.1734 14.3987 7.19802C14.3987 3.22266 11.1754 0 7.19935 0C3.22326 0 0 3.22266 0 7.19802C0 11.1734 3.22326 14.396 7.19935 14.396Z" fill="var(--pw-core-color-blue-600-day)"></path><path d="M3.59968 24C4.31066 24 5.00571 23.7895 5.59717 23.395C6.18863 23.0005 6.65002 22.4398 6.92312 21.7835C7.19622 21.1271 7.26882 20.4047 7.13176 19.7072C6.99469 19.0096 6.6541 18.3683 6.15294 17.8641C5.65178 17.3599 5.0125 17.0153 4.31573 16.8739C3.61897 16.7325 2.89592 16.8005 2.23778 17.0695C1.57964 17.3384 1.0159 17.7962 0.617646 18.385C0.219396 18.9739 0.00447861 19.6675 0 20.3783C0.000352998 21.3348 0.378999 22.2524 1.05334 22.9308C1.72769 23.6093 2.64302 23.9936 3.59968 24Z" fill="var(--pw-core-color-blue-600-day)"></path></svg></a><style data-emotion="css 1r3qwl0">.css-1r3qwl0{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;position:relative;}.css-1r3qwl0[data-white='true'] ul li a{color:var(--pw-core-color-greyscale-100);}.css-1r3qwl0[data-white='true'] ul li a:after{border-color:var(--pw-core-color-greyscale-100);}</style><nav data-white="true" class="css-1r3qwl0"><style data-emotion="css hhpoyy">.css-hhpoyy{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;margin:0;list-style:none;padding:0;}.css-hhpoyy li{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;display:none;height:100%;margin:0;padding:0;}@media (min-width:1200px){.css-hhpoyy li{display:-webkit-inline-box;display:-webkit-inline-flex;display:-ms-inline-flexbox;display:inline-flex;}}.css-hhpoyy li a{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;color:var(--pw-core-color-greyscale-1000);cursor:pointer;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;font:var(--font-body-1-heavy);outline:none;padding:0 8px;position:relative;-webkit-transition:color 0.25s ease-in,background 0.25s ease-in,opacity 0.25s ease-in;transition:color 0.25s ease-in,background 0.25s ease-in,opacity 0.25s ease-in;}.css-hhpoyy li a:hover{color:var(--pw-core-color-blue-600);}.css-hhpoyy li a:focus{-webkit-text-decoration:underline;text-decoration:underline;}@media (min-width:1280px){.css-hhpoyy li a{padding:0 12px;}}.css-hhpoyy li[data-has-more]{position:relative;}.css-hhpoyy li[data-has-more] >a{background:transparent;border:0;border-left:1px solid rgba(0,0,102,0.08);display:block;margin-left:12px;font-size:14px;padding-left:24px;padding-right:24px;}.css-hhpoyy li[data-has-more] >a:after{display:inline-block;padding:3px;content:'';-webkit-transform:rotate(45deg) translateX(-5px);-moz-transform:rotate(45deg) translateX(-5px);-ms-transform:rotate(45deg) translateX(-5px);transform:rotate(45deg) translateX(-5px);margin-left:10px;border:solid var(--pw-core-color-greyscale-1000);border-width:0 1px 1px 0;transform-origin:center;}.css-hhpoyy li[data-has-more]:hover div[data-has-more-options]{opacity:1;pointer-events:all;}.css-hhpoyy li[data-link-get-started] a,.css-hhpoyy li[data-link-login] a{border-radius:100px;box-sizing:border-box;cursor:pointer;height:41px;font:var(--font-body-1-heavy);line-height:1;outline:none;width:auto;}.css-hhpoyy li[data-link-get-started] a:focus,.css-hhpoyy li[data-link-login] a:focus{opacity:0.5;-webkit-text-decoration:none;text-decoration:none;}.css-hhpoyy li[data-link-login] a{background:hsla(0,0%,100%,0.3);-webkit-backdrop-filter:blur(8px);backdrop-filter:blur(8px);border:1px solid rgba(0,102,20,0.08);color:var(--pw-core-color-greyscale-1000);min-width:auto;-webkit-transition:border 0.25s ease;transition:border 0.25s ease;padding:12px 15px 13px;}.css-hhpoyy li[data-link-login] a:hover{border:1px solid #b5c4d7;-webkit-filter:brightness(100%);filter:brightness(100%);}.css-hhpoyy li[data-link-get-started]{display:none;}@media (min-width:1024px){.css-hhpoyy li[data-link-get-started]{display:-webkit-inline-box;display:-webkit-inline-flex;display:-ms-inline-flexbox;display:inline-flex;}}.css-hhpoyy li[data-link-get-started] a{background:var(--pw-core-color-blue-600);color:var(--pw-core-color-greyscale-100);margin-left:8px;padding:13px 17px 14px;-webkit-transition:color 0.25s ease-in,background 0.25s ease-in;transition:color 0.25s ease-in,background 0.25s ease-in;}.css-hhpoyy li[data-link-get-started] a:hover{background:var(--pw-core-color-blue-500);}</style><ul class="css-hhpoyy"><li><a href="../stocks.html" aria-label="Visit Stocks Page">Stocks</a></li><li><a href="../etfs.html" aria-label="Visit ETFs Page">ETFs</a></li><li><a href="../invest/crypto.html" aria-label="Visit Crypto Page">Crypto</a></li><li><a href="../high-yield-cash-account.html" aria-label="Visit High-Yield Cash Account Page">High-Yield Cash Account</a></li><li><a href="../invest/options.html" aria-label="Visit Options Page">Options</a></li><li><a href="../invest/bonds.html" aria-label="Visit Bonds Page">Bonds</a></li><li><a href="../invest/investment-plans.html" aria-label="Visit Investment Plans Page">Investment Plans</a></li><li><a href="../premium.html" aria-label="Visit Premium Page">Premium</a></li><li data-has-more="true"><a href="#" aria-label="More options">More</a><style data-emotion="css 1uh0nk3">.css-1uh0nk3{padding-top:55px;position:absolute;pointer-events:none;opacity:0;top:0;right:5px;}.css-1uh0nk3 ul{-webkit-backdrop-filter:blur(20px);backdrop-filter:blur(20px);background:hsla(0,0%,100%,0.3);border:1px solid var(--pw-core-color-greyscale-400);border-radius:32px;list-style:none;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;margin:0;padding:0;width:220px;}.css-1uh0nk3 ul li{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:start;-ms-flex-pack:start;-webkit-justify-content:flex-start;justify-content:flex-start;padding:0 13px;width:100%;}.css-1uh0nk3 ul li:first-of-type{padding:17px 13px 0 13px;}.css-1uh0nk3 ul li:last-of-type{padding:0 13px 17px 13px;}.css-1uh0nk3 ul li a{padding:13px 20px;border-radius:16px;font-size:16px;}</style><div data-has-more-options="true" class="css-1uh0nk3"><ul><li><a href="../about-us.html" aria-label="Visit About Us Page">About Us</a></li><li><a href="../learn.html" aria-label="Visit Learn Page">Learn</a></li><li><a href="https://help.public.com" aria-label="Visit Support Page">Support</a></li></ul></div></li><li data-link-login="true"><a href="../login.html" title="sign-in">Sign In</a></li><li data-link-get-started="true"><a href="../signup.html">Get Started</a></li></ul><style data-emotion="css 89vnpg">.css-89vnpg{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;background:transparent;border:none;cursor:pointer;height:40px;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;line-height:1;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;-webkit-transform:translateX(10px);-moz-transform:translateX(10px);-ms-transform:translateX(10px);transform:translateX(10px);width:40px;}@media (min-width:1200px){.css-89vnpg{display:none;}}.css-89vnpg span{height:2px;position:relative;width:20px;}.css-89vnpg span:before{background:var(--pw-core-color-greyscale-1000);content:'';display:block;height:2px;left:0;top:-4px;position:relative;width:20px;}.css-89vnpg span:after{background:var(--pw-core-color-greyscale-1000);content:'';display:block;height:2px;left:0;position:relative;top:4px;width:20px;}</style><button type="button" class="css-89vnpg"><span></span></button></nav></div></header></div><style data-emotion="css wk33vf">.css-wk33vf{background:var(--pw-core-color-greyscale-300);display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-flex-flow:wrap;-webkit-flex-flow:wrap;-ms-flex-flow:wrap;flex-flow:wrap;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;padding:16px;}.css-wk33vf >main{-webkit-box-flex:1;-webkit-flex-grow:1;-ms-flex-positive:1;flex-grow:1;width:100%;}.css-wk33vf >aside{display:none;}@media (min-width:970px){.css-wk33vf{padding:40px 0;}.css-wk33vf >aside{display:block;margin-left:14px;}}</style><div class="css-wk33vf"><style data-emotion="css 1yx4e2y">.css-1yx4e2y{background:var(--pw-core-color-greyscale-100);border-radius:12px;box-sizing:border-box;padding:24px;}@media (min-width:760px){.css-1yx4e2y{max-width:705px;padding:32px 48px;}}</style><main class="css-1yx4e2y"><style data-emotion="css 14sw3qr">.css-14sw3qr{margin-bottom:80px;}.css-14sw3qr >*{margin:0;}.css-14sw3qr >*+*{margin-top:16px;}</style><article class="css-14sw3qr"><style data-emotion="css 1v53bec">.css-1v53bec{font:var(--font-hxl);}</style><h1 class="css-1v53bec">Genetic Engineering</h1><style data-emotion="css 1ouyzbq">.css-1ouyzbq{font:var(--font-body-1-light);}</style><p class="css-1ouyzbq">Biotechnology refers to the application of technology to living organisms to create new products. In the medical field, this could include creating new vaccines and antibiotics. Biotech also has ties to agricultural innovation through the development of insect-resistant crops, and to food via nutrient-enhanced products. Industrial biotech is responsible for the creation of new consumer goods, like plastics and materials. Companies in this theme include Amgen, Eli Lilly, GlaxoSmithKline, and Vertex Pharmaceuticals.</p><style data-emotion="css 1inldgf">.css-1inldgf{color:var(--pw-core-color-greyscale-600);font:var(--font-body-1-light);}</style><p class="css-1inldgf">21 stocks</p></article><style data-emotion="css ib9iq6">.css-ib9iq6{margin-top:80px;}</style><style data-emotion="css 1gwnpnb">.css-1gwnpnb{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;line-height:34px;margin-bottom:24px;position:relative;margin-top:80px;}.css-1gwnpnb >h2{color:var(--pw-core-color-greyscale-1000);font:var(--font-h1);margin:0;}</style><div class="css-1gwnpnb"><h2>Stocks</h2><style data-emotion="css 79elbk">.css-79elbk{position:relative;}</style><div style="margin-left:auto" class="css-79elbk"><style data-emotion="css y8qn1t">.css-y8qn1t{border-radius:12px;font:var(--font-body-1-heavy);outline:none;padding:2px 4px 2px 6px;}.css-y8qn1t:focus{background-color:var(--pw-core-color-greyscale-200);}</style><style data-emotion="css jjef33">.css-jjef33{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;background:none;border:0;color:var(--pw-core-color-greyscale-600);cursor:pointer;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;margin:0;outline:none;padding:0;-webkit-transition:color 0.3s ease-in-out;transition:color 0.3s ease-in-out;border-radius:12px;font:var(--font-body-1-heavy);outline:none;padding:2px 4px 2px 6px;}.css-jjef33:disabled{cursor:not-allowed;opacity:0.3;}.css-jjef33:focus,.css-jjef33:hover{color:var(--pw-core-color-greyscale-1000);}.css-jjef33:focus{background-color:var(--pw-core-color-greyscale-200);}</style><button aria-label="Sort" class="css-jjef33">Sort by <style data-emotion="css 107d1c9">.css-107d1c9{fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;}</style><svg data-testid="ArrowDownIcon" color="inherit" width="20" height="20" viewBox="0 0 24 24" class="css-107d1c9"><path d="M4.99976 9.03436C5.00391 9.09486 5.00341 9.11026 5.01371 9.17016C5.03696 9.30487 5.08801 9.43442 5.16301 9.54873C5.20091 9.60653 5.24502 9.65698 5.29207 9.70739L11.2923 15.7076C11.3367 15.749 11.3468 15.7606 11.3952 15.7973C11.4496 15.8386 11.5083 15.8743 11.57 15.9036C11.8395 16.0318 12.1594 16.0318 12.429 15.9036C12.4907 15.8743 12.5493 15.8386 12.6037 15.7973C12.6521 15.7606 12.6623 15.749 12.7066 15.7076L18.7068 9.70739C18.7482 9.66303 18.7598 9.65288 18.7965 9.60448C18.893 9.47738 18.9581 9.32737 18.9853 9.17016C19.0046 9.05791 19.0046 8.94255 18.9853 8.8303C18.9698 8.74054 18.942 8.65299 18.9029 8.57074C18.7543 8.25832 18.4461 8.04081 18.102 8.00541C17.966 7.99146 17.8275 8.00571 17.6972 8.04707C17.5886 8.08152 17.4862 8.13457 17.3955 8.20337C17.347 8.24012 17.3369 8.25167 17.2926 8.29308L11.9995 13.5862L6.70633 8.29308L6.65643 8.24647C6.60942 8.20822 6.59847 8.19732 6.54767 8.16402C6.45247 8.10157 6.34661 8.05557 6.23601 8.02861C6.1475 8.00706 6.0561 7.99766 5.9651 8.00076C5.61933 8.01256 5.29707 8.20857 5.12751 8.51009C5.07171 8.60934 5.03306 8.71809 5.01371 8.8303C5.00341 8.8902 5.00391 8.9056 4.99976 8.9661C4.99976 8.98886 4.99976 9.01161 4.99976 9.03436Z"></path></svg></button></div></div><style data-emotion="css xw6udu">.css-xw6udu >*+*{margin-top:8px;}</style><section role="list" class="css-xw6udu"><style data-emotion="css 1wazmh6">.css-1wazmh6{height:80px;}@media (min-width: 760px){.css-1wazmh6{height:100px;}}.css-1wazmh6 >div{border-radius:12px;}.css-1wazmh6:hover >div{background-color:var(--pw-core-color-greyscale-200);border:2px solid var(--pw-core-color-greyscale-200);}</style><style data-emotion="css 9iapl">.css-9iapl{cursor:pointer;height:80px;outline:none;height:80px;}@media (min-width: 760px){.css-9iapl{height:100px;}}.css-9iapl >div{background:var(--pw-core-color-greyscale-200);border-radius:16px;box-sizing:border-box;height:100%;position:relative;-webkit-transition:-webkit-transform 0.2s ease-in;transition:transform 0.2s ease-in;z-index:1;}.css-9iapl:focus >div{background-color:var(--pw-core-color-greyscale-100);box-shadow:var(--elevation-300);}@media (min-width:560px){.css-9iapl:hover >div{border:2px solid var(--pw-core-color-greyscale-100);-webkit-transform:scale(1.04);-moz-transform:scale(1.04);-ms-transform:scale(1.04);transform:scale(1.04);z-index:2;background-color:var(--pw-core-color-greyscale-100);box-shadow:var(--elevation-300);}}@media (min-width: 760px){.css-9iapl{height:100px;}}.css-9iapl >div{border-radius:12px;}.css-9iapl:hover >div{background-color:var(--pw-core-color-greyscale-200);border:2px solid var(--pw-core-color-greyscale-200);}</style><div role="listitem" tabindex="0" class="css-9iapl"><div><style data-emotion="css 15lcc24">.css-15lcc24{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-background-size:688px auto;background-size:688px auto;box-sizing:border-box;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;height:100%;padding:16px;}@media (min-width: 760px){.css-15lcc24{padding:18px 24px;}}</style><article class="css-15lcc24"><a aria-label="Labcorp Holdings Inc" href="../stocks/lh.html"><style data-emotion="css qeujau">.css-qeujau{height:48px;position:relative;}@media (min-width: 760px){.css-qeujau{height:64px;}}</style><div class="css-qeujau"><style data-emotion="css 1atggoe">.css-1atggoe{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;background:var(--pw-core-color-greyscale-100);border-radius:100%;box-shadow:none;box-sizing:border-box;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;height:48px;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;overflow:hidden;padding:0px;width:48px;}@media (min-width: 760px){.css-1atggoe{height:64px;padding:0px;width:64px;}}</style><div data-logo="true" class="css-1atggoe"><style data-emotion="css 1dan62f">.css-1dan62f{border-radius:100%;height:100%;width:100%;object-fit:cover;}</style><img alt="LH logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/LH@2x.png" class="css-1dan62f"/></div></div></a><style data-emotion="css 1w41jg1">.css-1w41jg1{margin:0 8px;overflow:hidden;text-overflow:ellipsis;white-space:nowrap;}@media (min-width: 760px){.css-1w41jg1{margin:0 24px;}}</style><div class="css-1w41jg1"><style data-emotion="css 112zfr1">.css-112zfr1{color:var(--pw-core-color-greyscale-1000);display:block;font:var(--font-body-1-heavy);margin:0 0 4px;overflow:hidden;text-overflow:ellipsis;white-space:nowrap;}@media (min-width: 760px){.css-112zfr1{font:var(--font-h3);}}</style><a href="../stocks/lh.html" class="css-112zfr1">Labcorp Holdings Inc</a><style data-emotion="css 16ty995">.css-16ty995{color:var(--pw-core-color-greyscale-600);display:-webkit-inline-box;display:-webkit-inline-flex;display:-ms-inline-flexbox;display:inline-flex;font:var(--font-body-2-light);margin:4px 0 0;}@media (min-width: 760px){.css-16ty995{font:var(--font-body-1-light);}}</style><p class="css-16ty995">LH</p></div><style data-emotion="css zdpt2t">.css-zdpt2t{margin-left:auto;}</style><style data-emotion="css 1cjm6w8">.css-1cjm6w8{border-radius:100px;font:var(--font-body-1-heavy);height:48px;min-width:96px;padding:0 16px;color:var(--pw-core-color-green-600);-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;background-color:var(--pw-core-color-greyscale-300);border:0;border-radius:100px;box-sizing:border-box;cursor:pointer;display:-webkit-inline-box;display:-webkit-inline-flex;display:-ms-inline-flexbox;display:inline-flex;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;outline:none;position:relative;margin-left:auto;}.css-1cjm6w8:focus{background-color:var(--pw-core-color-green-200);}.css-1cjm6w8 >span{display:block;}.css-1cjm6w8:disabled{cursor:default;}</style><button class="css-1cjm6w8"><span>+6.86%</span><style data-emotion="css 39e5zc">.css-39e5zc{font:var(--font-body-3-heavy);opacity:0;position:absolute;top:2px;-webkit-transition:visibility 0.5s ease-in-out,opacity 0.5s ease-in-out;transition:visibility 0.5s ease-in-out,opacity 0.5s ease-in-out;visibility:hidden;}</style><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Charles River Laboratories" href="../stocks/crl.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="CRL logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/CRL@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/crl.html" class="css-112zfr1">Charles River Laboratories</a><p class="css-16ty995">CRL</p></div><button class="css-1cjm6w8"><span>+5.45%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="IQVIA Hlds" href="../stocks/iqv.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="IQV logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/IQV@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/iqv.html" class="css-112zfr1">IQVIA Hlds</a><p class="css-16ty995">IQV</p></div><button class="css-1cjm6w8"><span>+3.39%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Danaher" href="../stocks/dhr.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="DHR logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/DHR@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/dhr.html" class="css-112zfr1">Danaher</a><p class="css-16ty995">DHR</p></div><button class="css-1cjm6w8"><span>+2.49%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Bio-Rad Laboratories" href="../stocks/bio.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="BIO logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/BIO@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/bio.html" class="css-112zfr1">Bio-Rad Laboratories</a><p class="css-16ty995">BIO</p></div><button class="css-1cjm6w8"><span>+1.94%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Thermo Fisher Scientific" href="../stocks/tmo.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="TMO logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/TMO@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/tmo.html" class="css-112zfr1">Thermo Fisher Scientific</a><p class="css-16ty995">TMO</p></div><button class="css-1cjm6w8"><span>+1.78%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="IDEXX Laboratories" href="../stocks/idxx.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="IDXX logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/IDXX@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/idxx.html" class="css-112zfr1">IDEXX Laboratories</a><p class="css-16ty995">IDXX</p></div><button class="css-1cjm6w8"><span>+1.72%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Biogen" href="../stocks/biib.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="BIIB logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/BIIB@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/biib.html" class="css-112zfr1">Biogen</a><p class="css-16ty995">BIIB</p></div><button class="css-1cjm6w8"><span>+1.23%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Waters" href="../stocks/wat.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="WAT logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/WAT@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/wat.html" class="css-112zfr1">Waters</a><p class="css-16ty995">WAT</p></div><button class="css-1cjm6w8"><span>+0.96%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Quest Diagnostics" href="../stocks/dgx.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="DGX logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/DGX@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/dgx.html" class="css-112zfr1">Quest Diagnostics</a><p class="css-16ty995">DGX</p></div><button class="css-1cjm6w8"><span>+0.83%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Eli Lilly" href="../stocks/lly.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="LLY logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/LLY@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/lly.html" class="css-112zfr1">Eli Lilly</a><p class="css-16ty995">LLY</p></div><button class="css-1cjm6w8"><span>+0.82%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Agilent Technologies" href="../stocks/a.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="A logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/A@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/a.html" class="css-112zfr1">Agilent Technologies</a><p class="css-16ty995">A</p></div><button class="css-1cjm6w8"><span>+0.74%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Alnylam Pharmaceuticals" href="../stocks/alny.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="ALNY logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/ALNY@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/alny.html" class="css-112zfr1">Alnylam Pharmaceuticals</a><p class="css-16ty995">ALNY</p></div><button class="css-1cjm6w8"><span>+0.72%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="GlaxoSmithKline" href="../stocks/gsk.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="GSK logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/GSK@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/gsk.html" class="css-112zfr1">GlaxoSmithKline</a><p class="css-16ty995">GSK</p></div><button class="css-1cjm6w8"><span>+0.53%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Amgen" href="../stocks/amgn.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="AMGN logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/AMGN@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/amgn.html" class="css-112zfr1">Amgen</a><p class="css-16ty995">AMGN</p></div><style data-emotion="css pt9qiw">.css-pt9qiw{border-radius:100px;font:var(--font-body-1-heavy);height:48px;min-width:96px;padding:0 16px;color:var(--pw-core-color-red-600);-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;background-color:var(--pw-core-color-greyscale-300);border:0;border-radius:100px;box-sizing:border-box;cursor:pointer;display:-webkit-inline-box;display:-webkit-inline-flex;display:-ms-inline-flexbox;display:inline-flex;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;outline:none;position:relative;margin-left:auto;}.css-pt9qiw:focus{background-color:var(--pw-core-color-red-100);}.css-pt9qiw >span{display:block;}.css-pt9qiw:disabled{cursor:default;}</style><button class="css-pt9qiw"><span>-0.22%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Gilead Sciences" href="../stocks/gild.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="GILD logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/GILD@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/gild.html" class="css-112zfr1">Gilead Sciences</a><p class="css-16ty995">GILD</p></div><button class="css-pt9qiw"><span>-0.32%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Vertex Pharmaceuticals" href="../stocks/vrtx.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="VRTX logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/VRTX@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/vrtx.html" class="css-112zfr1">Vertex Pharmaceuticals</a><p class="css-16ty995">VRTX</p></div><button class="css-pt9qiw"><span>-0.98%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Regeneron Pharmaceuticals" href="../stocks/regn.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="REGN logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/REGN@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/regn.html" class="css-112zfr1">Regeneron Pharmaceuticals</a><p class="css-16ty995">REGN</p></div><button class="css-pt9qiw"><span>-1.35%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="CRISPR Therapeutics" href="../stocks/crsp.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="CRSP logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/CRSP@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/crsp.html" class="css-112zfr1">CRISPR Therapeutics</a><p class="css-16ty995">CRSP</p></div><button class="css-pt9qiw"><span>-3.05%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Editas Medicine" href="../stocks/edit.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="EDIT logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/EDIT@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/edit.html" class="css-112zfr1">Editas Medicine</a><p class="css-16ty995">EDIT</p></div><button class="css-pt9qiw"><span>-5.78%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Cellectis SA" href="../stocks/clls.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="CLLS logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/CLLS@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/clls.html" class="css-112zfr1">Cellectis SA</a><p class="css-16ty995">CLLS</p></div><button class="css-pt9qiw"><span>-14.16%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div></section><style data-emotion="css 1jo5pir">.css-1jo5pir{color:var(--pw-core-color-greyscale-600);font-size:14px;line-height:20px;margin-top:40px;}</style><div class="css-1jo5pir">Note: This Public Theme is based on data from one or more third-party data providers. This Theme is provided for informational purposes only by Public Holdings, Inc., and is not investment advice or an investment recommendation. You should not buy or sell anything included in this Public Theme without first determining it is appropriate for your portfolio or investment strategy. Investors should consider the investment objectives and unique risk profile of an Exchange Traded Product (“ETP”) and read the ETP’s prospectus carefully before investing.</div><style data-emotion="css szycb">.css-szycb{margin-bottom:40px;margin-top:40px;}</style><style data-emotion="css 1wl8wdp">.css-1wl8wdp{background:url(../_next/static/images/da5b8d23f198d1d8917adc7b443dbd31-banner-sm-bg@2x.jpg);-webkit-background-position:center;background-position:center;-webkit-background-size:cover;background-size:cover;border-radius:24px;box-sizing:border-box;cursor:pointer;margin:16px 0;max-width:705px;overflow:hidden;padding:24px 22px;position:relative;margin-bottom:40px;margin-top:40px;}@media (min-width:400px){.css-1wl8wdp{background-image:url(../_next/static/images/392a1929885f9b9d6ad46e183be82ee0-banner-md-bg@2x.jpg);}}@media (min-width:560px){.css-1wl8wdp{padding:38px 38px 32px;}}@media (min-width: 760px){.css-1wl8wdp{display:none;}}</style><div class="css-1wl8wdp" role="button" tabindex="0"><svg width="105" height="20" viewBox="0 0 126 24" fill="none"><path d="M83.5876 18.5712C83.9239 18.5731 84.2531 18.4756 84.5338 18.2908C84.8145 18.1061 85.034 17.8424 85.1646 17.5332C85.2952 17.224 85.331 16.8831 85.2676 16.5536C85.2041 16.2241 85.0442 15.9207 84.808 15.6819C84.5719 15.4431 84.2701 15.2794 83.9407 15.2117C83.6114 15.144 83.2694 15.1752 82.9579 15.3014C82.6463 15.4276 82.3793 15.6432 82.1904 15.9208C82.0016 16.1984 81.8995 16.5257 81.8969 16.8612C81.8952 17.0843 81.9377 17.3056 82.0218 17.5123C82.1058 17.7191 82.23 17.9073 82.387 18.0661C82.544 18.2249 82.7309 18.3512 82.9369 18.4379C83.1429 18.5246 83.3641 18.5699 83.5876 18.5712Z" fill="var(--pw-core-color-greyscale-100)"></path><path d="M92.2184 18.6362C94.2124 18.6362 96.0122 17.6193 97.0964 15.758L95.3404 14.6761C95.0469 15.246 94.5992 15.7225 94.0481 16.0515C93.497 16.3805 92.8646 16.5488 92.2226 16.5373C90.4228 16.5373 88.9262 15.3465 88.9262 12.9874C88.9262 10.5434 90.5305 9.39635 92.2878 9.39635C93.4797 9.39635 94.4986 9.96209 95.3447 10.9762L96.9036 9.63396C95.9286 8.3356 94.2109 7.29748 92.2864 7.29748C89.5101 7.29748 86.7593 9.39635 86.7593 12.9874C86.7537 16.5373 89.4421 18.6362 92.2184 18.6362Z" fill="var(--pw-core-color-greyscale-100)"></path><path d="M112.795 9.15309L113.403 9.28321V7.36112H111.299V18.3109H113.533V11.5575C113.533 10.2365 114.356 9.28462 115.571 9.28462C116.763 9.28462 117.609 10.2365 117.609 11.5575V18.3081H119.756V11.5575C119.756 10.2365 120.606 9.28462 121.75 9.28462C122.894 9.28462 123.68 10.1502 123.68 11.5575V18.3081H126V11.4302C126 8.8985 124.441 7.18716 122.293 7.18716C120.926 7.18716 119.821 7.85755 119.033 8.93952C118.448 7.85755 117.364 7.18716 116.019 7.18716C115.351 7.18154 114.695 7.36273 114.125 7.7102C113.555 8.05767 113.094 8.55753 112.795 9.15309Z" fill="var(--pw-core-color-greyscale-100)"></path><path d="M103.559 7.18857C100.328 7.18857 97.856 9.5689 97.856 12.8799C97.856 16.1908 100.328 18.5712 103.559 18.5712C106.875 18.5712 109.152 16.1668 109.152 12.8799C109.152 9.59294 106.875 7.18857 103.559 7.18857ZM103.623 16.4723C101.585 16.4723 100.024 14.9165 100.024 12.8148C100.024 10.7131 101.583 9.28745 103.623 9.28745C105.531 9.28745 106.984 10.7159 106.984 12.8148C106.984 14.9137 105.531 16.4723 103.623 16.4723Z" fill="var(--pw-core-color-greyscale-100)"></path><path d="M74.828 18.5712C75.8186 18.5553 76.7879 18.2814 77.6398 17.7765C78.4917 17.2717 79.1966 16.5534 79.6847 15.693L78.0223 14.611C77.7188 15.1879 77.2592 15.6681 76.6958 15.9972C76.1323 16.3262 75.4876 16.4908 74.835 16.4723C73.1443 16.4723 71.6038 15.2163 71.6038 12.8799C71.6038 10.4133 73.1443 9.28745 74.835 9.28745C76.0935 9.28745 77.1125 9.80651 78.0223 10.8885L79.4976 9.5689C78.9838 8.8385 78.3025 8.24133 77.5103 7.82725C76.7182 7.41317 75.8384 7.19418 74.9442 7.18857C72.1254 7.18857 69.3491 9.28744 69.3491 12.8799C69.3491 16.4723 72.0531 18.5712 74.828 18.5712Z" fill="var(--pw-core-color-greyscale-100)"></path><path d="M66.1987 5.43622C66.5357 5.43789 66.8657 5.33957 67.1467 5.15372C67.4276 4.96788 67.6469 4.7029 67.7767 4.39243C67.9065 4.08197 67.9409 3.74001 67.8755 3.41C67.8102 3.07998 67.648 2.77679 67.4097 2.53892C67.1713 2.30106 66.8675 2.13924 66.5368 2.07403C66.2062 2.00881 65.8635 2.04313 65.5524 2.17264C65.2413 2.30215 64.9758 2.521 64.7896 2.8014C64.6034 3.0818 64.5048 3.4111 64.5065 3.7475C64.5037 3.97005 64.5455 4.19093 64.6295 4.3971C64.7135 4.60327 64.8381 4.79057 64.9958 4.94795C65.1535 5.10534 65.3412 5.22962 65.5477 5.31348C65.7543 5.39733 65.9757 5.43907 66.1987 5.43622Z" fill="var(--pw-core-color-greyscale-100)"></path><path d="M67.2389 7.53508H65.0918V18.3109H67.2389V7.53508Z" fill="var(--pw-core-color-greyscale-100)"></path><path d="M62.2291 1.865H59.8879V18.3109H62.2291V1.865Z" fill="var(--pw-core-color-greyscale-100)"></path><path d="M52.5596 7.18857C50.934 7.18857 49.7408 7.85897 49.069 8.94094V1.86925H46.6839V18.3109H49.069V16.9475C49.7408 17.9644 50.934 18.5712 52.5596 18.5712C55.6774 18.5712 57.85 16.1668 57.85 12.8799C57.85 9.76408 55.5513 7.18857 52.5596 7.18857ZM52.3711 16.3662C50.2254 16.3662 48.7728 14.9165 48.7728 12.8827C48.7728 10.8913 50.2254 9.39918 52.3711 9.39918C54.3013 9.39918 55.6887 10.7838 55.6887 12.8827C55.6816 14.9137 54.2942 16.3662 52.3711 16.3662Z" fill="var(--pw-core-color-greyscale-100)"></path><path d="M38.878 18.4623C40.0273 18.4623 40.9811 17.9644 41.6968 16.9475V18.3109H43.9303V7.53508H41.6316V13.7667C41.6316 15.3465 40.6778 16.3634 39.1161 16.3634C37.7938 16.3634 37.0781 15.2164 37.0781 13.7667V7.53508H34.7355V14.1344C34.7355 16.6491 36.2973 18.4623 38.878 18.4623Z" fill="var(--pw-core-color-greyscale-100)"></path><path d="M27.6028 7.18857C26.0438 7.18857 24.8491 7.85897 23.8727 8.94094V7.53508H21.5967V22.165H23.8727V16.9475C24.8491 17.9644 26.041 18.5712 27.6028 18.5712C30.7036 18.5712 32.9371 15.9957 32.9371 12.8799C32.9371 9.5689 30.7036 7.18857 27.6028 7.18857ZM27.2995 16.3662C25.0872 16.3662 23.765 14.9165 23.765 12.8827C23.765 10.8913 25.0872 9.39918 27.2995 9.39918C29.4026 9.39918 30.7007 10.8913 30.7007 12.8827C30.7036 14.9137 29.4026 16.3662 27.2995 16.3662Z" fill="var(--pw-core-color-greyscale-100)"></path><path d="M7.19935 14.396C11.1754 14.396 14.3987 11.1734 14.3987 7.19802C14.3987 3.22266 11.1754 0 7.19935 0C3.22326 0 0 3.22266 0 7.19802C0 11.1734 3.22326 14.396 7.19935 14.396Z" fill="var(--pw-core-color-greyscale-100)"></path><path d="M3.59968 24C4.31066 24 5.00571 23.7895 5.59717 23.395C6.18863 23.0005 6.65002 22.4398 6.92312 21.7835C7.19622 21.1271 7.26882 20.4047 7.13176 19.7072C6.99469 19.0096 6.6541 18.3683 6.15294 17.8641C5.65178 17.3599 5.0125 17.0153 4.31573 16.8739C3.61897 16.7325 2.89592 16.8005 2.23778 17.0695C1.57964 17.3384 1.0159 17.7962 0.617646 18.385C0.219396 18.9739 0.00447861 19.6675 0 20.3783C0.000352998 21.3348 0.378999 22.2524 1.05334 22.9308C1.72769 23.6093 2.64302 23.9936 3.59968 24Z" fill="var(--pw-core-color-greyscale-100)"></path></svg><style data-emotion="css 6929f2">.css-6929f2{color:var(--pw-core-color-greyscale-100);font-size:23px;font-weight:600;line-height:120%;margin:15px 0;max-width:254px;}@media (min-width:560px){.css-6929f2{font-size:24px;}}</style><div class="css-6929f2">Own your future.<br/>Build your portfolio.</div><style data-emotion="css shxu4o">.css-shxu4o{background:rgba(255,255,255,0.2);-webkit-backdrop-filter:blur(54px);backdrop-filter:blur(54px);color:var(--pw-core-color-greyscale-100);}</style><style data-emotion="css wzufl6">.css-wzufl6{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;border:0;border-radius:100px;box-sizing:border-box;-webkit-column-gap:4px;column-gap:4px;cursor:pointer;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;outline:none;position:relative;background-color:var(--pw-core-color-blue-600);color:var(--pw-core-color-greyscale-100);--button-icon-size:12px;--button-icon-margin:-4px;font:var(--font-body-1-heavy);height:48px;min-width:92px;padding:0 22px;background:rgba(255,255,255,0.2);-webkit-backdrop-filter:blur(54px);backdrop-filter:blur(54px);color:var(--pw-core-color-greyscale-100);}.css-wzufl6:disabled,.css-wzufl6:disabled:hover{cursor:default;}.css-wzufl6 svg{fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;height:var(--button-icon-size);width:var(--button-icon-size);}.css-wzufl6:focus,.css-wzufl6:hover{-webkit-filter:brightness(90%);filter:brightness(90%);}.css-wzufl6:disabled,.css-wzufl6:disabled:hover{background-color:var(--pw-core-color-greyscale-200);color:var(--pw-core-color-greyscale-400);-webkit-filter:none;filter:none;}</style><button class="css-wzufl6"><style data-emotion="css k008qs">.css-k008qs{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;}</style><span class="css-k008qs">Download the app</span><style data-emotion="css 9whvzf">.css-9whvzf{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;margin-right:var(--button-icon-margin);opacity:1;}</style><span class="css-9whvzf"><svg data-testid="ArrowRightIcon" color="inherit" width="18" height="18" viewBox="0 0 24 24" class="css-107d1c9"><path d="M9.03414 19C9.09465 18.9958 9.11005 18.9964 9.16995 18.986C9.30466 18.9628 9.43421 18.9117 9.54852 18.8367C9.60632 18.7988 9.65677 18.7547 9.70717 18.7077L15.7074 12.7074C15.7488 12.6631 15.7604 12.653 15.7971 12.6045C15.8384 12.5501 15.874 12.4915 15.9034 12.4298C16.0316 12.1602 16.0316 11.8403 15.9034 11.5708C15.874 11.5091 15.8384 11.4504 15.7971 11.396C15.7604 11.3476 15.7488 11.3375 15.7074 11.2932L9.70717 5.29291C9.66282 5.25151 9.65267 5.23991 9.60427 5.20321C9.47716 5.10675 9.32716 5.04165 9.16995 5.0145C9.05769 4.9952 8.94234 4.9952 8.83008 5.0145C8.74033 5.03 8.65278 5.0578 8.57052 5.0969C8.25811 5.24546 8.0406 5.55362 8.0052 5.89774C7.99125 6.03374 8.0055 6.17225 8.04685 6.30256C8.0813 6.41111 8.13436 6.51356 8.20316 6.60427C8.23991 6.65272 8.25146 6.66282 8.29286 6.70717L13.586 12.0003L8.29286 17.2934L8.24626 17.3433C8.20801 17.3903 8.19711 17.4013 8.16381 17.4521C8.10135 17.5473 8.05535 17.6531 8.0284 17.7637C8.00685 17.8523 7.99745 17.9437 8.00055 18.0347C8.01235 18.3804 8.20836 18.7027 8.50987 18.8722C8.60913 18.928 8.71788 18.9667 8.83008 18.986C8.88999 18.9964 8.90539 18.9958 8.96589 19C8.98864 19 9.01139 19 9.03414 19Z"></path></svg></span></button><style data-emotion="css w9zmaf">.css-w9zmaf{display:none;height:192px;object-fit:cover;position:absolute;right:35px;top:18px;width:161px;}@media (min-width:690px){.css-w9zmaf{display:block;}}</style><img src="../_next/static/images/debd9660fbcf4bf5a0916e732dee6367-banner-md-glass@2x.png" width="auto" height="192" alt="" class="css-w9zmaf"/></div></main><aside><style data-emotion="css 1p0dr8w">.css-1p0dr8w{max-width:336px;}</style><div class="css-1p0dr8w"><style data-emotion="css zhxjkv">.css-zhxjkv{background:url(../_next/static/images/e69520615a1a5fbde2a654bb84f49523-all-assets@2x.jpeg);border-radius:12px;-webkit-background-size:100% auto;background-size:100% auto;box-sizing:border-box;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;height:214px;padding:0 16px 38px 0;width:100%;}</style><div class="css-zhxjkv"></div><style data-emotion="css dsd0po">.css-dsd0po{background:var(--pw-core-color-greyscale-100);border-radius:12px;box-sizing:border-box;margin-top:-22px;padding:24px 24px 32px;}</style><div class="css-dsd0po"><style data-emotion="css jg2kwt">.css-jg2kwt{font:var(--font-h2);margin:0 0 20px 0;}</style><h2 class="css-jg2kwt">Invest in everything on Public</h2><style data-emotion="css wy151o">.css-wy151o{font:var(--font-body-1-light);margin-bottom:20px;}</style><div class="css-wy151o">Public is an all-in-one investing platform where you can build a multi-asset portfolio that includes everything from stocks and options to bonds, crypto, and a High-Yield Cash Account.</div><style data-emotion="css 8bz49y">.css-8bz49y{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;border:0;border-radius:100px;box-sizing:border-box;-webkit-column-gap:4px;column-gap:4px;cursor:pointer;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;outline:none;position:relative;display:-webkit-inline-box;display:-webkit-inline-flex;display:-ms-inline-flexbox;display:inline-flex;width:100%;background-color:var(--pw-core-color-blue-600);color:var(--pw-core-color-greyscale-100);--button-icon-size:12px;--button-icon-margin:-4px;font:var(--font-body-1-heavy);height:48px;min-width:92px;padding:0 22px;}.css-8bz49y:disabled,.css-8bz49y:disabled:hover{cursor:default;}.css-8bz49y svg{fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;height:var(--button-icon-size);width:var(--button-icon-size);}.css-8bz49y:focus,.css-8bz49y:hover{-webkit-filter:brightness(90%);filter:brightness(90%);}.css-8bz49y:disabled,.css-8bz49y:disabled:hover{background-color:var(--pw-core-color-greyscale-200);color:var(--pw-core-color-greyscale-400);-webkit-filter:none;filter:none;}</style><a class="css-8bz49y" href="../signup.html"><span class="css-k008qs">Sign Up</span></a></div></div></aside></div><footer class="page-footer_footer__hDjNG"><div class="page-footer_footerContainer__p7Hox"><div class="page-footer_topContainer__umRXr"><div><div class="page-footer_navTitle__yziUh">Products</div><ul><li><a href="../stocks.html">Stocks</a></li><li><a href="../etfs.html">ETFs</a></li><li><a href="../invest/crypto.html">Crypto<!-- --> <span class="page-footer_bakkt__DKEFk">Offered by Bakkt Crypto</span></a></li><li><a href="../invest/options.html">Options</a></li><li><a href="../invest/bonds.html">Bonds</a></li><li><a href="../invest/treasuries.html">Treasuries</a></li><li><a href="../high-yield-cash-account.html">High-Yield Cash Account</a></li><li><a href="../premium.html">Premium</a></li><li><a href="../alpha.html">Alpha</a></li></ul></div><div><div class="page-footer_navTitle__yziUh">Resources</div><ul><li><a href="../about-us.html">About Us</a></li><li><a href="../learn.html">Learn</a></li><li><a href="../careers.html">Careers</a></li><li><a href="../disclosures/Public-Fee-Schedule-07.01.2025.pdf">Fee Schedule</a></li></ul></div><div><div class="page-footer_navTitle__yziUh">Quick Links</div><ul><li><a href="../themes.html">Investment Themes</a></li><li><a href="../glossary/investing.html">Investing Glossary</a></li><li><a href="../transfer-account.html">Transfer your Portfolio</a></li><li><a href="../live.html">Public Live</a></li><li><a href="../talks.html">Public Talks</a></li><li><a href="../treasury-yield-curve.html">Treasury Yield Curve</a></li><li><a href="../tools/high-yield-savings-calculator.html">High Yield Savings Calculator</a></li></ul></div><div><div class="page-footer_navTitle__yziUh">Contact Us</div><ul><li><a href="https://help.public.com/en">Help &amp; Support</a></li><li><a href="mailto:support@public.com">support@public.com</a></li><li><a href="mailto:press@public.com">press@public.com</a></li></ul><div class="page-footer_social__w0kqZ"><ul><li><a href="https://twitter.com/public" target="_blank" rel="noopener noreferrer nofollow" aria-label="Twitter"><style data-emotion="css 107d1c9">.css-107d1c9{fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;}</style><svg data-testid="TwitterIcon" color="inherit" aria-label="Twitter" width="28" height="28" viewBox="0 0 24 24" class="css-107d1c9"><path d="M21.4568 5.53571C20.7408 5.87054 19.963 6.11161 19.1605 6.20536C19.9877 5.66964 20.6173 4.82589 20.9136 3.82143C20.1482 4.31696 19.284 4.67857 18.3827 4.86607C17.6543 4.02232 16.6173 3.5 15.4692 3.5C13.2593 3.5 11.4815 5.44196 11.4815 7.82589C11.4815 8.16071 11.5185 8.49554 11.5803 8.81696C8.27161 8.62946 5.32099 6.91518 3.35803 4.29018C3.01235 4.93304 2.81482 5.66964 2.81482 6.47321C2.81482 7.97321 3.51852 9.29911 4.5926 10.0759C3.93827 10.0491 3.32099 9.84821 2.79012 9.52679C2.79012 9.54018 2.79012 9.56696 2.79012 9.58036C2.79012 11.683 4.1605 13.4241 5.98766 13.8259C5.65433 13.9196 5.2963 13.9732 4.93828 13.9732C4.67902 13.9732 4.4321 13.9464 4.18519 13.9062C4.69136 15.6205 6.1605 16.8661 7.91359 16.9062C6.54322 18.0714 4.82716 18.7545 2.96296 18.7545C2.62963 18.7545 2.32099 18.7411 2 18.7009C3.76543 19.933 5.8642 20.6429 8.12346 20.6429C15.4568 20.6429 19.4692 14.0536 19.4692 8.33482C19.4692 8.14732 19.4692 7.95982 19.4568 7.77232C20.2346 7.15625 20.9136 6.39286 21.4568 5.53571Z"></path></svg></a></li><li><a href="https://www.instagram.com/publicapp" target="_blank" rel="noopener noreferrer nofollow" aria-label="Instagram"><style data-emotion="css 107d1c9">.css-107d1c9{fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;}</style><svg data-testid="InstagramIcon" color="inherit" aria-label="Instagram" width="28" height="28" viewBox="0 0 28 28" class="css-107d1c9"><path fill-rule="evenodd" clip-rule="evenodd" d="M14 18.6667C16.5773 18.6667 18.6667 16.5773 18.6667 14C18.6667 11.4227 16.5773 9.33333 14 9.33333C11.4227 9.33333 9.33333 11.4227 9.33333 14C9.33333 16.5773 11.4227 18.6667 14 18.6667ZM14 16.9167C15.6108 16.9167 16.9167 15.6108 16.9167 14C16.9167 12.3892 15.6108 11.0833 14 11.0833C12.3892 11.0833 11.0833 12.3892 11.0833 14C11.0833 15.6108 12.3892 16.9167 14 16.9167Z"></path><path d="M19.8333 9.33333C20.4777 9.33333 21 8.811 21 8.16667C21 7.52233 20.4777 7 19.8333 7C19.189 7 18.6667 7.52233 18.6667 8.16667C18.6667 8.811 19.189 9.33333 19.8333 9.33333Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M7 3.5C5.067 3.5 3.5 5.067 3.5 7V21C3.5 22.933 5.067 24.5 7 24.5H21C22.933 24.5 24.5 22.933 24.5 21V7C24.5 5.067 22.933 3.5 21 3.5H7ZM21 5.25H7C6.0335 5.25 5.25 6.0335 5.25 7V21C5.25 21.9665 6.0335 22.75 7 22.75H21C21.9665 22.75 22.75 21.9665 22.75 21V7C22.75 6.0335 21.9665 5.25 21 5.25Z"></path></svg></a></li><li><a href="https://www.facebook.com/PublicHello" target="_blank" rel="noopener noreferrer nofollow" aria-label="Facebook"><style data-emotion="css 107d1c9">.css-107d1c9{fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;}</style><svg data-testid="FacebookIcon" color="inherit" aria-label="Facebook" width="28" height="28" viewBox="0 0 24 24" class="css-107d1c9"><path d="M16 3C16 3 15.75 3 14.6667 3C12.2708 3 10.6563 4.38616 10.6667 6.85714V9.42856H8V12H10.6563L10.6667 21H13.3333V12H15.6L16 9.42856H13.3333V7.21875C13.3333 5.57143 14.0956 5.57143 15.3646 5.57143H16V3Z"></path></svg></a></li><li><a href="https://www.linkedin.com/company/publichello" target="_blank" rel="noopener noreferrer nofollow" aria-label="LinkedIn"><style data-emotion="css 107d1c9">.css-107d1c9{fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;}</style><svg data-testid="LinkedInIcon" color="inherit" width="28" height="28" viewBox="0 0 24 24" class="css-107d1c9"><path fill-rule="evenodd" clip-rule="evenodd" d="M7.04328 8.52936H3.22571V19.9996H7.04328V8.52936Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M7.29475 4.98125C7.26997 3.8566 6.46573 3 5.15976 3C3.8538 3 3 3.8566 3 4.98125C3 6.0826 3.82856 6.96387 5.11021 6.96387H5.13461C6.46573 6.96387 7.29475 6.0826 7.29475 4.98125Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M20.811 13.423C20.811 9.89984 18.9277 8.2601 16.4156 8.2601C14.3887 8.2601 13.4812 9.37341 12.9745 10.1544V8.52975H9.15649C9.20681 9.60606 9.15649 20 9.15649 20H12.9745V13.5941C12.9745 13.2512 12.9993 12.9093 13.1002 12.6638C13.3762 11.979 14.0044 11.2699 15.059 11.2699C16.441 11.2699 16.9934 12.3217 16.9934 13.8631V19.9997H20.8109L20.811 13.423Z"></path></svg></a></li><li><a href="https://medium.com/the-public-blog/" target="_blank" rel="noopener noreferrer nofollow" aria-label="Blog"><style data-emotion="css 107d1c9">.css-107d1c9{fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;}</style><svg data-testid="BlogIcon" color="inherit" viewBox="0 0 1043.63 592.71" width="28" height="28" class="css-107d1c9"><g><path d="M588.67 296.36c0 163.67-131.78 296.35-294.33 296.35S0 460 0 296.36 131.78 0 294.34 0s294.33 132.69 294.33 296.36"></path><path d="M911.56 296.36c0 154.06-65.89 279-147.17 279s-147.17-124.94-147.17-279 65.88-279 147.16-279 147.17 124.9 147.17 279"></path><path d="M1043.63 296.36c0 138-23.17 249.94-51.76 249.94s-51.75-111.91-51.75-249.94 23.17-249.94 51.75-249.94 51.76 111.9 51.76 249.94"></path></g></svg></a></li><li><a href="https://www.tiktok.com/@public" target="_blank" rel="noopener noreferrer nofollow" aria-label="TikTok"><style data-emotion="css 107d1c9">.css-107d1c9{fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;}</style><svg data-testid="TikTokIcon" color="inherit" width="22" height="22" viewBox="0 0 22 22" class="css-107d1c9"><path d="M15.6495 0H11.9418V14.9855C11.9418 16.771 10.5158 18.2377 8.74125 18.2377C6.96665 18.2377 5.54064 16.771 5.54064 14.9855C5.54064 13.2319 6.93496 11.7971 8.6462 11.7333V7.97103C4.87517 8.03477 1.83301 11.1275 1.83301 14.9855C1.83301 18.8754 4.93854 22 8.77295 22C12.6073 22 15.7128 18.8435 15.7128 14.9855V7.30143C17.1072 8.32174 18.8184 8.92754 20.6247 8.95944V5.1971C17.8361 5.10145 15.6495 2.80579 15.6495 0Z"></path></svg></a></li></ul></div><ul class="page-footer_appStore__WCUf_"><li><a href="https://public.sng.link/Ag0a8/f14v?_ios_dl=matador%3A%2F%2F&amp;_android_dl=public%3A%2F%2F&amp;_smtype=3" target="_blank" rel="noopener noreferrer nofollow" aria-label="App Store"><svg width="144" height="49" viewBox="0 0 165 56" fill="none" aria-label="App Store"><path d="M151.806 0.000179188H13.1423C12.6369 0.000179188 12.1375 0.000179188 11.6334 0.00293592C11.2114 0.00569266 10.7927 0.013701 10.3667 0.0204412C9.44115 0.0313328 8.51777 0.112759 7.60459 0.264013C6.6927 0.418559 5.80937 0.709923 4.98448 1.12825C4.1606 1.55012 3.4078 2.09829 2.75339 2.75288C2.09554 3.40563 1.54717 4.16012 1.12937 4.98734C0.710411 5.81291 0.419907 6.69758 0.267886 7.61081C0.11442 8.52288 0.0318381 9.44548 0.0208823 10.3703C0.00809102 10.7929 0.00674022 11.2169 0 11.6396V43.4995C0.00674022 43.9275 0.00809102 44.3421 0.0208823 44.7703C0.0318414 45.695 0.114423 46.6176 0.267886 47.5296C0.419487 48.4434 0.710009 49.3286 1.12937 50.1544C1.54698 50.979 2.09542 51.7304 2.75339 52.3795C3.40532 53.037 4.15861 53.5856 4.98448 54.0042C5.80936 54.4237 6.6926 54.7168 7.60459 54.8737C8.51793 55.0237 9.44121 55.1052 10.3667 55.1174C10.7927 55.1268 11.2114 55.1321 11.6334 55.1321C12.1375 55.1349 12.6369 55.1349 13.1423 55.1349H151.806C152.302 55.1349 152.805 55.1349 153.3 55.1321C153.72 55.1321 154.151 55.1268 154.571 55.1174C155.495 55.1059 156.416 55.0244 157.328 54.8737C158.243 54.7157 159.129 54.4226 159.958 54.0042C160.783 53.5853 161.536 53.0368 162.187 52.3795C162.843 51.7279 163.393 50.977 163.816 50.1544C164.232 49.328 164.52 48.4428 164.669 47.5296C164.823 46.6175 164.908 45.6951 164.925 44.7703C164.93 44.3421 164.93 43.9275 164.93 43.4995C164.941 42.9988 164.941 42.5008 164.941 41.9919V13.1445C164.941 12.6397 164.941 12.139 164.93 11.6396C164.93 11.2169 164.93 10.7929 164.925 10.3702C164.908 9.44534 164.823 8.52295 164.669 7.61076C164.519 6.69806 164.232 5.81345 163.816 4.98728C162.965 3.32921 161.616 1.97955 159.958 1.12813C159.129 0.710821 158.243 0.419534 157.328 0.263889C156.417 0.111969 155.495 0.030514 154.571 0.0202482C154.151 0.0135218 153.72 0.00544455 153.3 0.00275674C152.805 0 152.302 0 151.806 0V0.000179188Z" fill="white"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M102.936 40.0773C100.683 40.0773 99.0336 38.9628 98.8438 37.2654L96.2216 37.2653C96.3872 40.3613 98.9501 42.3198 102.746 42.3198C106.803 42.3198 109.353 40.3142 109.353 37.1119C109.353 34.6082 107.895 33.1975 104.383 32.367L102.497 31.904C100.291 31.3589 99.389 30.6468 99.389 29.4367C99.389 27.9183 100.801 26.8751 102.864 26.8751C104.928 26.8751 106.34 27.9062 106.495 29.6143H109.081C108.997 26.6611 106.518 24.6326 102.9 24.6326C99.2463 24.6326 96.6726 26.6611 96.6726 29.6143C96.6726 31.9996 98.1318 33.4695 101.275 34.2287L103.493 34.7631C105.711 35.3082 106.648 36.1037 106.648 37.4323C106.648 38.9628 105.095 40.0773 102.936 40.0773ZM58.3107 37.408H51.7863L50.2195 42.0344H47.4561L53.6358 24.9178H56.507L62.6867 42.0344H59.8762L58.3107 37.408ZM52.4639 35.2747H57.6355L55.086 27.7664H55.0146L52.4639 35.2747ZM70.8268 42.164C73.9591 42.164 76.0347 39.6725 76.0347 35.7944C76.0347 31.9272 73.9469 29.4235 70.7796 29.4235C69.1499 29.371 67.6231 30.2186 66.806 31.6297H66.7589V29.5541H64.2795V46.1618H66.841V39.9807H66.9003C67.6827 41.4007 69.2077 42.2487 70.8268 42.164ZM73.4025 35.7948C73.4025 33.2682 72.0968 31.6072 70.1047 31.6072C68.1475 31.6072 66.8311 33.3032 66.8311 35.7948C66.8311 38.3092 68.1475 39.9932 70.1047 39.9932C72.0969 39.9932 73.4025 38.3442 73.4025 35.7948H73.4025ZM84.5584 42.164C87.6907 42.164 89.767 39.6725 89.767 35.7944C89.767 31.9272 87.6786 29.4235 84.5113 29.4235C82.8815 29.371 81.3548 30.2186 80.5377 31.6297H80.4906V29.5541H78.0112V46.1618H80.5727V39.9807H80.632C81.4143 41.4007 82.9394 42.2487 84.5584 42.164ZM87.133 35.7945C87.133 33.268 85.8273 31.6069 83.8351 31.6069C81.878 31.6069 80.5615 33.3029 80.5615 35.7945C80.5615 38.309 81.878 39.9929 83.8351 39.9929C85.8273 39.9929 87.133 38.344 87.133 35.7945ZM114.883 26.6035V29.5568H117.256V31.5853H114.883V38.465C114.883 39.5338 115.358 40.0318 116.401 40.0318C116.683 40.0269 116.964 40.0071 117.244 39.9726V41.989C116.775 42.0766 116.298 42.1163 115.821 42.1074C113.294 42.1074 112.309 41.1584 112.309 38.7382V31.5853H110.495V29.5568H112.309V26.6035H114.883ZM124.55 29.4021C120.944 29.4021 118.632 31.8694 118.632 35.7959C118.632 39.7331 120.921 42.1897 124.55 42.1897C128.181 42.1897 130.47 39.7331 130.47 35.7959C130.47 31.8694 128.169 29.4021 124.55 29.4021ZM127.862 35.7972C127.862 33.1038 126.628 31.5141 124.552 31.5141C122.476 31.5141 121.242 33.1159 121.242 35.7972C121.242 38.5015 122.476 40.0791 124.552 40.0791C126.628 40.0791 127.862 38.5015 127.862 35.7972ZM135.024 29.5544H132.581L132.581 42.0337H135.143V34.6317C135.057 33.8829 135.304 33.1342 135.817 32.5822C136.33 32.0302 137.059 31.73 137.812 31.7606C138.201 31.7492 138.59 31.8015 138.963 31.9154V29.5194C138.675 29.4548 138.38 29.4228 138.085 29.4238C136.677 29.3701 135.424 30.3111 135.083 31.6785H135.024V29.5544ZM150.776 38.3696C150.431 40.635 148.225 42.1897 145.402 42.1897C141.772 42.1897 139.519 39.7574 139.519 35.8551C139.519 31.9408 141.784 29.4021 145.295 29.4021C148.747 29.4021 150.918 31.7739 150.918 35.5576V36.4353H142.104V36.5901C142.022 37.5191 142.343 38.4388 142.985 39.1151C143.627 39.7914 144.529 40.1591 145.461 40.1248C146.704 40.2413 147.876 39.5275 148.343 38.3696L150.776 38.3696ZM148.355 34.6443H142.116C142.114 33.8018 142.449 32.9932 143.045 32.3985C143.642 31.8037 144.452 31.472 145.294 31.477C146.13 31.4591 146.936 31.7906 147.517 32.3919C148.098 32.9931 148.402 33.8095 148.355 34.6443Z" fill="black"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M81.4541 11.6311H82.679V20.2607H81.4541V11.6311ZM55.0418 13.1626C54.2922 12.371 53.2271 11.9573 52.1396 12.0353H49.1689V20.2598H52.1396C54.5894 20.2598 56.0095 18.7495 56.0095 16.1219C56.1466 15.0403 55.7915 13.9543 55.0418 13.1626ZM52.0009 19.0977H50.4502V13.1986H52.0009C52.7739 13.1557 53.5256 13.4605 54.0505 14.0296C54.5754 14.5988 54.8184 15.3727 54.7132 16.1397C54.8267 16.9099 54.5871 17.6903 54.0609 18.2641C53.5347 18.838 52.778 19.1441 52.0009 19.0977ZM57.4514 17.1558C57.3449 16.0433 57.8784 14.9666 58.828 14.3773C59.7776 13.7881 60.9792 13.7881 61.9288 14.3773C62.8784 14.9666 63.4118 16.0433 63.3054 17.1558C63.4138 18.2695 62.8809 19.3482 61.9304 19.9388C60.98 20.5293 59.7768 20.5293 58.8263 19.9388C57.8759 19.3482 57.3429 18.2695 57.4514 17.1558ZM60.3795 15.0227C61.4402 15.0227 62.0446 15.8095 62.0446 17.1549H62.0446C62.0446 18.5056 61.4402 19.2917 60.3795 19.2917C59.3148 19.2917 58.7158 18.511 58.7158 17.1549C58.7158 15.8095 59.3148 15.0227 60.3795 15.0227ZM71.0864 20.2606H69.8158L68.533 15.6894H68.4361L67.1586 20.2606H65.9001L64.1892 14.0539H65.4316L66.5435 18.79H66.635L67.9111 14.0539H69.0862L70.3623 18.79H70.4592L71.5656 14.0539H72.7906L71.0864 20.2606ZM75.4106 14.0539H74.2315L74.2314 20.2606H75.4564V16.6296C75.4124 16.2166 75.551 15.8049 75.8359 15.5026C76.1208 15.2003 76.5234 15.0374 76.9384 15.0567C77.8443 15.0567 78.2777 15.5528 78.2777 16.5502V20.2606H79.5026V16.2426C79.5924 15.6358 79.4014 15.021 78.9835 14.5719C78.5655 14.1228 77.9661 13.8881 77.3543 13.9341C76.5643 13.8699 75.8204 14.314 75.5021 15.0399H75.4106V14.0539ZM85.7591 14.3751C84.8094 14.9644 84.2759 16.0411 84.3822 17.1536C84.2739 18.2674 84.807 19.3461 85.7575 19.9366C86.708 20.5271 87.9112 20.5271 88.8617 19.9366C89.8122 19.3461 90.3453 18.2674 90.2369 17.1536C90.3433 16.0411 89.8097 14.9644 88.8601 14.3751C87.9104 13.7858 86.7088 13.7858 85.7591 14.3751ZM88.9782 17.1549C88.9782 15.8095 88.3738 15.0227 87.3131 15.0227C86.2484 15.0227 85.6494 15.8095 85.6494 17.1549C85.6494 18.511 86.2484 19.2917 87.3131 19.2917C88.3738 19.2917 88.9782 18.5056 88.9782 17.1549ZM93.8368 16.6542C92.3602 16.7457 91.5283 17.3898 91.5283 18.507C91.5304 19.0368 91.7565 19.5409 92.1506 19.8948C92.5448 20.2487 93.0703 20.4193 93.5972 20.3645C94.3488 20.3993 95.061 20.027 95.4615 19.39H95.5584V20.2623H96.7376V16.0215C96.7376 14.7104 95.86 13.9358 94.3039 13.9358C92.8959 13.9358 91.8931 14.6196 91.7679 15.6857H92.9538C93.0898 15.2469 93.5636 14.9958 94.2474 14.9958C95.0846 14.9958 95.518 15.366 95.518 16.0215V16.5572L93.8368 16.6542ZM95.5169 17.9752V17.4563L94.0012 17.5532C93.1465 17.6104 92.7588 17.9012 92.7588 18.4483C92.7588 19.0069 93.2434 19.332 93.9097 19.332C94.3042 19.372 94.698 19.2501 95.0009 18.9943C95.3039 18.7385 95.4901 18.3708 95.5169 17.9752ZM100.921 13.9511C99.3529 13.9511 98.3447 15.1935 98.3447 17.1547C98.3447 19.1206 99.3422 20.3631 100.921 20.363C101.722 20.3925 102.472 19.9754 102.87 19.2801H102.967V20.2607H104.141V11.6311H102.916V15.04H102.824C102.455 14.3389 101.713 13.9146 100.921 13.9511ZM99.6143 17.1562C99.6143 18.4727 100.235 19.2648 101.273 19.2648C102.305 19.2648 102.943 18.4612 102.943 17.1616C102.943 15.868 102.298 15.053 101.273 15.053C100.242 15.053 99.6143 15.8505 99.6143 17.1562H99.6143ZM110.587 14.3773C109.637 14.9666 109.104 16.0433 109.21 17.1558C109.102 18.2695 109.635 19.3482 110.585 19.9388C111.536 20.5293 112.739 20.5293 113.689 19.9388C114.64 19.3482 115.173 18.2695 115.064 17.1558C115.171 16.0433 114.637 14.9666 113.688 14.3773C112.738 13.7881 111.536 13.7881 110.587 14.3773ZM113.806 17.1549C113.806 15.8095 113.202 15.0227 112.141 15.0227C111.076 15.0227 110.478 15.8095 110.478 17.1549C110.478 18.511 111.077 19.2917 112.141 19.2917C113.202 19.2917 113.806 18.5056 113.806 17.1549ZM117.883 14.0535H116.704V20.2602H117.929V16.6292C117.885 16.2161 118.024 15.8045 118.309 15.5022C118.594 15.1998 118.996 15.037 119.411 15.0563C120.317 15.0563 120.751 15.5523 120.751 16.5498V20.2601H121.975V16.2422C122.065 15.6353 121.874 15.0206 121.456 14.5715C121.038 14.1224 120.439 13.8877 119.827 13.9337C119.037 13.8695 118.293 14.3135 117.975 15.0395H117.883V14.0535ZM128.904 12.509V14.0826H130.249V15.1143H128.904V18.3059C128.904 18.956 129.172 19.2407 129.782 19.2407C129.938 19.2402 130.094 19.2308 130.249 19.2124V20.2327C130.029 20.2721 129.806 20.293 129.582 20.2953C128.22 20.2953 127.678 19.8161 127.678 18.6195V15.1143H126.692V14.0825H127.678V12.509H128.904ZM133.129 11.6311H131.915L131.915 20.2607H133.14V16.6358C133.102 16.2098 133.254 15.7889 133.555 15.4856C133.857 15.1822 134.277 15.0273 134.703 15.0622C135.568 15.0622 136.03 15.5643 136.03 16.5557V20.2607H137.256V16.2535C137.337 15.6497 137.145 15.0413 136.732 14.5938C136.318 14.1464 135.727 13.9065 135.119 13.9396C134.317 13.8745 133.56 14.3192 133.226 15.0515H133.129V11.6311ZM144.4 18.5836C144.057 19.7544 142.924 20.5108 141.711 20.3792C140.883 20.4011 140.088 20.058 139.536 19.4411C138.984 18.8242 138.731 17.9958 138.844 17.1756C138.734 16.3532 138.986 15.5235 139.535 14.9013C140.084 14.2792 140.876 13.9259 141.706 13.933C143.433 13.933 144.474 15.1128 144.474 17.0619V17.4893H140.092V17.5579C140.053 18.0185 140.21 18.4741 140.525 18.8126C140.84 19.1511 141.282 19.3412 141.745 19.336C142.344 19.408 142.927 19.1107 143.221 18.5836L144.4 18.5836ZM143.227 16.585H140.092C140.086 16.157 140.254 15.7449 140.556 15.4422C140.859 15.1395 141.271 14.9718 141.699 14.9772C142.121 14.9675 142.528 15.1366 142.819 15.4428C143.11 15.749 143.258 16.1638 143.227 16.585Z" fill="black"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M32.137 10.8181C32.2758 12.6302 31.7027 14.4251 30.5395 15.8214C29.411 17.2251 27.701 18.0336 25.9001 18.015C25.7855 16.2551 26.3753 14.5218 27.5394 13.1969C28.7183 11.8541 30.3599 11.0048 32.137 10.8181ZM37.8338 21.4657C35.7621 22.7393 34.4873 24.9854 34.4559 27.4171C34.4589 30.1682 36.1065 32.651 38.6403 33.7227C38.153 35.3058 37.4184 36.8018 36.4638 38.1554C35.1818 40.0731 33.8377 41.9466 31.7043 41.9812C30.6897 42.0047 30.0048 41.7129 29.2911 41.4089C28.5467 41.0918 27.771 40.7613 26.5571 40.7613C25.2698 40.7613 24.4593 41.1024 23.6777 41.4313C23.0022 41.7156 22.3482 41.9909 21.4266 42.0291C19.3948 42.1043 17.8421 39.9823 16.5135 38.0826C13.8581 34.203 11.7904 27.1494 14.5624 22.3499C15.8642 20.0107 18.2981 18.5263 20.9737 18.4399C22.1261 18.4162 23.2318 18.8603 24.2012 19.2497C24.9426 19.5475 25.6042 19.8133 26.146 19.8133C26.6223 19.8133 27.2655 19.558 28.0151 19.2605C29.1959 18.7918 30.6407 18.2184 32.113 18.373C34.4008 18.4446 36.5209 19.5907 37.8338 21.4657Z" fill="black"></path></svg></a></li><li><a href="https://public.sng.link/Ag0a8/f14v?_ios_dl=matador%3A%2F%2F&amp;_android_dl=public%3A%2F%2F&amp;_smtype=3" target="_blank" rel="noopener noreferrer nofollow" aria-label="Google Play"><svg width="144" height="49" viewBox="0 0 165 56" fill="none" aria-label="Google Play"><path d="M151.806 0.000179188H13.1423C12.6369 0.000179188 12.1375 0.000179188 11.6334 0.00293592C11.2114 0.00569266 10.7927 0.013701 10.3667 0.0204412C9.44115 0.0313328 8.51777 0.112759 7.60459 0.264013C6.6927 0.418559 5.80937 0.709923 4.98448 1.12825C4.1606 1.55012 3.4078 2.09829 2.75339 2.75288C2.09554 3.40563 1.54717 4.16012 1.12937 4.98734C0.710411 5.81291 0.419907 6.69758 0.267886 7.61081C0.11442 8.52288 0.0318381 9.44548 0.0208823 10.3703C0.00809102 10.7929 0.00674022 11.2169 0 11.6396V43.4995C0.00674022 43.9275 0.00809102 44.3421 0.0208823 44.7703C0.0318414 45.695 0.114423 46.6176 0.267886 47.5296C0.419487 48.4434 0.710009 49.3286 1.12937 50.1544C1.54698 50.979 2.09542 51.7304 2.75339 52.3795C3.40532 53.037 4.15861 53.5856 4.98448 54.0042C5.80936 54.4237 6.6926 54.7168 7.60459 54.8737C8.51793 55.0237 9.44121 55.1052 10.3667 55.1174C10.7927 55.1268 11.2114 55.1321 11.6334 55.1321C12.1375 55.1349 12.6369 55.1349 13.1423 55.1349H151.806C152.302 55.1349 152.805 55.1349 153.3 55.1321C153.72 55.1321 154.151 55.1268 154.571 55.1174C155.495 55.1059 156.416 55.0244 157.328 54.8737C158.243 54.7157 159.129 54.4226 159.958 54.0042C160.783 53.5853 161.536 53.0368 162.187 52.3795C162.843 51.7279 163.393 50.977 163.816 50.1544C164.232 49.328 164.52 48.4428 164.669 47.5296C164.823 46.6175 164.908 45.6951 164.925 44.7703C164.93 44.3421 164.93 43.9275 164.93 43.4995C164.941 42.9988 164.941 42.5008 164.941 41.9919V13.1445C164.941 12.6397 164.941 12.139 164.93 11.6396C164.93 11.2169 164.93 10.7929 164.925 10.3702C164.908 9.44534 164.823 8.52295 164.669 7.61076C164.519 6.69806 164.232 5.81345 163.816 4.98728C162.965 3.32921 161.616 1.97955 159.958 1.12813C159.129 0.710821 158.243 0.419534 157.328 0.263889C156.417 0.111969 155.495 0.030514 154.571 0.0202482C154.151 0.0135218 153.72 0.00544455 153.3 0.00275674C152.805 0 152.302 0 151.806 0V0.000179188Z" fill="white"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M57.183 31.6094V33.8086H62.4612C62.3784 34.8444 61.9478 35.8218 61.2394 36.582C60.1716 37.6697 58.6938 38.2555 57.1708 38.1948C53.9319 38.1948 51.3062 35.5691 51.3062 32.3302C51.3062 29.0913 53.9319 26.4657 57.1708 26.4657C58.6587 26.4414 60.0955 27.0082 61.1661 28.0418L62.7177 26.4901C61.2576 25.0116 59.261 24.1873 57.183 24.2054C54.225 24.0902 51.4411 25.6027 49.9279 28.1469C48.4147 30.6911 48.4147 33.8594 49.9279 36.4036C51.4411 38.9478 54.225 40.4603 57.183 40.3451C59.2989 40.4408 61.3527 39.6166 62.8155 38.0848C64.0955 36.6785 64.7789 34.8297 64.7215 32.9289C64.7254 32.4658 64.6845 32.0035 64.5993 31.5483L57.183 31.6094ZM70.7312 30.0088C67.865 30.0155 65.5463 32.3433 65.5508 35.2095C65.5553 38.0757 67.8812 40.3962 70.7474 40.3939C73.6136 40.3917 75.936 38.0675 75.936 35.2013C75.9561 33.8139 75.4121 32.4776 74.4286 31.4987C73.4451 30.5198 72.1063 29.9821 70.7189 30.0088H70.7312ZM76.9375 35.2176C76.9285 32.353 79.2411 30.0222 82.1057 30.0088C83.493 29.9821 84.8318 30.5198 85.8153 31.4987C86.7988 32.4776 87.3428 33.8139 87.3227 35.2013C87.3227 38.066 85.0028 40.3894 82.1382 40.3939C79.2736 40.3983 76.9465 38.0821 76.9375 35.2176ZM79.0428 36.5696C79.6007 37.7375 80.8158 38.4456 82.107 38.3553C82.9174 38.3365 83.6858 37.9912 84.2379 37.3977C84.7901 36.8041 85.079 36.0128 85.0393 35.2031C85.0361 33.9088 84.2421 32.748 83.037 32.2758C81.8319 31.8037 80.4606 32.1161 79.5791 33.0638C78.6975 34.0115 78.4848 35.4017 79.0428 36.5696ZM67.6597 36.5781C68.2215 37.7452 69.4402 38.4498 70.732 38.3544H70.7198C71.5302 38.3356 72.2987 37.9903 72.8508 37.3968C73.4029 36.8033 73.6919 36.0119 73.6521 35.2022C73.6486 33.9069 72.853 32.7456 71.6464 32.2745C70.4397 31.8033 69.0677 32.1184 68.1875 33.0686C67.3072 34.0189 67.0978 35.4109 67.6597 36.5781ZM108.093 30.0104C110.118 30.085 111.888 31.4022 112.54 33.3214L112.796 33.8712L105.844 36.7424C106.28 37.7347 107.278 38.3598 108.361 38.3185C109.407 38.3212 110.377 37.7735 110.915 36.8768L112.686 38.0986C111.722 39.5421 110.097 40.4049 108.361 40.3955C106.981 40.4158 105.653 39.874 104.68 38.8947C103.708 37.9153 103.175 36.5827 103.205 35.2029C103.121 33.8547 103.598 32.5317 104.524 31.548C105.45 30.5643 106.742 30.0077 108.093 30.0104ZM105.451 35.0569C105.401 34.2935 105.661 33.542 106.171 32.972C106.681 32.402 107.4 32.0613 108.164 32.0268C108.969 31.9738 109.729 32.4064 110.094 33.1265L105.451 35.0569ZM102.094 40.0902H99.8088V24.8179H102.094V40.0902ZM96.0714 31.1706H95.9859C95.2894 30.3919 94.2938 29.9475 93.2491 29.9488C90.4758 30.0833 88.2964 32.371 88.2964 35.1475C88.2964 37.9241 90.4758 40.2117 93.2491 40.3462C94.2972 40.3639 95.2993 39.9165 95.9859 39.1244H96.0592V39.8697C96.0592 41.8612 94.9963 42.9242 93.2858 42.9242C92.1205 42.8969 91.0874 42.168 90.6711 41.0793L88.6796 41.9101C89.4465 43.7756 91.2689 44.9888 93.2858 44.9768C95.9615 44.9768 98.1729 43.4007 98.1729 39.5643V30.3154H96.0714V31.1706ZM93.4522 38.3547L93.456 38.3551H93.4437L93.4522 38.3547ZM95.511 37.3749C94.9866 37.9683 94.2431 38.322 93.4522 38.3547C91.8204 38.209 90.5693 36.8416 90.5693 35.2028C90.5693 33.5628 91.8223 32.1946 93.456 32.0506C94.2454 32.0911 94.985 32.4487 95.5072 33.0421C96.0293 33.6356 96.2897 34.4147 96.2294 35.2028C96.2968 35.9946 96.0372 36.7795 95.511 37.3749ZM123.244 24.8156H117.782V40.088H120.067V34.2967H123.256C125.031 34.4242 126.728 33.5496 127.654 32.0302C128.581 30.5109 128.581 28.6014 127.654 27.0821C126.728 25.5627 125.031 24.6881 123.256 24.8156H123.244ZM120.055 32.1469H123.244L123.293 32.1835C124.74 32.1835 125.914 31.0102 125.914 29.5628C125.914 28.1154 124.74 26.9421 123.293 26.9421H120.055V32.1469ZM137.331 29.9498C135.631 29.8482 134.033 30.7648 133.263 32.2834L135.291 33.1264C135.699 32.3734 136.514 31.9326 137.368 32.0024C137.954 31.9339 138.543 32.1037 139.002 32.4736C139.462 32.8435 139.753 33.3825 139.812 33.9694V34.1283C139.078 33.7398 138.259 33.5383 137.429 33.5418C135.242 33.5418 133.031 34.7636 133.031 36.975C133.074 37.9277 133.501 38.8222 134.215 39.455C134.928 40.0879 135.867 40.4052 136.818 40.335C137.99 40.4191 139.115 39.8569 139.75 38.8688H139.824V40.0906H142.023V34.2138C142.023 31.5381 139.995 29.9864 137.392 29.9864L137.331 29.9498ZM135.27 37.0227C135.27 37.939 136.308 38.3178 137.053 38.3178L137.114 38.3544C138.491 38.3209 139.632 37.2786 139.79 35.9109C139.156 35.557 138.439 35.3798 137.713 35.3977C136.565 35.3977 135.27 35.8009 135.27 37.0227ZM150.039 30.3164L147.425 36.9385H147.351L144.639 30.3164H142.195L146.264 39.5775L143.942 44.7213H146.325L152.58 30.3164H150.039ZM131.785 40.0902H129.5V24.8179H131.785V40.0902Z" fill="black"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M83.4092 12.9297C81.9678 14.4554 81.9678 16.8409 83.4092 18.3666C84.8961 19.8453 87.2981 19.8453 88.785 18.3666C90.2325 16.8433 90.2325 14.4529 88.785 12.9297C88.0739 12.2134 87.1064 11.8105 86.0971 11.8105C85.0878 11.8105 84.1202 12.2134 83.4092 12.9297ZM55.8737 18.3903C56.5008 17.7355 56.832 16.8523 56.7901 15.9467C56.7901 15.7623 56.7738 15.5783 56.7412 15.3969H53.1858V16.2766H55.8371C55.819 16.8307 55.6021 17.3597 55.2262 17.7671C54.3888 18.5766 53.1466 18.8028 52.0776 18.3405C51.0086 17.8781 50.3227 16.8181 50.339 15.6535C50.3124 14.8828 50.601 14.1345 51.1381 13.5812C51.6753 13.0279 52.4147 12.7174 53.1858 12.7212C53.9529 12.6793 54.6951 13.0006 55.1895 13.5886L55.8371 12.9411C55.5243 12.5813 55.1307 12.3008 54.6886 12.1225C54.2137 11.9193 53.7023 11.8153 53.1858 11.8171C52.1724 11.7945 51.1949 12.1925 50.4857 12.9167C49.394 14.0154 49.0675 15.6615 49.6569 17.0938C50.2464 18.5261 51.637 19.4655 53.1858 19.4777C54.1956 19.5136 55.173 19.1182 55.8737 18.3903ZM59.0874 12.8936H62.3863V11.9895H58.11V19.3202H62.3863V18.4161H59.0874V16.0947H62.093V15.215H59.0874V12.8936ZM66.392 19.3202H65.4512V12.8936H63.3986V11.9895H68.4935V12.8936H66.392V19.3202ZM72.0859 11.9893V19.32H73.0267V11.9893H72.0859ZM77.2082 19.32H76.2674V12.8934H74.2148V11.9893H79.2486V12.8934H77.2082V19.32ZM84.1071 17.7543C85.2083 18.851 86.9889 18.851 88.0901 17.7543C89.1716 16.5621 89.1716 14.7436 88.0901 13.5514C86.9889 12.4547 85.2083 12.4547 84.1071 13.5514C83.0255 14.7436 83.0255 16.5621 84.1071 17.7543ZM91.1992 11.9893V19.32H92.1522V13.3454L95.8787 19.32H96.8561V11.9893H95.9153V17.695L92.3477 11.9893H91.1992Z" fill="black"></path><path d="M83.4092 18.3666L83.3203 18.4506L83.323 18.4532L83.4092 18.3666ZM83.4092 12.9297L83.3224 12.8436L83.3203 12.8458L83.4092 12.9297ZM88.785 18.3666L88.8712 18.4533L88.8736 18.4508L88.785 18.3666ZM88.785 12.9297L88.8736 12.8455L88.8717 12.8436L88.785 12.9297ZM56.7901 15.9467L56.6678 15.9466L56.668 15.9523L56.7901 15.9467ZM55.8737 18.3903L55.9618 18.475L55.962 18.4748L55.8737 18.3903ZM56.7412 15.3969L56.8615 15.3753L56.8434 15.2747H56.7412V15.3969ZM53.1858 15.3969V15.2747H53.0636V15.3969H53.1858ZM53.1858 16.2766H53.0636V16.3987H53.1858V16.2766ZM55.8371 16.2766L55.9592 16.2806L55.9633 16.1544H55.8371V16.2766ZM55.2262 17.7671L55.3112 17.8551L55.316 17.85L55.2262 17.7671ZM52.0776 18.3405L52.1261 18.2283L52.0776 18.3405ZM50.339 15.6535L50.4614 15.6552L50.4611 15.6492L50.339 15.6535ZM51.1381 13.5812L51.2258 13.6663L51.1381 13.5812ZM53.1858 12.7212L53.1852 12.8436L53.1925 12.8432L53.1858 12.7212ZM55.1895 13.5886L55.096 13.6673L55.1817 13.7692L55.2759 13.675L55.1895 13.5886ZM55.8371 12.9411L55.9235 13.0275L56.004 12.9469L55.9293 12.8609L55.8371 12.9411ZM54.6886 12.1225L54.6405 12.2348L54.6429 12.2358L54.6886 12.1225ZM53.1858 11.8171L53.1831 11.9392L53.1862 11.9392L53.1858 11.8171ZM50.4857 12.9167L50.5723 13.0028L50.5729 13.0022L50.4857 12.9167ZM49.6569 17.0938L49.7699 17.0473L49.6569 17.0938ZM53.1858 19.4777L53.1902 19.3555L53.1868 19.3555L53.1858 19.4777ZM62.3863 12.8936V13.0158H62.5084V12.8936H62.3863ZM59.0874 12.8936V12.7715H58.9652V12.8936H59.0874ZM62.3863 11.9895H62.5084V11.8673H62.3863V11.9895ZM58.11 11.9895V11.8673H57.9878V11.9895H58.11ZM58.11 19.3202H57.9878V19.4424H58.11V19.3202ZM62.3863 19.3202V19.4424H62.5084V19.3202H62.3863ZM62.3863 18.4161H62.5084V18.2939H62.3863V18.4161ZM59.0874 18.4161H58.9652V18.5383H59.0874V18.4161ZM59.0874 16.0947V15.9725H58.9652V16.0947H59.0874ZM62.093 16.0947V16.2169H62.2152V16.0947H62.093ZM62.093 15.215H62.2152V15.0929H62.093V15.215ZM59.0874 15.215H58.9652V15.3372H59.0874V15.215ZM65.4512 19.3202H65.3291V19.4424H65.4512V19.3202ZM66.392 19.3202V19.4424H66.5142V19.3202H66.392ZM65.4512 12.8936H65.5734V12.7715H65.4512V12.8936ZM63.3986 12.8936H63.2765V13.0158H63.3986V12.8936ZM63.3986 11.9895V11.8673H63.2765V11.9895H63.3986ZM68.4935 11.9895H68.6157V11.8673H68.4935V11.9895ZM68.4935 12.8936V13.0158H68.6157V12.8936H68.4935ZM66.392 12.8936V12.7715H66.2698V12.8936H66.392ZM72.0859 19.32H71.9638V19.4422H72.0859V19.32ZM72.0859 11.9893V11.8671H71.9638V11.9893H72.0859ZM73.0267 19.32V19.4422H73.1489V19.32H73.0267ZM73.0267 11.9893H73.1489V11.8671H73.0267V11.9893ZM76.2674 19.32H76.1453V19.4422H76.2674V19.32ZM77.2082 19.32V19.4422H77.3304V19.32H77.2082ZM76.2674 12.8934H76.3896V12.7712H76.2674V12.8934ZM74.2148 12.8934H74.0927V13.0156H74.2148V12.8934ZM74.2148 11.9893V11.8671H74.0927V11.9893H74.2148ZM79.2486 11.9893H79.3708V11.8671H79.2486V11.9893ZM79.2486 12.8934V13.0156H79.3708V12.8934H79.2486ZM77.2082 12.8934V12.7712H77.086V12.8934H77.2082ZM88.0901 17.7543L88.1764 17.841L88.1806 17.8364L88.0901 17.7543ZM84.1071 17.7543L84.0164 17.8365L84.0208 17.8409L84.1071 17.7543ZM88.0901 13.5514L88.1807 13.4692L88.1763 13.4648L88.0901 13.5514ZM84.1071 13.5514L84.0207 13.4647L84.0166 13.4693L84.1071 13.5514ZM91.1992 19.32H91.077V19.4422H91.1992V19.32ZM91.1992 11.9893V11.8671H91.077V11.9893H91.1992ZM92.1522 19.32V19.4422H92.2744V19.32H92.1522ZM92.1522 13.3454L92.2559 13.2808L92.03 12.9187V13.3454H92.1522ZM95.8787 19.32L95.775 19.3846L95.8109 19.4422H95.8787V19.32ZM96.8561 19.32V19.4422H96.9783V19.32H96.8561ZM96.8561 11.9893H96.9783V11.8671H96.8561V11.9893ZM95.9153 11.9893V11.8671H95.7931V11.9893H95.9153ZM95.9153 17.695L95.8117 17.7598L96.0375 18.1209V17.695H95.9153ZM92.3477 11.9893L92.4513 11.9245L92.4154 11.8671H92.3477V11.9893ZM83.498 18.2827C82.1011 16.8041 82.1011 14.4922 83.498 13.0136L83.3203 12.8458C81.8345 14.4186 81.8345 16.8777 83.3203 18.4505L83.498 18.2827ZM88.6989 18.28C87.2596 19.7112 84.9346 19.7112 83.4953 18.28L83.323 18.4532C84.8576 19.9793 87.3366 19.9793 88.8712 18.4532L88.6989 18.28ZM88.6965 13.0138C90.0992 14.4899 90.0992 16.8063 88.6965 18.2824L88.8736 18.4508C90.3659 16.8803 90.3659 14.4159 88.8736 12.8455L88.6965 13.0138ZM86.0971 11.9327C87.0738 11.9327 88.0102 12.3226 88.6983 13.0157L88.8717 12.8436C88.1377 12.1042 87.1389 11.6884 86.0971 11.6884V11.9327ZM83.4959 13.0157C84.184 12.3226 85.1203 11.9327 86.0971 11.9327V11.6884C85.0552 11.6884 84.0565 12.1042 83.3225 12.8436L83.4959 13.0157ZM56.668 15.9523C56.7084 16.8246 56.3895 17.6752 55.7855 18.3057L55.962 18.4748C56.6122 17.7959 56.9556 16.8801 56.9121 15.941L56.668 15.9523ZM56.6209 15.4185C56.6523 15.5928 56.668 15.7695 56.6679 15.9466L56.9123 15.9467C56.9123 15.7551 56.8953 15.5639 56.8615 15.3753L56.6209 15.4185ZM53.1858 15.5191H56.7412V15.2747H53.1858V15.5191ZM53.308 16.2766V15.3969H53.0636V16.2766H53.308ZM55.8371 16.1544H53.1858V16.3987H55.8371V16.1544ZM55.316 17.85C55.7118 17.421 55.9401 16.864 55.9592 16.2806L55.715 16.2726C55.6978 16.7973 55.4925 17.2984 55.1364 17.6843L55.316 17.85ZM52.0291 18.4526C53.1434 18.9346 54.4382 18.6988 55.3111 17.855L55.1413 17.6793C54.3393 18.4545 53.1498 18.6711 52.1261 18.2283L52.0291 18.4526ZM50.2169 15.6517C50.1998 16.8657 50.9148 17.9707 52.0291 18.4526L52.1261 18.2283C51.1023 17.7856 50.4455 16.7704 50.4612 15.6552L50.2169 15.6517ZM51.0505 13.4961C50.4902 14.0733 50.1892 14.8538 50.2169 15.6577L50.4611 15.6492C50.4357 14.9118 50.7118 14.1958 51.2258 13.6663L51.0505 13.4961ZM53.1864 12.599C52.382 12.595 51.6108 12.919 51.0505 13.4961L51.2258 13.6663C51.7398 13.1369 52.4473 12.8397 53.1852 12.8433L53.1864 12.599ZM55.2831 13.51C54.7639 12.8925 53.9846 12.5552 53.1791 12.5992L53.1925 12.8432C53.9213 12.8033 54.6263 13.1086 55.096 13.6673L55.2831 13.51ZM55.7507 12.8547L55.1031 13.5022L55.2759 13.675L55.9235 13.0275L55.7507 12.8547ZM54.6429 12.2358C55.0671 12.4069 55.4447 12.6761 55.7449 13.0213L55.9293 12.8609C55.6038 12.4866 55.1943 12.1947 54.7343 12.0092L54.6429 12.2358ZM53.1862 11.9392C53.6861 11.9376 54.181 12.0382 54.6405 12.2348L54.7367 12.0102C54.2465 11.8004 53.7186 11.6931 53.1854 11.6949L53.1862 11.9392ZM50.5729 13.0022C51.2586 12.3022 52.2035 11.9174 53.1831 11.9392L53.1885 11.6949C52.1414 11.6716 51.1313 12.0829 50.3984 12.8312L50.5729 13.0022ZM49.7699 17.0473C49.1991 15.6605 49.5154 14.0667 50.5723 13.0028L50.399 12.8305C49.2727 13.9642 48.9358 15.6626 49.5439 17.1403L49.7699 17.0473ZM53.1868 19.3555C51.6871 19.3437 50.3406 18.4342 49.7699 17.0473L49.5439 17.1403C50.1521 18.6181 51.5869 19.5873 53.1848 19.5998L53.1868 19.3555ZM55.7857 18.3055C55.109 19.0085 54.1652 19.3903 53.1902 19.3555L53.1815 19.5998C54.2259 19.6369 55.2369 19.228 55.9618 18.475L55.7857 18.3055ZM62.3863 12.7715H59.0874V13.0158H62.3863V12.7715ZM62.2641 11.9895V12.8936H62.5084V11.9895H62.2641ZM58.11 12.1117H62.3863V11.8673H58.11V12.1117ZM58.2322 19.3202V11.9895H57.9878V19.3202H58.2322ZM62.3863 19.1981H58.11V19.4424H62.3863V19.1981ZM62.2641 18.4161V19.3202H62.5084V18.4161H62.2641ZM59.0874 18.5383H62.3863V18.2939H59.0874V18.5383ZM58.9652 16.0947V18.4161H59.2096V16.0947H58.9652ZM62.093 15.9725H59.0874V16.2169H62.093V15.9725ZM61.9708 15.215V16.0947H62.2152V15.215H61.9708ZM59.0874 15.3372H62.093V15.0929H59.0874V15.3372ZM58.9652 12.8936V15.215H59.2096V12.8936H58.9652ZM65.4512 19.4424H66.392V19.1981H65.4512V19.4424ZM65.3291 12.8936V19.3202H65.5734V12.8936H65.3291ZM63.3986 13.0158H65.4512V12.7715H63.3986V13.0158ZM63.2765 11.9895V12.8936H63.5208V11.9895H63.2765ZM68.4935 11.8673H63.3986V12.1117H68.4935V11.8673ZM68.6157 12.8936V11.9895H68.3713V12.8936H68.6157ZM66.392 13.0158H68.4935V12.7715H66.392V13.0158ZM66.5142 19.3202V12.8936H66.2698V19.3202H66.5142ZM72.2081 19.32V11.9893H71.9638V19.32H72.2081ZM73.0267 19.1978H72.0859V19.4422H73.0267V19.1978ZM72.9045 11.9893V19.32H73.1489V11.9893H72.9045ZM72.0859 12.1114H73.0267V11.8671H72.0859V12.1114ZM76.2674 19.4422H77.2082V19.1978H76.2674V19.4422ZM76.1453 12.8934V19.32H76.3896V12.8934H76.1453ZM74.2148 13.0156H76.2674V12.7712H74.2148V13.0156ZM74.0927 11.9893V12.8934H74.337V11.9893H74.0927ZM79.2486 11.8671H74.2148V12.1114H79.2486V11.8671ZM79.3708 12.8934V11.9893H79.1264V12.8934H79.3708ZM77.2082 13.0156H79.2486V12.7712H77.2082V13.0156ZM77.3304 19.32V12.8934H77.086V19.32H77.3304ZM88.0039 17.6677C86.9503 18.7169 85.2468 18.7169 84.1933 17.6677L84.0208 17.8409C85.1697 18.985 87.0274 18.985 88.1763 17.8409L88.0039 17.6677ZM87.9996 13.6335C89.0389 14.7791 89.0389 16.5265 87.9996 17.6722L88.1806 17.8364C89.3043 16.5976 89.3043 14.7081 88.1806 13.4693L87.9996 13.6335ZM84.1933 13.6379C85.2468 12.5888 86.9503 12.5888 88.0039 13.6379L88.1763 13.4648C87.0274 12.3207 85.1697 12.3207 84.0208 13.4648L84.1933 13.6379ZM84.1976 17.6722C83.1583 16.5265 83.1583 14.7791 84.1976 13.6335L84.0166 13.4693C82.8928 14.7081 82.8928 16.5976 84.0166 17.8364L84.1976 17.6722ZM91.3214 19.32V11.9893H91.077V19.32H91.3214ZM92.1522 19.1978H91.1992V19.4422H92.1522V19.1978ZM92.03 13.3454V19.32H92.2744V13.3454H92.03ZM95.9823 19.2553L92.2559 13.2808L92.0485 13.4101L95.775 19.3846L95.9823 19.2553ZM96.8561 19.1978H95.8787V19.4422H96.8561V19.1978ZM96.7339 11.9893V19.32H96.9783V11.9893H96.7339ZM95.9153 12.1114H96.8561V11.8671H95.9153V12.1114ZM96.0375 17.695V11.9893H95.7931V17.695H96.0375ZM92.2441 12.054L95.8117 17.7598L96.0189 17.6302L92.4513 11.9245L92.2441 12.054ZM91.1992 12.1114H92.3477V11.8671H91.1992V12.1114Z" fill="black"></path><path d="M11.6055 12.648C11.2072 13.1259 11.0062 13.7376 11.0434 14.3585V41.3844C11.0062 42.0054 11.2072 42.6171 11.6055 43.0949L11.691 43.1805L26.8289 28.0548V27.7004L11.691 12.5625L11.6055 12.648Z" fill="url(#GooglePlayIcon_paint0_linear)"></path><path d="M31.8374 33.1011L26.8281 28.0551V27.7008L31.8374 22.6426L31.9474 22.7037L37.9464 26.1125C39.6569 27.0777 39.6569 28.666 37.9464 29.6434L31.9718 33.04L31.8374 33.1011Z" fill="url(#GooglePlayIcon_paint1_linear)"></path><path d="M31.9849 33.027L26.8289 27.8711L11.6055 43.0946C12.3248 43.7269 13.3922 43.7576 14.1468 43.1679L31.9971 33.027" fill="url(#GooglePlayIcon_paint2_linear)"></path><path d="M31.9854 22.7156L14.1351 12.5748C13.3805 11.985 12.313 12.0158 11.5938 12.6481L26.8294 27.8716L31.9854 22.7156Z" fill="url(#GooglePlayIcon_paint3_linear)"></path><path opacity="0.2" d="M31.8382 32.9189L14.1346 42.9987C13.4101 43.5403 12.4155 43.5403 11.691 42.9987L11.6055 43.0842L11.691 43.1697C12.4141 43.7155 13.4115 43.7155 14.1346 43.1697L31.9849 33.0289L31.8382 32.9189Z" fill="black"></path><path opacity="0.12" fill-rule="evenodd" clip-rule="evenodd" d="M31.8357 32.9171L37.9446 29.4594C38.5759 29.1478 39.0271 28.5612 39.1664 27.8711C39.1034 28.634 38.6374 29.305 37.9446 29.6305L31.9456 33.027L31.8357 32.9171ZM11.0408 41.4502C11.061 41.9878 11.2582 42.5062 11.6055 42.9229L11.691 43.0206L11.6055 43.1062C11.2189 42.6423 11.0182 42.0523 11.0408 41.4502ZM11.0408 41.4502C11.0415 41.432 11.0423 41.4138 11.0434 41.3956V41.2124C11.0387 41.2919 11.0378 41.3713 11.0408 41.4502Z" fill="black"></path><path opacity="0.25" d="M14.1346 12.747L37.9472 26.2844C38.5785 26.596 39.0297 27.1826 39.169 27.8727C39.106 27.1099 38.64 26.4388 37.9472 26.1134L14.1346 12.576C12.4241 11.6108 11.0312 12.4171 11.0312 14.372V14.5553C11.0679 12.5882 12.4363 11.7818 14.1346 12.747Z" fill="white"></path><defs><linearGradient id="GooglePlayIcon_paint0_linear" x1="20.1986" y1="-5.79969" x2="-4.04097" y2="0.646869" gradientUnits="userSpaceOnUse"><stop stop-color="#00A0FF"></stop><stop offset="0.01" stop-color="#00A1FF"></stop><stop offset="0.26" stop-color="#00BEFF"></stop><stop offset="0.51" stop-color="#00D2FF"></stop><stop offset="0.76" stop-color="#00DFFF"></stop><stop offset="1" stop-color="#00E3FF"></stop></linearGradient><linearGradient id="GooglePlayIcon_paint1_linear" x1="40.1822" y1="15.4092" x2="10.6272" y2="15.4092" gradientUnits="userSpaceOnUse"><stop stop-color="#FFE000"></stop><stop offset="0.41" stop-color="#FFBD00"></stop><stop offset="0.78" stop-color="#FFA500"></stop><stop offset="1" stop-color="#FF9C00"></stop></linearGradient><linearGradient id="GooglePlayIcon_paint2_linear" x1="11.1582" y1="19.9631" x2="-8.31277" y2="52.715" gradientUnits="userSpaceOnUse"><stop stop-color="#FF3A44"></stop><stop offset="1" stop-color="#C31162"></stop></linearGradient><linearGradient id="GooglePlayIcon_paint3_linear" x1="-0.281989" y1="8.44029" x2="8.40892" y2="23.0656" gradientUnits="userSpaceOnUse"><stop stop-color="#32A071"></stop><stop offset="0.07" stop-color="#2DA771"></stop><stop offset="0.48" stop-color="#15CF74"></stop><stop offset="0.8" stop-color="#06E775"></stop><stop offset="1" stop-color="#00F076"></stop></linearGradient></defs></svg></a></li></ul></div><div><svg width="126" height="24" viewBox="0 0 126 24" fill="none" style="height:38px;margin-bottom:30px;object-position:top left;width:200px"><path d="M83.5876 18.5712C83.9239 18.5731 84.2531 18.4756 84.5338 18.2908C84.8145 18.1061 85.034 17.8424 85.1646 17.5332C85.2952 17.224 85.331 16.8831 85.2676 16.5536C85.2041 16.2241 85.0442 15.9207 84.808 15.6819C84.5719 15.4431 84.2701 15.2794 83.9407 15.2117C83.6114 15.144 83.2694 15.1752 82.9579 15.3014C82.6463 15.4276 82.3793 15.6432 82.1904 15.9208C82.0016 16.1984 81.8995 16.5257 81.8969 16.8612C81.8952 17.0843 81.9377 17.3056 82.0218 17.5123C82.1058 17.7191 82.23 17.9073 82.387 18.0661C82.544 18.2249 82.7309 18.3512 82.9369 18.4379C83.1429 18.5246 83.3641 18.5699 83.5876 18.5712Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M92.2184 18.6362C94.2124 18.6362 96.0122 17.6193 97.0964 15.758L95.3404 14.6761C95.0469 15.246 94.5992 15.7225 94.0481 16.0515C93.497 16.3805 92.8646 16.5488 92.2226 16.5373C90.4228 16.5373 88.9262 15.3465 88.9262 12.9874C88.9262 10.5434 90.5305 9.39635 92.2878 9.39635C93.4797 9.39635 94.4986 9.96209 95.3447 10.9762L96.9036 9.63396C95.9286 8.3356 94.2109 7.29748 92.2864 7.29748C89.5101 7.29748 86.7593 9.39635 86.7593 12.9874C86.7537 16.5373 89.4421 18.6362 92.2184 18.6362Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M112.795 9.15309L113.403 9.28321V7.36112H111.299V18.3109H113.533V11.5575C113.533 10.2365 114.356 9.28462 115.571 9.28462C116.763 9.28462 117.609 10.2365 117.609 11.5575V18.3081H119.756V11.5575C119.756 10.2365 120.606 9.28462 121.75 9.28462C122.894 9.28462 123.68 10.1502 123.68 11.5575V18.3081H126V11.4302C126 8.8985 124.441 7.18716 122.293 7.18716C120.926 7.18716 119.821 7.85755 119.033 8.93952C118.448 7.85755 117.364 7.18716 116.019 7.18716C115.351 7.18154 114.695 7.36273 114.125 7.7102C113.555 8.05767 113.094 8.55753 112.795 9.15309Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M103.559 7.18857C100.328 7.18857 97.856 9.5689 97.856 12.8799C97.856 16.1908 100.328 18.5712 103.559 18.5712C106.875 18.5712 109.152 16.1668 109.152 12.8799C109.152 9.59294 106.875 7.18857 103.559 7.18857ZM103.623 16.4723C101.585 16.4723 100.024 14.9165 100.024 12.8148C100.024 10.7131 101.583 9.28745 103.623 9.28745C105.531 9.28745 106.984 10.7159 106.984 12.8148C106.984 14.9137 105.531 16.4723 103.623 16.4723Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M74.828 18.5712C75.8186 18.5553 76.7879 18.2814 77.6398 17.7765C78.4917 17.2717 79.1966 16.5534 79.6847 15.693L78.0223 14.611C77.7188 15.1879 77.2592 15.6681 76.6958 15.9972C76.1323 16.3262 75.4876 16.4908 74.835 16.4723C73.1443 16.4723 71.6038 15.2163 71.6038 12.8799C71.6038 10.4133 73.1443 9.28745 74.835 9.28745C76.0935 9.28745 77.1125 9.80651 78.0223 10.8885L79.4976 9.5689C78.9838 8.8385 78.3025 8.24133 77.5103 7.82725C76.7182 7.41317 75.8384 7.19418 74.9442 7.18857C72.1254 7.18857 69.3491 9.28744 69.3491 12.8799C69.3491 16.4723 72.0531 18.5712 74.828 18.5712Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M66.1987 5.43622C66.5357 5.43789 66.8657 5.33957 67.1467 5.15372C67.4276 4.96788 67.6469 4.7029 67.7767 4.39243C67.9065 4.08197 67.9409 3.74001 67.8755 3.41C67.8102 3.07998 67.648 2.77679 67.4097 2.53892C67.1713 2.30106 66.8675 2.13924 66.5368 2.07403C66.2062 2.00881 65.8635 2.04313 65.5524 2.17264C65.2413 2.30215 64.9758 2.521 64.7896 2.8014C64.6034 3.0818 64.5048 3.4111 64.5065 3.7475C64.5037 3.97005 64.5455 4.19093 64.6295 4.3971C64.7135 4.60327 64.8381 4.79057 64.9958 4.94795C65.1535 5.10534 65.3412 5.22962 65.5477 5.31348C65.7543 5.39733 65.9757 5.43907 66.1987 5.43622Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M67.2389 7.53508H65.0918V18.3109H67.2389V7.53508Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M62.2291 1.865H59.8879V18.3109H62.2291V1.865Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M52.5596 7.18857C50.934 7.18857 49.7408 7.85897 49.069 8.94094V1.86925H46.6839V18.3109H49.069V16.9475C49.7408 17.9644 50.934 18.5712 52.5596 18.5712C55.6774 18.5712 57.85 16.1668 57.85 12.8799C57.85 9.76408 55.5513 7.18857 52.5596 7.18857ZM52.3711 16.3662C50.2254 16.3662 48.7728 14.9165 48.7728 12.8827C48.7728 10.8913 50.2254 9.39918 52.3711 9.39918C54.3013 9.39918 55.6887 10.7838 55.6887 12.8827C55.6816 14.9137 54.2942 16.3662 52.3711 16.3662Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M38.878 18.4623C40.0273 18.4623 40.9811 17.9644 41.6968 16.9475V18.3109H43.9303V7.53508H41.6316V13.7667C41.6316 15.3465 40.6778 16.3634 39.1161 16.3634C37.7938 16.3634 37.0781 15.2164 37.0781 13.7667V7.53508H34.7355V14.1344C34.7355 16.6491 36.2973 18.4623 38.878 18.4623Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M27.6028 7.18857C26.0438 7.18857 24.8491 7.85897 23.8727 8.94094V7.53508H21.5967V22.165H23.8727V16.9475C24.8491 17.9644 26.041 18.5712 27.6028 18.5712C30.7036 18.5712 32.9371 15.9957 32.9371 12.8799C32.9371 9.5689 30.7036 7.18857 27.6028 7.18857ZM27.2995 16.3662C25.0872 16.3662 23.765 14.9165 23.765 12.8827C23.765 10.8913 25.0872 9.39918 27.2995 9.39918C29.4026 9.39918 30.7007 10.8913 30.7007 12.8827C30.7036 14.9137 29.4026 16.3662 27.2995 16.3662Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M7.19935 14.396C11.1754 14.396 14.3987 11.1734 14.3987 7.19802C14.3987 3.22266 11.1754 0 7.19935 0C3.22326 0 0 3.22266 0 7.19802C0 11.1734 3.22326 14.396 7.19935 14.396Z" fill="var(--pw-core-color-blue-600-day)"></path><path d="M3.59968 24C4.31066 24 5.00571 23.7895 5.59717 23.395C6.18863 23.0005 6.65002 22.4398 6.92312 21.7835C7.19622 21.1271 7.26882 20.4047 7.13176 19.7072C6.99469 19.0096 6.6541 18.3683 6.15294 17.8641C5.65178 17.3599 5.0125 17.0153 4.31573 16.8739C3.61897 16.7325 2.89592 16.8005 2.23778 17.0695C1.57964 17.3384 1.0159 17.7962 0.617646 18.385C0.219396 18.9739 0.00447861 19.6675 0 20.3783C0.000352998 21.3348 0.378999 22.2524 1.05334 22.9308C1.72769 23.6093 2.64302 23.9936 3.59968 24Z" fill="var(--pw-core-color-blue-600-day)"></path></svg><div class="page-footer_public__krJ86"><div style="margin-bottom:12px">Check the background of this firm on<!-- --> <a href="https://brokercheck.finra.org/" target="_blank" rel="noopener noreferrer nofollow">FINRA’s BrokerCheck</a>.</div><div style="display:block;font-size:12px"><a rel="noopener noreferrer nofollow" href="https://files.brokercheck.finra.org/crs_127818.pdf">Open to the Public Investing, Inc. Customer Relationship Summary</a></div></div></div></div></div><div class="page-footer_bottomContainer__EfadX" style="padding-bottom:0px"><div class="page-footer_subNavWrapper__8L4JP"><div class="page-footer_footerContainer__p7Hox"><ul class="page-footer_subNav__Ivgmr"><li><a href="../disclosures.html">Disclosures</a></li><li><a href="../privacy-policy.html">Privacy Policy</a></li><li><a href="../terms-of-service.html">Terms of Service</a></li><li><a href="../wp-content/uploads/2021/10/Fractional-Shares-Disclosure.pdf">Fractional Shares Disclosure</a></li><li><a href="../markets/top-gainers.html">Markets</a></li><li><a href="../directory/stocks.html">Stocks Directory</a></li><li><a href="../directory/etfs.html">ETFs Directory</a></li><li><a href="../directory/stocks-options-chain.html">Options Chain</a></li><li><a href="../directory/otc-stocks.html">OTC Stocks</a></li><li><a href="../how-to-buy/crypto.html">How to buy Crypto</a></li><li><a href="../treasuries/6-month-tbills.html">Buy T-bills</a></li></ul></div></div><div class="page-footer_footerContainer__p7Hox"><div class="page-footer-copyright_copyright__t2fcx"><p>© Copyright <!-- -->2025<!-- --> Public Holdings, Inc. All Rights Reserved.</p><p>Market data powered by<!-- --> <a href="https://xignite.com/" target="_blank" rel="noopener noreferrer nofollow">Xignite</a>.</p><p><b>All investments</b> involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns. You should consult your legal, tax, or financial advisors before making any financial decisions. This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, open a brokerage account, or engage in any investment strategy.</p><p><b>Stocks, ETFs, Options, Bonds.</b><br/>Self-directed brokerage accounts and brokerage services for US-listed, registered securities, options, and Bonds, except for treasury securities offered through Jiko Securities, Inc., are offered to self-directed customers by Open to the Public Investing, Inc. (“Public Investing”), a registered broker-dealer and member of<!-- --> <a href="https://www.finra.org" target="_blank" rel="noopener noreferrer nofollow">FINRA</a> <!-- -->&amp;<!-- --> <a href="https://www.sipc.org" target="_blank" rel="noopener noreferrer nofollow">SIPC</a>. Additional information about your broker can be found by clicking<!-- --> <a href="https://brokercheck.finra.org/" target="_blank" rel="noopener noreferrer nofollow">here</a>. Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”). This is not an offer, solicitation of an offer, or advice to buy or sell securities or open a brokerage account in any jurisdiction where Public Investing is not registered. Securities products offered by Public Investing are not FDIC insured. Apex Clearing Corporation, our clearing firm, has additional insurance coverage in excess of the regular<!-- --> <a href="https://www.sipc.org" target="_blank" rel="noopener noreferrer nofollow">SIPC</a> <!-- -->limits. Additional information can be found<!-- --> <a href="https://help.public.com/en/articles/6594797-frequently-asked-questions-sipc" target="_blank" rel="noopener noreferrer nofollow">here</a>.</p><p><b>Options.</b><br/>Certain requirements must be met in order to trade options. Options can be risky and are not suitable for all investors. Options transactions are often complex, and investors can rapidly lose the entire amount of their investment or more in a short period of time. Investors should consider their investment objectives and risks carefully before investing in options. Refer to the<!-- --> <a href="https://www.theocc.com/company-information/documents-and-archives/options-disclosure-document" rel="noopener noreferrer nofollow" target="_blank">Characteristics and Risks of Standardized Options</a> <!-- -->before considering any options transaction. Supporting documentation for any claims, if applicable, will be furnished upon request. Tax considerations with options transactions are unique and investors considering options should consult their tax advisor as to how taxes affect the outcome of each options strategy.</p><p><b>Options Order Flow Rebates.</b><br/>If you are enrolled in our Options Order Flow Rebate Program, Public Investing will share a percentage of our estimated order flow revenue for each completed options trade as a rebate to help reduce your trading costs. Rebate rates vary monthly from $0.06-$0.18 and depend on your current and prior month’s options trading volume. This rebate will be deducted from your cost to place the trade and will be reflected on your trade confirmation. To learn more, see our<!-- --> <a href="../disclosures/Options-Order-Flow-Rebate-Program-TCs-06.03.2025.pdf" rel="noopener noreferrer nofollow" target="_blank">Options Rebate Program Terms &amp; Conditions</a>,<!-- --> <a href="https://help.public.com/en/articles/8609726-what-are-order-flow-rebates" rel="noopener noreferrer nofollow" target="_blank">Order Rebate FAQ</a> <!-- -->and<!-- --> <a href="../disclosures/Public-Fee-Schedule-07.01.2025.pdf" rel="noopener noreferrer nofollow" target="_blank">Fee Schedule</a>.</p><p><b>Bonds.</b><br/>“Bonds” shall refer to corporate debt securities and U.S. government securities offered on the Public platform through a self-directed brokerage account held at Public Investing and custodied at Apex Clearing. For purposes of this section, Bonds exclude treasury securities held in treasury accounts with Jiko Securities, Inc. as explained under the “ Treasury Accounts” section.<br/><br/>Investments in Bonds are subject to various risks including risks related to interest rates, credit quality, market valuations, liquidity, prepayments, early redemption, corporate events, tax ramifications and other factors. The value of Bonds fluctuate and any investments sold prior to maturity may result in gain or loss of principal. In general, when interest rates go up, Bond prices typically drop, and vice versa. Bonds with higher yields or offered by issuers with lower credit ratings generally carry a higher degree of risk. All fixed income securities are subject to price change and availability, and yield is subject to change. Bond ratings, if provided, are third party opinions on the overall bond&#x27;s credit worthiness at the time the rating is assigned. Ratings are not recommendations to purchase, hold, or sell securities, and they do not address the market value of securities or their suitability for investment purposes.<br/><br/><em>A Bond Account is a self-directed brokerage account with Public Investing. Deposits into this account are used to purchase 10 investment-grade and high-yield bonds. The Bond Account’s yield is the average, annualized yield to worst (YTW) across all ten bonds in the Bond Account, before fees. A bond’s yield is a function of its market price, which can fluctuate; therefore a bond’s YTW is not “locked in” until the bond is purchased, and your yield at time of purchase may be different from the yield shown here. The “locked in” YTW is not guaranteed; you may receive less than the YTW of the bonds in the Bond Account if you sell any of the bonds before maturity or if the issuer defaults on the bond. Public Investing charges a markup on each bond trade. See our<!-- --> <a href="../disclosures/Public-Fee-Schedule-07.01.2025.pdf" rel="noopener noreferrer nofollow" target="_blank">Fee Schedule</a></em>. <br/><br/><em>Bond Accounts are not recommendations of individual bonds or default allocations. The bonds in the Bond Account have not been selected based on your needs or risk profile. You should evaluate each bond before investing in a Bond Account. The bonds in your Bond Account will not be rebalanced and allocations will not be updated, except for Corporate Actions.</em><br/><br/>Fractional Bonds also carry additional risks including that they are only available on Public and cannot be transferred to other brokerages. Read more about the risks associated with<!-- --> <a href="../disclosures/Open-to-the-Public-Investing-Inc.-Fixed-Income-Disclosure.pdf" rel="noopener noreferrer nofollow" target="_blank">fixed income</a> <!-- -->and<!-- --> <a href="../disclosures/OTTP-Apex-Fractional-Bond-Disclosure-1.pdf" rel="noopener noreferrer nofollow" target="_blank">fractional bonds</a>. See<!-- --> <a href="../disclosures/Bond-Account-Disclosure-1.pdf" rel="noopener noreferrer nofollow" target="_blank">Bond Account Disclosures</a> <!-- -->to learn more.<br/><br/><b id="disclosures-hyca">High-Yield Cash Account.</b><br/>A High-Yield Cash Account is a secondary brokerage account with Public Investing. Funds in your High-Yield Cash Account are automatically deposited into partner banks (“Partner Banks”), where that cash earns interest and is eligible for FDIC insurance. See<!-- --> <a href="../disclosures/APEX-High-Yield-Cash-Account-Bank-Partners-List-01.06.2025.pdf" rel="noopener noreferrer nofollow" target="_blank">here</a> <!-- -->for a list of current Partner Banks. Your Annual Percentage Yield is variable and may change at the discretion of the Partner Banks or Public Investing. Apex Clearing and Public Investing receive administrative fees for operating this program, which reduce the amount of interest paid on swept cash. Neither Public Investing nor any of its affiliates is a bank.<!-- --> <a href="../disclosures/HIGH-YIELD-CASH-ACCOUNT-TERMS-AND-CONDITIONS-Effective-October-3-2024.pdf" rel="noopener noreferrer nofollow" target="_blank">Learn more</a>.</p><p><b>Cryptocurrency.</b><br/>Cryptocurrency trading, execution, and custody services are provided by Bakkt Crypto Solutions, LLC (NMLS ID 1828849) (“Bakkt”). Cryptocurrency is highly speculative, involves a high degree of risk, and has the potential for loss of the entire amount of an investment. Cryptocurrencies offered by Bakkt are not securities and are not FDIC insured or protected by<!-- --> <a href="https://www.sipc.org" target="_blank" rel="noopener noreferrer nofollow">SIPC</a>. Your cryptocurrency assets are held in your Bakkt account. Bakkt is a licensed virtual currency business by the New York State Department of Financial Services and a licensed money transmitter, but is not a registered broker-dealer or a<!-- --> <a href="https://www.finra.org" target="_blank" rel="noopener noreferrer nofollow">FINRA</a> <!-- -->member. Your Bakkt Crypto account is separate from your brokerage account with Public Investing, which holds US-listed stocks and ETFs. Please review the<!-- --> <a href="https://public.com/disclosures/bakkt-crypto-risk-disclosure" target="_blank" rel="noopener noreferrer nofollow">Risk Disclosures</a> <!-- -->before trading.</p><p><b>Treasury Accounts.</b><br/>Investing services in treasury accounts offering 6 month US Treasury Bills on the Public platform are through Jiko Securities, Inc. (“JSI”), a registered broker-dealer and member of<!-- --> <a href="https://www.finra.org" target="_blank" rel="noopener noreferrer nofollow">FINRA</a> <!-- -->&amp;<!-- --> <a href="https://www.sipc.org" target="_blank" rel="noopener noreferrer nofollow">SIPC</a>. See JSI’s<!-- --> <a href="https://brokercheck.finra.org/firm/summary/287507" target="_blank" rel="noopener noreferrer nofollow">FINRA BrokerCheck</a> <!-- -->and<!-- --> <a href="https://jiko.io/docs/JikoSecuritiesFormCRS.pdf" target="_blank" rel="noopener noreferrer nofollow">Form CRS</a> <!-- -->for further information. JSI uses funds from your Treasury Account to purchase T-bills in increments of $100 “par value” (the T-bill’s value at maturity). T-bills are purchased at a discount to the par value and the T-bill’s yield represents the difference in price between the “par value” and the “discount price.” Aggregate funds in your Treasury Account in excess of the T-bill purchases will remain in your Treasury Account as cash. The value of T-bills fluctuate and investors may receive more or less than their original investments if sold prior to maturity. T-bills are subject to price change and availability - yield is subject to change. Past performance is not indicative of future performance. Investments in T-bills involve a variety of risks, including credit risk, interest rate risk, and liquidity risk. As a general rule, the price of a T-bills moves inversely to changes in interest rates. Although T-bills are considered safer than many other financial instruments, you could lose all or a part of your investment. See<!-- --> <a href="../disclosures/treasuries_risk_disclosure.pdf" target="_blank" rel="noopener noreferrer nofollow">Jiko U.S. Treasuries Risk Disclosures</a> <!-- -->for further details.<br/><br/><b>Investments in T-bills: Not FDIC Insured; No Bank Guarantee; May Lose Value.</b><br/><br/>Banking services and bank accounts are offered by Jiko Bank, a division of Mid-Central National Bank. JSI and Jiko Bank are not affiliated with Public Holdings, Inc. (“Public”) or any of its subsidiaries. None of these entities provide legal, tax, or accounting advice. You should consult your legal, tax, or financial advisors before making any financial decisions. This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, open a brokerage account, or engage in any investment strategy.<br/><br/><b>Commission-free</b> trading refers to $0 commissions charged on trades of US listed registered securities placed during the US Markets Regular Trading Hours in self-directed brokerage accounts offered by Public Investing. Keep in mind that other fees such as regulatory fees, Premium subscription fees, commissions on trades during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see<!-- --> <a href="../disclosures/Public-Fee-Schedule-07.01.2025.pdf" rel="noopener noreferrer nofollow" target="_blank">Public’s Investing’s Fee Schedule</a> <!-- -->to learn more.<br/><br/><b>Fractional shares</b> are illiquid outside of Public and not transferable. For a complete explanation of conditions, restrictions and limitations associated with fractional shares, see our<!-- --> <a href="https://public.com//disclosures/public-fractional-shares-disclosure" rel="noopener noreferrer nofollow" target="_blank">Fractional Share Disclosure</a> <!-- -->to learn more.</p><p><b>Investment Plans.</b> Investment Plans (“Plans”) shown in our marketplace are for informational purposes only and are meant as helpful starting points as you discover, research and create a Plan that meets your specific investing needs. Plans are self-directed purchases of individually-selected assets, which may include stocks, ETFs and cryptocurrency. Plans are not recommendations of a Plan overall or its individual holdings or default allocations. Plans are created using defined, objective criteria based on generally accepted investment theory; they are not based on your needs or risk profile. You are responsible for establishing and maintaining allocations among assets within your Plan. Plans involve continuous investments, regardless of market conditions. Diversification does not eliminate risk. See our<!-- --> <a href="../disclosures/investment-plans.html" target="_blank" rel="noopener noreferrer nofollow">Investment Plans Terms and Conditions</a> <!-- -->and<!-- --> <a href="../disclosures/sponsored-content-disclosure.html" target="_blank" rel="noopener noreferrer nofollow">Sponsored Content and Conflicts of Interest Disclosure</a>.</p><p><b>Alpha.</b><br/>Alpha is an experiment brought to you by Public Holdings, Inc. (“Public”). Alpha is an AI research tool powered by GPT-4, a generative large language model. Alpha is experimental technology and may give inaccurate or inappropriate responses. Output from Alpha should not be construed as investment research or recommendations, and should not serve as the basis for any investment decision. All Alpha output is provided “as is.” Public makes no representations or warranties with respect to the accuracy, completeness, quality, timeliness, or any other characteristic of such output. Your use of Alpha output is at your sole risk. Please independently evaluate and verify the accuracy of any such output for your own use case.</p><p><b>Market Data.</b><br/>Quotes and other market data for Public’s product offerings are obtained from third party sources believed to be reliable, but Public makes no representation or warranty regarding the quality, accuracy, timeliness, and/or completeness of this information. Such information is time sensitive and subject to change based on market conditions and other factors. You assume full responsibility for any trading decisions you make based upon the market data provided, and Public is not liable for any loss caused directly or indirectly by your use of such information. Market data is provided solely for informational and/or educational purposes only. It is not intended as a recommendation and does not represent a solicitation or an offer to buy or sell any particular security.</p><div class="page-footer-copyright_disclosures__VYLbz"><a href="../disclosures.html" target="_blank" rel="nofollow">View Full Disclosures</a></div></div></div></div></footer><section class="Toastify" aria-live="polite" aria-atomic="false" aria-relevant="additions text" aria-label="Notifications Alt+T"></section></div><div id="drawer-root"></div><script id="__NEXT_DATA__" type="application/json">{"props":{"pageProps":{"theme":{"themeId":"2a206e44-2387-4810-807d-8d10034a186a","name":"Genetic Engineering","description":"The companies on the forefront of biotechnology and genetic engineering.","detailedDescription":"Biotechnology refers to the application of technology to living organisms to create new products. In the medical field, this could include creating new vaccines and antibiotics. Biotech also has ties to agricultural innovation through the development of insect-resistant crops, and to food via nutrient-enhanced products. Industrial biotech is responsible for the creation of new consumer goods, like plastics and materials. Companies in this theme include Amgen, Eli Lilly, GlaxoSmithKline, and Vertex Pharmaceuticals.","imageUrl":"https://prod-api.154310543964.hellopublic.com/static/themes/images/kWMrmJmBx5mZN9TnbZEO5eSl5IR1Ovzl.jpg","followersCount":1054,"shareUrl":"https://public.com/themes/genetic-engineering","assetCount":21,"following":false},"themeDetails":{"theme":{"themeId":"2a206e44-2387-4810-807d-8d10034a186a","name":"Genetic Engineering","description":"The companies on the forefront of biotechnology and genetic engineering.","detailedDescription":"Biotechnology refers to the application of technology to living organisms to create new products. In the medical field, this could include creating new vaccines and antibiotics. Biotech also has ties to agricultural innovation through the development of insect-resistant crops, and to food via nutrient-enhanced products. Industrial biotech is responsible for the creation of new consumer goods, like plastics and materials. Companies in this theme include Amgen, Eli Lilly, GlaxoSmithKline, and Vertex Pharmaceuticals.","imageUrl":"https://prod-api.154310543964.hellopublic.com/static/themes/images/kWMrmJmBx5mZN9TnbZEO5eSl5IR1Ovzl.jpg","followersCount":1054,"shareUrl":"https://public.com/themes/genetic-engineering","assetCount":21,"following":false},"entities":[{"instrument":{"symbol":"A","name":"Agilent Technologies","displayName":"Agilent Technologies","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"VRTX","name":"Vertex Pharmaceuticals","displayName":"Vertex Pharmaceuticals","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"ALNY","name":"Alnylam Pharmaceuticals","displayName":"Alnylam Pharmaceuticals","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"BIO","name":"Bio-Rad Laboratories","displayName":"Bio-Rad Laboratories","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"EDIT","name":"Editas Medicine","displayName":"Editas Medicine","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"WAT","name":"Waters","displayName":"Waters","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"AMGN","name":"Amgen","displayName":"Amgen","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"CLLS","name":"Cellectis SA","displayName":"Cellectis SA","availableForFractional":false,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"SELL_ALL_ONLY","instrumentClass":"DEPOSITORY_RECEIPT","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"IQV","name":"IQVIA Hlds","displayName":"IQVIA Hlds","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"DHR","name":"Danaher","displayName":"Danaher","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"CRSP","name":"CRISPR Therapeutics","displayName":"CRISPR Therapeutics","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"DGX","name":"Quest Diagnostics","displayName":"Quest Diagnostics","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"TMO","name":"Thermo Fisher Scientific","displayName":"Thermo Fisher Scientific","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[{"id":"8a5ae0b7-82f6-43db-aa1d-ae7ba3b6e245","name":"Life Technologies","description":"Life Technologies was a biotech company founded in November 2008 through a US$6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees, and owned more than 3,600 licenses and patents.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/7DV38FkIQcuO-acrTnksxA-thumbnail-300x300.png"}]},{"instrument":{"symbol":"LLY","name":"Eli Lilly","displayName":"Eli Lilly","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[{"id":"ec3556ba-e79c-48e8-9ed1-e77000e792af","name":"Cialis","description":"Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/NE3e8MaGRpWGaIVfh2dyOA-thumbnail-300x300.png"},{"id":"f0b9c23d-1faf-48ed-b14b-278aaf2be224","name":"Cymbalta","description":"Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/W4Hje2KxTJSKQx2cWRmXCw-thumbnail-300x300.png"},{"id":"8bfcfab4-31f4-48ce-9850-ae6cf2e67793","name":"Gemzar","description":"Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/sdJ66TnJSuSW_ZR8LtCOPA-thumbnail-300x300.png"},{"id":"ef47a1fc-917d-485e-92c7-29179d2d2b2a","name":"Methadone","description":"Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/hNwNMQUTReeWrrzWD4Gw6Q-thumbnail-300x300.png"},{"id":"e7579738-4aea-491d-8933-ab78dd6af1d4","name":"Prozac","description":"Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/xMWfDQuxRLqCugqvTgLeGQ-thumbnail-300x300.png"}]},{"instrument":{"symbol":"IDXX","name":"IDEXX Laboratories","displayName":"IDEXX Laboratories","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"GILD","name":"Gilead Sciences","displayName":"Gilead Sciences","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"REGN","name":"Regeneron Pharmaceuticals","displayName":"Regeneron Pharmaceuticals","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"CRL","name":"Charles River Laboratories","displayName":"Charles River Laboratories","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"LH","name":"Labcorp Holdings Inc","displayName":"Labcorp Holdings Inc","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":"2024-05-20","untradableReason":null,"newSymbol":"","newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"GSK","name":"GlaxoSmithKline","displayName":"GlaxoSmithKline","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"DEPOSITORY_RECEIPT","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"BIIB","name":"Biogen","displayName":"Biogen","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]}]},"universalThemesSeo":{"404866be-d726-4025-8d80-eb93f8737ca7":{"title":"Invest in companies that help you stay at home","description":"Invest in companies that help you stay at home, socially distant stocks \u0026 ETFs. #StayHome  Public offers commission-free trading and much more."},"ff0bb2e1-d3fc-499f-885a-fed54faaca08":{"title":"Invest in diverse \u0026 inclusive companies","description":"Invest in diverse \u0026 inclusivity-focused companies.  Public offers commission-free trading and much more."},"6b636830-4b33-4463-9374-530df175099a":{"title":"Invest in online sports \u0026 e-gaming companies","description":"Invest in online sports \u0026 e-gaming companies leading the charge in e-sports.  Public offers commission-free trading and much more."},"ceca1ad1-1c87-408d-a8a3-9b4255f1ffd3":{"title":"Invest in American companies","description":"Invest in American companies creating products that are \"made in America.\" Public offers commission-free trading and much more."},"97eebf4d-7db4-459e-bfd9-c051349741b0":{"title":"Invest in entertainment companies","description":"Invest in entertainment companies creating original content and distributing through streaming and traditional media outlets. Public offers commission-free trading and much more."},"7fdc398e-82fb-427a-82b1-16081d91ad31":{"title":"Invest in dividend paying companies","description":"Invest in dividend paying companies. Cash-rich companies that pay out regular dividends to investors.  Public offers commission-free trading and much more."},"33501ded-1571-4771-a8f1-4e2d13f7d154":{"title":"Invest in exchange-traded funds (ETFs)","description":"Invest in exchange-traded funds (ETFs). See a list of popular ETFs available in slices or fractional shares.  Public offers commission-free trading and much more."},"b6a2f00a-f413-4d26-8993-b56ea7d40863":{"title":"Invest in biomedical companies","description":"Invest in biomedical companies leading the charge to cure existing and emerging diseases.  Public offers commission-free trading and much more."},"f8c1f55a-66a8-47c6-9630-c9b7681390d8":{"title":"Invest in food delivery companies","description":"Invest in food deliver companies bringing the food you crave right to your face.  Public offers commission-free trading and much more."},"89550b52-5f22-4d85-b496-e223ca665aa3":{"title":"Invest in women-lead companies","description":"Invest in women-lead companies.  Public offers commission-free trading and much more."},"56cc8582-47c5-4f28-a19b-c236771c55ba":{"title":"Invest in e-commerce companies","description":"Invest in e-commerce companies that make it possible to shop from home in your pajamas.  Public offers commission-free trading and much more."},"de697c24-50f2-4c76-9ad0-047a850c3985":{"title":"Invest in sustainable \u0026 renewable energy companies","description":"Invest in sustainable and renewable energy companies.  Public offers commission-free trading and much more."},"4ce0e525-91dd-4573-8279-d5df93d33599":{"title":"Invest in plant-based food companies","description":"Invest in plant-based food companies that are innovating for a better-tasting green food future.  Public offers commission-free trading and much more."},"c11fb986-0bef-4152-8dcd-00dfd61e92c8":{"title":"Invest in recycling technology companies","description":"Invest in recycling technology companies foused on converting waste materials into reusable products.  Public offers commission-free trading and much more."},"707451b9-c565-425e-a21e-8c8c3fec181a":{"title":"Invest in cannabis companies","description":"Invest in cannabis companies. Cannabis (or Cannabiz) is growing rapidly, these companies offer you a chance to be a part.  Public offers commission-free trading and much more."},"1ff640fa-1f33-4a2d-a064-7dfc869f5308":{"title":"Invest in green companies","description":"Invest in green companies and those actively working to lower their carbon footprint.  Public offers commission-free trading and much more."},"37570678-4725-4b20-983f-1696ab16704b":{"title":"Invest in artificial intelligence \u0026 machine learning companies","description":"Invest in artificial intelligence \u0026 machine learning companies pushing the boundaries of AI, automation, and machine learning.  Public offers commission-free trading and much more."},"18d99fa8-7f86-486a-a364-f3074432496b":{"title":"Invest in SAAS \u0026 cloud companies","description":"Invest in software-as-a-service (SAAS) \u0026 cloud computing companies powering the present \u0026 future of business.  Public offers commission-free trading and much more."},"85f91c15-5859-4d1a-b8a0-1e4bf7617928":{"title":"Invest in virtual \u0026 augmented reality companies","description":"Invest in virtual (VR) \u0026 augmented (AR) reality companies.  VR \u0026 AR is a growing a tech sector. Public offers commission-free trading and much more."},"4f307f38-d692-4e35-8338-3e01259e8336":{"title":"Invest in media companies","description":"Invest in media companies that are behind the headlines and stories you read on your phone, TV, and everywhere else.  Public offers commission-free trading and much more."},"f7108117-fa99-422d-9642-e3d58e0b53ec":{"title":"Invest in space technology companies","description":"Invest in space technology companies that are poised to lead exploration of the final frontier.  Public offers commission-free trading and much more."},"5ba5f619-9c46-49cb-9cce-05f702105fec":{"title":"Invest in self-driving car technology companies","description":"Invest in self-driving car technology companies that are pioneering the self-driving car movement and networks that power them.  Public offers commission-free trading and much more."},"b4f9ba56-f8e2-4a17-85eb-7757c44f8f98":{"title":"Invest in social cause companies","description":"Invest in companies focused on creating a more conscientious, fair, and sustainable future.  Public offers commission-free trading and much more."},"fe6aa965-1c1a-4f6f-b6c1-90aa590f4496":{"title":"Invest in wearable technology companies","description":"Invest in wearable technology companies that are creating internet-enabled wearable devices.  Public offers commission-free trading and much more."},"2a206e44-2387-4810-807d-8d10034a186a":{"title":"Invest in biotechnology \u0026 genetic engineering companies","description":"Invest in biotechnology \u0026 genetic engineering companies.  Public offers commission-free trading and much more."},"a2a014d4-d9f3-4fc3-bf28-1d51d96c1a93":{"title":"Invest in payment processing companies","description":"Invest in companies behind payment processing and transactions.  Public offers commission-free trading and much more."},"c85cb917-b178-406f-a1c3-2fe925becb53":{"title":"Invest in large tech companies","description":"Invest in large tech companies that are some of the biggest companies in the world.  Public offers commission-free trading and much more."},"fdc1b410-e77e-4bb3-be55-3591d7856761":{"title":"Invest in blockchain technology companies","description":"Invest in blockchain technology companies that are leading the future of data security and the blockchain.  Public offers commission-free trading and much more."},"a08c9f31-cd53-4b01-82f3-fb7caa930acb":{"title":"Invest in health \u0026 wellness companies","description":"Invest in ahealth \u0026 wellness companies that are leaders in the active lifestyle community.  Public offers commission-free trading and much more."},"20386349-2797-4294-8692-8cb8f44866ed":{"title":"Invest in home \u0026 garden companies","description":"Invest in home \u0026 garden companies that are leading the way to help people improve their homes.  Public offers commission-free trading and much more."},"d323ee49-661c-4652-b944-bcf693a783e0":{"title":"Invest in privacy \u0026 security companies","description":"Invest in privacy and security companies that are devoted to keeping your information safe \u0026 secure.  Public offers commission-free trading and much more."},"a2fde2b2-70e9-46c1-8867-34684476206a":{"title":"Invest in household goods companies","description":"Invest in household goods companies that are likely found in almost any home pantry.  Public offers commission-free trading and much more."},"84f39b66-47a7-44c1-bbab-4f1f3cd8777f":{"title":"Invest in water technology companies","description":"Invest in water technology companies responsible for supplying and purifying drinking water.  Public offers commission-free trading and much more."},"ed06c94c-1b5e-41b2-a7de-2857c7b1c6d6":{"title":"Invest in telecom, communications, \u0026 I.T. companies","description":"Invest in telecom, communications, and information technology companies powering how we communicate.  Public offers commission-free trading and much more."},"35dee11e-1aa4-4d26-86e9-f312fae328d9":{"title":"Invest in Chinese companies","description":"Invest in Chinese companies. China is the world's second-largest economy and these companies are major players in it.  Public offers commission-free trading and much more."},"cc537995-40ac-44e6-b46f-3de00eeeacfc":{"title":"Invest in small businesses","description":"Invest in small businesses and the companies that power the small business economy.  Public offers commission-free trading and much more."},"af6fcef0-3a9c-4ec1-802f-a98c88b99956":{"title":"Invest in creative companies","description":"Invest in creative companies that are widely recognized for their design and creative output.  Public offers commission-free trading and much more."},"cNNSTHmE3jYrXlLbUEFqhawGn4GndJvr":{"title":"Invest in cryptocurrency \u0026 blockchain companies","description":""},"Y0wjKD4Ph4kyUYeBoLwNHW2OgmyxizYK":{"title":"Invest in SPACs","description":""},"MLDbQ7kMv18aMPSrkD35s9UXnibRuCDy":{"title":"Invest in education tech companies","description":""},"2KTdBiugykLbR5Oj9kmk5qHQhiseGLJM":{"title":"Invest in the top 20 most popular stocks","description":""},"jHoxWfr2cD9dJevSO0BDWJbfgGVDqZSW":{"title":"Invest in the business of sports \u0026 eSports","description":""}},"instruments":[{"instrument":{"symbol":"DHR","name":"Danaher","displayName":"Danaher","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"DHR","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":197.89,"high":204.68,"low":198.01,"volume":1,"volumeDate":"2025-07-25","last":202.81,"open":198.01,"gainPercentage":2.486,"gainValue":4.92,"ask":204.8,"bid":202.81,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":145222506100,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":3895480.2581,"highPriceLast52Weeks":281.7,"lowPriceLast52Weeks":171,"companyName":"Danaher Corp.","longBusinessDescription":"Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, and Diagnostics. The Biotechnology segment includes bioprocessing, discovery, and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.","dividendRate":1.18,"salesOrRevenue":23875000000,"oneYearAnnualRevenueGrowthRate":-0.0627877773126831,"threeYearAnnualRevenueGrowthRate":-6.6454,"fiveYearAnnualRevenueGrowthRate":7.3298,"earningsGrowth":-16.6022,"totalDebt":17146000000,"totalAssets":77542000000,"floatAsPercentOfSharesOutstanding":91.1289,"dividendYield":0.58,"betaTwelveMonth":0.8985,"salesOrRevenueTtm":24013000000,"ebitdaTtm":7573000000,"debtToEquityRatioQuarterly":35.4549623571674,"totalEnterpriseValue":184299260000,"industry":"MedicalSpecialties","sector":"HealthTechnology","preTaxInterestCoverageRatio":18.6474820143885,"fiveYearAverageDebtEquityRatio":42.45,"currentRatio":1.61940518256773,"peratio":43.08},"recommendation":{"currentConsensusRating":1.7,"recommendationTargetPrice":227.92,"totalRatings":37,"strongSellRatings":0,"sellRatings":0,"holdRatings":4,"buyRatings":18,"strongBuyRatings":15,"lastUpdated":"2025-07-23T19:22:40Z"},"earningEstimates":[{"actual":2.69,"estimate":2.51,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-01-27T11:08:45Z","audioUrl":"https://files.quartr.com/audio-files/9ba1a-2022-10-19-10-25-01.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/1863f-2022-01-27-09-12-08-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/9def3-2023-07-12-01-43-13.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-01-27T21:08:12Z","earningsSummary":null},{"actual":2.76,"estimate":2.66,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-04-21T10:11:53Z","audioUrl":"https://files.quartr.com/audio-files/63eb1-2022-10-28-04-52-13.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/29104-2022-04-21-11-32-02-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b211e-2023-01-25-12-34-58.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-04-21T11:02:32Z","earningsSummary":null},{"actual":2.76,"estimate":2.35,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-07-21T10:11:20Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_07_21_14_00_Q2_2022_Danaher_Corp_Earnings_Call.DM8LRGKLVHPI.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/c81c2-2022-07-21-11-51-34.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/3f226-2024-08-28-07-26-14.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-07-21T01:32:00Z","earningsSummary":null},{"actual":2.56,"estimate":2.26,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-10-20T10:04:44Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_10_20T12_00_00_00_00_Danaher_Corp_Earnings_Call_Q3_2022.HWAX4SC6QOEP_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/b10d8-2022-10-20-11-34-13.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/19aab-2022-10-20-10-36-02.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-10-20T12:00:00Z","earningsSummary":null},{"actual":2.87,"estimate":2.51,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-01-24T11:03:15Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_01_24T13_00_00_00_00_Danaher_Corp_Earnings_Call_Q4_2022.CRVWCPH4P96L_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/reports/12855-2023-01-24-12-19-04.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/conference-calls/6b723-2023-01-24-12-18-04.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-01-24T13:00:00Z","earningsSummary":null},{"actual":2.36,"estimate":2.25,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-04-25T10:18:45Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_04_25T12_00_00_00_00_Danaher_Corporation_Q1_2023.20VLWTE94NAZ_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/32966-2023-04-25-10-36-09.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/23a69-2023-04-25-10-11-09.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-04-25T12:00:00Z","earningsSummary":{"summary":"Danaher's Q1 performance showcased resilience and strategic focus amidst revenue challenges.\nThe company's strengths in operational efficiency and strategic initiatives position it well for future growth.\nChallenges in certain segments highlight the need for adaptive strategies and market diversification.\nOpportunities in China's market recovery and operational improvements offer avenues for sustained growth.","headline":"Danaher exceeds Q1 expectations, eyes growth in China market","lastUpdated":"2024-05-05T19:56:57.650742Z"}},{"actual":2.05,"estimate":2.01,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-07-25T10:01:56Z","audioUrl":"https://files.quartr.com/audio-files/live_f_dana.37MUD2Z7N7JA_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/e52dd-2023-07-25-10-34-04.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/9141b-2023-07-25-10-12-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-07-25T12:00:00Z","earningsSummary":{"summary":"Danaher navigated Q2 2023 with resilience amidst COVID-19 challenges, showcasing strong financial performance and strategic focus. While facing revenue declines in certain segments, the company remains confident in its ability to create shareholder value and improve human health. Capital deployment, inventory management, and market alignment present opportunities for future growth.","headline":"Danaher reports resilient Q2 performance amid COVID-19 challenges","lastUpdated":"2024-05-05T16:48:31.734472Z"}},{"actual":2.02,"estimate":1.76,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-10-24T10:12:15Z","audioUrl":"https://files.quartr.com/audio-files/4bdde-2023-10-24-01-20-00.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/1c165-2023-10-24-11-04-08.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/16ad3-2023-10-24-10-05-02.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-10-24T12:00:00Z","earningsSummary":{"summary":"Danaher's Q3 performance showed revenue declines in key segments, but strategic moves like spin-offs and acquisitions indicate a focus on long-term growth. Challenges in China and revenue projections for the year present short-term hurdles, while opportunities in drug development and diagnostics offer potential for future expansion.","headline":"Danaher reports Q3 revenue decline, eyes growth in diagnostics market","lastUpdated":"2024-05-07T05:29:20.046511Z"}},{"actual":2.09,"estimate":1.89,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-01-30T11:03:10Z","audioUrl":"https://files.quartr.com/audio-files/de58f-2024-01-30-02-08-08.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/86a15-2024-01-30-11-41-57.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/1592d-2024-01-30-11-41-57.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-01-30T13:00:00Z","earningsSummary":{"summary":"Danaher Corporation's 2023 performance showcased strong full-year sales and operating profit margin, but the fourth quarter saw a decline in core revenue. The company is focused on enhancing its portfolio and strengthening its growth trajectory, with expectations for improved growth in the second half of 2024. Challenges include the need for gradual improvement in demand and the pace of recovery in different geographies.","headline":"Danaher reports solid 2023 performance, anticipates gradual growth in 2024","lastUpdated":"2024-04-03T16:27:27.209285Z"}},{"actual":1.92,"estimate":1.71,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-04-23T10:05:35Z","audioUrl":"https://files.quartr.com/audio-files/c826b-2024-04-23-12-18-58.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/89d64-2024-04-23-10-28-21.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/5e375-2024-04-23-10-47-01.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-04-23T12:00:00Z","earningsSummary":{"summary":"Danaher's Q1 2024 performance exceeded expectations, driven by strong Diagnostics segment growth.\nWhile facing challenges in bioprocessing and margin expectations, the company remains focused on long-term sustainability.\nOpportunities lie in anticipated growth in Diagnostics and bioprocessing segments, with a focus on innovation and recurring revenue.\nContinuous monitoring of market trends and global capabilities position Danaher for future success.","headline":"Danaher beats Q1 expectations, eyes growth in Diagnostics segment","lastUpdated":"2024-05-07T01:21:15.175116Z"}},{"actual":1.72,"estimate":1.57,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-07-23T10:19:04Z","audioUrl":"https://files.quartr.com/audio-files/7ff0b-2024-07-23-01-29-04.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/13818-2024-07-23-10-27-06.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/cb794-2024-07-23-10-45-02.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-07-23T12:00:00Z","earningsSummary":{"summary":"Danaher Corporation delivered a strong performance in Q2 2024, surpassing revenue, earnings, and cash flow expectations, driven by bioprocessing and Cepheid's success.\nWhile facing challenges such as core revenue declines in the biotechnology segment, the company maintains a solid financial position with strong free cash flow.\nOpportunities lie in leveraging positive momentum in key segments, expanding market share, and enhancing sustainability efforts to drive future growth and profitability.\nOverall, Danaher's strategic focus on operational efficiency and growth areas positions it well to navigate challenges and capitalize on opportunities in the evolving market landscape.","headline":"Danaher beats Q2 expectations, eyes growth amid revenue challenges","lastUpdated":"2024-07-23T16:36:47.216105Z"}},{"actual":1.71,"estimate":1.57,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-10-22T10:01:53Z","audioUrl":"https://files.quartr.com/audio-files/82ec0-2024-10-22-01-54-04.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/189ac-2024-10-22-11-26-23.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/006ed-2024-10-22-10-50-01.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-10-22T12:00:00Z","earningsSummary":{"summary":"Danaher's Q3 performance exceeded expectations, driven by strong results in biotechnology and Cepheid's core revenue growth.\nWhile facing challenges in China market dynamics and core revenue declines in certain segments, the company remains optimistic about future growth.\nOpportunities lie in leveraging China's stimulus for 2025 outlook and strategic M\u0026A activities to fuel long-term growth and innovation.","headline":"Danaher surpasses Q3 expectations, eyes China stimulus for growth","lastUpdated":"2024-10-22T16:17:54.376520Z"}},{"actual":2.14,"estimate":2.16,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-01-29T11:00:44Z","audioUrl":"https://files.quartr.com/audio-files/31600-2025-01-29-02-48-02.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/ab3eb-2025-01-29-11-44-45.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/c84cb-2025-01-29-11-12-02.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-01-29T13:00:00Z","earningsSummary":{"summary":"Danaher's Q4 2024 performance showcased strong financial results, driven by better-than-expected core revenue and operational efficiency.\nWhile facing challenges in the Diagnostics segment, the company's focus on innovation and strategic acquisitions positions it well for long-term success.\nOpportunities for growth lie in continued investments in innovation, disciplined execution, and leveraging its strong cash flow for strategic initiatives.\nOverall, Danaher's performance, strengths, and strategic focus indicate a resilient business poised for sustained growth and market leadership.","headline":"Danaher reports robust Q4 earnings, eyes innovation for future growth","lastUpdated":"2025-01-29T16:17:16.305813Z"}},{"actual":1.88,"estimate":1.64,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-04-22T10:01:10Z","audioUrl":"https://files.quartr.com/audio-files/c7304-2025-04-22-01-15-23.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/d0f5d-2025-04-22-11-48-09.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/d728b-2025-04-22-10-09-10.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-04-22T12:00:00Z","earningsSummary":{"summary":"Danaher Corporation delivered a strong performance in Q1 2025, exceeding expectations across revenue, earnings, and cash flow. Despite challenges in certain segments, the company's strategic investments and strong recurring revenues showcase resilience and growth potential. With a focus on navigating macroeconomic uncertainties and seizing growth opportunities, Danaher remains well-positioned for future success. Investors can look forward to continued growth, supported by new product launches and a proactive approach to addressing challenges.","headline":"Danaher surpasses Q1 expectations, eyes growth amidst challenges","lastUpdated":"2025-04-22T15:42:39.589109Z"}},{"actual":1.8,"estimate":1.64,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-22T10:03:26Z","audioUrl":"https://files.quartr.com/audio-files/7b7d9-2025-07-22-01-09-08.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/699d7-2025-07-22-10-12-05.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/a3760-2025-07-22-10-52-01.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-07-22T12:00:00Z","earningsSummary":{"summary":"Danaher's Q2 performance reflects operational strength and financial growth, supported by a robust balance sheet. While facing challenges in certain segments, the company's focus on long-term growth initiatives and guidance raise optimism. Opportunities in innovation, market expansion, and operational efficiency position Danaher for continued success in 2025. Investors can be confident in Danaher's strategic direction and ability to navigate challenges for sustained growth.","headline":"Danaher reports solid Q2 results, raises guidance amid CFO change","lastUpdated":"2025-07-22T15:41:44.928893Z"}},{"actual":null,"estimate":1.73,"period":"Q3 2025","fiscalQuarter":"Q3","fiscalYear":2025,"lastUpdated":"2025-07-24T23:30:44Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-10-21T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2022-01-27","title":"Earnings data Q4 2021","quarter":"Q4","hash":"90655957c89a8964c966fab73ecdb173d581aeac6d5d23f1a2dfc57b4d0f515f"},{"date":"2022-04-21","title":"Earnings data Q1 2022","quarter":"Q1","hash":"be2acdf9d9108b2872784d9cdb810d7a64c6e289d9e6dc5582b5e212ab0b07e5"},{"date":"2022-07-21","title":"Earnings data Q2 2022","quarter":"Q2","hash":"c320ac4e617d474d3c2042ed953d1898ab70dc0b36cdb545c6d2b45de54b6107"},{"date":"2022-10-20","title":"Earnings data Q3 2022","quarter":"Q3","hash":"7128e705d2776431f606e28d2929feb2d195565c2fc55bb37800b566f7318b9c"},{"date":"2023-01-24","title":"Earnings data Q4 2022","quarter":"Q4","hash":"fe7bd7281a7c03dba4610c0ae4647c3918188a0c30dcd967800ad23e5a502db0"},{"date":"2023-04-25","title":"Earnings data Q1 2023","quarter":"Q1","hash":"3b376db48d7703f0cfb27563372ef1ef343d3414ae8a1af665960a813c3fc43a"},{"date":"2023-07-25","title":"Earnings data Q2 2023","quarter":"Q2","hash":"2299648b1e42b8522b0ba265a26b31d23b6cf3b076015f2125a97e774bddcc80"},{"date":"2023-10-24","title":"Earnings data Q3 2023","quarter":"Q3","hash":"0aa542297eac61ee43e7edb190924d00c16a01ac9c2c0963a6b29e71bf697ef9"},{"date":"2024-01-30","title":"Earnings data Q4 2023","quarter":"Q4","hash":"f6e8d7d18617229032136439594e56c9114739a04ba28a06aa355940c22018b8"},{"date":"2024-04-23","title":"Earnings data Q1 2024","quarter":"Q1","hash":"7de436b19699f7648d9b8d6a0fe14d1d420e8c1453d6c47ae1e415aa9ef68d6e"},{"date":"2024-07-23","title":"Earnings data Q2 2024","quarter":"Q2","hash":"4adc708985af155bc27c0f3e685d69fc150faf51ee7c03429f42dc43b79fbf89"},{"date":"2024-10-22","title":"Earnings data Q3 2024","quarter":"Q3","hash":"07b001e21e5911f3c4db80355d0230c3d82f0a5801eeacaa72d697325bd1fb9b"},{"date":"2025-01-29","title":"Earnings data Q4 2024","quarter":"Q4","hash":"c1a669403ae96581ce394f7f1f6e0f16de3f50a2846950105a6a5d97ed989305"},{"date":"2025-04-22","title":"Earnings data Q1 2025","quarter":"Q1","hash":"921cdc96cdb0d797289d1a6ba4d0ce526aacc2bdfe3c72d297fecc4a3a5c250d"},{"date":"2025-07-22","title":"Earnings data Q2 2025","quarter":"Q2","hash":"014b460213fcf1d55314887427b6517e6504301403bbe9309039f78f3057a27c"},{"date":"2025-10-21","title":"Earnings data Q3 2025","quarter":"Q3","hash":"f68b965945af1ee16e6ae9748ce59938c745625b876a4a81fa98f50b04546b3a"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Danaher","companyDescription":"Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental \u0026 Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment is composed of analytical instruments, reagents, consumables, software, and services that hospitals, physicians' offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental \u0026 Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q2 2025","values":[{"financialKey":"REVENUE","value":5936000000,"changePercentage":3.36,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":1981000000,"changePercentage":-14.43,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":3955000000,"changePercentage":15.37,"valueToRevenueRatio":0.6662735849056604},{"financialKey":"OPERATING_EXPENSES","value":2763000000,"changePercentage":22.26,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":2763000000,"changePercentage":22.26,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":1192000000,"changePercentage":2.05,"valueToRevenueRatio":0.20080862533692723},{"financialKey":"EBITDA","value":1803000000,"changePercentage":3.15,"valueToRevenueRatio":0.3037398921832884},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":611000000,"changePercentage":5.34,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":555000000,"changePercentage":-38.81,"valueToRevenueRatio":null},{"financialKey":"EPS","value":0.7718,"changePercentage":-36.83,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":81620000000,"changePercentage":3.9,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":10999000000,"changePercentage":14.47,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":2957000000,"changePercentage":24.56,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":4516000000,"changePercentage":36.93,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":2689000000,"changePercentage":0.67,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":837000000,"changePercentage":-33.89,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":70621000000,"changePercentage":2.43,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":6409000000,"changePercentage":11.6,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":61620000000,"changePercentage":2.1,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":2592000000,"changePercentage":-9.15,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":29278000000,"changePercentage":2.18,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":6792000000,"changePercentage":1.36,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":1702000000,"changePercentage":-10.47,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":5090000000,"changePercentage":6.04,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":22486000000,"changePercentage":2.43,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":16853000000,"changePercentage":3.34,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":5633000000,"changePercentage":-0.18,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":52342000000,"changePercentage":4.89,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":52334000000,"changePercentage":4.88,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":8000000,"changePercentage":60,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":81620000000,"changePercentage":3.9,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":18555000000,"changePercentage":1.89,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":15598000000,"changePercentage":-1.5,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":73.10239,"changePercentage":6.07,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":555000000,"changePercentage":-38.81,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":1338000000,"changePercentage":-5.58,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":1733000000,"changePercentage":6.12,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-395000000,"changePercentage":-82.87,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-258000000,"changePercentage":28.33,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":248000000,"changePercentage":-13.59,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":-27000000,"changePercentage":63.51,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":4000000,"changePercentage":-69.23,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-483000000,"changePercentage":17.58,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-247000000,"changePercentage":95.68,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":19000000,"changePercentage":100.43,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":0,"changePercentage":100,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":229000000,"changePercentage":14.5,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-39000000,"changePercentage":-11.43,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":131000000,"changePercentage":13000,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":964000000,"changePercentage":120.7,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":1090000000,"changePercentage":-3.54,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-25T02:40:46Z"},"dividend":{"dividendType":"CASH","dividendFrequency":"QUARTERLY","dividend":0.32,"priorDividend":0.27,"dividendYieldPercentage":0.65,"announcementDate":"2025-05-06","exDividendDate":"2025-06-27","payableDate":"2025-07-25","recordDate":"2025-06-27","updatedAt":"2025-05-27T07:12:51Z"},"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-07-17T02:50:52Z","bearsSay":["Danaher has encountered significant challenges with its projected FY'25 revenue, guiding a 3% organic growth that falls approximately 200 basis points below market expectations primarily due to a $300 million year-over-year decline in respiratory sales, pricing pressures in its China diagnostics operations, and weaker comparisons from prior industrial project revenues. Influential macroeconomic conditions, such as inflation, supply chain issues, and changes in government regulations, present further risks that could adversely affect the company's financial performance. Additionally, concerns surrounding the integration of acquired businesses and potential management disruptions could undermine Danaher's operational stability and future growth trajectory."],"bullsSay":["Danaher has successfully shifted its focus to the life science and diagnostic industries, which has been bolstered by a resurgence in biotech approvals and increased development activity in novel drug categories. The company’s Biotech segment has demonstrated strong momentum, evidenced by six consecutive quarters of order growth, including a remarkable 30% year-over-year growth in the fourth quarter, indicating robust demand. Furthermore, projections suggest that accelerating earnings per share could approach $9 in fiscal year 2026, driving potential multiple expansion, thereby enhancing the positive outlook for Danaher's stock."],"charts":[{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q3","value":60.29},{"key":"21 Q4","value":60.66},{"key":"22 Q1","value":61.19},{"key":"22 Q2","value":60.9},{"key":"22 Q3","value":59.81},{"key":"22 Q4","value":59.01},{"key":"23 Q1","value":60.97},{"key":"23 Q2","value":56.46},{"key":"23 Q3","value":58.19},{"key":"23 Q4","value":59},{"key":"24 Q1","value":60.16},{"key":"24 Q2","value":59.69},{"key":"24 Q3","value":58.65},{"key":"24 Q4","value":59.49},{"key":"25 Q1","value":61.15},{"key":"25 Q2","value":59.34}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q3","value":18.1},{"key":"21 Q4","value":26.43},{"key":"22 Q1","value":28.25},{"key":"22 Q2","value":28.44},{"key":"22 Q3","value":26.29},{"key":"22 Q4","value":27.43},{"key":"23 Q1","value":25.03},{"key":"23 Q2","value":19.96},{"key":"23 Q3","value":20.92},{"key":"23 Q4","value":20.87},{"key":"24 Q1","value":22.63},{"key":"24 Q2","value":20.33},{"key":"24 Q3","value":16.52},{"key":"24 Q4","value":21.79},{"key":"25 Q1","value":22.19},{"key":"25 Q2","value":12.8}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q3","value":15.45},{"key":"21 Q4","value":21.44},{"key":"22 Q1","value":21.9},{"key":"22 Q2","value":21.39},{"key":"22 Q3","value":20.24},{"key":"22 Q4","value":26.4},{"key":"23 Q1","value":19.93},{"key":"23 Q2","value":15.45},{"key":"23 Q3","value":16.42},{"key":"23 Q4","value":16.84},{"key":"24 Q1","value":18.77},{"key":"24 Q2","value":15.79},{"key":"24 Q3","value":14.1},{"key":"24 Q4","value":16.61},{"key":"25 Q1","value":16.61},{"key":"25 Q2","value":9.34}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Selling, general and administrative","dataPoints":[{"key":"21 Q3","value":2062},{"key":"21 Q4","value":2294},{"key":"22 Q1","value":2092},{"key":"22 Q2","value":2085},{"key":"22 Q3","value":2149},{"key":"22 Q4","value":2190},{"key":"23 Q1","value":2147},{"key":"23 Q2","value":2194},{"key":"23 Q3","value":2145},{"key":"23 Q4","value":2035},{"key":"24 Q1","value":1807},{"key":"24 Q2","value":1869},{"key":"24 Q3","value":2060},{"key":"24 Q4","value":2023},{"key":"25 Q1","value":1858},{"key":"25 Q2","value":2360}]},{"title":"Research and development","dataPoints":[{"key":"21 Q3","value":441},{"key":"21 Q4","value":495},{"key":"22 Q1","value":441},{"key":"22 Q2","value":431},{"key":"22 Q3","value":420},{"key":"22 Q4","value":453},{"key":"23 Q1","value":429},{"key":"23 Q2","value":418},{"key":"23 Q3","value":417},{"key":"23 Q4","value":407},{"key":"24 Q1","value":368},{"key":"24 Q2","value":391},{"key":"24 Q3","value":383},{"key":"24 Q4","value":442},{"key":"25 Q1","value":379},{"key":"25 Q2","value":403}]},{"title":"Other operating expenses","dataPoints":[{"key":"21 Q3","value":547}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q3","value":22.86},{"key":"21 Q4","value":20.53},{"key":"22 Q1","value":12.1},{"key":"22 Q2","value":7.38},{"key":"22 Q3","value":6},{"key":"22 Q4","value":2.71},{"key":"23 Q1","value":-6.78},{"key":"23 Q2","value":-7.66},{"key":"23 Q3","value":-10.31},{"key":"23 Q4","value":-23.47},{"key":"24 Q1","value":-19.13},{"key":"24 Q2","value":-19.76},{"key":"24 Q3","value":-15.64},{"key":"24 Q4","value":2.08},{"key":"25 Q1","value":-0.95},{"key":"25 Q2","value":3.36}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q3","value":42.66},{"key":"21 Q4","value":18.53},{"key":"22 Q1","value":12.28},{"key":"22 Q2","value":5.18},{"key":"22 Q3","value":-15.77},{"key":"22 Q4","value":-5.23},{"key":"23 Q1","value":1.7},{"key":"23 Q2","value":3.82},{"key":"23 Q3","value":-0.27},{"key":"23 Q4","value":-7.6},{"key":"24 Q1","value":-15.57},{"key":"24 Q2","value":-13.48},{"key":"24 Q3","value":-4.64},{"key":"24 Q4","value":0.94},{"key":"25 Q1","value":2.85},{"key":"25 Q2","value":22.26}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q3","value":715.1},{"key":"21 Q4","value":715.6},{"key":"22 Q1","value":716.3},{"key":"22 Q2","value":726.7},{"key":"22 Q3","value":728.5},{"key":"22 Q4","value":728.9},{"key":"23 Q1","value":729.4},{"key":"23 Q2","value":737.3},{"key":"23 Q3","value":739.4},{"key":"23 Q4","value":739.8},{"key":"24 Q1","value":740.6},{"key":"24 Q2","value":737.6},{"key":"24 Q3","value":723},{"key":"24 Q4","value":722.7},{"key":"25 Q1","value":716.3},{"key":"25 Q2","value":716.5}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q3","value":219607.21},{"key":"21 Q4","value":222336.92},{"key":"22 Q1","value":202283.12},{"key":"22 Q2","value":188651.32},{"key":"22 Q3","value":200993.15},{"key":"22 Q4","value":190388.68},{"key":"23 Q1","value":186945.22},{"key":"23 Q2","value":175846.05},{"key":"23 Q3","value":164664.38},{"key":"23 Q4","value":157429.44},{"key":"24 Q1","value":180706.4},{"key":"24 Q2","value":186317.76},{"key":"24 Q3","value":191305.8},{"key":"24 Q4","value":177639.66},{"key":"25 Q1","value":156368.29},{"key":"25 Q2","value":138929.35}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q3","value":7.59},{"key":"21 Q4","value":6.82},{"key":"22 Q1","value":6.58},{"key":"22 Q2","value":6.08},{"key":"22 Q3","value":6.56},{"key":"22 Q4","value":5.69},{"key":"23 Q1","value":6.52},{"key":"23 Q2","value":6.14},{"key":"23 Q3","value":5.99},{"key":"23 Q4","value":6.14},{"key":"24 Q1","value":7.79},{"key":"24 Q2","value":8.11},{"key":"24 Q3","value":8.25},{"key":"24 Q4","value":6.79},{"key":"25 Q1","value":6.81},{"key":"25 Q2","value":5.85}]}],"overlayChart":null}],"chartsLastUpdated":"2025-07-22T16:29:05Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.55,"sell":0.45,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"GILD","name":"Gilead Sciences","displayName":"Gilead Sciences","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"GILD","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":113.56,"high":113.7,"low":112.51,"volume":310,"volumeDate":"2025-07-25","last":113.2,"open":113.58,"gainPercentage":-0.317,"gainValue":-0.36,"ask":113.64,"bid":113.08,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":140812876000,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":8035005.5,"highPriceLast52Weeks":119.96,"lowPriceLast52Weeks":72.43,"companyName":"Gilead Sciences, Inc.","longBusinessDescription":"Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.","dividendRate":3.12,"salesOrRevenue":28727000000,"oneYearAnnualRevenueGrowthRate":6.16823120703674,"threeYearAnnualRevenueGrowthRate":1.6733,"fiveYearAnnualRevenueGrowthRate":5.2984,"earningsGrowth":1144.0052,"totalDebt":27322000000,"totalAssets":58995000000,"floatAsPercentOfSharesOutstanding":99.8384,"dividendYield":2.76,"betaTwelveMonth":0.3662,"salesOrRevenueTtm":28687000000,"ebitdaTtm":13677000000,"debtToEquityRatioQuarterly":130.216052604112,"totalEnterpriseValue":131594350000,"industry":"Biotechnology","sector":"HealthTechnology","preTaxInterestCoverageRatio":10.9109518935517,"fiveYearAverageDebtEquityRatio":125.19,"currentRatio":1.36916720674012,"peratio":23.8},"recommendation":{"currentConsensusRating":2.2,"recommendationTargetPrice":102.34,"totalRatings":38,"strongSellRatings":1,"sellRatings":0,"holdRatings":14,"buyRatings":14,"strongBuyRatings":9,"lastUpdated":"2025-05-21T12:00:57Z"},"earningEstimates":[{"actual":2.65,"estimate":1.74,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-10-28T20:10:48Z","audioUrl":"https://files.quartr.com/audio-files/f8c97-2022-10-19-04-27-09.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/6c632-2021-10-28-12-00-00-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/9fb51-2023-01-25-10-08-18.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-10-28T00:00:00Z","earningsSummary":null},{"actual":0.69,"estimate":1.58,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-01T21:15:20Z","audioUrl":"https://files.quartr.com/audio-files/fc905-2022-10-19-10-35-26.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/04784-2022-02-01-07-28-44-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/38498-2023-01-25-12-41-20.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-01T19:44:28Z","earningsSummary":null},{"actual":2.12,"estimate":1.8,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-04-28T20:14:46Z","audioUrl":"https://files.quartr.com/audio-files/4b5ad-2022-10-28-04-17-45.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/38f08-2022-04-28-04-09-40-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/89fb1-2023-01-25-01-23-19.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-04-28T16:40:09Z","earningsSummary":null},{"actual":1.58,"estimate":1.53,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-08-02T20:20:43Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_08_02_22_30_Q2_2022_Gilead_Sciences_Inc_Earnings_Call.IRK8Y6FE94DL_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/46bfe-2022-08-02-08-18-14.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/2b4ba-2022-08-02-08-18-14.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-02T01:00:00Z","earningsSummary":null},{"actual":1.9,"estimate":1.48,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-10-27T20:12:31Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_10_27T20_30_00_00_00_Gilead_Sciences_Inc_Earnings_Call_Q3_2022.YC8QPJSQOKZJ_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/dbec7-2022-10-27-08-42-05.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f0b7c-2022-10-27-08-42-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-10-27T20:30:00Z","earningsSummary":null},{"actual":1.67,"estimate":1.49,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-02T21:59:21Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_02_02T21_30_00_00_00_Gilead_Sciences_Inc_Earnings_Call_Q4_2022.V5VFGT84GJLT_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/reports/b9d3d-2023-02-02-09-43-11.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/conference-calls/39e82-2023-02-02-09-43-11.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-02T21:30:00Z","earningsSummary":{"summary":"Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.","headline":"Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth","lastUpdated":"2024-05-06T20:04:40.207569Z"}},{"actual":1.37,"estimate":1.54,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-04-27T20:06:44Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_04_27T20_30_00_00_00_Gilead_Sciences_Inc_Q1_2023.0FAPHEOFAACJ_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/4cfdc-2023-04-27-08-05-09.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/1e4a4-2023-04-27-08-05-09.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-04-27T20:30:00Z","earningsSummary":{"summary":"Gilead Sciences delivered strong sales driven by key products in Q1 2023.\nWhile facing challenges like lower Veklury sales, Gilead maintains revenue guidance.\nThe company's strengths lie in its pipeline, successful products, and manufacturing capabilities.\nOpportunities in new indications and therapies position Gilead for future growth.","headline":"Gilead reports strong Q1 sales, focuses on pipeline growth","lastUpdated":"2024-05-06T18:41:44.086286Z"}},{"actual":1.34,"estimate":1.61,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-03T20:15:28Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_08_03T21_00_00_00_00_Gilead_Sciences_Inc_Q2_2023.73QI67M9O4UX_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/f6c30-2023-08-03-08-23-05.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b1cd9-2023-08-03-08-23-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-03T21:00:00Z","earningsSummary":{"summary":"Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.\nTrodelvy's performance in different markets and potential Medicare coverage are key highlights.\nChallenges include unsuccessful trials and addressing revenue aspirations.\nOpportunities lie in expanding BD activities and exploring cell therapy beyond oncology.","headline":"Gilead Sciences reports robust Q2 performance and eyes future growth","lastUpdated":"2024-05-07T03:26:46.816619Z"}},{"actual":2.29,"estimate":1.92,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-11-07T21:06:05Z","audioUrl":"https://files.quartr.com/audio-files/15d27-2023-11-07-10-28-39.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/0db43-2023-11-07-09-07-16.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b754e-2023-11-07-09-09-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-07T21:30:00Z","earningsSummary":{"summary":"Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.\nWhile facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.\nThe company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.\nOverall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.","headline":"Gilead Sciences reports robust Q3 performance amidst market challenges","lastUpdated":"2024-05-06T21:05:20.385019Z"}},{"actual":1.72,"estimate":1.78,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-06T21:04:58Z","audioUrl":"https://files.quartr.com/audio-files/e686d-2024-02-07-10-59-29.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/c20ea-2024-02-06-09-14-41.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/cdab3-2024-02-06-09-04-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-06T22:00:00Z","earningsSummary":{"summary":"Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.","headline":"Gilead Sciences reports strong 2023 performance, eyes transformative therapies","lastUpdated":"2024-05-06T17:26:57.049520Z"}},{"actual":-1.32,"estimate":-1.49,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-04-25T20:04:34Z","audioUrl":"https://files.quartr.com/audio-files/d69c4-2024-04-25-09-15-37.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/5db00-2024-04-25-08-38-07.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/62635-2024-04-25-08-18-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-04-25T20:30:00Z","earningsSummary":{"summary":"Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.\nChallenges include IP R\u0026D charge from Sema Bay acquisition and competitive market dynamics.\nOpportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.\nOverall, Gilead remains focused on growth through innovation and strategic portfolio advancements.","headline":"Gilead Sciences reports robust Q1 performance and eyes future growth","lastUpdated":"2024-05-06T16:16:55.027380Z"}},{"actual":2.01,"estimate":1.6,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-08-08T20:03:28Z","audioUrl":"https://files.quartr.com/audio-files/bcb06-2024-08-08-09-18-38.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/2691f-2024-08-08-08-50-40.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/6288a-2024-08-08-08-44-09.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-08T20:30:00Z","earningsSummary":null},{"actual":2.02,"estimate":1.55,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-11-06T21:02:52Z","audioUrl":"https://files.quartr.com/audio-files/cc814-2024-11-06-10-24-35.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/f99b3-2024-11-06-09-22-22.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/e4eda-2024-11-06-09-22-09.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-11-06T21:30:00Z","earningsSummary":{"summary":"Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.\nThe company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.\nWhile challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.","headline":"Gilead Sciences reports robust Q3 performance and eyes market expansion","lastUpdated":"2024-11-07T03:38:23.538594Z"}},{"actual":1.9,"estimate":1.7,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-11T21:04:27Z","audioUrl":"https://files.quartr.com/audio-files/3b06c-2025-02-11-10-41-52.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/8f8f2-2025-02-11-09-56-44.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/dbd39-2025-02-11-09-05-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-11T21:30:00Z","earningsSummary":{"summary":"Gilead Sciences' robust financial performance in 2024, driven by HIV sales and new product launches, reflects resilience and strategic growth. The company's focus on pipeline expansion, expense management, and regulatory milestones positions them for sustained success. While challenges like market competition and regulatory uncertainties persist, Gilead's diverse portfolio and growth opportunities offer a promising outlook. Investors can look forward to Gilead's continued innovation in HIV, inflammation, and oncology, supported by a strong financial foundation.","headline":"Gilead Sciences excels in Q4 2024, poised for growth","lastUpdated":"2025-02-11T23:42:42.641293Z"}},{"actual":1.81,"estimate":1.76,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-04-24T20:03:21Z","audioUrl":"https://files.quartr.com/audio-files/d07d2-2025-04-24-09-58-41.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/1fcb9-2025-04-24-08-46-27.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f4b3b-2025-04-24-08-09-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-04-24T20:30:00Z","earningsSummary":{"summary":"Gilead Sciences posted strong Q1 2025 results driven by growth in HIV and liver disease sales, despite challenges in certain product segments. The company's focus on expense management, pipeline advancement, and policy engagement underscores its commitment to innovation and patient-centric healthcare. While facing headwinds in specific areas, Gilead's upcoming launches and tax advantages position it favorably for future growth and adaptation to policy changes. Overall, Gilead's performance reflects resilience and strategic foresight in navigating market dynamics and advancing its position in the healthcare industry.","headline":"Gilead Sciences reports robust Q1 results amidst evolving healthcare landscape","lastUpdated":"2025-04-24T23:42:08.927706Z"}},{"actual":null,"estimate":1.96,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-25T06:30:43Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-07T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-10-28","title":"Earnings data Q3 2021","quarter":"Q3","hash":"ccf12ef6be28fd468ba01855c94d025a567aca8a31f0276506b790a1fe9899db"},{"date":"2022-02-01","title":"Earnings data Q4 2021","quarter":"Q4","hash":"b248df9e6e385b113a036ed95649e85bc985517ee18d3aa069d5fa30e91ce74d"},{"date":"2022-04-28","title":"Earnings data Q1 2022","quarter":"Q1","hash":"6ba985ce145f12dddc7c61811c144f8b32d4f577d26223679c660926c61b6ad4"},{"date":"2022-08-02","title":"Earnings data Q2 2022","quarter":"Q2","hash":"ca0e5f307adfa7acf5522cd2217febfcf7cd81b6a22c553f035d67365de7e078"},{"date":"2022-10-27","title":"Earnings data Q3 2022","quarter":"Q3","hash":"98913d0dd4f041399810707f612ee7e76ff58fcb15563da5c389653180bae266"},{"date":"2023-02-02","title":"Earnings data Q4 2022","quarter":"Q4","hash":"a3636c6885fbd3ba09a8fa7760c0063f56bfccf0dc9c166302465c84f85a2786"},{"date":"2023-04-27","title":"Earnings data Q1 2023","quarter":"Q1","hash":"9fcf504a1fc0ac5d54212d6dc39c42f6271f76a9d29ad3782b777607f23b83bb"},{"date":"2023-08-03","title":"Earnings data Q2 2023","quarter":"Q2","hash":"3e4b41cd04eb3dd8cfb8a3fe40b30ff980c748ca2a74a560a426ba7477663024"},{"date":"2023-11-07","title":"Earnings data Q3 2023","quarter":"Q3","hash":"39fee44c8e56644745ef3e27720ff22f5e126ab50779c62d6d1a96c44da6c824"},{"date":"2024-02-06","title":"Earnings data Q4 2023","quarter":"Q4","hash":"f4c388c9c03925d0adb7734af9e77778626fa8f116265be1c7d26e1f577f15aa"},{"date":"2024-04-25","title":"Earnings data Q1 2024","quarter":"Q1","hash":"fe2fa9856a139bb0f10b40b6362589e2b9c0e221fbf9d6c770a0293508080363"},{"date":"2024-08-08","title":"Earnings data Q2 2024","quarter":"Q2","hash":"5eab0b50bcb4562f682d7d2ecd239a996aa6fb912c16f61b57556eb9b3265792"},{"date":"2024-11-06","title":"Earnings data Q3 2024","quarter":"Q3","hash":"69fa7c834c88ca6a02c49090d92e06167b80b2cd238bbfb1f909987f093aed69"},{"date":"2025-02-11","title":"Earnings data Q4 2024","quarter":"Q4","hash":"9b9964903ea6c1466da299bcfe489b1e7cf2769841dfc78a59eb3364a7eb5b7f"},{"date":"2025-04-24","title":"Earnings data Q1 2025","quarter":"Q1","hash":"a195a35814b1741876db789d76bc89762ef623dcb417cd6ebf329a545c7e6b79"},{"date":"2025-08-07","title":"Earnings data Q2 2025","quarter":"Q2","hash":"db7d568cb71d246b8b1254dbfe8bd633f88a75b5a006a586500efb1948f5dbfb"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Gilead Sciences","companyDescription":"Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":6646000000,"changePercentage":-0.6,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":1540000000,"changePercentage":-0.77,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":5106000000,"changePercentage":-0.55,"valueToRevenueRatio":0.7682816731868793},{"financialKey":"OPERATING_EXPENSES","value":2561000000,"changePercentage":-9.57,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":2561000000,"changePercentage":-9.57,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":2545000000,"changePercentage":10.56,"valueToRevenueRatio":0.3829371050255793},{"financialKey":"EBITDA","value":3241000000,"changePercentage":8.32,"valueToRevenueRatio":0.48766175142943124},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":696000000,"changePercentage":0.87,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":1315000000,"changePercentage":131.53,"valueToRevenueRatio":null},{"financialKey":"EPS","value":1.0445,"changePercentage":131.24,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":56434000000,"changePercentage":0.25,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":16901000000,"changePercentage":20.37,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":9130000000,"changePercentage":50.68,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":4388000000,"changePercentage":-6.02,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":1759000000,"changePercentage":-5.07,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":1624000000,"changePercentage":11.31,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":39533000000,"changePercentage":-6.43,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":5421000000,"changePercentage":1.88,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":27669000000,"changePercentage":-12.83,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":6443000000,"changePercentage":24.19,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":37355000000,"changePercentage":-3.82,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":12344000000,"changePercentage":-5.16,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":2806000000,"changePercentage":-23.48,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":9538000000,"changePercentage":17.03,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":25011000000,"changePercentage":-3.14,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":22146000000,"changePercentage":2.88,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":2865000000,"changePercentage":-33.29,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":19078000000,"changePercentage":9.3,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":19162000000,"changePercentage":9.25,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":-84000000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":56433000000,"changePercentage":0.25,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":24952000000,"changePercentage":-0.96,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":15822000000,"changePercentage":-17.31,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":15.39116,"changePercentage":9.34,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":1315000000,"changePercentage":131.53,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":1757000000,"changePercentage":-20.82,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":2790000000,"changePercentage":4.18,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-1033000000,"changePercentage":-125.05,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-415000000,"changePercentage":81.2,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":104000000,"changePercentage":-0.95,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":-16000000,"changePercentage":-100.83,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":273000000,"changePercentage":-93.25,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-776000000,"changePercentage":90.64,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-3426000000,"changePercentage":-151.73,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":-478000000,"changePercentage":-88.19,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":-1762000000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":1010000000,"changePercentage":2.02,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-176000000,"changePercentage":-51.72,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":19000000,"changePercentage":205.56,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-2065000000,"changePercentage":-51.06,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":1653000000,"changePercentage":-21.81,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:14:58Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-07-24T05:12:12Z","bearsSay":["Gilead Sciences is facing a negative outlook primarily due to anticipated declines in revenue across key segments, including a projected decrease in Veklury sales as COVID hospitalizations decline and a mid-teen percentage drop in HIV revenue for the first quarter of fiscal year 2025. Despite a forecast for operating margin expansion, driven by flat R\u0026D expenses and a significant reduction in SG\u0026A costs, the company's revenue growth prospects appear limited, especially with the modest outlook for the primary biliary cholangitis market and competitive pressures from emerging therapies. Additionally, concerns around the execution of the next-generation HIV treatment pipeline and the potential underperformance of CAR-T therapies further contribute to the bearish sentiment towards Gilead's stock performance."],"bullsSay":["Gilead Sciences demonstrates strong financial performance with its liver disease franchise achieving $3 billion in FY24 sales, marking a 9% year-over-year increase, bolstered by the successful launch of Livdelzi. The company's total HIV sales rose significantly, reaching $19.6 billion in FY24—a 16% increase year-over-year—driven by robust demand and favorable inventory dynamics, alongside Descovy's impressive 21% year-over-year growth, which outperformed consensus estimates. Additionally, Gilead's oncology portfolio shows promise with Yescarta and Tecartus maintaining steady sales, and Biktarvy has secured over 50% of the treatment market, reflecting solid growth across all business lines with the overall commercial portfolio increasing by 8% in HIV, 12% in oncology, and 9% in liver diseases year-over-year."],"charts":[{"title":"Revenue Segments","description":"Revenue segments as reported by the company.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Product sales","dataPoints":[{"key":"21 Q2","value":6152},{"key":"21 Q3","value":7356},{"key":"21 Q4","value":7160},{"key":"22 Q1","value":6534},{"key":"22 Q2","value":6138},{"key":"22 Q3","value":6978},{"key":"22 Q4","value":7333},{"key":"23 Q1","value":6306},{"key":"23 Q2","value":6564},{"key":"23 Q3","value":6994},{"key":"23 Q4","value":7070},{"key":"24 Q1","value":6647},{"key":"24 Q2","value":6912},{"key":"24 Q3","value":7515},{"key":"24 Q4","value":7536},{"key":"25 Q1","value":6613}]},{"title":"Royalty, contract and other revenues","dataPoints":[{"key":"21 Q2","value":65},{"key":"21 Q3","value":65},{"key":"21 Q4","value":84},{"key":"22 Q1","value":56},{"key":"22 Q2","value":122},{"key":"22 Q3","value":64},{"key":"22 Q4","value":56},{"key":"23 Q1","value":46},{"key":"23 Q2","value":35},{"key":"23 Q3","value":56},{"key":"23 Q4","value":45},{"key":"24 Q1","value":39},{"key":"24 Q2","value":41},{"key":"24 Q3","value":30},{"key":"24 Q4","value":33},{"key":"25 Q1","value":54}]}],"overlayChart":null},{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q2","value":77.64},{"key":"21 Q3","value":83.51},{"key":"21 Q4","value":63.73},{"key":"22 Q1","value":78.39},{"key":"22 Q2","value":76.96},{"key":"22 Q3","value":80.19},{"key":"22 Q4","value":81.1},{"key":"23 Q1","value":77.94},{"key":"23 Q2","value":78.14},{"key":"23 Q3","value":77.8},{"key":"23 Q4","value":70.62},{"key":"24 Q1","value":76.78},{"key":"24 Q2","value":77.79},{"key":"24 Q3","value":79.13},{"key":"24 Q4","value":79.11},{"key":"25 Q1","value":76.9}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q2","value":36.12},{"key":"21 Q3","value":51.77},{"key":"21 Q4","value":12.97},{"key":"22 Q1","value":2.98},{"key":"22 Q2","value":32.41},{"key":"22 Q3","value":40.28},{"key":"22 Q4","value":30.68},{"key":"23 Q1","value":26.82},{"key":"23 Q2","value":25.23},{"key":"23 Q3","value":37.19},{"key":"23 Q4","value":22.65},{"key":"24 Q1","value":-64.65},{"key":"24 Q2","value":38.01},{"key":"24 Q3","value":11.76},{"key":"24 Q4","value":32.39},{"key":"25 Q1","value":33.55}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q2","value":24.48},{"key":"21 Q3","value":34.92},{"key":"21 Q4","value":5.27},{"key":"22 Q1","value":0.28},{"key":"22 Q2","value":18.27},{"key":"22 Q3","value":25.4},{"key":"22 Q4","value":22.19},{"key":"23 Q1","value":15.9},{"key":"23 Q2","value":15.83},{"key":"23 Q3","value":30.92},{"key":"23 Q4","value":20.08},{"key":"24 Q1","value":-62.37},{"key":"24 Q2","value":23.21},{"key":"24 Q3","value":16.6},{"key":"24 Q4","value":23.55},{"key":"25 Q1","value":19.72}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Research and development","dataPoints":[{"key":"21 Q2","value":1134},{"key":"21 Q3","value":1147},{"key":"21 Q4","value":2027},{"key":"22 Q1","value":1186},{"key":"22 Q2","value":1102},{"key":"22 Q3","value":1149},{"key":"22 Q4","value":1548},{"key":"23 Q1","value":1447},{"key":"23 Q2","value":1407},{"key":"23 Q3","value":1457},{"key":"23 Q4","value":1408},{"key":"24 Q1","value":1520},{"key":"24 Q2","value":1351},{"key":"24 Q3","value":1395},{"key":"24 Q4","value":1641},{"key":"25 Q1","value":1379}]},{"title":"Acquired in-process research and development expenses","dataPoints":[{"key":"21 Q2","value":96},{"key":"21 Q3","value":19},{"key":"22 Q2","value":330},{"key":"22 Q3","value":448},{"key":"22 Q4","value":158},{"key":"23 Q1","value":481},{"key":"23 Q2","value":236},{"key":"23 Q3","value":91},{"key":"23 Q4","value":347},{"key":"24 Q1","value":4131},{"key":"24 Q2","value":38},{"key":"24 Q3","value":505},{"key":"24 Q4","value":-11},{"key":"25 Q1","value":253}]},{"title":"Selling, general and administrative","dataPoints":[{"key":"21 Q2","value":1351},{"key":"21 Q3","value":1190},{"key":"21 Q4","value":1650},{"key":"22 Q1","value":1083},{"key":"22 Q2","value":1357},{"key":"22 Q3","value":1213},{"key":"22 Q4","value":2020},{"key":"23 Q1","value":1319},{"key":"23 Q2","value":1849},{"key":"23 Q3","value":1315},{"key":"23 Q4","value":1608},{"key":"24 Q1","value":1375},{"key":"24 Q2","value":1377},{"key":"24 Q3","value":1433},{"key":"24 Q4","value":1906},{"key":"25 Q1","value":1258}]},{"title":"In-process research and development impairment","dataPoints":[{"key":"22 Q1","value":2700},{"key":"23 Q4","value":50},{"key":"24 Q1","value":2430},{"key":"24 Q3","value":1750}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q2","value":20.88},{"key":"21 Q3","value":12.83},{"key":"21 Q4","value":-2.39},{"key":"22 Q1","value":2.6},{"key":"22 Q2","value":0.69},{"key":"22 Q3","value":-5.11},{"key":"22 Q4","value":2},{"key":"23 Q1","value":-3.61},{"key":"23 Q2","value":5.42},{"key":"23 Q3","value":0.11},{"key":"23 Q4","value":-3.71},{"key":"24 Q1","value":5.26},{"key":"24 Q2","value":5.36},{"key":"24 Q3","value":7.02},{"key":"24 Q4","value":6.38},{"key":"25 Q1","value":-0.28}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q2","value":-63.45},{"key":"21 Q3","value":-31.41},{"key":"21 Q4","value":9.05},{"key":"22 Q1","value":128.78},{"key":"22 Q2","value":8.06},{"key":"22 Q3","value":19.27},{"key":"22 Q4","value":1.33},{"key":"23 Q1","value":-34.65},{"key":"23 Q2","value":25.21},{"key":"23 Q3","value":1.89},{"key":"23 Q4","value":-8.4},{"key":"24 Q1","value":191.22},{"key":"24 Q2","value":-20.79},{"key":"24 Q3","value":77.54},{"key":"24 Q4","value":3.6},{"key":"25 Q1","value":-69.44}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q2","value":1255},{"key":"21 Q3","value":1256},{"key":"21 Q4","value":1256},{"key":"22 Q1","value":1255},{"key":"22 Q2","value":1256},{"key":"22 Q3","value":1255},{"key":"22 Q4","value":1252},{"key":"23 Q1","value":1248},{"key":"23 Q2","value":1249},{"key":"23 Q3","value":1248},{"key":"23 Q4","value":1248},{"key":"24 Q1","value":1247},{"key":"24 Q2","value":1247},{"key":"24 Q3","value":1247},{"key":"24 Q4","value":1248},{"key":"25 Q1","value":1246}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q2","value":83834},{"key":"21 Q3","value":88296.8},{"key":"21 Q4","value":86538.4},{"key":"22 Q1","value":80194.5},{"key":"22 Q2","value":76992.8},{"key":"22 Q3","value":78437.5},{"key":"22 Q4","value":98532.4},{"key":"23 Q1","value":102585.6},{"key":"23 Q2","value":98795.9},{"key":"23 Q3","value":95222.4},{"key":"23 Q4","value":97094.4},{"key":"24 Q1","value":95894.3},{"key":"24 Q2","value":83174.9},{"key":"24 Q3","value":95146.1},{"key":"24 Q4","value":112320},{"key":"25 Q1","value":128587.2}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q2","value":3.37},{"key":"21 Q3","value":2.97},{"key":"21 Q4","value":2.99},{"key":"22 Q1","value":3.04},{"key":"22 Q2","value":3.07},{"key":"22 Q3","value":2.78},{"key":"22 Q4","value":3.33},{"key":"23 Q1","value":4.04},{"key":"23 Q2","value":3.74},{"key":"23 Q3","value":3.38},{"key":"23 Q4","value":3.41},{"key":"24 Q1","value":3.59},{"key":"24 Q2","value":2.99},{"key":"24 Q3","value":3.15},{"key":"24 Q4","value":3.71},{"key":"25 Q1","value":4.82}]}],"overlayChart":null}],"chartsLastUpdated":"2025-04-24T21:16:12Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.56,"sell":0.44,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"IQV","name":"IQVIA Hlds","displayName":"IQVIA Hlds","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"IQV","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":194.24,"high":206.78,"low":196.295,"volume":3,"volumeDate":"2025-07-25","last":200.82,"open":197.1,"gainPercentage":3.388,"gainValue":6.58,"ask":208.91,"bid":197.1,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":34139400000,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":2467314.5806,"highPriceLast52Weeks":252.88,"lowPriceLast52Weeks":134.645,"companyName":"IQVIA Holdings, Inc.","longBusinessDescription":"IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.","dividendRate":0,"salesOrRevenue":15405000000,"oneYearAnnualRevenueGrowthRate":2.95395308427454,"threeYearAnnualRevenueGrowthRate":3.5392,"fiveYearAnnualRevenueGrowthRate":7.0404,"earningsGrowth":-10.72,"totalDebt":14479000000,"totalAssets":26899000000,"floatAsPercentOfSharesOutstanding":99.1335,"dividendYield":0,"betaTwelveMonth":1.0689,"salesOrRevenueTtm":15697000000,"ebitdaTtm":3382000000,"debtToEquityRatioQuarterly":271.72031844929,"totalEnterpriseValue":48675934000,"industry":"Biotechnology","sector":"HealthTechnology","preTaxInterestCoverageRatio":3.19127988748242,"fiveYearAverageDebtEquityRatio":217.24,"currentRatio":0.837955625990491,"peratio":29.09},"recommendation":{"currentConsensusRating":1.8,"recommendationTargetPrice":223.21,"totalRatings":33,"strongSellRatings":0,"sellRatings":0,"holdRatings":7,"buyRatings":12,"strongBuyRatings":14,"lastUpdated":"2025-07-23T19:15:04Z"},"earningEstimates":[{"actual":2.55,"estimate":2.43,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-15T12:09:07Z","audioUrl":"https://files.quartr.com/audio-files/42aad-2022-10-19-11-57-12.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/c2804-2022-02-15-02-29-21-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/81bd6-2023-01-25-12-35-27.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-15T14:21:29Z","earningsSummary":null},{"actual":2.47,"estimate":2.42,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-04-27T11:29:11Z","audioUrl":"https://files.quartr.com/audio-files/dec05-2022-10-28-04-43-34.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/b515b-2024-07-29-08-46-32.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/acde5-2023-01-25-01-24-17.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-04-27T13:28:00Z","earningsSummary":null},{"actual":2.44,"estimate":2.39,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-07-21T11:51:51Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_07_21_15_00_Q2_2022_IQVIA_Holdings_Inc_Earnings_Call.VT3UVOQFAMKH.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/ab822-2022-07-21-02-53-39.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/500b9-2022-07-21-11-08-28.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-07-21T02:01:00Z","earningsSummary":null},{"actual":2.48,"estimate":2.39,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-10-26T11:04:15Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_10_26T13_00_00_00_00_IQVIA_Holdings_Inc_Earnings_Call_Q3_2022.D0ILF7U5ON6A_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/7112e-2022-10-26-03-25-54.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/77fbe-2022-10-26-11-55-21.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-10-26T12:00:00Z","earningsSummary":null},{"actual":2.78,"estimate":2.76,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-10T12:06:54Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_02_10T14_00_00_00_00_IQVIA_Holdings_Inc_Earnings_Call_Q4_2022.U9A4KKBMMTEI_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/reports/b7a36-2023-02-10-05-15-04.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/conference-calls/8cd74-2023-02-10-12-13-10.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-10T14:00:00Z","earningsSummary":{"summary":"IQVIA delivered a strong performance in Q4 2022 with revenue growth, operational achievements, and solid financial guidance for 2023, underlining its market position and strategic focus.\nWhile facing challenges from macroeconomic factors, wage inflation, and market conditions, the company is proactively addressing these issues through cost-cutting measures and debt reduction strategies.\nBy leveraging its strengths in stable operations, record bookings, and financial discipline, IQVIA aims to navigate challenges, capitalize on opportunities, and drive sustainable growth in the future.","headline":"IQVIA reports solid Q4 performance, addresses macro challenges proactively","lastUpdated":"2024-05-07T12:36:51.962604Z"}},{"actual":2.45,"estimate":2.41,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-04-27T11:03:05Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_04_27T13_00_00_00_00_IQVIA_Holdings_Inc_Q1_2023.46V7YESRD42I_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/cec84-2023-04-28-10-04-43.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/d01ee-2023-04-27-11-28-11.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-04-27T13:00:00Z","earningsSummary":{"summary":"IQVIA Hlds (IQV) Q1 2023 reflects strong financial performance and operational resilience.\nChallenges in backlog burn and industry dynamics are being managed effectively.\nOpportunities in M\u0026A activity and demand for real-world evidence drive growth.\nSteady guidance for 2023 positions the company well for future success.","headline":"IQVIA reports solid Q1 growth amidst industry challenges and opportunities","lastUpdated":"2024-05-07T10:56:02.912726Z"}},{"actual":2.43,"estimate":2.37,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-01T11:02:22Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_08_01T13_00_00_00_00_IQVIA_Holdings_Inc_Q2_2023.P579ZRR5133V_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/6de5d-2023-08-01-04-26-01.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/0c9cc-2023-08-01-11-49-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-01T13:00:00Z","earningsSummary":{"summary":"IQVIA's Q2 performance reflects solid growth and strategic wins in data and analytics solutions.\nWhile facing challenges in decision delays and economic uncertainties, the company's AI investments and strong R\u0026DS segment offer growth opportunities.\nWith a focus on leveraging AI across business areas and a vast patient data advantage, IQVIA is well-positioned for future success.","headline":"IQVIA posts strong Q2 results, eyes growth amid AI investments","lastUpdated":"2024-05-07T12:35:23.951086Z"}},{"actual":2.49,"estimate":2.44,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-11-01T11:02:31Z","audioUrl":"https://files.quartr.com/audio-files/e6ea8-2023-11-01-02-34-06.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/7390e-2023-11-01-04-06-27.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/d55f4-2023-11-01-12-08-18.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-01T13:00:00Z","earningsSummary":{"summary":"IQVIA's Q3 2023 performance showcased strength in R\u0026DS bookings and revenue growth, while TAS faced challenges from foreign exchange and weak demand. The company aims to drive growth through new contracts, cost reduction initiatives, and strategic pricing adjustments, with a focus on stabilizing performance and pursuing growth opportunities in 2024.","headline":"IQVIA reports mixed Q3 results, eyes growth through strategic initiatives","lastUpdated":"2024-05-07T12:00:11.814109Z"}},{"actual":2.84,"estimate":2.82,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-14T12:23:01Z","audioUrl":"https://files.quartr.com/audio-files/b9e82-2024-02-14-03-07-16.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/1fb51-2024-02-14-08-24-13.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/d9d02-2024-02-14-12-02-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-14T14:00:00Z","earningsSummary":{"summary":"IQVIA's strong performance in bookings and revenue growth positions it well for future success.\nWhile facing challenges in TAS and pricing negotiations, IQVIA's contract wins and guidance for 2024 show resilience.\nOpportunities lie in improving demand for TAS, increasing RFPs, and growth in the data business.\nOverall, IQVIA's strategic wins and financial outlook indicate a positive trajectory for the company.","headline":"IQVIA reports robust Q4 earnings, eyes growth amid challenges","lastUpdated":"2024-05-07T11:11:28.333586Z"}},{"actual":2.54,"estimate":2.48,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-05-02T11:08:39Z","audioUrl":"https://files.quartr.com/audio-files/8b941-2024-05-02-02-12-03.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/bcd73-2024-05-02-02-03-29.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b9636-2024-05-02-12-41-43.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-02T13:00:00Z","earningsSummary":{"summary":"IQVIA delivered a solid performance in Q1 2024, meeting revenue expectations and showcasing growth in bookings and pipeline. The company's strengths lie in technology-enabled solutions, global partnerships, and public health initiatives.\nChallenges include cancellations impacting revenue, pricing pressures, and the need to navigate market dynamics. However, IQVIA's opportunities in innovation, partnerships, and market expansion position it well for future growth.\nOverall, IQVIA's strategic focus on technology, client engagements, and public health initiatives, amidst challenges in cancellations and pricing pressures, presents a resilient outlook. The company's financial performance and industry leadership are key strengths.\nWith a proactive approach to challenges and a focus on seizing opportunities, IQVIA remains well-positioned for sustained growth and success in the evolving healthcare landscape. The company's adaptability and strategic initiatives drive confidence in its future prospects.","headline":"IQVIA reports solid Q1 performance, eyes growth through partnerships","lastUpdated":"2024-05-07T10:29:55.746686Z"}},{"actual":2.64,"estimate":2.56,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-07-22T11:02:15Z","audioUrl":"https://files.quartr.com/audio-files/057de-2024-07-22-02-59-04.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/5ed4e-2024-07-22-02-18-34.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/0b256-2024-07-22-11-34-04.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-07-22T13:00:00Z","earningsSummary":{"summary":"IQVIA Hlds delivered a strong Q2 performance with revenue and earnings growth, supported by efficient operations and solid financial metrics.\nWhile facing challenges such as pricing pressures and market dynamics, the company remains optimistic about future opportunities and growth potential.\nStrategic focus on addressing challenges and seizing opportunities will be key to sustaining performance and maximizing shareholder value in the dynamic healthcare landscape.","headline":"IQVIA reports robust Q2 earnings, eyes growth amidst market challenges","lastUpdated":"2024-07-22T17:08:22.682810Z"}},{"actual":2.84,"estimate":2.81,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-10-31T11:01:34Z","audioUrl":"https://files.quartr.com/audio-files/31d5f-2024-10-31-02-46-07.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/8c426-2024-10-31-07-00-37.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/25e7f-2024-10-31-11-58-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-10-31T13:00:00Z","earningsSummary":{"summary":"IQVIA Hlds demonstrated solid financial performance in Q3 2024, driven by revenue growth and increased EPS.\nWhile facing challenges like study delays and pricing pressures, the company's strategic strengths and opportunities for growth remain intact.\nWith a focus on share buybacks and R\u0026DS growth, IQVIA is positioning itself for sustained success in the future.","headline":"IQVIA Hlds reports Q3 growth, faces study delays and pricing challenges","lastUpdated":"2024-10-31T16:44:04.848454Z"}},{"actual":3.12,"estimate":3.11,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-06T12:06:33Z","audioUrl":"https://files.quartr.com/audio-files/efb13-2025-02-06-03-30-12.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/62518-2025-02-06-03-25-37.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/a2186-2025-02-06-01-26-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-06T14:00:00Z","earningsSummary":{"summary":"IQVIA's Q4 2024 Earnings Call highlighted strong operational performance, revenue growth, and innovation initiatives. The company's TAS business exceeded expectations, and it reaffirmed guidance for 2025, showcasing confidence in future growth. Despite industry challenges, IQVIA's focus on client relationships and innovation underscores its resilience and strategic positioning.","headline":"IQVIA reports robust Q4 results, reaffirms 2025 growth outlook","lastUpdated":"2025-02-06T21:54:36.400432Z"}},{"actual":2.7,"estimate":2.63,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-05-06T11:04:07Z","audioUrl":"https://files.quartr.com/audio-files/ea881-2025-05-06-02-02-26.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/12aa7-2025-05-06-02-12-32.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/a2ebf-2025-05-06-11-15-01.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-06T13:00:00Z","earningsSummary":{"summary":"IQVIA's Q1 2025 performance reflects solid revenue growth, margin improvement strategies, and a positive outlook for the full year, despite some challenges in specific segments. The company's strengths lie in its revenue guidance raise, cost reduction efforts, and ability to capitalize on real-world evidence opportunities, positioning it for future success. While facing challenges in certain revenue segments and FX risks, IQVIA's focus on innovation, cost efficiency, and market adaptability presents promising opportunities for sustained growth.","headline":"IQVIA posts strong Q1 results, raises guidance amid market uncertainties","lastUpdated":"2025-05-06T15:42:16.136400Z"}},{"actual":2.81,"estimate":2.66,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-22T11:01:30Z","audioUrl":"https://files.quartr.com/audio-files/490a3-2025-07-22-02-33-18.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/d8d63-2025-07-22-02-59-11.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/88878-2025-07-22-11-33-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-07-22T13:00:00Z","earningsSummary":{"summary":"IQVIA delivered exceptional Q2 results, surpassing $4 billion in revenue and narrowing full-year guidance ranges. The company's focus on AI innovation, strong market position, and strategic wins position it well for future growth.","headline":"IQVIA achieves record revenue, narrows guidance, and leads in AI innovation","lastUpdated":"2025-07-22T15:41:23.213079Z"}},{"actual":null,"estimate":2.89,"period":"Q3 2025","fiscalQuarter":"Q3","fiscalYear":2025,"lastUpdated":"2025-07-24T23:31:09Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-10-30T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2022-02-15","title":"Earnings data Q4 2021","quarter":"Q4","hash":"c06ee0ab60f77dd51b7251148da02b916615c6e78a0637aa8a2a93a0c6d9a386"},{"date":"2022-04-27","title":"Earnings data Q1 2022","quarter":"Q1","hash":"f5ee48b0d1ebe09ae46f8245e5aa91432fd556e5cf9ce20fd76b3c759032d066"},{"date":"2022-07-21","title":"Earnings data Q2 2022","quarter":"Q2","hash":"93687526cee80402090fc65475120fb31b4ed7019f675f07f684a15622d4022e"},{"date":"2022-10-26","title":"Earnings data Q3 2022","quarter":"Q3","hash":"5cd6f05f99e8e5d29f7a0e8da9d366e4789530eddac90b193bff541b928eac8b"},{"date":"2023-02-10","title":"Earnings data Q4 2022","quarter":"Q4","hash":"4fd4f17708afc3f2010f12a55c3ae6e1794c2d7a49a6cc6c792712c56c70879d"},{"date":"2023-04-27","title":"Earnings data Q1 2023","quarter":"Q1","hash":"80ec5f96eea407e820f4132c02faf453eda32afc5900166ab8319473b391aa84"},{"date":"2023-08-01","title":"Earnings data Q2 2023","quarter":"Q2","hash":"dc4a02dc4e9c53a31198c4a906e3c175c8337304c8810c757e1c15415888aa96"},{"date":"2023-11-01","title":"Earnings data Q3 2023","quarter":"Q3","hash":"f5ad7a68ac634dbd0964f1a9fab996eead92d73165c16fb042863686b039e4f2"},{"date":"2024-02-14","title":"Earnings data Q4 2023","quarter":"Q4","hash":"420be7dc8ad350d3bb11bba86c6588d4e5716bb6087dc4f87a84c4fe95e2f6ea"},{"date":"2024-05-02","title":"Earnings data Q1 2024","quarter":"Q1","hash":"8bc1364dcbafec24941ab6c67a494face91c213e42c70dcb86f84d964622192d"},{"date":"2024-07-22","title":"Earnings data Q2 2024","quarter":"Q2","hash":"c7f78963bcca4ddc76f50859271775ee68e817561efc662809388bcdefa4e418"},{"date":"2024-10-31","title":"Earnings data Q3 2024","quarter":"Q3","hash":"0a0e2e4b180b3a6042337a28b8b804790efe89a8317d91ad08837849baf72497"},{"date":"2025-02-06","title":"Earnings data Q4 2024","quarter":"Q4","hash":"038a08883e2d8ac5a7ca16f6df80813e7b9c323d819cd0b21b115c9de6fd0715"},{"date":"2025-05-06","title":"Earnings data Q1 2025","quarter":"Q1","hash":"29df36602bf74a2bb7e108f4e7aefefa5ea095939311f184728c21dcea07a061"},{"date":"2025-07-22","title":"Earnings data Q2 2025","quarter":"Q2","hash":"3bcf4fa8bf1bc58b756b86d0220d33ecbec899f7ae8956d50d24da36aa8e5364"},{"date":"2025-10-30","title":"Earnings data Q3 2025","quarter":"Q3","hash":"258dd14c06ff7667a2ec43aed9219ca277ceede5d3735578f390bbbe638b26b8"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"IQVIA Hlds","companyDescription":"IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment, which primarily serves biopharmaceutical customers, provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the broader healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q2 2025","values":[{"financialKey":"REVENUE","value":4015000000,"changePercentage":5.27,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":2970000000,"changePercentage":7.73,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":1045000000,"changePercentage":-1.14,"valueToRevenueRatio":0.2602739726027397},{"financialKey":"OPERATING_EXPENSES","value":509000000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":509000000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":536000000,"changePercentage":-2.19,"valueToRevenueRatio":0.13349937733499379},{"financialKey":"EBITDA","value":812000000,"changePercentage":-0.61,"valueToRevenueRatio":0.20224159402241593},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":276000000,"changePercentage":2.6,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":266000000,"changePercentage":-26.72,"valueToRevenueRatio":null},{"financialKey":"EPS","value":1.5358,"changePercentage":-22.02,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":28632000000,"changePercentage":8.46,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":6345000000,"changePercentage":12.86,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":2188000000,"changePercentage":30.39,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":3406000000,"changePercentage":3.34,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":751000000,"changePercentage":15.9,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":22287000000,"changePercentage":7.27,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":816000000,"changePercentage":6.25,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":20207000000,"changePercentage":5.88,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":1264000000,"changePercentage":36.94,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":22846000000,"changePercentage":16.06,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":7572000000,"changePercentage":14.38,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":1313000000,"changePercentage":12.51,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":124000000,"changePercentage":-32.97,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":6135000000,"changePercentage":16.46,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":15274000000,"changePercentage":16.92,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":14387000000,"changePercentage":17.13,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":887000000,"changePercentage":13.57,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":5786000000,"changePercentage":-13.82,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":5778000000,"changePercentage":-13.94,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":8000000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":28632000000,"changePercentage":8.46,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":15700000000,"changePercentage":16.73,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":13512000000,"changePercentage":14.78,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":33.98824,"changePercentage":-7.71,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":266000000,"changePercentage":-26.72,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":443000000,"changePercentage":-24.66,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":547000000,"changePercentage":-18.36,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-104000000,"changePercentage":-26.83,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-346000000,"changePercentage":-56.56,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":151000000,"changePercentage":5.59,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":-14000000,"changePercentage":41.67,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":181000000,"changePercentage":74.04,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-664000000,"changePercentage":-49.55,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":145000000,"changePercentage":155.77,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":-657000000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":827000000,"changePercentage":426.88,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-25000000,"changePercentage":-257.14,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":57000000,"changePercentage":1050,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":299000000,"changePercentage":196.04,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":292000000,"changePercentage":-34.38,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-25T02:40:46Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-07-17T06:15:03Z","bearsSay":["IQVIA Holdings Inc. faces significant headwinds, including a prolonged impact from COVID-19 and rising interest expenses, which have negatively influenced investor sentiment and earnings per share (EPS) growth since the first quarter of 2022. The company's backlog has seen a flat trend due to foreign exchange challenges, leading to a $500 million downward revision, while ongoing pricing pressures have contributed to a sequential decline in gross margins of 60 basis points. Furthermore, the outlook on research and development segment growth is hindered by an anticipated $100 million revenue decline related to COVID, further complicating the company’s ability to maintain positive growth in a deteriorating biopharma funding environment."],"bullsSay":["IQVIA Holdings is positioned for a positive financial outlook due to a robust increase in its RFP flow, which rose by 5% across all market segments, notably in the EBP sector, indicating strong organic demand. The company anticipates a 5.5% growth in NTM backlog, suggesting that secured contracts will support revenue growth as the market stabilizes, potentially accelerating revenue growth to 4-7% in 2025. Additionally, IQVIA's strategic plan to invest $2 billion in capital for mergers and acquisitions, as well as share repurchases, further underscores its commitment to enhancing business operations and shareholder value."],"charts":[{"title":"Revenue Segments","description":"Revenue segments as reported by the company.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Technology \u0026 Analytics Solutions","dataPoints":[{"key":"21 Q3","value":1337},{"key":"21 Q4","value":1496},{"key":"22 Q1","value":1439},{"key":"22 Q2","value":1408},{"key":"22 Q3","value":1400},{"key":"22 Q4","value":1499},{"key":"23 Q1","value":1444},{"key":"23 Q2","value":1456},{"key":"23 Q3","value":1431},{"key":"23 Q4","value":1531},{"key":"24 Q1","value":1453},{"key":"24 Q2","value":1495},{"key":"24 Q3","value":1554},{"key":"24 Q4","value":1658},{"key":"25 Q1","value":1546},{"key":"25 Q2","value":1628}]},{"title":"Research \u0026 Development Solutions","dataPoints":[{"key":"21 Q3","value":1853},{"key":"21 Q4","value":1944},{"key":"22 Q1","value":1934},{"key":"22 Q2","value":1950},{"key":"22 Q3","value":1979},{"key":"22 Q4","value":2058},{"key":"23 Q1","value":2026},{"key":"23 Q2","value":2096},{"key":"23 Q3","value":2122},{"key":"23 Q4","value":2151},{"key":"24 Q1","value":2095},{"key":"24 Q2","value":2147},{"key":"24 Q3","value":2162},{"key":"24 Q4","value":2123},{"key":"25 Q1","value":2102},{"key":"25 Q2","value":2201}]},{"title":"Contract Sales \u0026 Medical Solutions","dataPoints":[{"key":"21 Q3","value":201},{"key":"21 Q4","value":196},{"key":"22 Q1","value":195},{"key":"22 Q2","value":183},{"key":"22 Q3","value":183},{"key":"22 Q4","value":182},{"key":"23 Q1","value":182},{"key":"23 Q2","value":176},{"key":"23 Q3","value":183},{"key":"23 Q4","value":186},{"key":"24 Q1","value":189},{"key":"24 Q2","value":172},{"key":"24 Q3","value":180},{"key":"24 Q4","value":177},{"key":"25 Q1","value":181},{"key":"25 Q2","value":188}]}],"overlayChart":null},{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q3","value":33.55},{"key":"21 Q4","value":34.98},{"key":"22 Q1","value":34.89},{"key":"22 Q2","value":34.17},{"key":"22 Q3","value":34.83},{"key":"22 Q4","value":35.62},{"key":"23 Q1","value":34.33},{"key":"23 Q2","value":34.46},{"key":"23 Q3","value":35.06},{"key":"23 Q4","value":35.93},{"key":"24 Q1","value":34.59},{"key":"24 Q2","value":34.76},{"key":"24 Q3","value":35.36},{"key":"24 Q4","value":34.81},{"key":"25 Q1","value":33.89},{"key":"25 Q2","value":32.93}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q3","value":8.9},{"key":"21 Q4","value":12.73},{"key":"22 Q1","value":13.87},{"key":"22 Q2","value":12.79},{"key":"22 Q3","value":13.25},{"key":"22 Q4","value":10.13},{"key":"23 Q1","value":12.89},{"key":"23 Q2","value":14.05},{"key":"23 Q3","value":12.87},{"key":"23 Q4","value":12.95},{"key":"24 Q1","value":13.54},{"key":"24 Q2","value":13.63},{"key":"24 Q3","value":14.11},{"key":"24 Q4","value":15.81},{"key":"25 Q1","value":12.95},{"key":"25 Q2","value":12.59}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q3","value":7.69},{"key":"21 Q4","value":8.74},{"key":"22 Q1","value":9.1},{"key":"22 Q2","value":7.22},{"key":"22 Q3","value":7.94},{"key":"22 Q4","value":6.07},{"key":"23 Q1","value":7.91},{"key":"23 Q2","value":7.96},{"key":"23 Q3","value":8.11},{"key":"23 Q4","value":12.12},{"key":"24 Q1","value":7.7},{"key":"24 Q2","value":9.51},{"key":"24 Q3","value":7.31},{"key":"24 Q4","value":11.04},{"key":"25 Q1","value":6.5},{"key":"25 Q2","value":6.62}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Selling, general and administrative expenses","dataPoints":[{"key":"21 Q3","value":498},{"key":"21 Q4","value":542},{"key":"22 Q1","value":488},{"key":"22 Q2","value":483},{"key":"22 Q3","value":517},{"key":"22 Q4","value":583},{"key":"23 Q1","value":513},{"key":"23 Q2","value":482},{"key":"23 Q3","value":502},{"key":"23 Q4","value":556},{"key":"24 Q1","value":508},{"key":"24 Q2","value":509},{"key":"24 Q3","value":522},{"key":"24 Q4","value":453},{"key":"25 Q1","value":508},{"key":"25 Q2","value":509}]},{"title":"Depreciation and amortization","dataPoints":[{"key":"21 Q3","value":336},{"key":"21 Q4","value":262},{"key":"22 Q1","value":255},{"key":"22 Q2","value":270},{"key":"22 Q3","value":248},{"key":"22 Q4","value":357},{"key":"23 Q1","value":253},{"key":"23 Q2","value":259},{"key":"23 Q3","value":297},{"key":"23 Q4","value":316},{"key":"24 Q1","value":264},{"key":"24 Q2","value":269},{"key":"24 Q3","value":278},{"key":"24 Q4","value":303},{"key":"25 Q1","value":265},{"key":"25 Q2","value":276}]},{"title":"Restructuring costs","dataPoints":[{"key":"21 Q3","value":2},{"key":"21 Q4","value":5},{"key":"22 Q1","value":7},{"key":"22 Q2","value":4},{"key":"22 Q3","value":4},{"key":"22 Q4","value":13},{"key":"23 Q1","value":17},{"key":"23 Q2","value":20},{"key":"23 Q3","value":30},{"key":"23 Q4","value":17},{"key":"24 Q1","value":15},{"key":"24 Q2","value":28},{"key":"24 Q3","value":28},{"key":"24 Q4","value":-4},{"key":"25 Q1","value":29},{"key":"25 Q2","value":32}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q3","value":21.72},{"key":"21 Q4","value":10.25},{"key":"22 Q1","value":4.66},{"key":"22 Q2","value":3},{"key":"22 Q3","value":5.04},{"key":"22 Q4","value":2.83},{"key":"23 Q1","value":2.35},{"key":"23 Q2","value":5.28},{"key":"23 Q3","value":4.88},{"key":"23 Q4","value":3.45},{"key":"24 Q1","value":2.33},{"key":"24 Q2","value":2.31},{"key":"24 Q3","value":4.28},{"key":"24 Q4","value":2.33},{"key":"25 Q1","value":2.46},{"key":"25 Q2","value":5.32}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q3","value":4.63},{"key":"21 Q4","value":-3.35},{"key":"22 Q1","value":-3.1},{"key":"22 Q2","value":-8.69},{"key":"22 Q3","value":-8.01},{"key":"22 Q4","value":17.8},{"key":"23 Q1","value":4.4},{"key":"23 Q2","value":0.53},{"key":"23 Q3","value":7.8},{"key":"23 Q4","value":-6.72},{"key":"24 Q1","value":0.51},{"key":"24 Q2","value":5.91},{"key":"24 Q3","value":-0.12},{"key":"24 Q4","value":-15.41},{"key":"25 Q1","value":1.91},{"key":"25 Q2","value":1.36}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q3","value":191.5},{"key":"21 Q4","value":190.8},{"key":"22 Q1","value":190},{"key":"22 Q2","value":188.3},{"key":"22 Q3","value":186.5},{"key":"22 Q4","value":185.7},{"key":"23 Q1","value":185.8},{"key":"23 Q2","value":184.4},{"key":"23 Q3","value":182.9},{"key":"23 Q4","value":181.9},{"key":"24 Q1","value":181.9},{"key":"24 Q2","value":182.2},{"key":"24 Q3","value":182.1},{"key":"24 Q4","value":178.9},{"key":"25 Q1","value":175.7},{"key":"25 Q2","value":171.8}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q3","value":48334.6},{"key":"21 Q4","value":49512.6},{"key":"22 Q1","value":44992},{"key":"22 Q2","value":40898.76},{"key":"22 Q3","value":40862.15},{"key":"22 Q4","value":37659.96},{"key":"23 Q1","value":39705.46},{"key":"23 Q2","value":37027.52},{"key":"23 Q3","value":39707.59},{"key":"23 Q4","value":37344.07},{"key":"24 Q1","value":42473.65},{"key":"24 Q2","value":41395.84},{"key":"24 Q3","value":42975.6},{"key":"24 Q4","value":37730.01},{"key":"25 Q1","value":34085.8},{"key":"25 Q2","value":25855.9}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q3","value":3.56},{"key":"21 Q4","value":3.4},{"key":"22 Q1","value":3.15},{"key":"22 Q2","value":2.89},{"key":"22 Q3","value":2.87},{"key":"22 Q4","value":2.52},{"key":"23 Q1","value":2.72},{"key":"23 Q2","value":2.48},{"key":"23 Q3","value":2.66},{"key":"23 Q4","value":2.41},{"key":"24 Q1","value":2.84},{"key":"24 Q2","value":2.71},{"key":"24 Q3","value":2.76},{"key":"24 Q4","value":2.38},{"key":"25 Q1","value":2.23},{"key":"25 Q2","value":1.61}]}],"overlayChart":null}],"chartsLastUpdated":"2025-07-22T13:36:17Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":null,"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"BIIB","name":"Biogen","displayName":"Biogen","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"BIIB","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":130.98,"high":132.65,"low":130,"volume":3,"volumeDate":"2025-07-25","last":132.59,"open":130.78,"gainPercentage":1.229,"gainValue":1.61,"ask":133.21,"bid":132,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":19428147500,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":1456279.2581,"highPriceLast52Weeks":219.44,"lowPriceLast52Weeks":110.035,"companyName":"Biogen, Inc.","longBusinessDescription":"Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.","dividendRate":0,"salesOrRevenue":9266600000,"oneYearAnnualRevenueGrowthRate":-1.59711160666879,"threeYearAnnualRevenueGrowthRate":-3.6954,"fiveYearAnnualRevenueGrowthRate":-5.9426,"earningsGrowth":26.0993,"totalDebt":6716700000,"totalAssets":28049300000,"floatAsPercentOfSharesOutstanding":99.8144,"dividendYield":0,"betaTwelveMonth":0.6331,"salesOrRevenueTtm":9402300000,"ebitdaTtm":2875900000,"debtToEquityRatioQuarterly":38.9970963619123,"totalEnterpriseValue":26652728000,"industry":"PharmaceuticalsMajor","sector":"HealthTechnology","preTaxInterestCoverageRatio":8.37948717948718,"fiveYearAverageDebtEquityRatio":52.18,"currentRatio":1.43957413070563,"peratio":13.09},"recommendation":{"currentConsensusRating":2,"recommendationTargetPrice":252.36,"totalRatings":42,"strongSellRatings":0,"sellRatings":0,"holdRatings":13,"buyRatings":14,"strongBuyRatings":15,"lastUpdated":"2025-06-27T12:59:59Z"},"earningEstimates":[{"actual":4.77,"estimate":4.11,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-10-20T11:19:37Z","audioUrl":"https://files.quartr.com/audio-files/9571a-2022-10-18-06-21-47.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/14d49-2023-01-25-09-34-24.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-10-20T00:00:00Z","earningsSummary":null},{"actual":3.39,"estimate":3.4,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-03T14:41:57Z","audioUrl":"https://files.quartr.com/audio-files/2e11a-2022-10-19-10-09-29.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/8f86f-2022-02-03-07-35-58-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/bfc73-2023-01-25-12-58-20.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-03T19:58:35Z","earningsSummary":null},{"actual":3.62,"estimate":4.38,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-05-03T11:25:56Z","audioUrl":"https://files.quartr.com/audio-files/03493-2022-10-28-04-31-57.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/72c39-2022-05-03-10-31-35-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/38835-2023-01-25-01-50-21.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-05-03T10:35:31Z","earningsSummary":null},{"actual":5.25,"estimate":4.1,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-07-20T11:25:09Z","audioUrl":"https://files.quartr.com/audio-files/0d250-2022-07-20-01-14-16.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/c119c-2022-07-20-11-23-15.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/44ba8-2022-07-20-11-54-13.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-07-20T11:15:00Z","earningsSummary":null},{"actual":4.77,"estimate":4.16,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-10-25T11:09:43Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_10_25T12_00_00_00_00_Biogen_Inc_Earnings_Call_Q3_2022.LIB3X4MHB1KT_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/72e08-2022-10-25-11-12-32.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/c5072-2022-10-25-11-11-32.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-10-25T12:30:00Z","earningsSummary":null},{"actual":4.05,"estimate":3.48,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-15T12:06:49Z","audioUrl":"https://files.quartr.com/audio-files/5fb81-2023-02-15-02-59-13.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/reports/4dc8e-2023-02-15-12-48-01.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/conference-calls/10d18-2023-02-15-12-16-01.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-15T13:00:00Z","earningsSummary":{"summary":"Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.\nThe company is prioritizing cost-saving initiatives and strategic product launches for growth.\nChallenges include managing expenses, evaluating R\u0026D programs, and balancing cost reductions with investments.\nOpportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.","headline":"Biogen reports Q4 results, focuses on cost-saving and growth strategies","lastUpdated":"2024-05-07T16:10:17.712725Z"}},{"actual":3.4,"estimate":3.28,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-04-25T11:03:20Z","audioUrl":"https://files.quartr.com/audio-files/0f235-2023-04-25-02-31-08.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/ff45b-2023-04-25-11-31-08.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/bb30f-2023-04-25-10-55-59.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-04-25T12:00:00Z","earningsSummary":{"summary":"Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.\nThe company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.\nChallenges include reimbursement expectations and managing the transition period until 2025.\nOpportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.","headline":"Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches","lastUpdated":"2024-05-07T16:48:22.310080Z"}},{"actual":4.02,"estimate":3.77,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-07-25T11:05:40Z","audioUrl":"https://files.quartr.com/audio-files/3add5-2023-07-25-01-00-27.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/146d4-2023-07-25-11-38-07.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/e34ae-2023-07-25-11-38-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-07-25T12:00:00Z","earningsSummary":{"summary":"Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.","headline":"Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism","lastUpdated":"2024-05-07T16:28:11.565125Z"}},{"actual":4.36,"estimate":3.99,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-11-08T12:03:44Z","audioUrl":"https://files.quartr.com/audio-files/c33e5-2023-11-08-02-28-10.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/cd6c5-2023-11-08-12-07-15.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/e86b2-2023-11-08-12-53-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-08T13:00:00Z","earningsSummary":{"summary":"Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.\nStrengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.\nChallenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.\nOpportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.","headline":"Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion","lastUpdated":"2024-05-07T17:47:23.339462Z"}},{"actual":2.95,"estimate":3.18,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-13T12:06:20Z","audioUrl":"https://files.quartr.com/audio-files/91d5c-2024-02-13-02-13-29.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/8ff6a-2024-02-13-12-45-14.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/9f917-2024-02-13-12-29-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-13T13:00:00Z","earningsSummary":{"summary":"Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.\nThe company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.\nChallenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.\nOverall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.","headline":"Biogen reports Q4 revenue decline but eyes growth opportunities","lastUpdated":"2024-05-07T18:41:10.906324Z"}},{"actual":3.67,"estimate":3.44,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-04-24T11:49:21Z","audioUrl":"https://files.quartr.com/audio-files/c8135-2024-04-24-02-06-14.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/2f62f-2024-04-24-11-21-17.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/ba4ae-2024-04-24-11-23-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-04-24T12:30:00Z","earningsSummary":{"summary":"Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.","headline":"Biogen reports robust Q1 earnings, focuses on market expansion","lastUpdated":"2024-05-07T17:24:58.956518Z"}},{"actual":5.28,"estimate":4.02,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-08-01T11:08:29Z","audioUrl":"https://files.quartr.com/audio-files/08718-2024-08-01-01-49-47.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/0abe4-2024-08-01-10-23-58.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/ed9c6-2024-08-01-10-58-57.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-01T12:30:00Z","earningsSummary":{"summary":"Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R\u0026D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.","headline":"Biogen reports robust Q2 earnings, eyes growth in new launches","lastUpdated":"2024-08-01T16:31:22.406392Z"}},{"actual":4.08,"estimate":3.79,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-10-30T11:38:32Z","audioUrl":"https://files.quartr.com/audio-files/cd1ab-2024-10-30-01-15-42.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/36514-2024-10-30-11-11-11.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/faf67-2024-10-30-10-22-57.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-10-30T12:30:00Z","earningsSummary":{"summary":"Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.\nThe company faces challenges in certain product segments but shows strength in new product development.\nOpportunities lie in expanding market presence, new product launches, and potential business development.\nDespite profitability challenges, Biogen's focus on growth strategies positions it for future success.","headline":"Biogen reports mixed Q3 results, focuses on growth strategies","lastUpdated":"2024-10-30T16:45:26.845886Z"}},{"actual":3.44,"estimate":3.35,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-12T12:00:34Z","audioUrl":"https://files.quartr.com/audio-files/14f8e-2025-02-12-02-56-56.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/1fc81-2025-02-12-12-02-07.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/3b214-2025-02-12-12-45-02.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-12T13:30:00Z","earningsSummary":{"summary":"Biogen's Q4 2024 performance was marked by revenue growth and successful product launches. While facing challenges like revenue decline, the company is focused on cost-saving measures and growth investments. Opportunities lie in expanding product lines, exploring external partnerships, and driving innovation. Overall, Biogen's financial results and strategic focus position it for continued growth and success.","headline":"Biogen reports revenue growth and product success amidst future challenges","lastUpdated":"2025-02-12T17:50:21.306894Z"}},{"actual":3.02,"estimate":2.52,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-05-01T11:02:47Z","audioUrl":"https://files.quartr.com/audio-files/daf18-2025-05-01-01-21-44.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/81594-2025-05-01-11-42-17.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f0763-2025-05-01-10-52-54.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-01T12:30:00Z","earningsSummary":{"summary":"Biogen's Q1 performance reflects a strong start to the year, driven by rare disease products and successful product launches, despite challenges in the MS franchise. The company's focus on R\u0026D advancements and disciplined approach to business development position it well for future growth and innovation. With adjusted full-year EPS guidance and a robust late-stage pipeline, Biogen remains resilient in navigating market challenges and capitalizing on growth opportunities.","headline":"Biogen reports solid Q1 earnings, eyes pipeline expansion for growth","lastUpdated":"2025-05-01T15:50:19.515065Z"}},{"actual":null,"estimate":3.92,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-23T23:30:21Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-07-31T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-10-20","title":"Earnings data Q3 2021","quarter":"Q3","hash":"4f896454ac9d34e397edbca5f9affcd4f0b004fd5fb67901d29933751bd163a5"},{"date":"2022-02-03","title":"Earnings data Q4 2021","quarter":"Q4","hash":"703dd9445d719a9088b8a1ffe00a1dcecf2a79e25ee9d0288383d1090d2a357b"},{"date":"2022-05-03","title":"Earnings data Q1 2022","quarter":"Q1","hash":"0919ede1b9df0f295eb3a7660a1889b707425e1b6090f707a923e6a50087ecf4"},{"date":"2022-07-20","title":"Earnings data Q2 2022","quarter":"Q2","hash":"d1c223afb644cf293f5053ba5e60a8ce1086075cc5fd70a49dbbe10d44202af6"},{"date":"2022-10-25","title":"Earnings data Q3 2022","quarter":"Q3","hash":"e59d33dd9ca7a7c5fb33000037cc3fe9efa3d6b646ec3f955354e6154d3fb714"},{"date":"2023-02-15","title":"Earnings data Q4 2022","quarter":"Q4","hash":"8bbd9412e515647891290a9b2fec429b0acfb5d4aabc3c6067dc583163b0bc35"},{"date":"2023-04-25","title":"Earnings data Q1 2023","quarter":"Q1","hash":"f9feb7f03cc6d64f45d23485f4fe672694b031bf608412cf59c75b7e079cd25a"},{"date":"2023-07-25","title":"Earnings data Q2 2023","quarter":"Q2","hash":"968a69f738489d72bcfd35096a63559ae5f79874e749586508b2b4838555db0e"},{"date":"2023-11-08","title":"Earnings data Q3 2023","quarter":"Q3","hash":"52395b8129e380885f2acc5d01d34713c6f2e9dc67bdd76bcfdd73c9c80d4bcf"},{"date":"2024-02-13","title":"Earnings data Q4 2023","quarter":"Q4","hash":"2bdbff0e8fc2010570f3c57d4d3bf093ee7730fcb20f880e84fb77f5cf154377"},{"date":"2024-04-24","title":"Earnings data Q1 2024","quarter":"Q1","hash":"212c4e3eaae42eee1bf5c2e30fab148706c7130f5e6ad0b355a5a29144b913cb"},{"date":"2024-08-01","title":"Earnings data Q2 2024","quarter":"Q2","hash":"ec240630089dd6504f0d13d9ed61f7da8b4d14afa8776197bce8c161ebc6746e"},{"date":"2024-10-30","title":"Earnings data Q3 2024","quarter":"Q3","hash":"b0a2d28b2870625eaaf7beb98165b77a29ceed257b14f36809330ebef3a09a43"},{"date":"2025-02-12","title":"Earnings data Q4 2024","quarter":"Q4","hash":"62f50334306217986713dae24ddd568eb096c069d199a5c3d2b589c55b6d21cb"},{"date":"2025-05-01","title":"Earnings data Q1 2025","quarter":"Q1","hash":"1468f876f9687a0bcb583fdedd60fdcd4e669ccb1ebcd3044ed8340566e3904f"},{"date":"2025-07-31","title":"Earnings data Q2 2025","quarter":"Q2","hash":"4bb7c6f5bad87ee0b59a142c94e4c04eb3ccd25a889fc64f7dab37b94a4d83a1"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Biogen","companyDescription":"Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":2336000000,"changePercentage":6.17,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":812500000,"changePercentage":17.79,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":1523500000,"changePercentage":0.86,"valueToRevenueRatio":0.6521832191780822},{"financialKey":"OPERATING_EXPENSES","value":935200000,"changePercentage":-3.1,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":935200000,"changePercentage":-3.1,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":588300000,"changePercentage":7.87,"valueToRevenueRatio":0.25184075342465756},{"financialKey":"EBITDA","value":771500000,"changePercentage":11.33,"valueToRevenueRatio":0.3302654109589041},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":183200000,"changePercentage":24.12,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":240500000,"changePercentage":-38.87,"valueToRevenueRatio":null},{"financialKey":"EPS","value":1.6405,"changePercentage":-39.16,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":28033100000,"changePercentage":5.52,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":7626000000,"changePercentage":12.87,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":2598300000,"changePercentage":141.84,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":1996500000,"changePercentage":-0.16,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":2273900000,"changePercentage":-9.65,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":757300000,"changePercentage":-35.01,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":20407100000,"changePercentage":3.01,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":3478800000,"changePercentage":-6.06,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":16061700000,"changePercentage":10.68,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":866600000,"changePercentage":-45.7,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":11054400000,"changePercentage":-2.64,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":5297400000,"changePercentage":64.37,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":1749100000,"changePercentage":599.64,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":626100000,"changePercentage":170.8,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":2922200000,"changePercentage":6.59,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":5757000000,"changePercentage":-29.2,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":4872100000,"changePercentage":-27.25,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":884900000,"changePercentage":-38.34,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":16978700000,"changePercentage":11.61,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":16978700000,"changePercentage":11.61,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":28033100000,"changePercentage":5.52,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":6621200000,"changePercentage":-4.68,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":4022900000,"changePercentage":-31.49,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":115.89556,"changePercentage":10.92,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":240500000,"changePercentage":-38.87,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":259300000,"changePercentage":-53.13,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":592800000,"changePercentage":-24.18,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-333500000,"changePercentage":-45.82,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-47300000,"changePercentage":28.33,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":47100000,"changePercentage":-61.04,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-94400000,"changePercentage":61.07,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-23000000,"changePercentage":94.77,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":-24300000,"changePercentage":48.19,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":0,"changePercentage":100,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":1300000,"changePercentage":-82.19,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":34300000,"changePercentage":248.48,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":223300000,"changePercentage":811.43,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":222200000,"changePercentage":-56.2,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:13:03Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-07-17T05:28:55Z","bearsSay":["Biogen's outlook appears negative primarily due to management's guidance indicating a mid-single-digit decline in total revenue for 2025, largely driven by the expected entry of Sandoz's biosimilar for Tysabri in the U.S. Additionally, the company anticipates a significant impact on non-GAAP EPS from foreign exchange headwinds and continued erosion in its multiple sclerosis business, despite potential revenue growth from newly launched products. Concerns about declining core pharmaceutical revenue, particularly from established MS products affected by biosimilars and generics, further exacerbate the adverse financial outlook."],"bullsSay":["Biogen has demonstrated strong commercial execution with rapid uptake of new product launches, particularly Leqembi, Skyclaris, and Zurzuvae, which have exceeded consensus expectations. The company is also well-positioned for future growth through strategic initiatives like its expanding biosimilar pipeline and anticipated expansion into international markets, particularly in China and Japan. Furthermore, Biogen is on track to achieve significant cost savings from its \"Fit for Growth\" initiative, which is expected to contribute positively to earnings and overall stock performance."],"charts":[{"title":"Revenue Segments","description":"Revenue segments as reported by the company.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Product, net","dataPoints":[{"key":"21 Q2","value":2236},{"key":"21 Q3","value":2205.7},{"key":"21 Q4","value":2193.5},{"key":"22 Q1","value":2066.3},{"key":"22 Q2","value":2054.9},{"key":"22 Q3","value":1962.1},{"key":"22 Q4","value":1904.5},{"key":"23 Q1","value":1763.3},{"key":"23 Q2","value":1845.8},{"key":"23 Q3","value":1805.2},{"key":"23 Q4","value":1832.4},{"key":"24 Q1","value":1711.9},{"key":"24 Q2","value":1899.6},{"key":"24 Q3","value":1769.4},{"key":"24 Q4","value":1832.6},{"key":"25 Q1","value":1726.5}]},{"title":"Revenue from anti-CD20 therapeutic programs","dataPoints":[{"key":"21 Q2","value":440},{"key":"21 Q3","value":415.4},{"key":"21 Q4","value":414.1},{"key":"22 Q1","value":399.4},{"key":"22 Q2","value":436.3},{"key":"22 Q3","value":416.9},{"key":"22 Q4","value":447.9},{"key":"23 Q1","value":399.5},{"key":"23 Q2","value":433.4},{"key":"23 Q3","value":420.9},{"key":"23 Q4","value":435.8},{"key":"24 Q1","value":394},{"key":"24 Q2","value":444.5},{"key":"24 Q3","value":446.2},{"key":"24 Q4","value":465.2},{"key":"25 Q1","value":378.2}]},{"title":"Other","dataPoints":[{"key":"21 Q2","value":99},{"key":"21 Q3","value":157.8},{"key":"21 Q4","value":126.2},{"key":"22 Q1","value":66.1},{"key":"22 Q2","value":97.9},{"key":"22 Q3","value":129.5},{"key":"22 Q4","value":191.6},{"key":"23 Q1","value":319.1},{"key":"23 Q2","value":197.5},{"key":"23 Q3","value":304.2},{"key":"23 Q4","value":118.1},{"key":"24 Q1","value":184.6},{"key":"24 Q2","value":120.8},{"key":"24 Q3","value":250.2},{"key":"24 Q4","value":156.9},{"key":"25 Q1","value":326.3}]},{"title":"Revenue from LEQEMBI Collaboration","dataPoints":[{"key":"23 Q1","value":-18.9},{"key":"23 Q2","value":-20.7}]}],"overlayChart":null},{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q2","value":83.43},{"key":"21 Q3","value":81.58},{"key":"21 Q4","value":75.85},{"key":"22 Q1","value":70.22},{"key":"22 Q2","value":81.3},{"key":"22 Q3","value":81.28},{"key":"22 Q4","value":77.55},{"key":"23 Q1","value":73.08},{"key":"23 Q2","value":75.86},{"key":"23 Q3","value":73.93},{"key":"23 Q4","value":74.08},{"key":"24 Q1","value":76.32},{"key":"24 Q2","value":77.84},{"key":"24 Q3","value":74.09},{"key":"24 Q4","value":76.22},{"key":"25 Q1","value":74.11}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q2","value":17.5},{"key":"21 Q3","value":28.57},{"key":"21 Q4","value":21.47},{"key":"22 Q1","value":24.12},{"key":"22 Q2","value":49.03},{"key":"22 Q3","value":54.65},{"key":"22 Q4","value":23.73},{"key":"23 Q1","value":17.79},{"key":"23 Q2","value":28.83},{"key":"23 Q3","value":-5.59},{"key":"23 Q4","value":12.21},{"key":"24 Q1","value":20.29},{"key":"24 Q2","value":28.34},{"key":"24 Q3","value":18.29},{"key":"24 Q4","value":11.87},{"key":"25 Q1","value":12.8}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q2","value":16.16},{"key":"21 Q3","value":11.84},{"key":"21 Q4","value":13.46},{"key":"22 Q1","value":11.99},{"key":"22 Q2","value":40.86},{"key":"22 Q3","value":45.23},{"key":"22 Q4","value":21.63},{"key":"23 Q1","value":15.74},{"key":"23 Q2","value":24.08},{"key":"23 Q3","value":-2.7},{"key":"23 Q4","value":10.46},{"key":"24 Q1","value":17.17},{"key":"24 Q2","value":23.67},{"key":"24 Q3","value":15.75},{"key":"24 Q4","value":10.86},{"key":"25 Q1","value":9.89}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Research and development","dataPoints":[{"key":"21 Q2","value":585.1},{"key":"21 Q3","value":702.4},{"key":"21 Q4","value":699.5},{"key":"22 Q1","value":551.7},{"key":"22 Q2","value":528.6},{"key":"22 Q3","value":549.2},{"key":"22 Q4","value":601.6},{"key":"23 Q1","value":570.6},{"key":"23 Q2","value":584.2},{"key":"23 Q3","value":736.3},{"key":"23 Q4","value":570.9},{"key":"24 Q1","value":452.9},{"key":"24 Q2","value":513.9},{"key":"24 Q3","value":542.7},{"key":"24 Q4","value":532.3},{"key":"25 Q1","value":434.1}]},{"title":"Selling, general and administrative","dataPoints":[{"key":"21 Q2","value":637.3},{"key":"21 Q3","value":654.1},{"key":"21 Q4","value":787.9},{"key":"22 Q1","value":634.9},{"key":"22 Q2","value":572.6},{"key":"22 Q3","value":563.3},{"key":"22 Q4","value":632.8},{"key":"23 Q1","value":605},{"key":"23 Q2","value":548},{"key":"23 Q3","value":788.2},{"key":"23 Q4","value":608.5},{"key":"24 Q1","value":581.5},{"key":"24 Q2","value":553.8},{"key":"24 Q3","value":588.4},{"key":"24 Q4","value":680},{"key":"25 Q1","value":572.5}]},{"title":"Amortization and impairment of acquired intangible assets","dataPoints":[{"key":"21 Q2","value":604.1},{"key":"21 Q3","value":111},{"key":"21 Q4","value":68.1},{"key":"22 Q1","value":66.9},{"key":"22 Q2","value":67.5},{"key":"22 Q3","value":56.5},{"key":"22 Q4","value":175},{"key":"23 Q1","value":50.2},{"key":"23 Q2","value":52.9},{"key":"23 Q3","value":60.9},{"key":"23 Q4","value":76.6},{"key":"24 Q1","value":78.3},{"key":"24 Q2","value":86.9},{"key":"24 Q3","value":130.3},{"key":"24 Q4","value":151.2},{"key":"25 Q1","value":111.8}]},{"title":"Collaboration profit sharing","dataPoints":[{"key":"21 Q2","value":-15.2},{"key":"21 Q3","value":21.2},{"key":"21 Q4","value":-67.3},{"key":"22 Q1","value":-117.3},{"key":"22 Q2","value":29.4},{"key":"22 Q3","value":45.3},{"key":"22 Q4","value":35.2},{"key":"23 Q1","value":57.1},{"key":"23 Q2","value":56.9},{"key":"23 Q3","value":50.5},{"key":"23 Q4","value":54.3},{"key":"24 Q1","value":65.6},{"key":"24 Q2","value":62.4},{"key":"24 Q3","value":69.3},{"key":"24 Q4","value":57.1},{"key":"25 Q1","value":58.1}]},{"title":"(Gain) loss on fair value remeasurement of contingent consideration","dataPoints":[{"key":"21 Q2","value":0.3},{"key":"21 Q3","value":-15.6},{"key":"21 Q4","value":-1.6},{"key":"22 Q1","value":-7.1},{"key":"22 Q2","value":-4.5},{"key":"22 Q3","value":-2.1},{"key":"22 Q4","value":-195.3},{"key":"24 Q3","value":23.8},{"key":"24 Q4","value":3.9},{"key":"25 Q1","value":9.6}]},{"title":"Acquired in-process research and development","dataPoints":[{"key":"21 Q2","value":18},{"key":"25 Q1","value":200.7}]},{"title":"Restructuring charges","dataPoints":[{"key":"22 Q1","value":38.1},{"key":"22 Q2","value":70.6},{"key":"22 Q3","value":15.4},{"key":"22 Q4","value":6.9},{"key":"23 Q1","value":9.6},{"key":"23 Q2","value":34.4},{"key":"23 Q3","value":76},{"key":"23 Q4","value":98.8},{"key":"24 Q1","value":11.5},{"key":"24 Q2","value":6.6},{"key":"24 Q3","value":6.8},{"key":"24 Q4","value":5.3},{"key":"25 Q1","value":35.3}]},{"title":"Other (income) expense, net","dataPoints":[{"key":"22 Q2","value":-428.6},{"key":"22 Q3","value":-56},{"key":"22 Q4","value":113.1},{"key":"23 Q1","value":69.4},{"key":"23 Q2","value":-121.2},{"key":"23 Q3","value":300},{"key":"23 Q4","value":67.3},{"key":"24 Q1","value":93.7},{"key":"24 Q2","value":85.2},{"key":"24 Q3","value":14.8},{"key":"24 Q4","value":149.9},{"key":"25 Q1","value":68.4}]},{"title":"Gain on sale of building","dataPoints":[{"key":"22 Q3","value":-503.7}]},{"title":"Gain on sale of PRV","dataPoints":[{"key":"24 Q2","value":-88.6}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q2","value":-24.63},{"key":"21 Q3","value":-17.69},{"key":"21 Q4","value":-4.16},{"key":"22 Q1","value":-6.02},{"key":"22 Q2","value":-6.7},{"key":"22 Q3","value":-9.73},{"key":"22 Q4","value":-6.94},{"key":"23 Q1","value":-2.72},{"key":"23 Q2","value":-5.14},{"key":"23 Q3","value":0.87},{"key":"23 Q4","value":-6.2},{"key":"24 Q1","value":-7},{"key":"24 Q2","value":0.36},{"key":"24 Q3","value":-2.55},{"key":"24 Q4","value":2.87},{"key":"25 Q1","value":6.13}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q2","value":41.17},{"key":"21 Q3","value":-19.97},{"key":"21 Q4","value":-44.79},{"key":"22 Q1","value":-6.02},{"key":"22 Q2","value":-54.33},{"key":"22 Q3","value":-54.66},{"key":"22 Q4","value":-7.89},{"key":"23 Q1","value":16.68},{"key":"23 Q2","value":38.25},{"key":"23 Q3","value":201.23},{"key":"23 Q4","value":7.82},{"key":"24 Q1","value":-5.76},{"key":"24 Q2","value":5.63},{"key":"24 Q3","value":-31.6},{"key":"24 Q4","value":7},{"key":"25 Q1","value":16.13}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q2","value":149.7},{"key":"21 Q3","value":148},{"key":"21 Q4","value":146.9},{"key":"22 Q1","value":147.1},{"key":"22 Q2","value":145.9},{"key":"22 Q3","value":144.4},{"key":"22 Q4","value":144.1},{"key":"23 Q1","value":144.4},{"key":"23 Q2","value":144.7},{"key":"23 Q3","value":144.8},{"key":"23 Q4","value":144.9},{"key":"24 Q1","value":145.2},{"key":"24 Q2","value":145.6},{"key":"24 Q3","value":145.7},{"key":"24 Q4","value":145.7},{"key":"25 Q1","value":146.1}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q2","value":45350.268},{"key":"21 Q3","value":48507.296},{"key":"21 Q4","value":37771.369},{"key":"22 Q1","value":31988.513},{"key":"22 Q2","value":29825.753},{"key":"22 Q3","value":30667.672},{"key":"22 Q4","value":40699.172},{"key":"23 Q1","value":39955.047},{"key":"23 Q2","value":43099.908},{"key":"23 Q3","value":38729.511},{"key":"23 Q4","value":35589.903},{"key":"24 Q1","value":34006.13},{"key":"24 Q2","value":31642.374},{"key":"24 Q3","value":30481.751},{"key":"24 Q4","value":24575.073},{"key":"25 Q1","value":20885.872}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q2","value":4.09},{"key":"21 Q3","value":4.36},{"key":"21 Q4","value":3.45},{"key":"22 Q1","value":3.16},{"key":"22 Q2","value":2.88},{"key":"22 Q3","value":3.06},{"key":"22 Q4","value":4},{"key":"23 Q1","value":4.06},{"key":"23 Q2","value":4.39},{"key":"23 Q3","value":3.83},{"key":"23 Q4","value":3.73},{"key":"24 Q1","value":3.71},{"key":"24 Q2","value":3.21},{"key":"24 Q3","value":3.09},{"key":"24 Q4","value":2.5},{"key":"25 Q1","value":2.15}]}],"overlayChart":null}],"chartsLastUpdated":"2025-05-01T12:54:42Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":null,"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"CRL","name":"Charles River Laboratories","displayName":"Charles River Laboratories","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"CRL","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":167.95,"high":184.17,"low":173.5,"volume":1744443,"volumeDate":"2025-07-24","last":177.1,"open":173.5,"gainPercentage":5.448,"gainValue":9.15,"ask":184,"bid":107,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":8698390500,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":1042791.2419,"highPriceLast52Weeks":254.15,"lowPriceLast52Weeks":91.8609,"companyName":"Charles River Laboratories International, Inc.","longBusinessDescription":"Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The Research Models and Services segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The Discovery and Safety Assessment segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.","dividendRate":0,"salesOrRevenue":4049989000,"oneYearAnnualRevenueGrowthRate":-1.92327764094086,"threeYearAnnualRevenueGrowthRate":4.7488,"fiveYearAnnualRevenueGrowthRate":9.374,"earningsGrowth":-107.3128,"totalDebt":2781082000,"totalAssets":7528345000,"floatAsPercentOfSharesOutstanding":98.8761,"dividendYield":0,"betaTwelveMonth":1.4673,"salesOrRevenueTtm":4022597000,"ebitdaTtm":911636000,"debtToEquityRatioQuarterly":93.5823282209511,"totalEnterpriseValue":12093120760,"industry":"MiscellaneousCommercialServices","sector":"CommercialServices","preTaxInterestCoverageRatio":4.48877169643988,"fiveYearAverageDebtEquityRatio":96.34,"currentRatio":1.43318665531299,"peratio":-272.46},"recommendation":{"currentConsensusRating":2.1,"recommendationTargetPrice":196.13,"totalRatings":31,"strongSellRatings":0,"sellRatings":1,"holdRatings":12,"buyRatings":8,"strongBuyRatings":10,"lastUpdated":"2025-07-09T12:43:55Z"},"earningEstimates":[{"actual":2.7,"estimate":2.58,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-11-03T11:30:43Z","audioUrl":"https://files.quartr.com/audio-files/f7581-2022-10-19-04-14-28.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/dbd7f-2023-02-22-12-48-54.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/2503c-2024-08-28-11-36-31.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-11-03T00:00:00Z","earningsSummary":null},{"actual":2.49,"estimate":2.43,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-16T12:07:07Z","audioUrl":"https://files.quartr.com/audio-files/16a39-2022-10-19-11-43-16.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/4c7f5-2022-02-16-03-25-27-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/8b69b-2023-01-25-12-05-28.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-16T15:27:25Z","earningsSummary":null},{"actual":2.75,"estimate":2.71,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-05-04T11:51:03Z","audioUrl":"https://files.quartr.com/audio-files/d237c-2022-10-28-05-21-05.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/5122c-2022-05-04-09-38-19-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/7e955-2023-01-25-01-16-23.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-05-04T09:19:38Z","earningsSummary":null},{"actual":2.77,"estimate":2.74,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-08-03T11:13:39Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_08_03_15_30_Q2_2022_Charles_River_Laboratories_International_Inc_Earnings_Call.AMECVN7P75Z5_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/9c2ef-2022-08-03-12-55-04.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/ec2f7-2022-08-03-11-08-13.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-03T09:40:00Z","earningsSummary":null},{"actual":2.63,"estimate":2.5,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-11-02T11:08:09Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_11_02T13_00_00_00_00_Charles_River_Laboratories_International_Inc_Earnings_Call_Q3_2022.KEI5IBE887YA_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/8d514-2022-11-02-02-40-06.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f3dd9-2022-11-02-11-19-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-02T11:00:00Z","earningsSummary":null},{"actual":2.98,"estimate":2.75,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-22T12:01:45Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_02_22T13_30_00_00_00_Charles_River_Laboratories_International_Inc_Earnings_Call_Q4_2022.43I5RKSK6S5L_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/26862-2023-02-22-12-30-53.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/0ecb2-2023-02-22-12-19-11.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-22T13:30:00Z","earningsSummary":{"summary":"Charles River Laboratories delivered a robust performance in Q4 2022, achieving record revenue and exceeding earnings expectations.\nWhile facing challenges such as NHP supply constraints and regulatory issues, the company showcased operational strength and strategic resilience.\nManagement's focus on addressing headwinds and exploring growth opportunities positions Charles River Laboratories for future success.\nNavigating uncertainties in 2023, the company aims to maintain financial stability and drive growth through strategic initiatives.","headline":"Charles River Labs posts record revenue in Q4 2022","lastUpdated":"2024-05-09T09:43:31.010010Z"}},{"actual":2.78,"estimate":2.59,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-05-11T11:00:57Z","audioUrl":"https://files.quartr.com/audio-files/85268-2023-05-11-06-16-24.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/0ca04-2023-05-11-11-47-27.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/e9df4-2023-05-11-11-57-01.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-11T12:30:00Z","earningsSummary":{"summary":"Charles River Laboratories (CRL) had a strong Q1 performance, exceeding expectations and narrowing 2023 guidance amidst NHP supply constraints impact.\nClients continue to choose Charles River for its expertise and solutions, with segments showing growth potential and disciplined capital deployment.\nChallenges include NHP supply issues, margin impact concerns, and predicting demand trends, while opportunities lie in rebounding growth and market positioning.\nOverall, Charles River remains focused on navigating challenges, leveraging strengths, and capitalizing on growth opportunities in the biopharmaceutical market.","headline":"Charles River Laboratories reports strong Q1 performance amidst NHP challenges","lastUpdated":"2024-05-09T10:56:26.315027Z"}},{"actual":2.69,"estimate":2.64,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-09T11:03:56Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_08_09T12_30_00_00_00_Charles_River_Laboratories_International_Inc_Q2_2023.JJ2XG54K7W2O_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/60773-2023-08-09-11-46-19.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/30e9c-2023-08-09-11-16-11.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-09T12:30:00Z","earningsSummary":{"summary":"Charles River Laboratories (CRL) delivered a strong Q2 performance, facing challenges in the DSA segment but expecting improvements in various business segments. The company is capitalizing on its strengths in client mix and global footprint for NHP work, while addressing challenges such as inflationary pressures and aggressive pricing from competitors.","headline":"Charles River Labs reports strong Q2 performance amidst market challenges","lastUpdated":"2024-05-09T11:20:58.073217Z"}},{"actual":2.72,"estimate":2.37,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-11-08T12:00:53Z","audioUrl":"https://files.quartr.com/audio-files/93663-2023-11-08-03-01-18.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/0e366-2023-11-08-01-38-09.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/e7b5b-2023-11-08-12-06-01.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-08T13:30:00Z","earningsSummary":{"summary":"Charles River Laboratories delivered a solid performance in Q3, exceeding earnings expectations despite challenges from cautious client spending and margin pressures. Strategic initiatives focusing on innovation, compliance, and cost-saving measures are key strengths. Opportunities in successful client support, advanced technology investments, and supply chain enhancements position the company for future growth.","headline":"Charles River Labs surpasses Q3 expectations amidst client caution","lastUpdated":"2024-05-09T12:16:36.953016Z"}},{"actual":2.46,"estimate":2.4,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-14T12:07:18Z","audioUrl":"https://files.quartr.com/audio-files/7eb62-2024-02-14-03-45-17.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/fbb57-2024-02-14-12-44-22.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f49d5-2024-02-14-12-03-08.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-14T13:30:00Z","earningsSummary":{"summary":"Charles River Laboratories reported solid revenue growth in 2023, with a focus on operational efficiency and revenue enhancement strategies.\nWhile facing challenges like revenue decline in Q4 and fluctuating cancellation rates, the company is optimistic about stable client spending and growth opportunities in 2024.\nWith a strong performance in the pharma business and strategic acquisitions, Charles River Laboratories is poised for margin improvement and revenue expansion in the coming year.\nThe company's confidence in pricing strategy, supply stability, and potential for share gains highlight its competitive position and growth prospects.","headline":"Charles River Labs reports solid 2023 growth, eyes stable 2024","lastUpdated":"2024-05-09T10:03:53.421210Z"}},{"actual":2.27,"estimate":2.07,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-05-09T11:07:34Z","audioUrl":"https://files.quartr.com/audio-files/4376b-2024-05-09-02-53-09.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/cee49-2024-05-09-11-55-19.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/db561-2024-05-09-11-31-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-09T12:30:00Z","earningsSummary":{"summary":"Charles River Laboratories navigated mixed Q1 results with strong performances in Manufacturing and RMS segments.\nChallenges include slow recovery in Discovery business and potential staff availability constraints in Safety Assessment.\nOpportunities lie in sequential improvements in DSA, increased bookings, and careful management of demand environment.","headline":"Charles River Labs reports mixed Q1 results, eyes sequential improvements","lastUpdated":"2024-05-09T17:05:03.991168Z"}},{"actual":2.8,"estimate":2.39,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-08-07T11:00:56Z","audioUrl":"https://files.quartr.com/audio-files/14f08-2024-08-07-02-57-29.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/e6d77-2024-08-07-11-14-12.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/e3c22-2024-08-07-11-13-12.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-07T13:00:00Z","earningsSummary":{"summary":"Charles River Laboratories faces challenges from softening demand trends impacting revenue but is taking actions to streamline costs and optimize operations. Despite revenue decline, the company's manufacturing segment shows growth potential. Opportunities exist in cost savings initiatives and focusing on CDMO business growth.","headline":"Charles River Labs Q2 revenue declines, focuses on cost efficiency","lastUpdated":"2024-08-07T16:12:12.168808Z"}},{"actual":2.59,"estimate":2.43,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-11-06T12:04:11Z","audioUrl":"https://files.quartr.com/audio-files/fdef4-2024-11-06-04-19-11.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/df953-2024-11-06-12-02-37.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/d4896-2024-11-06-12-01-21.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-11-06T14:30:00Z","earningsSummary":{"summary":"Charles River Laboratories (CRL) delivered strong financial performance in Q3, focusing on cost management and strategic growth initiatives. Despite challenges in the biopharmaceutical sector, opportunities exist in CDMO and Biologics Testing businesses.","headline":"Charles River Labs beats Q3 expectations, eyes biopharma opportunities","lastUpdated":"2024-11-07T02:47:42.952081Z"}},{"actual":2.66,"estimate":2.53,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-19T12:01:14Z","audioUrl":"https://files.quartr.com/audio-files/405ee-2025-02-19-03-00-13.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/40432-2025-02-19-12-25-37.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/d02ba-2025-02-19-12-42-04.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-19T13:30:00Z","earningsSummary":{"summary":"Charles River Laboratories (CRL) navigated revenue declines in Q4 2024, with a cautious outlook for 2025. Operational improvements and cost-saving initiatives aim to mitigate challenges and drive future growth. The company's focus on margin expansion and efficiency enhancements positions it for long-term success. Challenges in pricing and revenue are balanced with opportunities for investment and potential benefits from external factors.","headline":"Charles River Labs reports revenue decline, eyes cost savings in 2025","lastUpdated":"2025-02-19T16:02:02.568806Z"}},{"actual":2.34,"estimate":2.09,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-05-07T11:02:07Z","audioUrl":"https://files.quartr.com/audio-files/d2dc9-2025-05-07-02-10-50.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/2f4f2-2025-05-07-11-20-35.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f05de-2025-05-07-11-19-10.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-07T13:00:00Z","earningsSummary":{"summary":"Charles River Laboratories navigated mixed performance in Q1 2025, with revenue growth from specific client segments but declines in others, supported by cost-saving initiatives. The company's strategic investments in NAMs and focus on client needs position it well for future growth opportunities, despite ongoing challenges in the biotech funding landscape. With a strong emphasis on efficiency, revenue diversification, and strategic value creation, Charles River Laboratories aims to sustain its market position amidst evolving industry trends.","headline":"Charles River Labs reports mixed Q1 performance, eyes strategic growth","lastUpdated":"2025-05-07T15:42:08.615749Z"}},{"actual":null,"estimate":2.49,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-23T23:30:36Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-06T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-03","title":"Earnings data Q3 2021","quarter":"Q3","hash":"8ce9df615c71d6ad23baa1e1af4966d3c945c6981b77772c91b5dfb99178df06"},{"date":"2022-02-16","title":"Earnings data Q4 2021","quarter":"Q4","hash":"1167f4961913c78f3c5d1f597a56ed476bae0f9d18f07b7d4678c6957897a372"},{"date":"2022-05-04","title":"Earnings data Q1 2022","quarter":"Q1","hash":"68a4e200400e137e62f3dcaf4bf2c21074693c87c68643bc35e0e7b960f45852"},{"date":"2022-08-03","title":"Earnings data Q2 2022","quarter":"Q2","hash":"55c05cecc660970e8f7ee833169352e3c36c7d370f00037d42fa046992e3f51e"},{"date":"2022-11-02","title":"Earnings data Q3 2022","quarter":"Q3","hash":"e4f4ef5e104f4baff6464fd2ed36c3f91a0f980cc4f0e257094cdf774528dab4"},{"date":"2023-02-22","title":"Earnings data Q4 2022","quarter":"Q4","hash":"c1852dc0d9b43f695c3408fb4c56005233ab55e84f12eb0fdb18c2c9715e7907"},{"date":"2023-05-11","title":"Earnings data Q1 2023","quarter":"Q1","hash":"770c33778de896cf701657334f50bbba8ea65555cdf21038b7264422fbe31172"},{"date":"2023-08-09","title":"Earnings data Q2 2023","quarter":"Q2","hash":"039a791d9f1411705a540ebddd8f48541ee359553aa594c4037a4adc57a6ef86"},{"date":"2023-11-08","title":"Earnings data Q3 2023","quarter":"Q3","hash":"d900b8e55ce4a0ca495367d09cde38abe48d651550cb0e4745b1e0bd4b9eb97e"},{"date":"2024-02-14","title":"Earnings data Q4 2023","quarter":"Q4","hash":"0634aaec3174bf968b16f79856d0a0d75c292d801c720848cab68481b3757c39"},{"date":"2024-05-09","title":"Earnings data Q1 2024","quarter":"Q1","hash":"70115d5bc1741e49f75249f14313870f2d8cc5b2d2b1d08e0d49c08e9f6c0118"},{"date":"2024-08-07","title":"Earnings data Q2 2024","quarter":"Q2","hash":"b618df991ccdb024f2212f504fa09b26649ed317d09e30b736e38cb57d987156"},{"date":"2024-11-06","title":"Earnings data Q3 2024","quarter":"Q3","hash":"5d650ab812d7bacecbaaef523ac2cf17b8d9d706ae1b484b3cc6c5529432a44a"},{"date":"2025-02-19","title":"Earnings data Q4 2024","quarter":"Q4","hash":"dea0e78b49c817cb5449002153522f53fafdca54b7f0ec323825412d4c596fca"},{"date":"2025-05-07","title":"Earnings data Q1 2025","quarter":"Q1","hash":"a44b34cd42502f2c2a147aeb60ab7bcd5d661b9011e745ab241eadf286fed715"},{"date":"2025-08-06","title":"Earnings data Q2 2025","quarter":"Q2","hash":"f8b2e6bea5e20e0cc9b6b25033812d2e0f10671a69b7e9ad941cbc7b9b1cc731"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Charles River Laboratories","companyDescription":"Charles River Laboratories International, Inc. is an early-stage contract research company, which provides research models required in the research and development of new drugs, devices, and therapies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The Research Models and Services segment consists of the commercial production and sale of research models, research products, and the provision of services related to the maintenance and monitoring of research models and the management of the clients’ research operations. The Discovery and Safety Assessment segment offers integrated drug discovery services directed at the identification, screening, and selection of a lead compound for drug development and offers safety assessment services, including bioanalysis, drug metabolism, pharmacokinetics, toxicology, and pathology. The Manufacturing Support segment consists of Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services, Biologics Solutions, which performs specialized testing of biologics as well as contract development and manufacturing, and Avian Vaccine Services, which supplies specific-pathogen-free chicken eggs and chickens. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":984168000,"changePercentage":-2.71,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":709333000,"changePercentage":2.6,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":274835000,"changePercentage":-14.17,"valueToRevenueRatio":0.27925618390356116},{"financialKey":"OPERATING_EXPENSES","value":176321000,"changePercentage":-0.51,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":176321000,"changePercentage":-0.51,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":98514000,"changePercentage":-31.1,"valueToRevenueRatio":0.10009876362572244},{"financialKey":"EBITDA","value":218878000,"changePercentage":-4.14,"valueToRevenueRatio":0.2223990213053056},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":120364000,"changePercentage":41.01,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":25878000,"changePercentage":-65.26,"valueToRevenueRatio":null},{"financialKey":"EPS","value":0.5008,"changePercentage":-64.42,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":7582366000,"changePercentage":-7,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":1506358000,"changePercentage":-9.7,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":230260000,"changePercentage":-31.75,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":756629000,"changePercentage":-3.86,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":290156000,"changePercentage":-19.69,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":229313000,"changePercentage":25.61,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":6076008000,"changePercentage":-6.3,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":1989977000,"changePercentage":-0.66,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":3529107000,"changePercentage":-9.46,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":556924000,"changePercentage":-4.57,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":4340584000,"changePercentage":-2.43,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":1051055000.0000001,"changePercentage":10.08,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":3469000,"changePercentage":32,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":41409000,"changePercentage":21.43,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":1006177000,"changePercentage":9.6,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":3289529000,"changePercentage":-5.85,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":2985865000,"changePercentage":-3.01,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":303664000,"changePercentage":-26.92,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":3241782000,"changePercentage":-12.48,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":3194336000,"changePercentage":-12.25,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":47446000,"changePercentage":-25.27,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":7582366000,"changePercentage":-7,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":2989334000,"changePercentage":-2.98,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":2759074000,"changePercentage":0.56,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":65.03789,"changePercentage":-7.98,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":25878000,"changePercentage":-65.26,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":171697000,"changePercentage":32.19,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":170410000,"changePercentage":-4.25,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":1287000,"changePercentage":102.68,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-64619000,"changePercentage":24.68,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":59324000,"changePercentage":-25.04,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":-3700000,"changePercentage":41.87,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":36581000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-156824000,"changePercentage":1.1,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-86185000,"changePercentage":-569.78,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":-353132000,"changePercentage":-3005.48,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":266947000,"changePercentage":3077.94,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":0,"changePercentage":100,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":5265000,"changePercentage":162.78,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":26158000,"changePercentage":-51.61,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":112373000,"changePercentage":121.45,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:13:37Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":null,"bearsSay":[],"bullsSay":[],"charts":[{"title":"Revenue Segments","description":"Revenue segments as reported by the company.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Service revenue","dataPoints":[{"key":"21 Q2","value":715.32},{"key":"21 Q3","value":703.859},{"key":"21 Q4","value":709.819},{"key":"22 Q1","value":720.485},{"key":"22 Q2","value":782.827},{"key":"22 Q3","value":812.894},{"key":"22 Q4","value":900.698},{"key":"23 Q1","value":857.366},{"key":"23 Q2","value":874.891},{"key":"23 Q3","value":869.759},{"key":"23 Q4","value":838.003},{"key":"24 Q1","value":816.862},{"key":"24 Q2","value":842.9},{"key":"24 Q3","value":832.463},{"key":"24 Q4","value":811.913},{"key":"25 Q1","value":797.923}]},{"title":"Product revenue","dataPoints":[{"key":"21 Q2","value":199.287},{"key":"21 Q3","value":192.078},{"key":"21 Q4","value":195.231},{"key":"22 Q1","value":193.444},{"key":"22 Q2","value":190.304},{"key":"22 Q3","value":176.263},{"key":"22 Q4","value":199.145},{"key":"23 Q1","value":172.007},{"key":"23 Q2","value":185.046},{"key":"23 Q3","value":156.864},{"key":"23 Q4","value":175.473},{"key":"24 Q1","value":194.698},{"key":"24 Q2","value":183.217},{"key":"24 Q3","value":177.3},{"key":"24 Q4","value":190.636},{"key":"25 Q1","value":186.245}]}],"overlayChart":null},{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q2","value":37.39},{"key":"21 Q3","value":37.63},{"key":"21 Q4","value":38.35},{"key":"22 Q1","value":36.85},{"key":"22 Q2","value":36.65},{"key":"22 Q3","value":37.42},{"key":"22 Q4","value":36.26},{"key":"23 Q1","value":36.68},{"key":"23 Q2","value":37.64},{"key":"23 Q3","value":35.24},{"key":"23 Q4","value":35.92},{"key":"24 Q1","value":34.09},{"key":"24 Q2","value":34.47},{"key":"24 Q3","value":34.56},{"key":"24 Q4","value":28.35},{"key":"25 Q1","value":32.28}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q2","value":15.03},{"key":"21 Q3","value":17.38},{"key":"21 Q4","value":19.09},{"key":"22 Q1","value":16.27},{"key":"22 Q2","value":19.25},{"key":"22 Q3","value":15.26},{"key":"22 Q4","value":14.89},{"key":"23 Q1","value":16.31},{"key":"23 Q2","value":15.56},{"key":"23 Q3","value":14.75},{"key":"23 Q4","value":13.11},{"key":"24 Q1","value":12.45},{"key":"24 Q2","value":14.77},{"key":"24 Q3","value":11.62},{"key":"24 Q4","value":-16.73},{"key":"25 Q1","value":7.58}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q2","value":9.67},{"key":"21 Q3","value":11.54},{"key":"21 Q4","value":15.2},{"key":"22 Q1","value":10.17},{"key":"22 Q2","value":11.23},{"key":"22 Q3","value":9.75},{"key":"22 Q4","value":17.03},{"key":"23 Q1","value":10.01},{"key":"23 Q2","value":9.15},{"key":"23 Q3","value":8.51},{"key":"23 Q4","value":18.45},{"key":"24 Q1","value":7.21},{"key":"24 Q2","value":9.16},{"key":"24 Q3","value":6.89},{"key":"24 Q4","value":-21.4},{"key":"25 Q1","value":2.58}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Selling, general and administrative","dataPoints":[{"key":"21 Q2","value":171.501},{"key":"21 Q3","value":148.573},{"key":"21 Q4","value":144.112},{"key":"22 Q1","value":150.033},{"key":"22 Q2","value":131.711},{"key":"22 Q3","value":183.714},{"key":"22 Q4","value":199.64},{"key":"23 Q1","value":174.846},{"key":"23 Q2","value":199.758},{"key":"23 Q3","value":176.109},{"key":"23 Q4","value":197.142},{"key":"24 Q1","value":186.291},{"key":"24 Q2","value":169.791},{"key":"24 Q3","value":199.213},{"key":"24 Q4","value":195.708},{"key":"25 Q1","value":177.799}]},{"title":"Amortization of intangible assets","dataPoints":[{"key":"21 Q2","value":32.97},{"key":"21 Q3","value":32.852},{"key":"21 Q4","value":30.193},{"key":"22 Q1","value":38.007},{"key":"22 Q2","value":37.604},{"key":"22 Q3","value":35.533},{"key":"22 Q4","value":35.434},{"key":"23 Q1","value":34.916},{"key":"23 Q2","value":34.274},{"key":"23 Q3","value":34.229},{"key":"23 Q4","value":34.021},{"key":"24 Q1","value":32.575},{"key":"24 Q2","value":32.27},{"key":"24 Q3","value":32.403},{"key":"24 Q4","value":41.223},{"key":"25 Q1","value":65.264}]},{"title":"Goodwill impairment","dataPoints":[{"key":"24 Q4","value":215}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q2","value":33.99},{"key":"21 Q3","value":20.54},{"key":"21 Q4","value":14.42},{"key":"22 Q1","value":10.84},{"key":"22 Q2","value":6.4},{"key":"22 Q3","value":10.4},{"key":"22 Q4","value":21.52},{"key":"23 Q1","value":12.63},{"key":"23 Q2","value":8.92},{"key":"23 Q3","value":3.79},{"key":"23 Q4","value":-7.85},{"key":"24 Q1","value":-1.73},{"key":"24 Q2","value":-3.19},{"key":"24 Q3","value":-1.64},{"key":"24 Q4","value":-1.08},{"key":"25 Q1","value":-2.71}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q2","value":31.52},{"key":"21 Q3","value":15.91},{"key":"21 Q4","value":1.91},{"key":"22 Q1","value":1.88},{"key":"22 Q2","value":-17.19},{"key":"22 Q3","value":20.85},{"key":"22 Q4","value":34.86},{"key":"23 Q1","value":11.55},{"key":"23 Q2","value":38.22},{"key":"23 Q3","value":-4.06},{"key":"23 Q4","value":-1.66},{"key":"24 Q1","value":4.34},{"key":"24 Q2","value":-13.66},{"key":"24 Q3","value":10.12},{"key":"24 Q4","value":95.5},{"key":"25 Q1","value":11.06}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q2","value":50.297},{"key":"21 Q3","value":50.425},{"key":"21 Q4","value":50.471},{"key":"22 Q1","value":50.64},{"key":"22 Q2","value":50.823},{"key":"22 Q3","value":50.87},{"key":"22 Q4","value":50.906},{"key":"23 Q1","value":51.097},{"key":"23 Q2","value":51.216},{"key":"23 Q3","value":51.283},{"key":"23 Q4","value":51.311},{"key":"24 Q1","value":51.437},{"key":"24 Q2","value":51.551},{"key":"24 Q3","value":51.394},{"key":"24 Q4","value":51.138},{"key":"25 Q1","value":50.677}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q2","value":16794.973},{"key":"21 Q3","value":20941.956},{"key":"21 Q4","value":19608.741},{"key":"22 Q1","value":15615.198},{"key":"22 Q2","value":12418.549},{"key":"22 Q3","value":10981.714},{"key":"22 Q4","value":11116.547},{"key":"23 Q1","value":11580.011},{"key":"23 Q2","value":10190.14},{"key":"23 Q3","value":10528.502},{"key":"23 Q4","value":10090.821},{"key":"24 Q1","value":12283.464},{"key":"24 Q2","value":11680.89},{"key":"24 Q3","value":10680.701},{"key":"24 Q4","value":9850.764},{"key":"25 Q1","value":8496.506}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q2","value":4.59},{"key":"21 Q3","value":5.84},{"key":"21 Q4","value":5.42},{"key":"22 Q1","value":4.27},{"key":"22 Q2","value":3.19},{"key":"22 Q3","value":2.78},{"key":"22 Q4","value":2.53},{"key":"23 Q1","value":2.81},{"key":"23 Q2","value":2.4},{"key":"23 Q3","value":2.56},{"key":"23 Q4","value":2.49},{"key":"24 Q1","value":3.04},{"key":"24 Q2","value":2.85},{"key":"24 Q3","value":2.64},{"key":"24 Q4","value":2.46},{"key":"25 Q1","value":2.16}]}],"overlayChart":null}],"chartsLastUpdated":"2025-05-07T13:28:12Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":null,"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"CLLS","name":"Cellectis SA","displayName":"Cellectis SA","availableForFractional":false,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"SELL_ALL_ONLY","instrumentClass":"DEPOSITORY_RECEIPT","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"CLLS","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":2.33,"high":2.4,"low":2,"volume":4552,"volumeDate":"2025-07-25","last":2,"open":2.32,"gainPercentage":-14.163,"gainValue":-0.33,"ask":2.3,"bid":2.25,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":144187200,"instrumentClass":"DEPOSITORY_RECEIPT","averageDailyVolumeLast3Months":93567.0968,"highPriceLast52Weeks":2.43,"lowPriceLast52Weeks":1.1,"companyName":"Cellectis SA","longBusinessDescription":"Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.","dividendRate":0,"salesOrRevenue":41505000,"oneYearAnnualRevenueGrowthRate":5397.35099337748,"threeYearAnnualRevenueGrowthRate":1754.8206,"fiveYearAnnualRevenueGrowthRate":1118.4653,"earningsGrowth":38.3159,"totalDebt":109646000,"totalAssets":392553000,"floatAsPercentOfSharesOutstanding":85.7231,"dividendYield":0,"betaTwelveMonth":0.6843,"salesOrRevenueTtm":47632000,"ebitdaTtm":-45637500,"debtToEquityRatioQuarterly":93.6482393032942,"totalEnterpriseValue":12359422.7999999,"industry":"PharmaceuticalsMajor","sector":"HealthTechnology","preTaxInterestCoverageRatio":-9.08940485721911,"fiveYearAverageDebtEquityRatio":57.78,"currentRatio":1.67205924868825,"peratio":-3.16},"recommendation":{"currentConsensusRating":2,"recommendationTargetPrice":23.67,"totalRatings":12,"strongSellRatings":1,"sellRatings":0,"holdRatings":2,"buyRatings":4,"strongBuyRatings":5,"lastUpdated":"2025-05-13T14:19:53Z"},"earningEstimates":[{"actual":-0.71,"estimate":-0.83,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-11-04T22:10:17Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2021-11-04T00:00:00Z","earningsSummary":null},{"actual":-0.48,"estimate":-0.92,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-03-03T21:56:28Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-03-03T00:00:00Z","earningsSummary":null},{"actual":-0.64,"estimate":null,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-05-12T23:52:55Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-05-12T00:00:00Z","earningsSummary":null},{"actual":-0.36,"estimate":-0.56,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-08-04T22:27:11Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-08-04T00:00:00Z","earningsSummary":null},{"actual":-0.58,"estimate":-0.45,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-11-03T21:51:12Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-11-03T00:00:00Z","earningsSummary":null},{"actual":-0.57,"estimate":-0.71,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-03-08T21:49:46Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2023-03-08T00:00:00Z","earningsSummary":null},{"actual":-0.55,"estimate":-0.48,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-05-04T20:45:19Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2023-05-04T00:00:00Z","earningsSummary":null},{"actual":-0.15,"estimate":-0.45,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-03T20:53:57Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2023-08-03T00:00:00Z","earningsSummary":null},{"actual":-0.36,"estimate":-0.42,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-11-06T22:02:43Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2023-11-06T00:00:00Z","earningsSummary":null},{"actual":-0.57,"estimate":-0.22,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-04-29T22:02:51Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2024-04-29T00:00:00Z","earningsSummary":null},{"actual":-0.14,"estimate":-0.33,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-05-28T20:36:00Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2024-05-28T00:00:00Z","earningsSummary":null},{"actual":-0.27,"estimate":-0.3,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-08-06T23:00:23Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2024-08-06T00:00:00Z","earningsSummary":null},{"actual":-0.22,"estimate":-0.21,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-11-04T21:38:17Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2024-11-04T00:00:00Z","earningsSummary":null},{"actual":-0.16,"estimate":-0.21,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-03-13T22:17:15Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-03-13T00:00:00Z","earningsSummary":null},{"actual":-0.17,"estimate":-0.23,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-05-12T20:31:55Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-05-12T00:00:00Z","earningsSummary":null},{"actual":null,"estimate":-0.15,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-10T23:31:23Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-05T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-04","title":"Earnings data Q3 2021","quarter":"Q3","hash":"905c30ea3697530cc3e4d9acb85d29845d6ee3a3034a5935c6137dc714ebebdc"},{"date":"2022-03-03","title":"Earnings data Q4 2021","quarter":"Q4","hash":"57ea6d638d39418ac1d6c1ddcabfacf953503fbd61a2cc76fe5e495142f99ce1"},{"date":"2022-05-12","title":"Earnings data Q1 2022","quarter":"Q1","hash":"1e634dab886dc36eb0356fe7e573c83c72634bdb5052af4b2e4a79772fddcdb9"},{"date":"2022-08-04","title":"Earnings data Q2 2022","quarter":"Q2","hash":"9bfd9fe6c134570f2004fcd24be49f178d94dfe72a3ee01ecd6e29b59464c312"},{"date":"2022-11-03","title":"Earnings data Q3 2022","quarter":"Q3","hash":"cc433fc8a3c523d54385f1095193e6470dd1ce82d8c1052293e198f7aaf6adbd"},{"date":"2023-03-08","title":"Earnings data Q4 2022","quarter":"Q4","hash":"bbf3794820f8e47e5d88c2f569478825ee37c4d70beeb8d9be70d5d634dbd9af"},{"date":"2023-05-04","title":"Earnings data Q1 2023","quarter":"Q1","hash":"262ab24679371ab6cbe54aa7dc604a9b411199779c9c0db51675514a656e9081"},{"date":"2023-08-03","title":"Earnings data Q2 2023","quarter":"Q2","hash":"72d2699dea1f8ce3315803db0569c115545bf4945816df52317db8ad578a3d99"},{"date":"2023-11-06","title":"Earnings data Q3 2023","quarter":"Q3","hash":"c345c4cdd3e5d386b11dc14f9311d58229e70a71076972df89c10e6324af8e68"},{"date":"2024-04-29","title":"Earnings data Q4 2023","quarter":"Q4","hash":"422ff7b45bc60778b7ee9556e3b997808535bd771e6c30516ec12463ddb0788b"},{"date":"2024-05-28","title":"Earnings data Q1 2024","quarter":"Q1","hash":"6a0e82fd33f5f9764bf5e01d4e59c0408e9f50aa3506a746251086b70a22cd1a"},{"date":"2024-08-06","title":"Earnings data Q2 2024","quarter":"Q2","hash":"a07e90d780677e40f3817c0cb9a280e2e44ca76e5373f5ff23227cbdacab1eeb"},{"date":"2024-11-04","title":"Earnings data Q3 2024","quarter":"Q3","hash":"982b34a78364c0f50aa4a143aff7b03394a4cd175543874b57e3aa8b3c4d2496"},{"date":"2025-03-13","title":"Earnings data Q4 2024","quarter":"Q4","hash":"0deb730d295e71fc073904d299e11795930b6c3b1bb453572dbcc9d440e2001a"},{"date":"2025-05-12","title":"Earnings data Q1 2025","quarter":"Q1","hash":"79cf6369f6a570bdb33c79e3081f2df235589edaf01fd7b8a1f951a82e8442c9"},{"date":"2025-08-05","title":"Earnings data Q2 2025","quarter":"Q2","hash":"cc5555d1959cb6c6d07a0b179c025027d124ab7d44cf4a6fdc24874e99001c49"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Cellectis SA","companyDescription":"Cellectis SA operates as a clinical stage biotechnological company. The firm operates through the segments: Therapeutics and Plants. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and monogenic diseases. The Plants segment focuses on using Calyxt's proprietary PlantSpringTM technology platform to engineer plant metabolism to produce innovative, high-value, and sustainable materials and products for use in helping customers meet their sustainability targets and financial goals. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":10655000,"changePercentage":135.31,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":0,"changePercentage":100,"valueToRevenueRatio":0},{"financialKey":"OPERATING_EXPENSES","value":21704000,"changePercentage":-5.05,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":21704000,"changePercentage":-5.05,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":-15979000,"changePercentage":30.22,"valueToRevenueRatio":-1.499671515720319},{"financialKey":"EBITDA","value":-11049000,"changePercentage":39.73,"valueToRevenueRatio":-1.0369779446269358},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":4930000,"changePercentage":7.9,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":-18128000,"changePercentage":-421.25,"valueToRevenueRatio":null},{"financialKey":"EPS","value":-0.181,"changePercentage":-330.28,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":364087000,"changePercentage":2.72,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":271825000,"changePercentage":5.33,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":243691000,"changePercentage":14.36,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":25521000,"changePercentage":-36.82,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":2613000,"changePercentage":-42.91,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":92262000,"changePercentage":-4.28,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":72933000,"changePercentage":-16.97,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":242000,"changePercentage":-64.25,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":19087000,"changePercentage":142.5,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":247883000,"changePercentage":-6.07,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":162569000,"changePercentage":2.6,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":24648000,"changePercentage":83.27,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":137921000,"changePercentage":-4.79,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":85314000,"changePercentage":-19.09,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":84175000,"changePercentage":-7.1,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":1139000,"changePercentage":-92.32,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":116204000,"changePercentage":28.31,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":116204000,"changePercentage":28.31,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":364087000,"changePercentage":2.72,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":108823000,"changePercentage":4.58,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":-134868000,"changePercentage":-23.69,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":1.15868,"changePercentage":-7.94,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":-18128000.0000001,"changePercentage":-421.25,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":-17311999.9999994,"changePercentage":26.46,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":-6092999.9999996405,"changePercentage":58.41,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-11218999.9999998,"changePercentage":-26.18,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":4222999.99999969,"changePercentage":305.9,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":395000.000000127,"changePercentage":54.9,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":4616999.99999988,"changePercentage":356.93,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-789000.0000003171,"changePercentage":-55.01,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-3937999.99999993,"changePercentage":-132.49,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":1411999.99999962,"changePercentage":628.84,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-15615000,"changePercentage":-13.67,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":-17707000,"changePercentage":25.47,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:13:21Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":false},"advancedInfo":{"updateDate":"2024-11-24T01:39:26Z","bearsSay":["Cellectis SA's reliance on clinical-stage development carries inherent risks, particularly reflected in the delayed timelines for its UCART product candidates, which may hinder potential revenue streams and investor confidence. Additionally, the company’s increasing operational costs and R\u0026D expenditures, without corresponding advancements in monetizable products, contribute to a concerning financial outlook. Furthermore, the competitive landscape in the gene-editing and immuno-oncology sectors poses significant challenges, as Cellectis must navigate scientific and regulatory hurdles to achieve commercial viability."],"bullsSay":["Cellectis SA is making significant strides in the biotechnology sector, particularly with its proprietary gene-editing technologies, which position the company favorably within the competitive landscape of immuno-oncology. The company’s robust portfolio of allogeneic UCART product candidates and gene-edited HSPC candidates highlights its commitment to innovative therapeutic solutions, potentially resulting in expansive market opportunities. Furthermore, Cellectis's advancements in clinical trial progress and collaborations with leading industry partners underscore its strong growth prospects, enhancing investor confidence in the company's long-term value."],"charts":[],"chartsLastUpdated":null,"etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.59,"sell":0.41,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"WAT","name":"Waters","displayName":"Waters","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"WAT","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":295.63,"high":305,"low":294.19,"volume":24,"volumeDate":"2025-07-25","last":298.47,"open":294.33,"gainPercentage":0.961,"gainValue":2.84,"ask":305,"bid":297.16,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":17765949200,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":665094.2258,"highPriceLast52Weeks":423.56,"lowPriceLast52Weeks":279.615,"companyName":"Waters Corp.","longBusinessDescription":"Waters Corp. engages in the provision of workflow solutions involving liquid chromatography, mass spectrometry, and thermal analysis. It operates through the Waters and TA (TA Instruments) segments. The Waters segment consists of liquid chromatography instruments, mass spectrometry, and precision chemistry consumable products and services. The TA segment products and services include thermal analysis, rheometry and calorimetry instrument systems, and service sales. The company was founded by James Logan Waters in 1958 and is headquartered in Milford, MA.","dividendRate":0,"salesOrRevenue":2958387000,"oneYearAnnualRevenueGrowthRate":0.0666685608520588,"threeYearAnnualRevenueGrowthRate":2.0744,"fiveYearAnnualRevenueGrowthRate":4.4576,"earningsGrowth":8.3056,"totalDebt":1702342000,"totalAssets":4553795000,"floatAsPercentOfSharesOutstanding":99.7887,"dividendYield":0,"betaTwelveMonth":0.9837,"salesOrRevenueTtm":2983253000,"ebitdaTtm":1044958000.0000001,"debtToEquityRatioQuarterly":78.2858412441519,"totalEnterpriseValue":23469587960,"industry":"MedicalSpecialties","sector":"HealthTechnology","preTaxInterestCoverageRatio":9.49882355564972,"fiveYearAverageDebtEquityRatio":317.8,"currentRatio":1.81055060048763,"peratio":27.07},"recommendation":{"currentConsensusRating":2.6,"recommendationTargetPrice":290.16,"totalRatings":29,"strongSellRatings":1,"sellRatings":0,"holdRatings":19,"buyRatings":5,"strongBuyRatings":4,"lastUpdated":"2025-07-16T12:37:17Z"},"earningEstimates":[{"actual":2.66,"estimate":2.35,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-11-02T10:57:34Z","audioUrl":"https://files.quartr.com/audio-files/ea728-2022-10-19-04-29-55.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/9255a-2024-08-07-09-37-27.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/075c8-2023-01-25-11-31-56.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-11-02T00:00:00Z","earningsSummary":null},{"actual":3.67,"estimate":3.47,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-01T11:54:38Z","audioUrl":"https://files.quartr.com/audio-files/05223-2022-10-19-10-50-30.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/682ff-2022-02-01-01-43-37-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/1274b-2023-01-25-12-07-21.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-01T01:37:43Z","earningsSummary":null},{"actual":2.8,"estimate":2.32,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-05-03T11:02:39Z","audioUrl":"https://files.quartr.com/audio-files/b184e-2022-10-28-04-44-57.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/298aa-2024-08-07-09-17-27.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/4d303-2023-01-25-01-51-21.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-05-03T10:36:00Z","earningsSummary":null},{"actual":2.75,"estimate":2.66,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-08-02T12:09:40Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_08_02_14_00_Q2_2022_Waters_Corp_Earnings_Call.IKT4QAZ3C68A_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/42235-2024-08-07-09-03-27.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/78314-2022-08-02-11-24-17.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-02T09:08:00Z","earningsSummary":null},{"actual":2.64,"estimate":2.57,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-11-01T10:52:55Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_11_01T12_00_00_00_00_Waters_Corp_Earnings_Call_Q3_2022.GCS99NE3JQC9_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/bc511-2024-08-07-09-52-26.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/ac0eb-2022-11-01-11-27-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-01T12:00:00Z","earningsSummary":null},{"actual":3.84,"estimate":3.73,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-15T11:51:23Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_02_15T13_00_00_00_00_Waters_Corporation_Earnings_Call_Q4_2022.T0NDC8P82YRB_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/reports/0e936-2023-02-15-12-43-00.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/conference-calls/5da41-2023-02-15-12-43-00.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-15T13:00:00Z","earningsSummary":{"summary":"Waters Corporation's strong performance in Q4 2022 and full-year results, coupled with the Wyatt Technology acquisition, positions the company for continued growth.\nDespite challenges in China and FX headwinds, Waters sees opportunities in pricing increases, revenue synergies from acquisitions, and growth in bioanalytical applications.","headline":"Waters reports robust Q4 earnings, eyes growth through acquisitions","lastUpdated":"2024-05-09T05:45:02.458550Z"}},{"actual":2.49,"estimate":2.61,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-05-09T10:51:18Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_05_09T12_00_00_00_00_Waters_Corporation_Q1_2023.3BIFVOPRLPKI_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/0c033-2023-05-09-11-47-50.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/25743-2023-05-09-11-56-01.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-09T12:00:00Z","earningsSummary":{"summary":"Waters Corporation faces challenges from weaker demand in key sectors but maintains strengths in certain divisions and sustainability efforts. The acquisition of Wyatt Technology presents growth opportunities, with a focus on maintaining pricing strength and capitalizing on ongoing pharma activity.","headline":"Waters Corp reports Q1 revenue growth below expectations, eyes biotech","lastUpdated":"2024-05-09T05:16:47.391289Z"}},{"actual":2.8,"estimate":2.59,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-02T10:51:23Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_08_02T12_00_00_00_00_Waters_Corporation_Q2_2023.SISA97V0GRXV_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/415d0-2023-08-02-02-46-22.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/67996-2023-08-02-11-46-01.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-02T12:00:00Z","earningsSummary":{"summary":"Waters Corporation delivered strong Q2 performance with 5% constant currency growth and non-GAAP EPS above expectations, driven by operational excellence and margin expansion.\nWhile challenges persist in the China Pharma market and cautious spending trends impact growth outlook, Waters remains well-positioned for growth above market rates.\nThe company's strategic strengths in innovation, execution, and margin expansion, coupled with growth opportunities in key segments and regions, position it for continued success.","headline":"Waters (WAT) reports robust Q2 growth, eyes Chinese market recovery","lastUpdated":"2024-05-09T04:44:34.092131Z"}},{"actual":2.84,"estimate":2.55,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-11-07T11:55:02Z","audioUrl":"https://files.quartr.com/audio-files/ad82a-2023-11-07-02-27-02.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/ad923-2023-11-07-06-09-40.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/e1d09-2023-11-07-12-21-01.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-07T13:00:00Z","earningsSummary":{"summary":"Waters Corporation navigated through challenges in China, focusing on margin expansion, cost management, and workforce optimization. Despite headwinds, the company showcased resilience, positive cash flow, and growth opportunities in service attachment rates and e-commerce sales.","headline":"Waters expands margins amidst China challenges, eyes service growth","lastUpdated":"2024-05-09T03:49:59.983016Z"}},{"actual":3.62,"estimate":3.55,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-06T11:53:09Z","audioUrl":"https://files.quartr.com/audio-files/cd557-2024-02-06-02-04-08.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/05a53-2024-02-06-12-21-05.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/7e6e9-2024-02-06-12-57-01.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-06T13:00:00Z","earningsSummary":{"summary":"Waters navigated a challenging Q4 2023 with sales decline and cautious Q1 2024 guidance. Despite China's struggles, the company's operational resilience and focus on sustainability are strengths. Opportunities lie in PFAS testing, e-commerce growth, and large molecule applications.","headline":"Waters faces sales decline in Q4 2023, eyes PFAS market","lastUpdated":"2024-05-09T03:46:37.992333Z"}},{"actual":2.21,"estimate":2.1,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-05-07T10:59:54Z","audioUrl":"https://files.quartr.com/audio-files/11776-2024-05-07-01-46-08.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/5a90a-2024-05-07-11-50-13.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/c802c-2024-05-07-11-52-02.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-07T12:00:00Z","earningsSummary":{"summary":"Waters Corporation's Q1 2024 performance was solid, with a focus on margin expansion and innovation. Challenges include sales decline and concerns about revenue targets. Opportunities exist in China's pharma market stabilization and margin progression.","headline":"Waters Corp exceeds EPS guidance, eyes China stimulus for growth","lastUpdated":"2024-05-07T17:48:56.302006Z"}},{"actual":2.63,"estimate":2.56,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-07-31T10:51:21Z","audioUrl":"https://files.quartr.com/audio-files/4e772-2024-07-31-01-39-06.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/5d385-2024-07-31-11-13-05.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/9057e-2024-07-31-11-57-04.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-07-31T12:00:00Z","earningsSummary":{"summary":"Waters Corporation delivered strong Q2 results, exceeding expectations with resilient margins.\nWhile facing sales declines, the company showcased operational efficiency and strategic focus.\nGuidance reflects caution on ex-China markets but highlights opportunities for growth.\nStrategic flexibility in debt management and product innovation position the company for long-term success.","headline":"Waters Corporation surpasses Q2 expectations, eyes long-term growth strategies","lastUpdated":"2024-07-31T16:43:22.877976Z"}},{"actual":2.93,"estimate":2.68,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-11-01T10:04:21Z","audioUrl":"https://files.quartr.com/audio-files/6dc0e-2024-11-01-01-10-11.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/43e41-2024-11-01-10-48-25.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/966c8-2024-11-01-10-16-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-11-01T12:00:00Z","earningsSummary":{"summary":"Waters Corporation's strong Q3 performance exceeded expectations, driven by sales growth in key sectors and recurring revenue expansion.\nDespite challenges like China sales decline and negative sales growth projections, the company remains optimistic about future opportunities.\nWith a focus on operational excellence, strategic positioning, and market confidence, Waters is poised for continued success and growth.","headline":"Waters Corporation excels in Q3, eyes growth in key markets","lastUpdated":"2024-11-01T16:28:40.271771Z"}},{"actual":4.1,"estimate":4.03,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-12T11:00:57Z","audioUrl":"https://files.quartr.com/audio-files/a56ee-2025-02-12-02-57-11.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/44f5c-2025-02-12-12-25-09.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/44db4-2025-02-12-11-36-04.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-12T13:00:00Z","earningsSummary":{"summary":"Waters Corporation demonstrated strong financial performance in Q4 2024, driven by revenue growth in key markets and operational efficiency improvements. While facing challenges in flat full-year sales and debt management, the company is optimistic about growth opportunities in 2025.","headline":"Waters (WAT) reports robust Q4 earnings, eyes growth in 2025","lastUpdated":"2025-02-12T15:45:52.894385Z"}},{"actual":2.25,"estimate":2.22,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-05-06T10:17:34Z","audioUrl":"https://files.quartr.com/audio-files/a5545-2025-05-06-01-35-14.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/bbae1-2025-05-06-11-27-17.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/e01de-2025-05-06-10-53-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-06T12:00:00Z","earningsSummary":{"summary":"Waters Corporation's Q1 2025 earnings call highlighted robust performance, strategic resilience, and proactive measures to drive growth amidst market challenges. The company's focus on innovation, revenue guidance raise, and financial strength underscore a positive outlook for sustained performance and shareholder value creation. While facing challenges in pricing, tariffs, and market dynamics, Waters remains poised to capitalize on opportunities through strategic initiatives and market expansion efforts.","headline":"Waters excels in Q1, raises guidance and mitigates tariffs","lastUpdated":"2025-05-06T15:42:34.675770Z"}},{"actual":null,"estimate":2.94,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-22T23:31:09Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-04T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-02","title":"Earnings data Q3 2021","quarter":"Q3","hash":"d2295eb03e5d57107caa615e36d65020850101135ec660143747759336efbe7b"},{"date":"2022-02-01","title":"Earnings data Q4 2021","quarter":"Q4","hash":"154052bda79c2b1fc0e109cb959a014758ca1be9c75c2bd33b805ec0fe4c9d26"},{"date":"2022-05-03","title":"Earnings data Q1 2022","quarter":"Q1","hash":"11d3a714389b219df1c53869d4864f4b4618296c1ec2dc06c00a0c8a415e50cf"},{"date":"2022-08-02","title":"Earnings data Q2 2022","quarter":"Q2","hash":"961d82097dc369c344c4de5fa094a7d37b2e9ee72ce3243d0e50bbc57014ff0b"},{"date":"2022-11-01","title":"Earnings data Q3 2022","quarter":"Q3","hash":"78090083ad70c7c6bfcea58fd882d882f1e08e8d52e1a7f9640ae7022bd349c5"},{"date":"2023-02-15","title":"Earnings data Q4 2022","quarter":"Q4","hash":"0a87b84ad9d7ecfbaf699678a8e63c153f6daecdabbb5b0d035645b4e98c9efe"},{"date":"2023-05-09","title":"Earnings data Q1 2023","quarter":"Q1","hash":"da1157087c07ced493deefbe840943f6c0a9bdc0a824156a5d553fda58a34f09"},{"date":"2023-08-02","title":"Earnings data Q2 2023","quarter":"Q2","hash":"1cadce0c15101e3010dbe792fb450a7b1da7f9d26417440cb12a56ef60792f68"},{"date":"2023-11-07","title":"Earnings data Q3 2023","quarter":"Q3","hash":"6d1245e06cd824a1986b7cc15b99364cea3f304bb37028313657bcde36804435"},{"date":"2024-02-06","title":"Earnings data Q4 2023","quarter":"Q4","hash":"376fda5eceb711f92a581d989ebb21b63a57c863b5f9cfd9b3f2dbe9cddc7c10"},{"date":"2024-05-07","title":"Earnings data Q1 2024","quarter":"Q1","hash":"0e921145ce41084feb06b5a7bbf04fc70d5f7fafd0a4418e4925d669199e1d73"},{"date":"2024-07-31","title":"Earnings data Q2 2024","quarter":"Q2","hash":"57779b7655512274e6d03c5c064821cabbabaacbfcd2ff13c0690d653c06962b"},{"date":"2024-11-01","title":"Earnings data Q3 2024","quarter":"Q3","hash":"5414a0c07fd6423a0399bb35e146e4fc9967b16aaa02a39d2f718d70460bc2a5"},{"date":"2025-02-12","title":"Earnings data Q4 2024","quarter":"Q4","hash":"59feac0233695404aa1f997bbfc0919281b56a081266c71e4088d7c7ce1f2f35"},{"date":"2025-05-06","title":"Earnings data Q1 2025","quarter":"Q1","hash":"2a62d82ad13e0db294173ce436f8e9e3bdfb519163eaf133720ae6140c034410"},{"date":"2025-08-04","title":"Earnings data Q2 2025","quarter":"Q2","hash":"f5d57e3b7f8990f7458979b924cd67586c89e363e214c1c99100cd9fcf0a79b1"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Waters","companyDescription":"Waters Corp. engages in the provision of workflow solutions involving liquid chromatography, mass spectrometry, and thermal analysis. It operates through the Waters and TA (TA Instruments) segments. The Waters segment consists of liquid chromatography instruments, mass spectrometry, and precision chemistry consumable products and services. The TA segment products and services include thermal analysis, rheometry and calorimetry instrument systems, and service sales. The company was founded by James Logan Waters in 1958 and is headquartered in Milford, MA.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":661705000,"changePercentage":3.9,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":287348000,"changePercentage":4.94,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":374357000,"changePercentage":3.12,"valueToRevenueRatio":0.565746065089428},{"financialKey":"OPERATING_EXPENSES","value":221503000,"changePercentage":1.08,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":221503000,"changePercentage":1.08,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":152854000,"changePercentage":6.24,"valueToRevenueRatio":0.2310002191308816},{"financialKey":"EBITDA","value":202223000,"changePercentage":5.11,"valueToRevenueRatio":0.30560899494487725},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":49369000,"changePercentage":1.76,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":121381000,"changePercentage":18.77,"valueToRevenueRatio":null},{"financialKey":"EPS","value":2.0328,"changePercentage":18.21,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":4591576000,"changePercentage":1.83,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":1739883000,"changePercentage":5.9,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":382872000,"changePercentage":13.2,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":713278000,"changePercentage":13.88,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":511499000,"changePercentage":-5.04,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":132234000.00000001,"changePercentage":-5.4,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":2851693000,"changePercentage":-0.5,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":721043000,"changePercentage":0.89,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":1860774000,"changePercentage":-2.52,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":269876000,"changePercentage":11.35,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":2629179000,"changePercentage":-19.16,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":960969000,"changePercentage":13.26,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":127304000,"changePercentage":65.59,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":172868000,"changePercentage":43.44,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":660797000,"changePercentage":1.5,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":1668210000,"changePercentage":-30.61,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":1408975000,"changePercentage":-31.66,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":259235000,"changePercentage":-24.26,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":1962397000,"changePercentage":56.18,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":1962397000,"changePercentage":56.18,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":4591576000,"changePercentage":1.83,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":1536279000,"changePercentage":-28.16,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":1153407000,"changePercentage":-35.93,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":32.98257,"changePercentage":55.68,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":121381000,"changePercentage":18.77,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":259553000,"changePercentage":-1.26,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":185933000,"changePercentage":11.96,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":73620000,"changePercentage":-23.94,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-26248000,"changePercentage":11.75,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":25742000,"changePercentage":-10.17,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":-506000,"changePercentage":53.54,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-51484000,"changePercentage":10.17,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-173247000,"changePercentage":40.7,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":-5688000,"changePercentage":-774.73,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":-170000000,"changePercentage":43.33,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":2441000,"changePercentage":-65.03,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":-2541000,"changePercentage":-301.03,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":57517000,"changePercentage":199.53,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":233811000,"changePercentage":-0.17,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:13:42Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2024-11-27T05:47:36Z","bearsSay":["Waters has revised its organic growth outlook downward from 0.5-1.5% to a decline of 2-1%, indicating a significant deterioration in financial performance. The company's revenue for the third quarter of 2023 experienced a 4% organic decline, driven largely by a more than 20% decrease in sales from China, which has had a notable negative impact across various segments. Additionally, the lackluster performance of newly launched products has contributed to an overall challenging environment, culminating in an 8% organic revenue decline for the fourth quarter of 2023."],"bullsSay":["Waters Corporation experienced a solid organic revenue growth of 4.2% in 3Q24, reaching $655.7 million, outperforming sales estimates, with significant contributions from the pharmaceutical sector, particularly in the U.S. and Europe, which saw growth rates of 6% and 5%, respectively. The company also reported strong adoption of its mass spectrometry products, notably the Xevo TQ Absolute, with unit sales increasing over 70% year-over-year, driven by demand in PFAS applications and various pharmaceutical quality assurance processes. Additionally, all geographic regions returned to positive growth, reflecting resilient performance across diverse end markets and a promising rebound in pharmaceutical growth trends."],"charts":[{"title":"Revenue Segments","description":"Revenue segments as reported by the company.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Waters","dataPoints":[{"key":"21 Q2","value":607.324},{"key":"21 Q3","value":581.811},{"key":"21 Q4","value":742.07},{"key":"22 Q1","value":613.156},{"key":"22 Q2","value":635.152},{"key":"22 Q3","value":623.401},{"key":"22 Q4","value":754.753},{"key":"23 Q1","value":602.075},{"key":"23 Q2","value":653.235},{"key":"23 Q3","value":629.348},{"key":"23 Q4","value":716.932},{"key":"24 Q1","value":561.899},{"key":"24 Q2","value":622.561},{"key":"24 Q3","value":655.652},{"key":"24 Q4","value":764.309},{"key":"25 Q1","value":587.297}]},{"title":"TA","dataPoints":[{"key":"21 Q2","value":74.323},{"key":"21 Q3","value":77.422},{"key":"21 Q4","value":94.379},{"key":"22 Q1","value":77.416},{"key":"22 Q2","value":79.167},{"key":"22 Q3","value":85.154},{"key":"22 Q4","value":103.757},{"key":"23 Q1","value":82.599},{"key":"23 Q2","value":87.341},{"key":"23 Q3","value":82.344},{"key":"23 Q4","value":102.542},{"key":"24 Q1","value":74.94},{"key":"24 Q2","value":85.968},{"key":"24 Q3","value":84.653},{"key":"24 Q4","value":108.405},{"key":"25 Q1","value":74.408}]}],"overlayChart":null},{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q2","value":58.88},{"key":"21 Q3","value":58.87},{"key":"21 Q4","value":58.03},{"key":"22 Q1","value":58.63},{"key":"22 Q2","value":56.99},{"key":"22 Q3","value":56.65},{"key":"22 Q4","value":59.44},{"key":"23 Q1","value":58.46},{"key":"23 Q2","value":59.34},{"key":"23 Q3","value":59.05},{"key":"23 Q4","value":61.15},{"key":"24 Q1","value":58.89},{"key":"24 Q2","value":59.31},{"key":"24 Q3","value":59.25},{"key":"24 Q4","value":60.06},{"key":"25 Q1","value":58.17}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q2","value":28.81},{"key":"21 Q3","value":29.09},{"key":"21 Q4","value":31.34},{"key":"22 Q1","value":28.3},{"key":"22 Q2","value":27.94},{"key":"22 Q3","value":27.09},{"key":"22 Q4","value":33.34},{"key":"23 Q1","value":25.43},{"key":"23 Q2","value":26.98},{"key":"23 Q3","value":25.21},{"key":"23 Q4","value":32.24},{"key":"24 Q1","value":21.01},{"key":"24 Q2","value":26.69},{"key":"24 Q3","value":28.51},{"key":"24 Q4","value":33.48},{"key":"25 Q1","value":22.93}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q2","value":24.54},{"key":"21 Q3","value":24.45},{"key":"21 Q4","value":25.85},{"key":"22 Q1","value":23.14},{"key":"22 Q2","value":23.07},{"key":"22 Q3","value":22.01},{"key":"22 Q4","value":26.44},{"key":"23 Q1","value":20.58},{"key":"23 Q2","value":20.32},{"key":"23 Q3","value":18.9},{"key":"23 Q4","value":26.38},{"key":"24 Q1","value":16.04},{"key":"24 Q2","value":20.14},{"key":"24 Q3","value":21.81},{"key":"24 Q4","value":26.51},{"key":"25 Q1","value":18.34}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Selling and administrative expenses","dataPoints":[{"key":"21 Q2","value":158.213},{"key":"21 Q3","value":152.545},{"key":"21 Q4","value":173.014},{"key":"22 Q1","value":157.475},{"key":"22 Q2","value":161.877},{"key":"22 Q3","value":164.417},{"key":"22 Q4","value":174.257},{"key":"23 Q1","value":181.956},{"key":"23 Q2","value":186.953},{"key":"23 Q3","value":186.748},{"key":"23 Q4","value":180.357},{"key":"24 Q1","value":174.536},{"key":"24 Q2","value":173.247},{"key":"24 Q3","value":169.097},{"key":"24 Q4","value":173.268},{"key":"25 Q1","value":174.881}]},{"title":"Research and development expenses","dataPoints":[{"key":"21 Q2","value":44.949},{"key":"21 Q3","value":41.986},{"key":"21 Q4","value":43.331},{"key":"22 Q1","value":40.472},{"key":"22 Q2","value":44.006},{"key":"22 Q3","value":43.435},{"key":"22 Q4","value":48.277},{"key":"23 Q1","value":42.691},{"key":"23 Q2","value":45.873},{"key":"23 Q3","value":41.995},{"key":"23 Q4","value":44.386},{"key":"24 Q1","value":44.595},{"key":"24 Q2","value":46.182},{"key":"24 Q3","value":45.336},{"key":"24 Q4","value":46.914},{"key":"25 Q1","value":46.622}]},{"title":"Purchased intangibles amortization","dataPoints":[{"key":"21 Q2","value":1.809},{"key":"21 Q3","value":1.759},{"key":"21 Q4","value":1.735},{"key":"22 Q1","value":1.673},{"key":"22 Q2","value":1.598},{"key":"22 Q3","value":1.592},{"key":"22 Q4","value":1.503},{"key":"23 Q1","value":1.479},{"key":"23 Q2","value":6.815},{"key":"23 Q3","value":12.116},{"key":"23 Q4","value":12.148},{"key":"24 Q1","value":11.834},{"key":"24 Q2","value":11.744},{"key":"24 Q3","value":11.759},{"key":"24 Q4","value":11.753},{"key":"25 Q1","value":11.712}]},{"title":"Litigation provision","dataPoints":[{"key":"21 Q4","value":5.165},{"key":"24 Q1","value":10.242},{"key":"24 Q3","value":1.326}]},{"title":"Acquired in-process research and development","dataPoints":[{"key":"22 Q1","value":9.797}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q2","value":31.09},{"key":"21 Q3","value":11.02},{"key":"21 Q4","value":6.33},{"key":"22 Q1","value":13.48},{"key":"22 Q2","value":4.79},{"key":"22 Q3","value":7.48},{"key":"22 Q4","value":2.64},{"key":"23 Q1","value":-0.85},{"key":"23 Q2","value":3.68},{"key":"23 Q3","value":0.44},{"key":"23 Q4","value":-4.55},{"key":"24 Q1","value":-6.99},{"key":"24 Q2","value":-4.33},{"key":"24 Q3","value":4.02},{"key":"24 Q4","value":6.5},{"key":"25 Q1","value":3.9}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q2","value":35.08},{"key":"21 Q3","value":13.42},{"key":"21 Q4","value":10.31},{"key":"22 Q1","value":14.36},{"key":"22 Q2","value":1.22},{"key":"22 Q3","value":6.7},{"key":"22 Q4","value":0.35},{"key":"23 Q1","value":7.98},{"key":"23 Q2","value":15.5},{"key":"23 Q3","value":15},{"key":"23 Q4","value":5.74},{"key":"24 Q1","value":6.67},{"key":"24 Q2","value":-3.53},{"key":"24 Q3","value":-5.54},{"key":"24 Q4","value":-2.09},{"key":"25 Q1","value":-3.31}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q2","value":61.685},{"key":"21 Q3","value":61.359},{"key":"21 Q4","value":60.984},{"key":"22 Q1","value":60.58},{"key":"22 Q2","value":60.206},{"key":"22 Q3","value":59.801},{"key":"22 Q4","value":59.329},{"key":"23 Q1","value":59.023},{"key":"23 Q2","value":58.857},{"key":"23 Q3","value":59.093},{"key":"23 Q4","value":59.142},{"key":"24 Q1","value":59.232},{"key":"24 Q2","value":59.339},{"key":"24 Q3","value":59.367},{"key":"24 Q4","value":59.386},{"key":"25 Q1","value":59.439}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q2","value":19524.104},{"key":"21 Q3","value":24035.302},{"key":"21 Q4","value":21331.227},{"key":"22 Q1","value":19710.188},{"key":"22 Q2","value":19110.769},{"key":"22 Q3","value":19088.599},{"key":"22 Q4","value":18768.907},{"key":"23 Q1","value":19091.816},{"key":"23 Q2","value":16379.785},{"key":"23 Q3","value":16329.937},{"key":"23 Q4","value":16334.666},{"key":"24 Q1","value":19470.802},{"key":"24 Q2","value":18936.084},{"key":"24 Q3","value":19327.817},{"key":"24 Q4","value":21722.567},{"key":"25 Q1","value":23013.592}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q2","value":7.16},{"key":"21 Q3","value":9.11},{"key":"21 Q4","value":6.38},{"key":"22 Q1","value":7.14},{"key":"22 Q2","value":6.69},{"key":"22 Q3","value":6.74},{"key":"22 Q4","value":5.47},{"key":"23 Q1","value":6.97},{"key":"23 Q2","value":5.53},{"key":"23 Q3","value":5.74},{"key":"23 Q4","value":4.98},{"key":"24 Q1","value":7.64},{"key":"24 Q2","value":6.68},{"key":"24 Q3","value":6.53},{"key":"24 Q4","value":6.22},{"key":"25 Q1","value":8.69}]}],"overlayChart":null}],"chartsLastUpdated":"2025-05-06T15:47:00Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":null,"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"A","name":"Agilent Technologies","displayName":"Agilent Technologies","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"A","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":119.47,"high":122.75,"low":119.43,"volume":426,"volumeDate":"2025-07-25","last":120.35,"open":119.43,"gainPercentage":0.737,"gainValue":0.88,"ask":125,"bid":110,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":34187222700,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":1997993.7097,"highPriceLast52Weeks":153.84,"lowPriceLast52Weeks":96.43,"companyName":"Agilent Technologies, Inc.","longBusinessDescription":"Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.","dividendRate":0.98,"salesOrRevenue":6510000000,"oneYearAnnualRevenueGrowthRate":-4.72705985657837,"threeYearAnnualRevenueGrowthRate":1.1418,"fiveYearAnnualRevenueGrowthRate":5.038,"earningsGrowth":-4.0842,"totalDebt":3574000000,"totalAssets":11931000000,"floatAsPercentOfSharesOutstanding":99.6128,"dividendYield":0.8099999999999999,"betaTwelveMonth":0.9788,"salesOrRevenueTtm":6628000000,"ebitdaTtm":1864000000,"debtToEquityRatioQuarterly":56.9589308996089,"totalEnterpriseValue":40165210000,"industry":"MedicalSpecialties","sector":"HealthTechnology","preTaxInterestCoverageRatio":16.59375,"fiveYearAverageDebtEquityRatio":52.78,"currentRatio":2.09145129224652,"peratio":29.68},"recommendation":{"currentConsensusRating":2.1,"recommendationTargetPrice":119.13,"totalRatings":31,"strongSellRatings":0,"sellRatings":1,"holdRatings":9,"buyRatings":12,"strongBuyRatings":9,"lastUpdated":"2025-07-08T12:44:23Z"},"earningEstimates":[{"actual":1.21,"estimate":1.04,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2021-11-22T21:15:25Z","audioUrl":"https://files.quartr.com/audio-files/663af-2022-10-19-05-36-21.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/8fdf9-2021-11-22-12-00-00-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/e818d-2025-03-03-08-29-18.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-11-22T00:00:00Z","earningsSummary":null},{"actual":1.21,"estimate":1.03,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-02-22T21:16:58Z","audioUrl":"https://files.quartr.com/audio-files/10506-2022-10-19-11-18-31.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/a8dde-2024-08-29-04-08-40.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-22T11:45:05Z","earningsSummary":null},{"actual":1.13,"estimate":1.07,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-05-24T21:10:32Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_05_24_22_30_Q2_2022_Agilent_Technologies_Inc_Earnings_Call.DRVU2J2V45VL.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/32760-2022-05-24-08-20-16.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/e3d40-2024-08-29-04-14-40.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-05-24T00:00:00Z","earningsSummary":null},{"actual":1.34,"estimate":1.18,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-08-16T20:08:33Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_08_16_22_30_Q3_2022_Agilent_Technologies_Inc_Earnings_Call.WEBVHGYYINZC_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/cfa2f-2022-08-16-10-41-09.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/a411e-2024-08-29-04-08-40.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-16T18:00:00Z","earningsSummary":null},{"actual":1.53,"estimate":1.39,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2022-11-21T21:22:26Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_11_21T21_30_00_00_00_Agilent_Technologies_Inc_Earnings_Call_Q4_2022.P7GTV8BKMP37_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/753d0-2022-11-21-09-13-12.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/e32db-2023-07-12-01-19-04.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-21T21:30:00Z","earningsSummary":null},{"actual":1.37,"estimate":1.3,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-02-28T21:29:08Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_02_28T21_30_00_00_00_Agilent_Technologies_Inc_Earnings_Call_Q1_2023.G15J9YDVZ24Z_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/e8054-2023-02-28-09-08-09.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/aa0d8-2024-08-29-04-58-39.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-28T21:30:00Z","earningsSummary":{"summary":"Agilent Technologies delivered robust Q1 results, raised full-year guidance, and remains confident in its growth drivers. Despite challenges in the genomics market and uncertainties ahead, the company is strategically positioned to capitalize on opportunities and drive continued success.","headline":"Agilent Technologies posts strong Q1 earnings, eyes PFAS testing and CRISPR expansion","lastUpdated":"2024-05-06T01:45:17.820138Z"}},{"actual":1.27,"estimate":1.26,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-05-23T20:16:17Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_05_23T20_30_00_00_00_Agilent_Technologies_Inc_Q2_2023.E5N2DETI94ZJ_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/0ff7e-2023-05-23-08-40-11.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/1429f-2024-08-29-04-56-39.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-23T20:30:00Z","earningsSummary":{"summary":"Agilent Technologies delivered strong Q2 results but revised down second-half forecasts due to economic uncertainties. The company remains focused on driving margin expansion, cost efficiencies, and customer service excellence. Challenges from macroeconomic factors and market dynamics are being addressed with a strategic outlook for long-term growth.","headline":"Agilent reports strong Q2 earnings but revises down second-half forecast","lastUpdated":"2024-05-07T07:54:32.235795Z"}},{"actual":1.43,"estimate":1.37,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-08-15T20:10:49Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_08_15T20_30_00_00_00_Agilent_Technologies_Inc_Q3_2023.T3BB53FAIYGZ_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/61191-2023-08-15-08-53-22.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/eb55d-2023-08-15-08-04-08.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-15T20:30:00Z","earningsSummary":{"summary":"Agilent Technologies faces revenue challenges in China but sees growth opportunities in companion diagnostics and liquid biopsy markets. The company remains confident in its ability to drive earnings growth despite recent setbacks.","headline":"Agilent Technologies faces China revenue challenges but eyes growth opportunities","lastUpdated":"2024-05-06T23:42:47.204146Z"}},{"actual":1.38,"estimate":1.35,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2023-11-20T21:05:53Z","audioUrl":"https://files.quartr.com/audio-files/2db1a-2023-11-20-10-59-40.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/55cc9-2023-11-20-09-54-39.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/db1eb-2023-11-20-09-28-08.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-20T21:30:00Z","earningsSummary":{"summary":"Agilent Technologies reported mixed Q4 results with revenue decline but exceeded EPS guidance. While facing challenges in China and certain segments, the company anticipates slow but steady recovery for FY 2024. Agilent is focusing on cost-saving measures, pricing trends, and investments in growth areas like genomics and environmental solutions.","headline":"Agilent reports mixed Q4 results, eyes steady recovery in 2024","lastUpdated":"2024-05-06T23:02:08.081442Z"}},{"actual":1.29,"estimate":1.22,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-02-27T22:43:37Z","audioUrl":"https://files.quartr.com/audio-files/a64d2-2024-02-27-10-17-46.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/fa3b0-2024-02-27-10-06-07.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b95ef-2024-02-27-10-47-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-27T21:30:00Z","earningsSummary":{"summary":"Agilent Technologies' Q1 performance showed revenue decline but with strengths in certain segments like ACG and consumables. Challenges include revenue declines in DGG and LSAG impacting margins. Opportunities lie in global growth prospects and potential market surprises.","headline":"Agilent reports Q1 revenue decline, eyes global growth opportunities","lastUpdated":"2024-05-07T07:08:22.296937Z"}},{"actual":1.22,"estimate":1.19,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-05-29T20:11:51Z","audioUrl":"https://files.quartr.com/audio-files/16bf0-2024-05-29-09-18-37.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/fe316-2024-05-29-08-20-14.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/e0157-2024-05-29-08-42-08.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-29T20:30:00Z","earningsSummary":{"summary":"Agilent Technologies navigated a challenging market in Q2 2024 with revenue declines across all end markets. The company remains focused on customer-centric strategies, cost optimization, and growth investments while addressing visibility challenges and exploring opportunities in high-growth segments.","headline":"Agilent Technologies faces revenue decline but eyes growth opportunities ahead","lastUpdated":"2024-05-30T00:12:44.096743Z"}},{"actual":1.32,"estimate":1.26,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-08-21T20:06:47Z","audioUrl":"https://files.quartr.com/audio-files/c55c2-2024-08-21-09-33-33.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/736d8-2024-08-21-08-28-11.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/1eb9c-2024-08-21-08-53-08.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-21T20:30:00Z","earningsSummary":{"summary":"Agilent Technologies delivered a solid performance in Q3 2024, exceeding earnings per share guidance and raising revenue and EPS midpoint guidance.\nWhile facing revenue decline, the company's strategic investments and acquisitions signal a focus on growth and innovation.\nChallenges include market dynamics and integration risks, but opportunities exist in leveraging digital initiatives and financial strength for future growth.","headline":"Agilent reports Q3 earnings beat, eyes growth through acquisitions","lastUpdated":"2024-08-22T00:22:28.306509Z"}},{"actual":1.46,"estimate":1.4,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2024-11-25T21:22:20Z","audioUrl":"https://files.quartr.com/audio-files/e8064-2024-11-25-10-44-43.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/969a2-2024-11-26-04-05-50.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/d8e80-2024-11-25-09-37-08.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-11-25T21:30:00Z","earningsSummary":{"summary":"Agilent Technologies' Q4 2024 earnings call highlighted strong financial performance, strategic acquisitions, and a focus on margin expansion for sustainable growth.\nDespite regional challenges and market uncertainties, the company remains optimistic about future prospects and is committed to driving EPS growth.\nWith a new market-focused approach and ongoing transformation initiatives, Agilent is well-positioned to capitalize on opportunities and navigate potential challenges in FY 2025.","headline":"Agilent Technologies reports robust Q4 performance and outlines growth strategies","lastUpdated":"2024-11-26T05:04:12.491580Z"}},{"actual":1.31,"estimate":1.27,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-02-26T21:04:47Z","audioUrl":"https://files.quartr.com/audio-files/8e110-2025-02-26-10-12-46.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/de138-2025-02-26-09-19-19.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/962cd-2025-02-26-09-57-08.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-26T21:30:00Z","earningsSummary":{"summary":"Agilent Technologies showcased resilience and strong performance in Q1 2025, driven by key segments and exceeding revenue targets. While facing challenges in certain sectors and gross margin impact, the company remains focused on growth opportunities and margin expansion. Management's confidence in strategic initiatives and market positioning bodes well for future value creation and shareholder returns. Overall, Agilent's Q1 performance reflects a balance of strengths, challenges, and opportunities for sustained growth and profitability.","headline":"Agilent Technologies exceeds Q1 expectations, eyes margin expansion opportunities","lastUpdated":"2025-02-27T02:03:33.378782Z"}},{"actual":1.31,"estimate":1.26,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-05-28T20:05:54Z","audioUrl":"https://files.quartr.com/audio-files/dd214-2025-05-28-09-06-39.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/09c26-2025-05-28-09-45-20.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/2eeca-2025-05-28-08-59-09.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-28T20:30:00Z","earningsSummary":{"summary":"Agilent Technologies reported strong revenue growth, exceeding expectations with adjusted EPS at $1.20. The company showcased strength in key segments and successful cost-saving initiatives. While facing challenges from potential supply chain disruptions and inflation, Agilent remains optimistic about long-term growth opportunities.","headline":"Agilent Technologies excels in Q2, eyes long-term growth in PFAS testing","lastUpdated":"2025-05-28T23:31:55.760034Z"}},{"actual":null,"estimate":1.37,"period":"Q3 2025","fiscalQuarter":"Q3","fiscalYear":2025,"lastUpdated":"2025-07-24T23:30:05Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-27T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-22","title":"Earnings data Q4 2021","quarter":"Q4","hash":"add7bece4ad2305320105c3a60e9b4d522365f7c69b8bf1eb07637c37e144504"},{"date":"2022-02-22","title":"Earnings data Q1 2022","quarter":"Q1","hash":"ab22562bb2d7abef49209b91ceb7ef55fb6919d4f88332373fb4e8ce828d7937"},{"date":"2022-05-24","title":"Earnings data Q2 2022","quarter":"Q2","hash":"b35dddcca4648ef97385cca0b0f3c2333e1372898a0ec69d1270f1fc9953f78c"},{"date":"2022-08-16","title":"Earnings data Q3 2022","quarter":"Q3","hash":"3b75a6045cd57cfbf188c3d9bb2274f4ff59619d468b377f0fee9d0e70faf175"},{"date":"2022-11-21","title":"Earnings data Q4 2022","quarter":"Q4","hash":"c7b13fa72ad27fa123db0a6dcfc48115e1a88d49ca48cd75d314fed345019385"},{"date":"2023-02-28","title":"Earnings data Q1 2023","quarter":"Q1","hash":"aed7fc9aa9184040421ee438268f10046d27bfc2b0e92c186386d7a4296a9d54"},{"date":"2023-05-23","title":"Earnings data Q2 2023","quarter":"Q2","hash":"36e726229189f24a4167c884ebcd6ae4e4cebbd4fa99879ab20e13d143422d38"},{"date":"2023-08-15","title":"Earnings data Q3 2023","quarter":"Q3","hash":"2c496caa8384834d16cc981e6b1f020154deb833f5ea442b102552e2772bf7ee"},{"date":"2023-11-20","title":"Earnings data Q4 2023","quarter":"Q4","hash":"d9a0dd9212c6565fd34c73091da862f838bddbeca9084c7a1aedbffbc44090e9"},{"date":"2024-02-27","title":"Earnings data Q1 2024","quarter":"Q1","hash":"a45a241d7e007882effdfcd634712a85784141bc63146ebbaaf2369fdc51a698"},{"date":"2024-05-29","title":"Earnings data Q2 2024","quarter":"Q2","hash":"86a565c688d2e5d8f43d2c0dc74dd19f81a02dfc3d44b7284c0b69e1873ad3f2"},{"date":"2024-08-21","title":"Earnings data Q3 2024","quarter":"Q3","hash":"5b8546f076b1cc59a38ebd7f595b5b8793ad922e9326acfa362a9ef098b028f4"},{"date":"2024-11-25","title":"Earnings data Q4 2024","quarter":"Q4","hash":"6fd0d12f2922e7082a44582b1d65d0d53f0a2b7eda724fffbd9178ff454c2a4b"},{"date":"2025-02-26","title":"Earnings data Q1 2025","quarter":"Q1","hash":"d77f2f838f7a8b25d43636a3e7eb9dcc8b01a7540818798435fd94bd8337e0f5"},{"date":"2025-05-28","title":"Earnings data Q2 2025","quarter":"Q2","hash":"decc8613cf1d6535c90ba5905c763ea39aeb63c281a18c329bd478e49c91c765"},{"date":"2025-08-27","title":"Earnings data Q3 2025","quarter":"Q3","hash":"55d191230f3f391d20251144df8f7a4deeb3fbd078faa2fdcc696cf040015415"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Agilent Technologies","companyDescription":"Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q2 2025","values":[{"financialKey":"REVENUE","value":1668000000,"changePercentage":6.04,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":786000000,"changePercentage":9.62,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":882000000,"changePercentage":3.04,"valueToRevenueRatio":0.5287769784172662},{"financialKey":"OPERATING_EXPENSES","value":522000000,"changePercentage":5.88,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":522000000,"changePercentage":5.88,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":360000000,"changePercentage":-0.83,"valueToRevenueRatio":0.2158273381294964},{"financialKey":"EBITDA","value":433000000,"changePercentage":1.64,"valueToRevenueRatio":0.2595923261390887},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":73000000,"changePercentage":15.87,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":215000000,"changePercentage":-30.19,"valueToRevenueRatio":null},{"financialKey":"EPS","value":0.7544,"changePercentage":-28.23,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":12158000000,"changePercentage":11.99,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":4208000000,"changePercentage":0.12,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":1486000000,"changePercentage":-11.07,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":1366000000,"changePercentage":9.37,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":991000000,"changePercentage":-0.9,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":365000000,"changePercentage":28.98,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":7950000000,"changePercentage":19.49,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":2094000000,"changePercentage":36.59,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":4969000000,"changePercentage":13.45,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":887000000,"changePercentage":19.86,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":6022000000,"changePercentage":29.73,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":2012000000,"changePercentage":2.76,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":146000000,"changePercentage":-65.24,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":1866000000,"changePercentage":21.33,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":4010000000,"changePercentage":49.4,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":3349000000,"changePercentage":56.79,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":661000000,"changePercentage":20.62,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":6136000000,"changePercentage":-1.26,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":6136000000,"changePercentage":-1.26,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":12158000000,"changePercentage":11.99,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":3495000000,"changePercentage":36.74,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":2009000000,"changePercentage":127.01,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":21.6105,"changePercentage":1.41,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":215000000,"changePercentage":-30.19,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":221000000,"changePercentage":-33.63,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":357000000,"changePercentage":-12.5,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-136000000,"changePercentage":-81.33,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-114000000,"changePercentage":-4.59,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":114000000,"changePercentage":10.68,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":0,"changePercentage":100,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-228000000,"changePercentage":-9.09,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-116000000,"changePercentage":60.14,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":-164000000,"changePercentage":25.79,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":70000000,"changePercentage":1.45,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-12000000,"changePercentage":-1100,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":28000000,"changePercentage":411.11,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":19000000,"changePercentage":125,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":107000000,"changePercentage":-53.48,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:13:50Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2024-11-30T16:59:26Z","bearsSay":["Agilent Technologies has experienced significant challenges, particularly in its Chinese market, which saw a decline of 21%, resulting in a revised full-year outlook reflecting a double-digit decline instead of a previously anticipated mid-single-digit decrement. The company's fiscal year 2024 revenue forecast has been lowered to approximately $6.46 billion, down from an earlier estimate of $6.79 billion, translating to an organic growth expectation of -4.9%. Additionally, Agilent's second-quarter organic revenue declined by 7.5%, which, although aligned with the company's guidance, fell short of market expectations, contributing to a broader negative outlook for the company."],"bullsSay":["Agilent Technologies has demonstrated positive momentum with a book-to-bill ratio exceeding 1.0x and year-over-year order growth for the first time in seven quarters, indicating a rebound in demand across its diverse customer base. Notably, the clinical business is experiencing substantial order growth of around 50%, fostering a favorable long-term outlook despite short-term challenges. Additionally, the company's expansion efforts, such as the groundbreaking for new facilities in Frederick, CO, signal potential for revenue doubling, reinforcing Agilent's strategic positioning for future growth in resilient end markets like biopharmaceuticals and diagnostics."],"charts":[{"title":"Revenue Segments","description":"Revenue segments as reported by the company.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Life Sciences and Applied Markets Group","dataPoints":[{"key":"21 Q3","value":680},{"key":"21 Q4","value":747},{"key":"22 Q1","value":976},{"key":"22 Q2","value":896},{"key":"22 Q3","value":1019},{"key":"22 Q4","value":1116},{"key":"23 Q1","value":1033},{"key":"23 Q2","value":968},{"key":"23 Q3","value":927},{"key":"23 Q4","value":928},{"key":"24 Q1","value":846},{"key":"24 Q2","value":754},{"key":"24 Q3","value":782},{"key":"24 Q4","value":833}]},{"title":"Diagnostics and Genomics Group","dataPoints":[{"key":"21 Q3","value":346},{"key":"21 Q4","value":341},{"key":"22 Q1","value":339},{"key":"22 Q2","value":358},{"key":"22 Q3","value":340},{"key":"22 Q4","value":352},{"key":"23 Q1","value":342},{"key":"23 Q2","value":362},{"key":"23 Q3","value":349},{"key":"23 Q4","value":356},{"key":"24 Q1","value":407},{"key":"24 Q2","value":417},{"key":"24 Q3","value":385},{"key":"24 Q4","value":442}]},{"title":"Agilent CrossLab Group","dataPoints":[{"key":"21 Q3","value":560},{"key":"21 Q4","value":572},{"key":"22 Q1","value":359},{"key":"22 Q2","value":353},{"key":"22 Q3","value":359},{"key":"22 Q4","value":381},{"key":"23 Q1","value":381},{"key":"23 Q2","value":387},{"key":"23 Q3","value":396},{"key":"23 Q4","value":404},{"key":"24 Q1","value":405},{"key":"24 Q2","value":402},{"key":"24 Q3","value":411},{"key":"24 Q4","value":426},{"key":"25 Q1","value":696},{"key":"25 Q2","value":713}]},{"title":"Life Sciences and Diagnostics Markets","dataPoints":[{"key":"25 Q1","value":647},{"key":"25 Q2","value":654}]},{"title":"Applied Markets","dataPoints":[{"key":"25 Q1","value":338},{"key":"25 Q2","value":301}]}],"overlayChart":null},{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q3","value":53.72},{"key":"21 Q4","value":54.21},{"key":"22 Q1","value":54.36},{"key":"22 Q2","value":53.57},{"key":"22 Q3","value":54.65},{"key":"22 Q4","value":54.73},{"key":"23 Q1","value":55.12},{"key":"23 Q2","value":53.81},{"key":"23 Q3","value":39.35},{"key":"23 Q4","value":54.2},{"key":"24 Q1","value":54.76},{"key":"24 Q2","value":54.41},{"key":"24 Q3","value":54.18},{"key":"24 Q4","value":53.85},{"key":"25 Q1","value":53.48},{"key":"25 Q2","value":51.91}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q3","value":21.18},{"key":"21 Q4","value":23.79},{"key":"22 Q1","value":22.46},{"key":"22 Q2","value":22.4},{"key":"22 Q3","value":23.92},{"key":"22 Q4","value":25.47},{"key":"23 Q1","value":24.25},{"key":"23 Q2","value":22.3},{"key":"23 Q3","value":7.95},{"key":"23 Q4","value":24.17},{"key":"24 Q1","value":23.16},{"key":"24 Q2","value":23.07},{"key":"24 Q3","value":21.1},{"key":"24 Q4","value":23.98},{"key":"25 Q1","value":22.36},{"key":"25 Q2","value":17.98}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q3","value":16.64},{"key":"21 Q4","value":26.62},{"key":"22 Q1","value":16.9},{"key":"22 Q2","value":17.05},{"key":"22 Q3","value":19.15},{"key":"22 Q4","value":19.9},{"key":"23 Q1","value":20.04},{"key":"23 Q2","value":17.58},{"key":"23 Q3","value":6.63},{"key":"23 Q4","value":28.13},{"key":"24 Q1","value":20.98},{"key":"24 Q2","value":19.58},{"key":"24 Q3","value":17.87},{"key":"24 Q4","value":20.63},{"key":"25 Q1","value":18.91},{"key":"25 Q2","value":12.88}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Research and development","dataPoints":[{"key":"21 Q3","value":113},{"key":"21 Q4","value":116},{"key":"22 Q1","value":117},{"key":"22 Q2","value":115},{"key":"22 Q3","value":116},{"key":"22 Q4","value":119},{"key":"23 Q1","value":123},{"key":"23 Q2","value":126},{"key":"23 Q3","value":118},{"key":"23 Q4","value":114},{"key":"24 Q1","value":128},{"key":"24 Q2","value":113},{"key":"24 Q3","value":127},{"key":"24 Q4","value":111},{"key":"25 Q1","value":113},{"key":"25 Q2","value":112}]},{"title":"Selling, general and administrative","dataPoints":[{"key":"21 Q3","value":403},{"key":"21 Q4","value":389},{"key":"22 Q1","value":417},{"key":"22 Q2","value":386},{"key":"22 Q3","value":412},{"key":"22 Q4","value":422},{"key":"23 Q1","value":419},{"key":"23 Q2","value":415},{"key":"23 Q3","value":407},{"key":"23 Q4","value":393},{"key":"24 Q1","value":396},{"key":"24 Q2","value":380},{"key":"24 Q3","value":395},{"key":"24 Q4","value":397},{"key":"25 Q1","value":410},{"key":"25 Q2","value":454}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q3","value":25.77},{"key":"21 Q4","value":11.94},{"key":"22 Q1","value":8.14},{"key":"22 Q2","value":5.38},{"key":"22 Q3","value":8.32},{"key":"22 Q4","value":11.39},{"key":"23 Q1","value":4.9},{"key":"23 Q2","value":6.85},{"key":"23 Q3","value":-2.68},{"key":"23 Q4","value":-8.71},{"key":"24 Q1","value":-5.58},{"key":"24 Q2","value":-8.39},{"key":"24 Q3","value":-5.62},{"key":"24 Q4","value":0.77},{"key":"25 Q1","value":1.39},{"key":"25 Q2","value":6.04}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q3","value":17.54},{"key":"21 Q4","value":3.27},{"key":"22 Q1","value":4.71},{"key":"22 Q2","value":-5.29},{"key":"22 Q3","value":2.33},{"key":"22 Q4","value":7.13},{"key":"23 Q1","value":1.5},{"key":"23 Q2","value":7.98},{"key":"23 Q3","value":-0.57},{"key":"23 Q4","value":-6.28},{"key":"24 Q1","value":-3.32},{"key":"24 Q2","value":-8.87},{"key":"24 Q3","value":-0.57},{"key":"24 Q4","value":0.2},{"key":"25 Q1","value":-0.19},{"key":"25 Q2","value":14.81}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q3","value":303},{"key":"21 Q4","value":303},{"key":"22 Q1","value":301},{"key":"22 Q2","value":299},{"key":"22 Q3","value":298},{"key":"22 Q4","value":296},{"key":"23 Q1","value":296},{"key":"23 Q2","value":296},{"key":"23 Q3","value":294},{"key":"23 Q4","value":292},{"key":"24 Q1","value":293},{"key":"24 Q2","value":293},{"key":"24 Q3","value":290},{"key":"24 Q4","value":286},{"key":"25 Q1","value":285},{"key":"25 Q2","value":285}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q3","value":41325.867},{"key":"21 Q4","value":49013.886},{"key":"22 Q1","value":46887.974},{"key":"22 Q2","value":41146.586},{"key":"22 Q3","value":36573.54},{"key":"22 Q4","value":37950.752},{"key":"23 Q1","value":42199.24},{"key":"23 Q2","value":43202.68},{"key":"23 Q3","value":37390.332},{"key":"23 Q4","value":34986.856},{"key":"24 Q1","value":34858.21},{"key":"24 Q2","value":40131.624},{"key":"24 Q3","value":40553.6},{"key":"24 Q4","value":39157.976},{"key":"25 Q1","value":39043.86},{"key":"25 Q2","value":38410.305}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q3","value":6.51},{"key":"21 Q4","value":7.38},{"key":"22 Q1","value":7},{"key":"22 Q2","value":6.4},{"key":"22 Q3","value":5.32},{"key":"22 Q4","value":5.13},{"key":"23 Q1","value":6.01},{"key":"23 Q2","value":6.29},{"key":"23 Q3","value":5.59},{"key":"23 Q4","value":5.18},{"key":"24 Q1","value":5.26},{"key":"24 Q2","value":6.38},{"key":"24 Q3","value":6.42},{"key":"24 Q4","value":5.76},{"key":"25 Q1","value":5.81},{"key":"25 Q2","value":5.76}]}],"overlayChart":null}],"chartsLastUpdated":"2025-05-28T21:46:38Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":null,"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"CRSP","name":"CRISPR Therapeutics","displayName":"CRISPR Therapeutics","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"CRSP","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":68.14,"high":69.57,"low":65.3446,"volume":1639,"volumeDate":"2025-07-25","last":66.06,"open":68.55,"gainPercentage":-3.053,"gainValue":-2.08,"ask":66.48,"bid":66.08,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":5705186000,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":2994283.8387,"highPriceLast52Weeks":71.13,"lowPriceLast52Weeks":30.04,"companyName":"CRISPR Therapeutics AG","longBusinessDescription":"CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.","dividendRate":0,"salesOrRevenue":37314000,"oneYearAnnualRevenueGrowthRate":-89.9478995490374,"threeYearAnnualRevenueGrowthRate":10231.8863,"fiveYearAnnualRevenueGrowthRate":31550.1689,"earningsGrowth":-67.2927,"totalDebt":223693000,"totalAssets":2242034000,"floatAsPercentOfSharesOutstanding":94.7038,"dividendYield":0,"betaTwelveMonth":1.3314,"salesOrRevenueTtm":37675000,"ebitdaTtm":-455179000,"debtToEquityRatioQuarterly":11.9922806096788,"totalEnterpriseValue":1640242199.3600001,"industry":"Biotechnology","sector":"HealthTechnology","preTaxInterestCoverageRatio":null,"fiveYearAverageDebtEquityRatio":9.31,"currentRatio":15.6354784967391,"peratio":-14.63},"recommendation":{"currentConsensusRating":2,"recommendationTargetPrice":80.94,"totalRatings":32,"strongSellRatings":0,"sellRatings":2,"holdRatings":9,"buyRatings":8,"strongBuyRatings":13,"lastUpdated":"2025-07-22T16:17:34Z"},"earningEstimates":[{"actual":-1.67,"estimate":-1.76,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-11-03T22:48:57Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/8cfc0-2023-01-25-12-50-15.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-11-03T09:27:54Z","earningsSummary":null},{"actual":-1.84,"estimate":-1.77,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-15T23:13:27Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/502b9-2023-01-25-12-05-53.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-15T13:09:48Z","earningsSummary":null},{"actual":-2.32,"estimate":null,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-05-09T22:39:27Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/6db6d-2022-06-06-04-36-31.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-05-09T16:31:00Z","earningsSummary":null},{"actual":-2.4,"estimate":-2.23,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-08-08T12:45:09Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/0127c-2024-08-29-10-23-15.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-08T15:00:00Z","earningsSummary":null},{"actual":-2.24,"estimate":-2.29,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-11-01T21:08:24Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/e2d73-2022-11-01-08-07-24.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-01T20:00:00Z","earningsSummary":null},{"actual":-1.41,"estimate":-2.3,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-22T07:31:54Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/3b136-2023-02-21-09-03-18.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-21T21:00:00Z","earningsSummary":null},{"actual":-0.67,"estimate":-1.7,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-05-08T20:49:27Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/0b03e-2023-05-09-09-38-04.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-08T20:00:00Z","earningsSummary":null},{"actual":-0.98,"estimate":-2.12,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-07T20:59:34Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/811f7-2023-08-07-08-44-10.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-07T20:00:00Z","earningsSummary":null},{"actual":-1.41,"estimate":-1.96,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-11-06T23:06:05Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/743f2-2023-11-06-10-38-46.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-06T21:00:00Z","earningsSummary":null},{"actual":1.1,"estimate":-0.07,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-21T23:04:19Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/03e13-2024-02-21-12-39-47.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-21T12:00:00Z","earningsSummary":null},{"actual":-1.43,"estimate":-1.42,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-05-08T22:39:05Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/ab0ad-2024-05-08-08-32-21.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-08T20:00:00Z","earningsSummary":null},{"actual":-1.49,"estimate":-1.52,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-08-05T22:04:22Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/73de7-2024-08-05-08-32-27.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-05T20:00:00Z","earningsSummary":null},{"actual":-1.01,"estimate":-1.42,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-11-05T22:33:10Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/b3fc1-2024-11-05-02-32-08.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-11-05T14:00:00Z","earningsSummary":null},{"actual":-0.44,"estimate":-1.21,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-11T22:17:29Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/4e355-2025-02-11-09-01-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-11T21:00:00Z","earningsSummary":null},{"actual":-1.58,"estimate":-1.25,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-05-06T20:33:34Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/c4adb-2025-05-06-08-02-21.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-06T16:30:00Z","earningsSummary":null},{"actual":null,"estimate":-1.43,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-25T06:00:16Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-08T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-03","title":"Earnings data Q3 2021","quarter":"Q3","hash":"c3b929268b1ec9b3a5811d232b5b58599c2bfd3c459503763218990e494a34d5"},{"date":"2022-02-15","title":"Earnings data Q4 2021","quarter":"Q4","hash":"c59d6f019b2299d645230081e768ef2886d0768aa16190c915869d0b60f4f7e5"},{"date":"2022-05-09","title":"Earnings data Q1 2022","quarter":"Q1","hash":"46944384f9f184d6f1a30d2ac6ad5616c61e4eb9fcf96c1c8cdfd61b2f5f355a"},{"date":"2022-08-08","title":"Earnings data Q2 2022","quarter":"Q2","hash":"b14f48e014cf2385801e54cf08c8f82d282648c1b395975976921a3fb4b7a017"},{"date":"2022-11-01","title":"Earnings data Q3 2022","quarter":"Q3","hash":"964db75e33a53e163ca23f762310a61d28778330f601df26760fc073b6c07ef8"},{"date":"2023-02-21","title":"Earnings data Q4 2022","quarter":"Q4","hash":"2bbb03591e14736c5eb4aaf9c4ccd883dbe4bbcb880d813c616d2d75cce9bfcc"},{"date":"2023-05-08","title":"Earnings data Q1 2023","quarter":"Q1","hash":"e40fd6308857721557e799ffadc92d632f164aad61ef7f95e4fe1203b6b8ae47"},{"date":"2023-08-07","title":"Earnings data Q2 2023","quarter":"Q2","hash":"151517b09a8d151150237958ffcc3fcc7864f5ff7de4f4da39345f304d215a9a"},{"date":"2023-11-06","title":"Earnings data Q3 2023","quarter":"Q3","hash":"e4621bf349badbe465b74479e7317e2df9232a568f66b9677f89af1585aee51a"},{"date":"2024-02-21","title":"Earnings data Q4 2023","quarter":"Q4","hash":"9f40bfaf6ed578443c906c57e8152d6c506caa16c8aa8bb6f13d36b6ef612221"},{"date":"2024-05-08","title":"Earnings data Q1 2024","quarter":"Q1","hash":"fefeda2fb189977818a57a9cb0358582b8411cbe6808ed322e971c3154c415dc"},{"date":"2024-08-05","title":"Earnings data Q2 2024","quarter":"Q2","hash":"62b9de821c4f484668f97e29afbf20a9cfca0a62388ef7f0c85cead2f3f29f33"},{"date":"2024-11-05","title":"Earnings data Q3 2024","quarter":"Q3","hash":"e7ea71a0dc90d95722c423402f801d640b58c61e5ca978d6e935513af9d26884"},{"date":"2025-02-11","title":"Earnings data Q4 2024","quarter":"Q4","hash":"6f8e80c1e1df394115aceb379d36943eb3cbd5c06a92160feb3f6f251c95f9ad"},{"date":"2025-05-06","title":"Earnings data Q1 2025","quarter":"Q1","hash":"586ae74b586b780584b6eecdf071518b5c8bf4dce93336d62ce9f66ff888478f"},{"date":"2025-08-08","title":"Earnings data Q2 2025","quarter":"Q2","hash":"6da75fdf92afb47566d6fda560052f43206428ebb88630501c264fbbda45eb08"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"CRISPR Therapeutics","companyDescription":"CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":865000,"changePercentage":71.63,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":62245000,"changePercentage":20.17,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":-61380000,"changePercentage":-19.66,"valueToRevenueRatio":-70.95953757225433},{"financialKey":"OPERATING_EXPENSES","value":87044000,"changePercentage":-2.52,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":87044000,"changePercentage":-2.52,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":-148424000,"changePercentage":-5.57,"valueToRevenueRatio":-171.5884393063584},{"financialKey":"EBITDA","value":-143688000,"changePercentage":-5.84,"valueToRevenueRatio":-166.11329479768787},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":4736000,"changePercentage":-2.01,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":-135996000,"changePercentage":-16.64,"valueToRevenueRatio":null},{"financialKey":"EPS","value":-1.5825,"changePercentage":-11.02,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":2166102000,"changePercentage":-11.19,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":1867611000,"changePercentage":-11.89,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":1858798000,"changePercentage":-11.83,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":8813000,"changePercentage":-23.36,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":298491000,"changePercentage":-6.54,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":269703000,"changePercentage":-9.65,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":28788000,"changePercentage":37.85,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":336942000,"changePercentage":-5.11,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":119447000,"changePercentage":0.38,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":17506000,"changePercentage":9.47,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":1241000,"changePercentage":2.82,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":100700000,"changePercentage":-1.07,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":217495000,"changePercentage":-7.88,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":201852000,"changePercentage":-7.8,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":15643000,"changePercentage":-8.82,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":1829160000,"changePercentage":-12.23,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":1829160000,"changePercentage":-12.23,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":2166102000,"changePercentage":-11.19,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":219358000,"changePercentage":-6.63,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":-1639440000,"changePercentage":12.48,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":21.18041,"changePercentage":-13.77,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":-135996000,"changePercentage":-16.64,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":-53947000,"changePercentage":-149.15,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":-108795000,"changePercentage":-8,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":54848000,"changePercentage":-73.94,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-19755000,"changePercentage":79.8,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":206000,"changePercentage":-71.43,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":-19549000,"changePercentage":79.86,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-412000,"changePercentage":71.43,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":10588000,"changePercentage":-96.54,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":10588000,"changePercentage":-96.54,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":41000,"changePercentage":472.73,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-63073000,"changePercentage":-119.84,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":-54153000,"changePercentage":-149.67,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:12:32Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-07-24T08:59:41Z","bearsSay":["CRISPR Therapeutics faces a negative outlook primarily due to uncertainties surrounding regulatory approvals for its various gene therapy products, which could lead to downward revisions in financial projections; any delays or complexities in the approval process could materially impact financial metrics. The company's reported net loss of $4.34 per share for 2024, while narrower than previous estimates, underscores ongoing financial challenges, with a significant portion attributed to Casgevy net losses amounting to $213 million in 2024. Additionally, slow uptake of Casgevy since its approval late in 2023, along with low probabilities of success for other pipeline candidates, increases the risk of further financial difficulties."],"bullsSay":["CRISPR Therapeutics is anticipated to experience significant growth due to the expected removal of spending limits associated with its approved drug, Casgevy, which targets high unmet medical needs in sickle-cell disease and transfusion-dependent beta-thalassemia. The company is poised to benefit from advancements in its gene editing programs, particularly CTX112, which could capture market share from established CD19 CAR-T therapies that generate approximately $3 billion annually, given its advantages in scalability and lower cost of goods sold. Additionally, the anticipated major inflection point in 2025 with the Casgevy launch and the positive potential read-through from the pelacarsen Phase 3 data are likely to provide considerable momentum for CRISPR's financial performance moving forward."],"charts":[{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Operating Margin","dataPoints":[{"key":"21 Q2","value":84.66},{"key":"21 Q3","value":-15637.02},{"key":"21 Q4","value":-1129.53},{"key":"22 Q1","value":-18720.43},{"key":"22 Q2","value":-115987.35},{"key":"22 Q3","value":-194029.79},{"key":"22 Q4","value":-2192350},{"key":"23 Q1","value":-64.49},{"key":"23 Q2","value":-136.04},{"key":"23 Q4","value":34.58},{"key":"24 Q1","value":-27894.25},{"key":"24 Q2","value":-29257.26},{"key":"24 Q3","value":-18294.02},{"key":"24 Q4","value":-180.97},{"key":"25 Q1","value":-17158.85}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q2","value":84.29},{"key":"21 Q3","value":-15431.19},{"key":"21 Q4","value":-1095.04},{"key":"22 Q1","value":-19065.64},{"key":"22 Q2","value":-117616.46},{"key":"22 Q3","value":-185690.43},{"key":"22 Q4","value":-1842916.67},{"key":"23 Q1","value":-53.07},{"key":"23 Q2","value":-111.06},{"key":"23 Q4","value":44.4},{"key":"24 Q1","value":-23133.14},{"key":"24 Q2","value":-24450.3},{"key":"24 Q3","value":-14276.08},{"key":"24 Q4","value":-104.54},{"key":"25 Q1","value":-15722.09}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"R\u0026D","dataPoints":[{"key":"21 Q2","value":108.277},{"key":"21 Q3","value":105.321},{"key":"21 Q4","value":134.47},{"key":"22 Q1","value":118.245},{"key":"22 Q2","value":123.223},{"key":"22 Q3","value":116.622},{"key":"22 Q4","value":103.555},{"key":"23 Q1","value":99.935},{"key":"23 Q2","value":101.555},{"key":"23 Q3","value":90.698},{"key":"23 Q4","value":95.144},{"key":"24 Q1","value":76.172},{"key":"24 Q2","value":80.165},{"key":"24 Q3","value":82.16},{"key":"24 Q4","value":82.155},{"key":"25 Q1","value":72.484}]},{"title":"G\u0026A","dataPoints":[{"key":"21 Q2","value":29.806},{"key":"21 Q3","value":24.352},{"key":"21 Q4","value":24.127},{"key":"22 Q1","value":28.021},{"key":"22 Q2","value":26.273},{"key":"22 Q3","value":27.001},{"key":"22 Q4","value":21.169},{"key":"23 Q1","value":22.36},{"key":"23 Q2","value":19.032},{"key":"23 Q3","value":18.291},{"key":"23 Q4","value":16.479},{"key":"24 Q1","value":17.953},{"key":"24 Q2","value":19.481},{"key":"24 Q3","value":17.419},{"key":"24 Q4","value":18.124},{"key":"25 Q1","value":19.296}]},{"title":"Collaboration expense, net","dataPoints":[{"key":"22 Q1","value":30.646},{"key":"22 Q2","value":33.922},{"key":"22 Q3","value":38.859},{"key":"22 Q4","value":6.823},{"key":"23 Q1","value":42.192},{"key":"23 Q2","value":44.636},{"key":"23 Q3","value":23.422},{"key":"23 Q4","value":20},{"key":"24 Q1","value":46.966},{"key":"24 Q2","value":52.131},{"key":"24 Q3","value":11.153},{"key":"25 Q1","value":57.509}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q2","value":2046947.73},{"key":"21 Q3","value":456.76},{"key":"21 Q4","value":3386.22},{"key":"22 Q1","value":74.4},{"key":"22 Q2","value":-99.98},{"key":"22 Q3","value":-88.59},{"key":"22 Q4","value":-99.95},{"key":"23 Q1","value":10538.3},{"key":"23 Q2","value":44203.8},{"key":"23 Q4","value":3353333.33},{"key":"24 Q1","value":-99.5},{"key":"24 Q2","value":-99.26},{"key":"24 Q4","value":-82.26},{"key":"25 Q1","value":71.63}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q2","value":71.04},{"key":"21 Q3","value":40.12},{"key":"21 Q4","value":46.67},{"key":"22 Q1","value":53.73},{"key":"22 Q2","value":32.83},{"key":"22 Q3","value":40.72},{"key":"22 Q4","value":-17.06},{"key":"23 Q1","value":-7.02},{"key":"23 Q2","value":-9.92},{"key":"23 Q3","value":-27.44},{"key":"23 Q4","value":0.06},{"key":"24 Q1","value":-14.22},{"key":"24 Q2","value":-8.14},{"key":"24 Q3","value":-16.37},{"key":"24 Q4","value":-23.81},{"key":"25 Q1","value":5.81}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q2","value":75.827},{"key":"21 Q3","value":76.289},{"key":"21 Q4","value":76.65},{"key":"22 Q1","value":77.098},{"key":"22 Q2","value":77.513},{"key":"22 Q3","value":78.022},{"key":"22 Q4","value":78.337},{"key":"23 Q1","value":78.677},{"key":"23 Q2","value":79.091},{"key":"23 Q3","value":79.414},{"key":"23 Q4","value":79.688},{"key":"24 Q1","value":81.795},{"key":"24 Q2","value":84.921},{"key":"24 Q3","value":85.235},{"key":"24 Q4","value":85.464},{"key":"25 Q1","value":85.939}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q2","value":9221.852},{"key":"21 Q3","value":9581.288},{"key":"21 Q4","value":6696.374},{"key":"22 Q1","value":4841.215},{"key":"22 Q2","value":4556.912},{"key":"22 Q3","value":5654.332},{"key":"22 Q4","value":4155.7},{"key":"23 Q1","value":3821.185},{"key":"23 Q2","value":4487.94},{"key":"23 Q3","value":4101.415},{"key":"23 Q4","value":4384.673},{"key":"24 Q1","value":5855.459},{"key":"24 Q2","value":4912.085},{"key":"24 Q3","value":4324.909},{"key":"24 Q4","value":4035.525},{"key":"25 Q1","value":3643.04}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q2","value":2.56},{"key":"21 Q3","value":2906.94},{"key":"21 Q4","value":129.78},{"key":"22 Q1","value":1287.56},{"key":"22 Q2","value":7210.3},{"key":"22 Q3","value":15038.12},{"key":"22 Q4","value":173154.17},{"key":"23 Q1","value":9.55},{"key":"23 Q2","value":16.03},{"key":"23 Q4","value":5.45},{"key":"24 Q1","value":2904.49},{"key":"24 Q2","value":2375.28},{"key":"24 Q3","value":1796.06},{"key":"24 Q4","value":28.27},{"key":"25 Q1","value":1052.9}]}],"overlayChart":null}],"chartsLastUpdated":"2025-05-12T14:08:27Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.48,"sell":0.52,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"IDXX","name":"IDEXX Laboratories","displayName":"IDEXX Laboratories","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"IDXX","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":540.68,"high":551.1,"low":537.525,"volume":625362,"volumeDate":"2025-07-24","last":549.97,"open":537.81,"gainPercentage":1.718,"gainValue":9.29,"ask":874.45,"bid":392,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":44229632300,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":579566.0323,"highPriceLast52Weeks":551.1,"lowPriceLast52Weeks":356.14,"companyName":"IDEXX Laboratories, Inc.","longBusinessDescription":"IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.","dividendRate":0,"salesOrRevenue":3897504000,"oneYearAnnualRevenueGrowthRate":6.46145962540355,"threeYearAnnualRevenueGrowthRate":6.6359,"fiveYearAnnualRevenueGrowthRate":10.2312,"earningsGrowth":4.6562,"totalDebt":986948000,"totalAssets":3293443000,"floatAsPercentOfSharesOutstanding":99.0061,"dividendYield":0,"betaTwelveMonth":0.8519,"salesOrRevenueTtm":3931836000,"ebitdaTtm":1282073000,"debtToEquityRatioQuarterly":73.1594951150301,"totalEnterpriseValue":35115908240,"industry":"MedicalSpecialties","sector":"HealthTechnology","preTaxInterestCoverageRatio":31.2455021761428,"fiveYearAverageDebtEquityRatio":97.34,"currentRatio":1.10490374604058,"peratio":50.82},"recommendation":{"currentConsensusRating":2.3,"recommendationTargetPrice":473.43,"totalRatings":15,"strongSellRatings":1,"sellRatings":0,"holdRatings":5,"buyRatings":5,"strongBuyRatings":4,"lastUpdated":"2025-07-17T19:37:44Z"},"earningEstimates":[{"actual":2.03,"estimate":1.91,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-11-02T10:50:18Z","audioUrl":"https://files.quartr.com/audio-files/b2b1a-2022-10-19-04-45-21.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/1d40f-2021-11-02-12-00-00-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/0ef19-2023-01-25-10-19-20.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-11-02T00:00:00Z","earningsSummary":null},{"actual":1.89,"estimate":1.71,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-02T11:47:03Z","audioUrl":"https://files.quartr.com/audio-files/dc5ee-2022-10-19-10-11-33.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/cfacc-2022-02-02-01-03-50-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/8b9d2-2023-01-25-12-20-21.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-02T01:50:03Z","earningsSummary":null},{"actual":2.27,"estimate":2.26,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-05-04T10:47:41Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_05_04_14_30_Q1_2022_IDEXX_Laboratories_Inc_Earnings_Call.LNXAUYQO7KU1.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/9faae-2022-05-04-09-59-13-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/4940d-2023-01-25-01-06-23.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-05-04T09:13:59Z","earningsSummary":null},{"actual":1.56,"estimate":1.65,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-08-02T12:08:05Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_08_02_14_30_Q2_2022_IDEXX_Laboratories_Inc_Earnings_Call.70F86CWNMXYZ_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/0e904-2022-08-02-11-52-07.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/2b27e-2022-08-02-11-52-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-02T00:49:00Z","earningsSummary":null},{"actual":2.15,"estimate":2.05,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-11-01T10:34:51Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_11_01T12_30_00_00_00_IDEXX_Laboratories_Inc_Earnings_Call_Q3_2022.WPNK0EXRKAJA_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/2a08f-2022-11-01-11-17-47.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/5a98f-2022-11-01-11-16-47.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-01T12:30:00Z","earningsSummary":null},{"actual":2.05,"estimate":1.94,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-06T11:31:09Z","audioUrl":"https://files.quartr.com/audio-files/91ef5-2023-02-06-02-56-39.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/4d77a-2023-03-07-07-13-08.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/conference-calls/2f3a2-2023-02-06-12-24-16.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-06T13:30:00Z","earningsSummary":{"summary":"IDEXX Laboratories delivered strong Q4 results with revenue and profit growth, driven by gains in key segments and customer retention.\nWhile facing challenges from inflationary costs and international headwinds, the company aims for continued growth and market differentiation.\nOpportunities lie in expanding organic revenue, focusing on international markets, and enhancing customer engagement for future success.","headline":"IDEXX Labs reports robust Q4 performance, eyes international growth","lastUpdated":"2024-05-10T00:33:55.694217Z"}},{"actual":2.55,"estimate":2.42,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-05-02T10:34:52Z","audioUrl":"https://files.quartr.com/audio-files/6afc2-2023-05-02-03-26-38.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/ae1c4-2023-05-02-12-53-13.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/439dc-2023-05-02-11-59-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-02T12:30:00Z","earningsSummary":{"summary":"IDEXX Laboratories delivered a strong Q1 performance with revenue and profit growth across segments.\nThe company's focus on innovation, cloud adoption, and pet oncology diagnostics positions it well for future growth.\nChallenges include U.S. clinical vet visit trends and potential market share competition in lab modalities.\nOpportunities lie in pet oncology diagnostics, cloud adoption, and international market growth for IDEXX.","headline":"IDEXX reports robust Q1 performance, eyes pet oncology growth","lastUpdated":"2024-05-10T01:40:23.802838Z"}},{"actual":2.67,"estimate":2.43,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-01T10:32:35Z","audioUrl":"https://files.quartr.com/audio-files/129d4-2023-08-01-04-56-00.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/4d046-2023-08-01-11-05-14.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/1c59a-2023-08-01-11-34-13.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-01T12:30:00Z","earningsSummary":{"summary":"IDEXX Laboratories demonstrated robust growth in revenues and profitability, driven by strong performance in key segments.\nWhile facing challenges in international markets and margin pressures, the company is poised to capitalize on pet healthcare trends.\nStrategic initiatives like product launches and pricing adjustments position IDEXX well for sustained growth and market leadership.","headline":"IDEXX Laboratories excels in Q2, eyes pet healthcare trends","lastUpdated":"2024-05-10T01:46:30.702671Z"}},{"actual":2.53,"estimate":2.37,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-11-01T10:40:15Z","audioUrl":"https://files.quartr.com/audio-files/1149d-2023-11-01-01-29-34.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/e0ed7-2023-11-01-02-36-26.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/6ced5-2023-11-01-11-28-12.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-01T12:30:00Z","earningsSummary":{"summary":"IDEXX Laboratories demonstrated strong financial performance in Q3, driven by revenue growth and operational efficiency.\nWhile facing challenges in clinical visit trends and capacity management, the company's strategic focus on innovation and market expansion positions it well for future growth.\nOpportunities lie in addressing capacity constraints, expanding the sales force, and enhancing customer engagement through diagnostics testing.\nOverall, IDEXX's commitment to providing integrated solutions and quality services underscores its resilience and potential for sustained success.","headline":"IDEXX Laboratories excels in Q3 earnings amidst capacity challenges","lastUpdated":"2024-05-09T23:42:44.889516Z"}},{"actual":2.32,"estimate":2.12,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-05T11:32:47Z","audioUrl":"https://files.quartr.com/audio-files/bb2e0-2024-02-05-02-19-31.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/060dc-2024-02-05-01-28-03.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/ffef9-2024-02-05-11-27-32.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-05T13:30:00Z","earningsSummary":{"summary":"IDEXX Laboratories delivered strong financial performance in Q4 2023 and aims for continued growth in 2024.\nThe company's focus on innovation, customer feedback, and operational efficiency positions it well for future success.\nChallenges include managing expenses, revenue diversification, and maintaining customer value perception.\nOpportunities lie in organic revenue growth, margin improvement, and the launch of new diagnostic tests and platforms.","headline":"IDEXX Labs posts robust Q4 results, eyes growth through innovation","lastUpdated":"2024-05-10T00:22:07.668991Z"}},{"actual":2.81,"estimate":2.67,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-05-01T10:33:08Z","audioUrl":"https://files.quartr.com/audio-files/05742-2024-05-01-01-34-51.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/1d2ca-2024-08-07-09-10-38.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b74eb-2024-05-01-10-13-40.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-01T12:30:00Z","earningsSummary":{"summary":"IDEXX Laboratories delivered strong financial performance in Q1 2024, driven by solid organic revenue growth and profit gains.\nThe company remains committed to innovation, customer-centric solutions, and increasing standard of care in Companion Animal Healthcare.\nChallenges in clinical visit growth levels and macro impacts on consumer demand are being addressed through operational focus and technology investments.\nOpportunities for growth and improvement in software integration and diagnostic utilization dynamics present avenues for future success.","headline":"IDEXX Laboratories reports strong Q1 earnings and growth opportunities","lastUpdated":"2024-05-10T02:21:17.269002Z"}},{"actual":3.02,"estimate":2.87,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-08-06T10:32:25Z","audioUrl":"https://files.quartr.com/audio-files/fcc6d-2024-08-06-02-35-17.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/6cb80-2024-08-07-09-37-37.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/167fe-2024-08-06-11-45-02.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-06T13:00:00Z","earningsSummary":{"summary":"IDEXX Laboratories navigated Q2 2024 with solid revenue growth and a focus on innovation and cost management. Despite challenges from sector trends and macroeconomic headwinds, the company remains optimistic about long-term growth prospects. Ongoing launches and a strong balance sheet position IDEXX well for future opportunities.","headline":"IDEXX Laboratories reports solid Q2 growth amidst sector challenges","lastUpdated":"2024-08-06T18:17:12.485759Z"}},{"actual":2.79,"estimate":2.68,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-10-31T10:34:45Z","audioUrl":"https://files.quartr.com/audio-files/99966-2024-10-31-01-17-43.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/f645c-2024-12-09-01-36-40.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/2b1b9-2024-10-31-11-18-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-10-31T12:30:00Z","earningsSummary":null},{"actual":2.53,"estimate":2.4,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-03T11:33:24Z","audioUrl":"https://files.quartr.com/audio-files/3da34-2025-02-03-02-30-34.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/60df4-2025-02-03-12-13-07.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f5cbe-2025-02-03-12-12-01.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-03T13:30:00Z","earningsSummary":{"summary":"IDEXX Laboratories demonstrated strong performance in Q4 2024 and full year 2024, driven by revenue growth, operational improvements, and strategic initiatives.\nDespite facing challenges in instrument placements and revenue streams, IDEXX maintained financial strength, solid cash flow, and a focus on long-term growth drivers.\nLooking ahead, IDEXX has opportunities to capitalize on its market position, drive revenue growth, and enhance profitability through strategic outlook and operational efficiencies.","headline":"IDEXX Labs reports robust Q4 performance and outlines growth opportunities","lastUpdated":"2025-02-03T16:03:59.803832Z"}},{"actual":2.91,"estimate":2.85,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-05-01T11:50:33Z","audioUrl":"https://files.quartr.com/audio-files/0088e-2025-05-01-01-26-40.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/4bf2c-2025-05-01-06-00-58.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/1dfc0-2025-05-01-10-42-32.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-01T12:30:00Z","earningsSummary":{"summary":"IDEXX Laboratories delivered a strong Q1 performance with revenue growth, margin improvement, and EPS increase, driven by commercial success and innovation. While facing challenges in managing tariffs and balancing expenses, the company remains confident in its 2025 guidance and growth prospects. Opportunities lie in revenue growth projections, innovation focus, and customer interest in new diagnostic solutions, positioning IDEXX for continued success.","headline":"IDEXX Laboratories reports robust Q1 performance and growth opportunities","lastUpdated":"2025-05-01T17:42:11.647873Z"}},{"actual":null,"estimate":3.3,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-23T23:31:07Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-04T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-02","title":"Earnings data Q3 2021","quarter":"Q3","hash":"20538e26e9066297d5fcb9a2bd4146a724f933360d36453993130dfeb9faafe6"},{"date":"2022-02-02","title":"Earnings data Q4 2021","quarter":"Q4","hash":"63a1de7b7a5f21ac163b7d5b4e4855bb6d9de0eb539b69642deb585fa5300893"},{"date":"2022-05-04","title":"Earnings data Q1 2022","quarter":"Q1","hash":"526f8327150f5aef109cf75ca42481dbdf4941dd8fb3f925f9f576f2e077e12d"},{"date":"2022-08-02","title":"Earnings data Q2 2022","quarter":"Q2","hash":"402c325956f405089fd13bb7803282809cdd3e2e45c030ecf6b1a3055abab2f4"},{"date":"2022-11-01","title":"Earnings data Q3 2022","quarter":"Q3","hash":"571866bd36f1949c4a79f9e30bbfcb09e6be49d76242b5ee1222c688f426bb29"},{"date":"2023-02-06","title":"Earnings data Q4 2022","quarter":"Q4","hash":"117190c98cfec1015c468314e9cdb43f82ab4f81fe38d29e520468f5a5898c11"},{"date":"2023-05-02","title":"Earnings data Q1 2023","quarter":"Q1","hash":"a47ca39287368cc06247b986d51ed776cf61e473b9aeb36b407fcd472a7b9c4c"},{"date":"2023-08-01","title":"Earnings data Q2 2023","quarter":"Q2","hash":"a0e36a4c3b1217f9c5a5b14b125c9e64d101d3cfa8165d98a734d098cedad21b"},{"date":"2023-11-01","title":"Earnings data Q3 2023","quarter":"Q3","hash":"c6becae5b5e8f5b36451e313a6f3a910c20b67686df497a1a6afa880ddc53f53"},{"date":"2024-02-05","title":"Earnings data Q4 2023","quarter":"Q4","hash":"cd9a544f77deffe28be50e80f75290c4b6910ae4c727e7eda2bd2ab1cf7b7c9b"},{"date":"2024-05-01","title":"Earnings data Q1 2024","quarter":"Q1","hash":"8311f24af1a8f2f2b1f5ed89e0d2a5b3e978fcb10cd0793817bc75432fd6a312"},{"date":"2024-08-06","title":"Earnings data Q2 2024","quarter":"Q2","hash":"6120aaeedd4ba523a934bfad5358ca88cd3098eee4ffd9ccbc10f7d18fb61bc7"},{"date":"2024-10-31","title":"Earnings data Q3 2024","quarter":"Q3","hash":"f5042744d0ac148eecea71aa930a75fdb6cb9c84fdc551f825f99828d6e7ce43"},{"date":"2025-02-03","title":"Earnings data Q4 2024","quarter":"Q4","hash":"1d92bdab55f1d0f4a9e7cc4d6799dc81d6de49ca82f605aef819ba8f22b4be7d"},{"date":"2025-05-01","title":"Earnings data Q1 2025","quarter":"Q1","hash":"f82b00b7725da7f0350025c7c0b723105df5a15a5f8c3c29e61cb03936874582"},{"date":"2025-08-04","title":"Earnings data Q2 2025","quarter":"Q2","hash":"28f15c0beb99ea14585e50d92889c74cc1c98916f9dc23b8dd74d08f0c497feb"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"IDEXX Laboratories","companyDescription":"IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":998427000,"changePercentage":3.56,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":371303000,"changePercentage":0.29,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":627124000,"changePercentage":5.6,"valueToRevenueRatio":0.6281120202077869},{"financialKey":"OPERATING_EXPENSES","value":306845000,"changePercentage":4.33,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":306845000,"changePercentage":4.33,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":320279000,"changePercentage":6.84,"valueToRevenueRatio":0.32078359259114586},{"financialKey":"EBITDA","value":354342000,"changePercentage":7.48,"valueToRevenueRatio":0.35490025810600073},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":34063000,"changePercentage":13.91,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":242677000,"changePercentage":3.01,"valueToRevenueRatio":null},{"financialKey":"EPS","value":2.9623,"changePercentage":5.57,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":3213689000,"changePercentage":-4.17,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":1255406000,"changePercentage":-13.27,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":163970000,"changePercentage":-58.74,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":604153000,"changePercentage":4.48,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":395987000,"changePercentage":1.38,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":91296000,"changePercentage":12.42,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":1958283000,"changePercentage":2.74,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":833623000,"changePercentage":0.6,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":514894000,"changePercentage":-1.74,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":609766000,"changePercentage":10.19,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":1765676000,"changePercentage":-1.06,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":1136213000,"changePercentage":18.74,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":512556000.00000006,"changePercentage":48.88,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":101928000,"changePercentage":-24.04,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":521729000,"changePercentage":9.05,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":629463000,"changePercentage":-23.95,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":546803000,"changePercentage":-24.54,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":82660000,"changePercentage":-19.79,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":1448013000,"changePercentage":-7.71,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":1448013000,"changePercentage":-7.71,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":3213689000,"changePercentage":-4.17,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":1059359000,"changePercentage":-0.9,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":895389000,"changePercentage":33.34,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":17.93427,"changePercentage":-5.27,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":242677000,"changePercentage":3.01,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":237962000,"changePercentage":19.83,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":298649000,"changePercentage":6.66,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-60687000,"changePercentage":25.46,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-29610000,"changePercentage":72.31,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":30026000,"changePercentage":-0.82,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-59636000,"changePercentage":72.16,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-330321000,"changePercentage":-129.27,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":-393697000,"changePercentage":-194.06,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-6124000,"changePercentage":39.9,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":-2327000,"changePercentage":42.77,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-124296000,"changePercentage":-120,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":207936000,"changePercentage":23.54,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:13:25Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":null,"bearsSay":[],"bullsSay":[],"charts":[{"title":"Revenue Segments","description":"Revenue segments as reported by the company.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"CAG","dataPoints":[{"key":"21 Q2","value":745.595},{"key":"21 Q3","value":732.495},{"key":"21 Q4","value":719.103},{"key":"22 Q1","value":761.184},{"key":"22 Q2","value":784.087},{"key":"22 Q3","value":764.99},{"key":"22 Q4","value":748.532},{"key":"23 Q1","value":827.279},{"key":"23 Q2","value":866.652},{"key":"23 Q3","value":837.16},{"key":"23 Q4","value":821.265},{"key":"24 Q1","value":889.285},{"key":"24 Q2","value":922.298},{"key":"24 Q3","value":891.99},{"key":"24 Q4","value":870.471},{"key":"25 Q1","value":919.836}]},{"title":"Water","dataPoints":[{"key":"21 Q2","value":37.191},{"key":"21 Q3","value":38.143},{"key":"21 Q4","value":37.131},{"key":"22 Q1","value":36.371},{"key":"22 Q2","value":39.195},{"key":"22 Q3","value":40.84},{"key":"22 Q4","value":39.314},{"key":"23 Q1","value":38.883},{"key":"23 Q2","value":43.029},{"key":"23 Q3","value":44.45},{"key":"23 Q4","value":41.787},{"key":"24 Q1","value":43.071},{"key":"24 Q2","value":46.726},{"key":"24 Q3","value":50.162},{"key":"24 Q4","value":45.153},{"key":"25 Q1","value":45.321}]},{"title":"LPD","dataPoints":[{"key":"21 Q2","value":33.524},{"key":"21 Q3","value":29.126},{"key":"21 Q4","value":33.967},{"key":"22 Q1","value":30.87},{"key":"22 Q2","value":29.889},{"key":"22 Q3","value":28.452},{"key":"22 Q4","value":33.396},{"key":"23 Q1","value":29.208},{"key":"23 Q2","value":29.911},{"key":"23 Q3","value":29.747},{"key":"23 Q4","value":32.793},{"key":"24 Q1","value":28.205},{"key":"24 Q2","value":30.306},{"key":"24 Q3","value":28.992},{"key":"24 Q4","value":34.557},{"key":"25 Q1","value":28.596}]},{"title":"Other","dataPoints":[{"key":"21 Q2","value":9.832},{"key":"21 Q3","value":10.657},{"key":"21 Q4","value":10.889},{"key":"22 Q1","value":8.124},{"key":"22 Q2","value":7.375},{"key":"22 Q3","value":7.379},{"key":"22 Q4","value":7.326},{"key":"23 Q1","value":4.825},{"key":"23 Q2","value":4.038},{"key":"23 Q3","value":4.17},{"key":"23 Q4","value":5.756},{"key":"24 Q1","value":3.534},{"key":"24 Q2","value":4.248},{"key":"24 Q3","value":4.399},{"key":"24 Q4","value":4.107},{"key":"25 Q1","value":4.674}]}],"overlayChart":null},{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q2","value":59.22},{"key":"21 Q3","value":58.35},{"key":"21 Q4","value":56.97},{"key":"22 Q1","value":59.62},{"key":"22 Q2","value":59.73},{"key":"22 Q3","value":60.19},{"key":"22 Q4","value":58.52},{"key":"23 Q1","value":60.31},{"key":"23 Q2","value":60.7},{"key":"23 Q3","value":59.85},{"key":"23 Q4","value":58.35},{"key":"24 Q1","value":61.51},{"key":"24 Q2","value":61.69},{"key":"24 Q3","value":61.09},{"key":"24 Q4","value":59.79},{"key":"25 Q1","value":62.43}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q2","value":31.38},{"key":"21 Q3","value":27.88},{"key":"21 Q4","value":24.86},{"key":"22 Q1","value":29.68},{"key":"22 Q2","value":20.8},{"key":"22 Q3","value":29.08},{"key":"22 Q4","value":27.33},{"key":"23 Q1","value":31.14},{"key":"23 Q2","value":31.38},{"key":"23 Q3","value":30.06},{"key":"23 Q4","value":27.2},{"key":"24 Q1","value":31},{"key":"24 Q2","value":26.28},{"key":"24 Q3","value":31.15},{"key":"24 Q4","value":27.42},{"key":"25 Q1","value":31.7}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q2","value":24.52},{"key":"21 Q3","value":21.61},{"key":"21 Q4","value":20.31},{"key":"22 Q1","value":23.18},{"key":"22 Q2","value":15.33},{"key":"22 Q3","value":21.49},{"key":"22 Q4","value":20.78},{"key":"23 Q1","value":23.77},{"key":"23 Q2","value":23.76},{"key":"23 Q3","value":23.18},{"key":"23 Q4","value":21.57},{"key":"24 Q1","value":24.43},{"key":"24 Q2","value":20.25},{"key":"24 Q3","value":23.86},{"key":"24 Q4","value":22.65},{"key":"25 Q1","value":24.3}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Sales and marketing","dataPoints":[{"key":"21 Q2","value":119.032},{"key":"21 Q3","value":124.434},{"key":"21 Q4","value":128.458},{"key":"22 Q1","value":132.292},{"key":"22 Q2","value":130.257},{"key":"22 Q3","value":130.021},{"key":"22 Q4","value":131.935},{"key":"23 Q1","value":147.804},{"key":"23 Q2","value":140.532},{"key":"23 Q3","value":135.698},{"key":"23 Q4","value":142.032},{"key":"24 Q1","value":149.453},{"key":"24 Q2","value":142.665},{"key":"24 Q3","value":146.281},{"key":"24 Q4","value":150.108},{"key":"25 Q1","value":156.223}]},{"title":"General and administrative","dataPoints":[{"key":"21 Q2","value":73.326},{"key":"21 Q3","value":82.098},{"key":"21 Q4","value":83.466},{"key":"22 Q1","value":77.949},{"key":"22 Q2","value":81.488},{"key":"22 Q3","value":83.764},{"key":"22 Q4","value":83.047},{"key":"23 Q1","value":70.101},{"key":"23 Q2","value":89.669},{"key":"23 Q3","value":89.034},{"key":"23 Q4","value":87.021},{"key":"24 Q1","value":92.024},{"key":"24 Q2","value":157.243},{"key":"24 Q3","value":91.887},{"key":"24 Q4","value":101.137},{"key":"25 Q1","value":91.561}]},{"title":"Research and development","dataPoints":[{"key":"21 Q2","value":37.697},{"key":"21 Q3","value":40.427},{"key":"21 Q4","value":45.306},{"key":"22 Q1","value":40.168},{"key":"22 Q2","value":123.221},{"key":"22 Q3","value":48.013},{"key":"22 Q4","value":43.418},{"key":"23 Q1","value":44.667},{"key":"23 Q2","value":46.505},{"key":"23 Q3","value":47.967},{"key":"23 Q4","value":51.812},{"key":"24 Q1","value":52.635},{"key":"24 Q2","value":55.45},{"key":"24 Q3","value":53.978},{"key":"24 Q4","value":57.729},{"key":"25 Q1","value":59.061}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q2","value":29.57},{"key":"21 Q3","value":12.28},{"key":"21 Q4","value":11.12},{"key":"22 Q1","value":7.57},{"key":"22 Q2","value":4.16},{"key":"22 Q3","value":3.85},{"key":"22 Q4","value":3.43},{"key":"23 Q1","value":7.61},{"key":"23 Q2","value":9.65},{"key":"23 Q3","value":8.78},{"key":"23 Q4","value":8.81},{"key":"24 Q1","value":7.1},{"key":"24 Q2","value":6.35},{"key":"24 Q3","value":6.56},{"key":"24 Q4","value":5.84},{"key":"25 Q1","value":3.56}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q2","value":23.62},{"key":"21 Q3","value":-1.51},{"key":"21 Q4","value":14.63},{"key":"22 Q1","value":12.21},{"key":"22 Q2","value":45.6},{"key":"22 Q3","value":6.01},{"key":"22 Q4","value":0.45},{"key":"23 Q1","value":4.86},{"key":"23 Q2","value":-17.39},{"key":"23 Q3","value":4.16},{"key":"23 Q4","value":8.69},{"key":"24 Q1","value":12.01},{"key":"24 Q2","value":28.42},{"key":"24 Q3","value":7.13},{"key":"24 Q4","value":10.01},{"key":"25 Q1","value":4.33}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q2","value":85.325},{"key":"21 Q3","value":85.123},{"key":"21 Q4","value":84.828},{"key":"22 Q1","value":84.41},{"key":"22 Q2","value":83.922},{"key":"22 Q3","value":83.247},{"key":"22 Q4","value":82.934},{"key":"23 Q1","value":82.992},{"key":"23 Q2","value":83.086},{"key":"23 Q3","value":83.097},{"key":"23 Q4","value":83.088},{"key":"24 Q1","value":83.096},{"key":"24 Q2","value":82.63},{"key":"24 Q3","value":82.304},{"key":"24 Q4","value":81.846},{"key":"25 Q1","value":81.319}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q2","value":47114.844},{"key":"21 Q3","value":57197.804},{"key":"21 Q4","value":53250.947},{"key":"22 Q1","value":44401.855},{"key":"22 Q2","value":34221.629},{"key":"22 Q3","value":30579.953},{"key":"22 Q4","value":32192.657},{"key":"23 Q1","value":39716.818},{"key":"23 Q2","value":39815.476},{"key":"23 Q3","value":41437.649},{"key":"23 Q4","value":39007.24},{"key":"24 Q1","value":45411.299},{"key":"24 Q2","value":41482.326},{"key":"24 Q3","value":39983.612},{"key":"24 Q4","value":35899.865},{"key":"25 Q1","value":35309.686}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q2","value":14.26},{"key":"21 Q3","value":17.64},{"key":"21 Q4","value":16.62},{"key":"22 Q1","value":13.27},{"key":"22 Q2","value":9.94},{"key":"22 Q3","value":9.08},{"key":"22 Q4","value":9.71},{"key":"23 Q1","value":11.03},{"key":"23 Q2","value":10.55},{"key":"23 Q3","value":11.32},{"key":"23 Q4","value":10.82},{"key":"24 Q1","value":11.78},{"key":"24 Q2","value":10.33},{"key":"24 Q3","value":10.25},{"key":"24 Q4","value":9.4},{"key":"25 Q1","value":8.84}]}],"overlayChart":null}],"chartsLastUpdated":"2025-05-01T14:39:33Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":null,"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"ALNY","name":"Alnylam Pharmaceuticals","displayName":"Alnylam Pharmaceuticals","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"ALNY","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":325.64,"high":332.185,"low":324.3,"volume":677122,"volumeDate":"2025-07-24","last":328,"open":326.35,"gainPercentage":0.725,"gainValue":2.36,"ask":521.52,"bid":131.84,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":42767264000,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":935142,"highPriceLast52Weeks":333.7,"lowPriceLast52Weeks":205.87,"companyName":"Alnylam Pharmaceuticals, Inc.","longBusinessDescription":"Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.","dividendRate":0,"salesOrRevenue":2248243000,"oneYearAnnualRevenueGrowthRate":22.9695803514975,"threeYearAnnualRevenueGrowthRate":40.6932,"fiveYearAnnualRevenueGrowthRate":63.5329,"earningsGrowth":21.1595,"totalDebt":2743419000,"totalAssets":4301817000,"floatAsPercentOfSharesOutstanding":95.6292,"dividendYield":0,"betaTwelveMonth":0.9729,"salesOrRevenueTtm":2348099000,"ebitdaTtm":-57815000,"debtToEquityRatioQuarterly":2358.25529518777,"totalEnterpriseValue":30086471810,"industry":"PharmaceuticalsMajor","sector":"HealthTechnology","preTaxInterestCoverageRatio":-1.24691593001452,"fiveYearAverageDebtEquityRatio":319.46,"currentRatio":3.03847909537078,"peratio":-156.72},"recommendation":{"currentConsensusRating":1.8,"recommendationTargetPrice":263.97,"totalRatings":43,"strongSellRatings":0,"sellRatings":1,"holdRatings":9,"buyRatings":13,"strongBuyRatings":20,"lastUpdated":"2025-07-21T12:07:31Z"},"earningEstimates":[{"actual":-1.51,"estimate":-1.57,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-10-28T12:15:31Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2021-10-28T00:00:00Z","earningsSummary":null},{"actual":-1.69,"estimate":-1.54,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-10T13:07:46Z","audioUrl":"https://files.quartr.com/audio-files/e0cf5-2022-10-19-11-02-05.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/2b75a-2022-02-10-08-01-11-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/addcb-2025-03-17-11-40-17.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-10T08:11:00Z","earningsSummary":null},{"actual":-1.49,"estimate":-1.84,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-04-28T13:28:16Z","audioUrl":"https://files.quartr.com/audio-files/cce78-2022-10-28-04-01-40.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/032a5-2022-04-28-02-12-33-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/64cb4-2024-08-30-01-33-40.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-04-28T14:33:12Z","earningsSummary":null},{"actual":-2.03,"estimate":-1.62,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-07-28T12:11:43Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_07_28_14_30_Q2_2022_Alnylam_Pharmaceuticals_Inc_Earnings_Call.E3WPTY3ZB4VM_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/03178-2022-07-28-09-05-41.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/6a79d-2024-08-30-01-37-40.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-07-28T00:07:00Z","earningsSummary":null},{"actual":-1.58,"estimate":-1.78,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-10-27T12:05:39Z","audioUrl":"https://files.quartr.com/audio-files/02311-2022-10-27-03-25-39.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/b890e-2025-04-02-09-14-40.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/5fcb3-2024-08-30-01-32-40.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-10-27T12:30:00Z","earningsSummary":null},{"actual":-1.39,"estimate":-1.9,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-23T13:07:40Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_02_23T13_30_00_00_00_Alnylam_Pharmaceuticals_Inc_Earnings_Call_Q4_2022.WR6BQ8D61F52_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/2974f-2025-04-02-09-56-40.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b11e3-2025-03-17-11-25-20.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-23T13:30:00Z","earningsSummary":{"summary":"Alnylam Pharmaceuticals had a strong financial performance in 2022, driven by the success of AMVUTTRA and advancements in ATTR amyloidosis treatments.\nWhile facing challenges such as FDA requests and the need for self-sustainability, the company is poised for growth with projected revenues and pipeline opportunities.\nOpportunities lie in market expansion, innovative pipeline programs, and upcoming regulatory milestones, positioning Alnylam for continued success in RNAi therapeutics.","headline":"Alnylam Pharmaceuticals reports robust 2022 performance and growth opportunities","lastUpdated":"2024-05-08T23:13:04.943272Z"}},{"actual":-1.06,"estimate":-1.76,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-05-04T12:01:27Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_05_04T12_30_00_00_00_Alnylam_Pharmaceuticals_Inc_Q1_2023.5WCCMXMNGNIT_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/f740f-2023-05-04-02-23-12.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/c99b3-2023-05-05-06-33-10.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-04T12:30:00Z","earningsSummary":{"summary":"Alnylam Pharmaceuticals reported strong financial performance in Q1 2023, driven by the TTR franchise and key product sales growth. Despite challenges with the FDA's partial clinical hold, the company remains optimistic about pipeline development and addressing unmet patient needs with RNAi therapeutics.","headline":"Alnylam Pharmaceuticals posts robust Q1 growth despite FDA challenges","lastUpdated":"2024-05-08T23:25:30.254380Z"}},{"actual":-1.62,"estimate":-1.72,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-03T12:03:39Z","audioUrl":"https://files.quartr.com/audio-files/Alnylam_Pharmaceuticals_Inc.__NasdaqGS_ALNY__Aug-03-2023_-_Audio.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/1e07a-2023-08-03-02-36-03.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/389f4-2023-08-04-04-05-42.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-03T12:30:00Z","earningsSummary":{"summary":"Alnylam Pharmaceuticals delivered strong financial results, positive clinical data, and strategic partnerships in Q2 2023, positioning itself for continued growth.\nWhile facing challenges such as market competition and regulatory complexities, Alnylam remains focused on innovation, patient care, and commercial success.\nThe company's emphasis on R\u0026D, market positioning, and leveraging its RNAi platform underscores its commitment to advancing therapies and driving value for stakeholders.","headline":"Alnylam Pharmaceuticals excels in Q2, poised for growth and innovation","lastUpdated":"2024-05-08T23:20:15.441156Z"}},{"actual":1.74,"estimate":-1.36,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-11-02T12:08:49Z","audioUrl":"https://files.quartr.com/audio-files/873ee-2023-11-02-01-58-27.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/7d43d-2023-11-02-06-03-15.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/2f516-2023-11-02-12-49-11.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-02T12:30:00Z","earningsSummary":{"summary":"Alnylam Pharmaceuticals delivered strong financial results in Q3 2023, showcasing growth and innovation in its product portfolio and pipeline. Despite challenges, the company remains focused on long-term strategies and seizing opportunities in the evolving healthcare landscape.","headline":"Alnylam Pharmaceuticals reports robust Q3 growth and eyes HELIOS-B opportunities","lastUpdated":"2024-05-09T00:09:48.801029Z"}},{"actual":-0.77,"estimate":-1.33,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-15T13:06:22Z","audioUrl":"https://files.quartr.com/audio-files/aec19-2024-02-15-02-35-54.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/d8789-2024-02-15-02-55-23.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/7cee7-2024-02-15-01-47-12.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-15T13:30:00Z","earningsSummary":{"summary":"Alnylam Pharmaceuticals demonstrated strong financial performance in 2023, with notable achievements in commercial RNAi therapeutics and franchise growth. The company's strategic focus on innovation, study optimization, and market positioning bodes well for future success and market leadership in RNAi therapeutics.","headline":"Alnylam Pharmaceuticals excels in 2023, poised for market leadership","lastUpdated":"2024-05-09T01:16:44.029079Z"}},{"actual":-0.16,"estimate":-1.18,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-05-02T12:03:49Z","audioUrl":"https://files.quartr.com/audio-files/50638-2024-05-02-01-04-36.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/7a239-2024-05-02-01-44-16.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/171e3-2024-05-02-07-50-39.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-02T12:30:00Z","earningsSummary":{"summary":"Alnylam Pharmaceuticals showcased strong financial performance, strategic focus on patient needs, and readiness for upcoming milestones.\nWhile facing challenges in meeting guidance and ensuring successful launches, the company is well-positioned for growth and innovation.\nOpportunities lie in upcoming milestones, secondary endpoint focus, and future catalysts, driving potential value creation and differentiation.","headline":"Alnylam Pharmaceuticals reports robust Q1 performance and strategic readiness","lastUpdated":"2024-05-09T02:14:27.743152Z"}},{"actual":0.56,"estimate":-1.08,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-08-01T12:03:00Z","audioUrl":"https://files.quartr.com/audio-files/2cc28-2024-08-01-01-09-37.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/8451d-2024-08-01-12-11-40.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/da5ad-2024-08-01-12-30-29.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-01T12:30:00Z","earningsSummary":{"summary":"Alnylam Pharmaceuticals demonstrated strong financial performance and clinical advancements in Q2 2024, driven by key revenue growth drivers and pipeline progress.\nWhile facing challenges such as rising expenses, the company's strategic strengths in franchise performance and margin improvement position it well for future opportunities.\nWith upcoming milestones and increased guidance, Alnylam is poised to capitalize on growth prospects and maintain its position as a leader in rare disease therapeutics.","headline":"Alnylam Pharmaceuticals excels in Q2 2024, poised for sustained growth","lastUpdated":"2024-08-01T22:27:47.184249Z"}},{"actual":-0.5,"estimate":-0.93,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-10-31T12:01:52Z","audioUrl":"https://files.quartr.com/audio-files/c2a8c-2024-10-31-01-50-29.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/28933-2024-10-31-12-57-20.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b8f1a-2024-10-31-12-37-24.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-10-31T12:30:00Z","earningsSummary":null},{"actual":0.06,"estimate":-0.14,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-13T13:01:16Z","audioUrl":"https://files.quartr.com/audio-files/50e0d-2025-02-13-02-24-40.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/b8ac0-2025-02-13-01-10-36.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/50a8a-2025-02-13-01-36-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-13T13:30:00Z","earningsSummary":{"summary":"Alnylam Pharmaceuticals showcased strong financial and commercial performance in 2024, with notable achievements in net product revenues and pipeline advancements. While facing challenges in various operational aspects, the company is well-positioned for growth and success in the coming year.","headline":"Alnylam Pharmaceuticals excels in 2024, poised for growth in 2025","lastUpdated":"2025-02-13T17:35:34.433613Z"}},{"actual":-0.01,"estimate":-1.03,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-05-01T12:01:05Z","audioUrl":"https://files.quartr.com/audio-files/edf86-2025-05-01-01-55-39.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/7e8d4-2025-05-01-12-12-44.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/eb37a-2025-05-01-12-52-10.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-01T12:30:00Z","earningsSummary":{"summary":"Alnylam Pharmaceuticals demonstrated strong financial performance and portfolio advancements in Q1 2025, driven by the success of the TTR franchise and positive market reception of key products. While challenges like sustaining profitability and market acceptance persist, the company's focus on innovation and transformative therapies positions them well for future growth and success. Opportunities for market expansion, revenue growth, and addressing unmet medical needs underscore Alnylam's potential to deliver value to both patients and investors in the coming quarters.","headline":"Alnylam Pharmaceuticals reports robust Q1 performance and eyes growth opportunities","lastUpdated":"2025-05-01T21:31:50.987388Z"}},{"actual":null,"estimate":-0.16,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-24T23:30:18Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-07-31T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-10-28","title":"Earnings data Q3 2021","quarter":"Q3","hash":"f27cd31b1a70102e83e457143e6b39fa91a7fcbf71b3b95bc628a3e7bf1d9cf2"},{"date":"2022-02-10","title":"Earnings data Q4 2021","quarter":"Q4","hash":"11469eaccdb6e9220ed58500135f5ec25da1bce97717a5c9adb32f8c18454b8d"},{"date":"2022-04-28","title":"Earnings data Q1 2022","quarter":"Q1","hash":"63460a84294191a52d0cdba596d782ba475834a4959669fca79b2ecd5fbbdb97"},{"date":"2022-07-28","title":"Earnings data Q2 2022","quarter":"Q2","hash":"d90923332e6d2c0148c4999ffa4383a99fb67199973ae8037fca965e732ac40f"},{"date":"2022-10-27","title":"Earnings data Q3 2022","quarter":"Q3","hash":"103614226b6a676ed5b246908cbd2073ccc09a806a79a7801165843d5760f7c8"},{"date":"2023-02-23","title":"Earnings data Q4 2022","quarter":"Q4","hash":"12ca440e9118d0ecf8382304876bc31b3a850f186ca836b19e2a0d84fa77022f"},{"date":"2023-05-04","title":"Earnings data Q1 2023","quarter":"Q1","hash":"8b3f608ed4b13edfa8f05898242cd551e35c520fb2e76c90637f85c6c73e16d9"},{"date":"2023-08-03","title":"Earnings data Q2 2023","quarter":"Q2","hash":"b8539c78538d501dccdf34a6ac60779ff56dfa364200cffd92f1356d1b22d00b"},{"date":"2023-11-02","title":"Earnings data Q3 2023","quarter":"Q3","hash":"5479946449c07b9d34d16cb83e3d13109b3f459d14276009a41f7db16663ebc6"},{"date":"2024-02-15","title":"Earnings data Q4 2023","quarter":"Q4","hash":"7e695e817f374e8d105e3a4208eb673047d4642095f243b36c3c322a9d303a11"},{"date":"2024-05-02","title":"Earnings data Q1 2024","quarter":"Q1","hash":"b670f43bc465feffe6c63eeba1e23c93d4fd4a8c7572909db8c577ad3ff7543a"},{"date":"2024-08-01","title":"Earnings data Q2 2024","quarter":"Q2","hash":"741c01dc9bae4f5d24c74dc58c50295c2c860ddf833925edf46f347cbbd0cd37"},{"date":"2024-10-31","title":"Earnings data Q3 2024","quarter":"Q3","hash":"f0de8783a73c91d952795937956791a604690afc6b9ba4e752d3e4ed2d194619"},{"date":"2025-02-13","title":"Earnings data Q4 2024","quarter":"Q4","hash":"962b6843a8c555e1078eb27c821e034b39a74d442e563c0ebfc8c8fa0428e262"},{"date":"2025-05-01","title":"Earnings data Q1 2025","quarter":"Q1","hash":"7657e0e8e5b86669ec676cd35d407720fd667f725a74cadfe7667926f41f7959"},{"date":"2025-07-31","title":"Earnings data Q2 2025","quarter":"Q2","hash":"9a893a657c9d6eb1807a058b83c4cd59612e9cd4a567344beaec6237d60116c3"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Alnylam Pharmaceuticals","companyDescription":"Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":594189000,"changePercentage":20.2,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":71041000,"changePercentage":7.68,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":523148000,"changePercentage":22.13,"valueToRevenueRatio":0.8804403985937135},{"financialKey":"OPERATING_EXPENSES","value":505071000,"changePercentage":7.05,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":505071000,"changePercentage":7.05,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":18077000,"changePercentage":141.62,"valueToRevenueRatio":0.03042297989360288},{"financialKey":"EBITDA","value":32482000,"changePercentage":208.57,"valueToRevenueRatio":0.054666107921890174},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":14405000,"changePercentage":6.57,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":-57479000,"changePercentage":12.82,"valueToRevenueRatio":null},{"financialKey":"EPS","value":-0.4432,"changePercentage":15.21,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":4213810999.9999995,"changePercentage":10.18,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":3268258000,"changePercentage":9.36,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":2632222000,"changePercentage":11,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":418035000,"changePercentage":30.08,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":65581000,"changePercentage":-30.22,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":152420000,"changePercentage":-24.53,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":945552999.9999995,"changePercentage":13.13,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":695917000,"changePercentage":-3.2,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":249636000,"changePercentage":113.64,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":4098376000,"changePercentage":1.35,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":1075623000,"changePercentage":14.22,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":127804000,"changePercentage":45.49,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":947819000,"changePercentage":11,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":3022753000,"changePercentage":-2.55,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":2594448000,"changePercentage":-0.08,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":428305000,"changePercentage":-15.27,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":115435000,"changePercentage":152.64,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":115435000,"changePercentage":152.64,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":4213810999.9999995,"changePercentage":10.18,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":2722252000,"changePercentage":1.41,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":90030000,"changePercentage":-71.24,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":0.88584,"changePercentage":151.09,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":-57479000,"changePercentage":12.82,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":-118314000,"changePercentage":-45.14,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":98732000,"changePercentage":148.18,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-217046000,"changePercentage":-78.94,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":113769000,"changePercentage":268.25,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":8970000,"changePercentage":-30.86,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":122739000,"changePercentage":324.6,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-17940000,"changePercentage":30.86,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":44084000,"changePercentage":52.48,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":49365000,"changePercentage":90.9,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-5281000,"changePercentage":-273.03,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":14058000,"changePercentage":241.41,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":53597000,"changePercentage":141.18,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":-127284000,"changePercentage":-34.71,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:13:07Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-07-24T07:42:42Z","bearsSay":["Alnylam Pharmaceuticals is experiencing substantial financial losses, with a projected timeline indicating that profitability is unlikely for several years, which raises concerns about its long-term viability. The company faces significant risks associated with the regulatory approval of its drug candidates; failure to secure these approvals could lead to downward revisions of its financial projections and valuation metrics. Additionally, potential legal challenges related to intellectual property disputes and increased competition in the RNAi therapeutics market could further hinder revenue growth and extend the path to profitability."],"bullsSay":["Alnylam Pharmaceuticals reported a strong financial performance, with total product revenue reaching $451 million in the fourth quarter of 2023, representing a 30% year-over-year increase, and full-year product revenue growing by 33% to $1.65 billion. The company's growing diagnosis rate for ATTR-CM, which has increased approximately tenfold since 2019, along with their plans to expand physician and health system coverage for ATTR-PN, signal robust market potential and increased market access opportunities. Furthermore, with significant advancements in their clinical programs and positive preclinical results in ophthalmic treatments, Alnylam is well-positioned for growth in a variety of therapeutic areas, supporting a favorable outlook for the company's financial trajectory."],"charts":[],"chartsLastUpdated":"1970-01-01T00:00:00Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":null,"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"AMGN","name":"Amgen","displayName":"Amgen","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"AMGN","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":309.22,"high":311.28,"low":307.35,"volume":1,"volumeDate":"2025-07-25","last":308.55,"open":309.23,"gainPercentage":-0.217,"gainValue":-0.67,"ask":310,"bid":301.2,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":165909186300,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":2660251.6935,"highPriceLast52Weeks":340.89,"lowPriceLast52Weeks":253.3,"companyName":"Amgen, Inc.","longBusinessDescription":"Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.","dividendRate":9.26,"salesOrRevenue":33232000000,"oneYearAnnualRevenueGrowthRate":18.6433416636915,"threeYearAnnualRevenueGrowthRate":8.7994,"fiveYearAnnualRevenueGrowthRate":7.5734,"earningsGrowth":56.9861,"totalDebt":60879000000,"totalAssets":91839000000,"floatAsPercentOfSharesOutstanding":99.7943,"dividendYield":3,"betaTwelveMonth":0.4816,"salesOrRevenueTtm":33929000000,"ebitdaTtm":14489000000,"debtToEquityRatioQuarterly":924.456259062349,"totalEnterpriseValue":189912240000,"industry":"Biotechnology","sector":"HealthTechnology","preTaxInterestCoverageRatio":2.57847394540943,"fiveYearAverageDebtEquityRatio":778,"currentRatio":1.17041898470097,"peratio":28.17},"recommendation":{"currentConsensusRating":2.3,"recommendationTargetPrice":285.74,"totalRatings":35,"strongSellRatings":1,"sellRatings":3,"holdRatings":12,"buyRatings":9,"strongBuyRatings":10,"lastUpdated":"2025-07-23T13:24:45Z"},"earningEstimates":[{"actual":4.67,"estimate":4.27,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-11-02T20:20:05Z","audioUrl":"https://files.quartr.com/audio-files/87346-2022-10-19-04-32-23.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/d4a7d-2021-11-02-12-00-00-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/92f29-2023-01-25-10-32-20.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-11-02T00:00:00Z","earningsSummary":null},{"actual":4.36,"estimate":4.12,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-03-02T22:54:36Z","audioUrl":"https://files.quartr.com/audio-files/0581c-2022-10-19-11-20-07.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/d616a-2022-02-08-07-57-51-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/06088-2023-01-25-12-40-26.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-08T19:51:57Z","earningsSummary":null},{"actual":4.25,"estimate":4.15,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-04-27T20:13:40Z","audioUrl":"https://files.quartr.com/audio-files/94463-2022-10-28-04-38-37.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/7e979-2022-04-27-02-28-16-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/63fa2-2023-01-25-01-05-18.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-04-27T14:16:28Z","earningsSummary":null},{"actual":4.65,"estimate":4.4,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-08-04T20:04:38Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_08_04_23_00_Q2_2022_Amgen_Inc_Earnings_Call.Z33P63PZYS1Z_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/0247c-2022-08-05-12-45-52.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b9932-2022-08-04-08-22-30.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-04T00:54:00Z","earningsSummary":null},{"actual":4.7,"estimate":4.44,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-11-03T20:14:34Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_11_03T20_30_00_00_00_Amgen_Inc_Earnings_Call_Q3_2022.NDBPWKSFIV7G_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/a21c9-2022-11-03-08-28-09.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/913b5-2022-11-03-08-33-02.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-03T15:45:00Z","earningsSummary":null},{"actual":4.09,"estimate":4.09,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-01-31T21:07:12Z","audioUrl":"https://files.quartr.com/audio-files/6d952-2023-02-01-07-34-35.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/reports/88fa4-2023-01-31-09-08-30.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/conference-calls/1a16e-2023-01-31-09-24-15.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-01-31T21:30:00Z","earningsSummary":{"summary":"Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.","headline":"Amgen reports robust Q4 results, navigates pricing challenges for growth","lastUpdated":"2024-05-07T02:47:31.210712Z"}},{"actual":3.98,"estimate":3.85,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-04-27T20:08:51Z","audioUrl":"https://files.quartr.com/audio-files/4ad8e-2023-04-27-10-00-32.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/8a639-2023-04-27-08-02-06.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/d5678-2023-04-27-08-37-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-04-27T20:30:00Z","earningsSummary":{"summary":"Amgen's Q1 2023 earnings call highlighted strong performance, innovative R\u0026D focus, and growth in key markets like Asia-Pacific.\nDespite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.\nOpportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.\nOverall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.","headline":"Amgen reports robust Q1 performance, eyes growth in Asia-Pacific","lastUpdated":"2024-05-05T21:48:04.517661Z"}},{"actual":5,"estimate":4.49,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-03T20:07:04Z","audioUrl":"https://files.quartr.com/audio-files/b76e8-2023-08-03-09-24-54.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/6c42a-2023-08-03-08-26-10.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/e6574-2023-08-03-08-26-10.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-03T20:30:00Z","earningsSummary":{"summary":"Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.\nWhile facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.\nWith a solid financial outlook, increased R\u0026D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.\nUpdates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.","headline":"Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions","lastUpdated":"2024-05-05T23:14:01.348462Z"}},{"actual":4.96,"estimate":4.66,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-10-31T11:09:05Z","audioUrl":"https://files.quartr.com/audio-files/4c377-2023-10-31-01-53-36.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/d3b6d-2023-10-31-11-23-14.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/7bebc-2023-10-31-11-25-14.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-10-31T12:00:00Z","earningsSummary":{"summary":"Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R\u0026D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.","headline":"Amgen reports revenue and earnings growth, eyes AI for innovation","lastUpdated":"2024-05-05T23:53:50.223512Z"}},{"actual":4.71,"estimate":4.62,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-06T21:02:51Z","audioUrl":"https://files.quartr.com/audio-files/31703-2024-02-06-10-43-59.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/f8352-2024-02-06-09-50-12.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/21e6e-2024-02-06-09-34-12.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-06T21:30:00Z","earningsSummary":{"summary":"Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.\nDespite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.\nOpportunities lie in expanding the rare disease portfolio, advancing R\u0026D initiatives, and exploring new therapeutic areas.\nOverall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.","headline":"Amgen reports record sales in Q4 2023, eyes rare diseases","lastUpdated":"2024-05-05T21:27:51.954595Z"}},{"actual":3.96,"estimate":3.87,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-05-02T20:27:45Z","audioUrl":"https://files.quartr.com/audio-files/ffc8d-2024-05-02-09-46-40.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/41c9f-2024-05-02-08-07-06.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/827b9-2024-05-02-08-00-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-02T20:30:00Z","earningsSummary":{"summary":"Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.\nDespite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.\nThe company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.\nWith a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.","headline":"Amgen reports strong Q1 growth, eyes new markets and innovations","lastUpdated":"2024-05-06T00:15:03.188606Z"}},{"actual":4.97,"estimate":5,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-08-06T20:03:32Z","audioUrl":"https://files.quartr.com/audio-files/40a37-2024-08-06-09-07-55.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/c1fb6-2024-08-06-08-33-05.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/e5862-2024-08-06-08-20-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-06T20:30:00Z","earningsSummary":{"summary":"Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.\nWhile facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.\nWith a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.","headline":"Amgen reports strong Q2 earnings, eyes growth in diverse markets","lastUpdated":"2024-08-07T00:22:21.536118Z"}},{"actual":5.58,"estimate":5.11,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-10-30T20:02:04Z","audioUrl":"https://files.quartr.com/audio-files/b108b-2024-10-30-10-05-26.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/f7643-2024-10-30-08-33-07.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/bfa11-2024-10-30-08-20-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-10-30T20:30:00Z","earningsSummary":{"summary":"Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.","headline":"Amgen reports strong Q3 earnings and outlines growth strategies","lastUpdated":"2024-10-31T00:21:45.793807Z"}},{"actual":5.31,"estimate":5.08,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-04T21:08:35Z","audioUrl":"https://files.quartr.com/audio-files/a3808-2025-02-04-10-09-55.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/e134f-2025-02-04-09-22-11.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/63c9b-2025-02-04-09-35-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-04T21:30:00Z","earningsSummary":null},{"actual":4.9,"estimate":4.3,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-05-01T20:01:43Z","audioUrl":"https://files.quartr.com/audio-files/95892-2025-05-01-09-54-49.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/ed5dc-2025-05-01-08-13-23.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/69248-2025-05-01-08-19-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-01T20:30:00Z","earningsSummary":{"summary":"Amgen's Q1 2025 performance reflects strong revenue growth and a focus on meeting patient needs across various therapeutic areas. While challenges exist in evaluating new opportunities like rocutilimab, the company's diverse portfolio and innovation-driven approach present promising growth opportunities.","headline":"Amgen reports robust Q1 earnings, eyes growth in diverse portfolio","lastUpdated":"2025-05-01T23:31:33.438248Z"}},{"actual":null,"estimate":5.26,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-24T23:30:19Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-05T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-02","title":"Earnings data Q3 2021","quarter":"Q3","hash":"e0e2168d0f65969307354ee490405e33a9972646a470b47ea500a860a4a575da"},{"date":"2022-02-07","title":"Earnings data Q4 2021","quarter":"Q4","hash":"f0929c2255c905ce0d56431da7ac9b95962e9c696a4974ca443a576e148161a0"},{"date":"2022-04-27","title":"Earnings data Q1 2022","quarter":"Q1","hash":"498bde4adbab6bb399119d4200642447f1a253d737b40df4b191cfb57345d9c6"},{"date":"2022-08-04","title":"Earnings data Q2 2022","quarter":"Q2","hash":"66876d41a02dbe6e4d181a8e1f9506ccbbe83436b83ca882177771c59d29e2a9"},{"date":"2022-11-03","title":"Earnings data Q3 2022","quarter":"Q3","hash":"3b0c6bc5b5bee070621b4f86d906a42d89192311e4a5018aff5bfa8aec442a7b"},{"date":"2023-01-31","title":"Earnings data Q4 2022","quarter":"Q4","hash":"8b2fbee7f8c0f1be873b08c7f7ca473ad77a460021c3f665d9fc9a4514d18f66"},{"date":"2023-04-27","title":"Earnings data Q1 2023","quarter":"Q1","hash":"e9c61a9f0de74922ce54f2bc9df3357daf2fa1f3b2a6343c7e7c58f6c8d4d515"},{"date":"2023-08-03","title":"Earnings data Q2 2023","quarter":"Q2","hash":"2722d6841cd28f91c43f0ed22a45d556212980c369b90d73584436315672fe81"},{"date":"2023-10-31","title":"Earnings data Q3 2023","quarter":"Q3","hash":"3073d862da99735bbd92af337b8d6b56779545e5d9d751de1e8e4f76087c778e"},{"date":"2024-02-06","title":"Earnings data Q4 2023","quarter":"Q4","hash":"c9d397882cf9e012ea8115a8f3eb8b7b3298db49b04b84f5086fdd15e053f596"},{"date":"2024-05-02","title":"Earnings data Q1 2024","quarter":"Q1","hash":"9c48306f877c7fe5fce95504c760d99832415b536eb2a12dad68ce9521b60351"},{"date":"2024-08-06","title":"Earnings data Q2 2024","quarter":"Q2","hash":"a2fa6641a680f13b854e2aedbea0cc409fed58c1072f3573ee663e3ef5869a15"},{"date":"2024-10-30","title":"Earnings data Q3 2024","quarter":"Q3","hash":"15464be47d3b93851f1924c4b259f30cb27215486b3a145089a46155b8911b76"},{"date":"2025-02-04","title":"Earnings data Q4 2024","quarter":"Q4","hash":"68f857c6061826bdd934658e9c8c5fcbbbae0d484ec275dfb541ce0848d98c6e"},{"date":"2025-05-01","title":"Earnings data Q1 2025","quarter":"Q1","hash":"9f2ecf7bc46d1e6ee1fcb50f03bc660ea2015703f0eca60364058a8f8eafd55c"},{"date":"2025-08-05","title":"Earnings data Q2 2025","quarter":"Q2","hash":"2c987065d350e79b00d8327195f32d67be856925efe6b2ae97c87188083845df"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Amgen","companyDescription":"Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":8093000000,"changePercentage":9.42,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":2968000000,"changePercentage":-7.25,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":5125000000,"changePercentage":22.14,"valueToRevenueRatio":0.6332633139750402},{"financialKey":"OPERATING_EXPENSES","value":4003000000,"changePercentage":22.94,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":3173000000,"changePercentage":0.7,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":830000000,"changePercentage":690.48,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":1122000000,"changePercentage":19.36,"valueToRevenueRatio":0.13863832942048684},{"financialKey":"EBITDA","value":2509000000,"changePercentage":7.27,"valueToRevenueRatio":0.3100210058074879},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":1387000000,"changePercentage":-0.86,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":1730000000,"changePercentage":1630.97,"valueToRevenueRatio":null},{"financialKey":"EPS","value":3.1978,"changePercentage":1616.98,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":89367000000,"changePercentage":-3.89,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":26929000000,"changePercentage":-3.92,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":8810000000,"changePercentage":-9.25,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":8132000000,"changePercentage":20.01,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":6729000000,"changePercentage":-22.87,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":3258000000,"changePercentage":15.49,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":62438000000,"changePercentage":-3.87,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":6681000000,"changePercentage":11.31,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":44369000000,"changePercentage":-11.16,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":11388000000,"changePercentage":26.43,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":83160000000,"changePercentage":-5.45,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":23008000000,"changePercentage":16.71,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":3368000000,"changePercentage":-14.93,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":19640000000,"changePercentage":24.66,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":60152000000,"changePercentage":-11.86,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":54013000000,"changePercentage":-10.07,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":6139000000,"changePercentage":-24.98,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":6207000000,"changePercentage":23.6,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":6207000000,"changePercentage":23.6,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":89367000000,"changePercentage":-3.89,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":57381000000,"changePercentage":-10.37,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":48571000000,"changePercentage":-10.57,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":11.54361,"changePercentage":23.3,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":1730000000,"changePercentage":1630.97,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":1391000000,"changePercentage":101.89,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":2407000000,"changePercentage":74.29,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-1016000000,"changePercentage":-46.82,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-447000000,"changePercentage":-105.99,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":411000000,"changePercentage":78.7,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-858000000,"changePercentage":-91.95,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-4107000000,"changePercentage":-140.46,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":-2801000000,"changePercentage":-583.17,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":1279000000,"changePercentage":5.88,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-27000000,"changePercentage":70,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-3163000000,"changePercentage":-155.91,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":980000000,"changePercentage":113.51,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:12:45Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-07-17T06:13:19Z","bearsSay":["Amgen faces significant risks that may negatively impact its financial outlook, primarily due to heightened competition within its core business franchise, which could lead to market share erosion and increased pricing pressure. Additionally, the company is experiencing challenges related to lower-than-expected uptake for its newer products and potential regulatory setbacks for its late-stage pipeline and biosimilars. Looking ahead, management anticipates a potential mid-single-digit decline in pricing for its cholesterol-lowering drug, Repatha, which may further strain revenue growth as the competitive landscape evolves."],"bullsSay":["Amgen's financial outlook appears robust due to substantial sales growth from its flagship product Tavneos, which saw a remarkable 81% increase in the fourth quarter of 2024, contributing to overall U.S. sales of approximately $716 million in 2022, following a label expansion. The acquisition of Horizon Therapeutics has strengthened the company’s portfolio by adding several rare-disease treatments, including Tepezza, further enhancing its growth prospects alongside a strong emerging pipeline that includes promising candidates like Olpasiran and Imdelltra. Moreover, Amgen's strong cash position, coupled with a well-diversified product portfolio across key therapeutic areas, supports sustained long-term growth potential and reinforces the company's status as a high-quality player in the biotechnology sector."],"charts":[{"title":"Revenue Segments","description":"Revenue segments as reported by the company.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Product sales","dataPoints":[{"key":"21 Q2","value":6114},{"key":"21 Q3","value":6320},{"key":"21 Q4","value":6271},{"key":"22 Q1","value":5731},{"key":"22 Q2","value":6281},{"key":"22 Q3","value":6237},{"key":"22 Q4","value":6552},{"key":"23 Q1","value":5846},{"key":"23 Q2","value":6683},{"key":"23 Q3","value":6548},{"key":"23 Q4","value":7833},{"key":"24 Q1","value":7118},{"key":"24 Q2","value":8041},{"key":"24 Q3","value":8151},{"key":"24 Q4","value":8716},{"key":"25 Q1","value":7873}]},{"title":"Other revenues","dataPoints":[{"key":"21 Q2","value":412},{"key":"21 Q3","value":386},{"key":"21 Q4","value":575},{"key":"22 Q1","value":507},{"key":"22 Q2","value":313},{"key":"22 Q3","value":415},{"key":"22 Q4","value":287},{"key":"23 Q1","value":259},{"key":"23 Q2","value":303},{"key":"23 Q3","value":355},{"key":"23 Q4","value":363},{"key":"24 Q1","value":329},{"key":"24 Q2","value":347},{"key":"24 Q3","value":352},{"key":"24 Q4","value":370},{"key":"25 Q1","value":276}]}],"overlayChart":null},{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q2","value":74.91},{"key":"21 Q3","value":76},{"key":"21 Q4","value":74.9},{"key":"22 Q1","value":74.97},{"key":"22 Q2","value":77.1},{"key":"22 Q3","value":76.12},{"key":"22 Q4","value":74.45},{"key":"23 Q1","value":71.82},{"key":"23 Q2","value":74.04},{"key":"23 Q3","value":73.83},{"key":"23 Q4","value":62.03},{"key":"24 Q1","value":57.02},{"key":"24 Q2","value":61.42},{"key":"24 Q3","value":61.07},{"key":"24 Q4","value":65.74},{"key":"25 Q1","value":63.57}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q2","value":12.68},{"key":"21 Q3","value":35.46},{"key":"21 Q4","value":33.65},{"key":"22 Q1","value":40.07},{"key":"22 Q2","value":32.99},{"key":"22 Q3","value":39.98},{"key":"22 Q4","value":32.6},{"key":"23 Q1","value":31.46},{"key":"23 Q2","value":38.41},{"key":"23 Q3","value":29.27},{"key":"23 Q4","value":15.5},{"key":"24 Q1","value":13.3},{"key":"24 Q2","value":22.75},{"key":"24 Q3","value":24.07},{"key":"24 Q4","value":25.43},{"key":"25 Q1","value":14.45}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q2","value":7.11},{"key":"21 Q3","value":28.09},{"key":"21 Q4","value":27.73},{"key":"22 Q1","value":23.66},{"key":"22 Q2","value":19.97},{"key":"22 Q3","value":32.21},{"key":"22 Q4","value":23.62},{"key":"23 Q1","value":46.53},{"key":"23 Q2","value":19.73},{"key":"23 Q3","value":25.06},{"key":"23 Q4","value":9.35},{"key":"24 Q1","value":-1.52},{"key":"24 Q2","value":8.89},{"key":"24 Q3","value":33.28},{"key":"24 Q4","value":6.9},{"key":"25 Q1","value":21.22}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Research and development","dataPoints":[{"key":"21 Q2","value":1082},{"key":"21 Q3","value":1422},{"key":"21 Q4","value":1348},{"key":"22 Q1","value":959},{"key":"22 Q2","value":1039},{"key":"22 Q3","value":1112},{"key":"22 Q4","value":1324},{"key":"23 Q1","value":1058},{"key":"23 Q2","value":1113},{"key":"23 Q3","value":1079},{"key":"23 Q4","value":1534},{"key":"24 Q1","value":1343},{"key":"24 Q2","value":1447},{"key":"24 Q3","value":1450},{"key":"24 Q4","value":1724},{"key":"25 Q1","value":1486}]},{"title":"Acquired in-process research and development","dataPoints":[{"key":"21 Q2","value":1505}]},{"title":"Selling, general and administrative","dataPoints":[{"key":"21 Q2","value":1384},{"key":"21 Q3","value":1305},{"key":"21 Q4","value":1425},{"key":"22 Q1","value":1228},{"key":"22 Q2","value":1327},{"key":"22 Q3","value":1287},{"key":"22 Q4","value":1572},{"key":"23 Q1","value":1258},{"key":"23 Q2","value":1294},{"key":"23 Q3","value":1353},{"key":"23 Q4","value":2274},{"key":"24 Q1","value":1808},{"key":"24 Q2","value":1785},{"key":"24 Q3","value":1625},{"key":"24 Q4","value":1878},{"key":"25 Q1","value":1687}]},{"title":"Other","dataPoints":[{"key":"21 Q2","value":90},{"key":"21 Q3","value":-8},{"key":"21 Q4","value":51},{"key":"22 Q1","value":-10},{"key":"22 Q2","value":542},{"key":"22 Q3","value":5},{"key":"22 Q4","value":-34},{"key":"23 Q1","value":148},{"key":"23 Q2","value":82},{"key":"23 Q3","value":644},{"key":"23 Q4","value":5},{"key":"24 Q1","value":105},{"key":"24 Q2","value":11},{"key":"24 Q3","value":71},{"key":"24 Q4","value":61},{"key":"25 Q1","value":830}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q2","value":5.16},{"key":"21 Q3","value":4.41},{"key":"21 Q4","value":3.2},{"key":"22 Q1","value":5.71},{"key":"22 Q2","value":1.04},{"key":"22 Q3","value":-0.81},{"key":"22 Q4","value":-0.1},{"key":"23 Q1","value":-2.13},{"key":"23 Q2","value":5.94},{"key":"23 Q3","value":3.77},{"key":"23 Q4","value":19.84},{"key":"24 Q1","value":21.98},{"key":"24 Q2","value":20.07},{"key":"24 Q3","value":23.18},{"key":"24 Q4","value":10.86},{"key":"25 Q1","value":9.43}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q2","value":69.56},{"key":"21 Q3","value":12.87},{"key":"21 Q4","value":-6.77},{"key":"22 Q1","value":-4.6},{"key":"22 Q2","value":-28.39},{"key":"22 Q3","value":-11.59},{"key":"22 Q4","value":1.35},{"key":"23 Q1","value":13.18},{"key":"23 Q2","value":-14.41},{"key":"23 Q3","value":27.95},{"key":"23 Q4","value":33.23},{"key":"24 Q1","value":32.14},{"key":"24 Q2","value":30.29},{"key":"24 Q3","value":2.28},{"key":"24 Q4","value":-3.93},{"key":"25 Q1","value":22.94}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q2","value":573},{"key":"21 Q3","value":567},{"key":"21 Q4","value":562},{"key":"22 Q1","value":548},{"key":"22 Q2","value":535},{"key":"22 Q3","value":535},{"key":"22 Q4","value":535},{"key":"23 Q1","value":534},{"key":"23 Q2","value":535},{"key":"23 Q3","value":535},{"key":"23 Q4","value":535},{"key":"24 Q1","value":536},{"key":"24 Q2","value":537},{"key":"24 Q3","value":537},{"key":"24 Q4","value":537},{"key":"25 Q1","value":538}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q2","value":140958},{"key":"21 Q3","value":130523.4},{"key":"21 Q4","value":118638.2},{"key":"22 Q1","value":125930.4},{"key":"22 Q2","value":130593.5},{"key":"22 Q3","value":129149},{"key":"22 Q4","value":142952},{"key":"23 Q1","value":130509.6},{"key":"23 Q2","value":123531.5},{"key":"23 Q3","value":133001},{"key":"23 Q4","value":145787.5},{"key":"24 Q1","value":156833.6},{"key":"24 Q2","value":157770.6},{"key":"24 Q3","value":175652.7},{"key":"24 Q4","value":159327.9},{"key":"25 Q1","value":158871.4}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q2","value":5.4},{"key":"21 Q3","value":4.87},{"key":"21 Q4","value":4.33},{"key":"22 Q1","value":5.05},{"key":"22 Q2","value":4.95},{"key":"22 Q3","value":4.85},{"key":"22 Q4","value":5.23},{"key":"23 Q1","value":5.34},{"key":"23 Q2","value":4.42},{"key":"23 Q3","value":4.82},{"key":"23 Q4","value":4.45},{"key":"24 Q1","value":5.26},{"key":"24 Q2","value":4.7},{"key":"24 Q3","value":5.16},{"key":"24 Q4","value":4.38},{"key":"25 Q1","value":4.87}]}],"overlayChart":null}],"chartsLastUpdated":"2025-05-01T23:50:21Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.52,"sell":0.48,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"EDIT","name":"Editas Medicine","displayName":"Editas Medicine","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"EDIT","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":3.46,"high":3.58,"low":3.18,"volume":3013,"volumeDate":"2025-07-25","last":3.26,"open":3.46,"gainPercentage":-5.78,"gainValue":-0.2,"ask":3.26,"bid":3.24,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":272904100,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":2473325.7903,"highPriceLast52Weeks":5.85,"lowPriceLast52Weeks":0.9101,"companyName":"Editas Medicine, Inc.","longBusinessDescription":"Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.","dividendRate":0,"salesOrRevenue":32314000,"oneYearAnnualRevenueGrowthRate":-58.6370211077404,"threeYearAnnualRevenueGrowthRate":71.6179,"fiveYearAnnualRevenueGrowthRate":96.9868,"earningsGrowth":-44.6954,"totalDebt":35032000,"totalAssets":341589000,"floatAsPercentOfSharesOutstanding":99.0929,"dividendYield":0,"betaTwelveMonth":2.2186,"salesOrRevenueTtm":35836000,"ebitdaTtm":-200923000,"debtToEquityRatioQuarterly":49.8766421018904,"totalEnterpriseValue":-130311460.60000001,"industry":"Biotechnology","sector":"HealthTechnology","preTaxInterestCoverageRatio":null,"fiveYearAverageDebtEquityRatio":7.82,"currentRatio":3.07523866838088,"peratio":-1.07},"recommendation":{"currentConsensusRating":2.2,"recommendationTargetPrice":12.7,"totalRatings":23,"strongSellRatings":1,"sellRatings":0,"holdRatings":9,"buyRatings":5,"strongBuyRatings":8,"lastUpdated":"2025-06-04T17:01:02Z"},"earningEstimates":[{"actual":-0.57,"estimate":-0.82,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-11-08T12:40:27Z","audioUrl":"https://files.quartr.com/audio-files/fdf9d-2022-10-19-05-49-00.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/16031-2023-01-25-11-29-57.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-11-08T00:00:00Z","earningsSummary":null},{"actual":-0.61,"estimate":-0.72,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-24T11:39:02Z","audioUrl":"https://files.quartr.com/audio-files/68d7d-2022-10-19-12-18-11.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/57309-2023-01-25-12-12-41.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-24T11:36:38Z","earningsSummary":null},{"actual":-0.74,"estimate":-0.79,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-05-04T10:49:37Z","audioUrl":"https://files.quartr.com/audio-files/29aaa-2023-01-13-09-03-01.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/cf2ba-2022-05-04-12-35-45-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/3e7b3-2023-01-25-02-48-34.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-05-04T12:45:35Z","earningsSummary":null},{"actual":-0.78,"estimate":-0.82,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-08-03T10:55:28Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_08_03_14_00_Q2_2022_Editas_Medicine_Inc_Earnings_Call.O3VUUEV9QMPV_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/b4d32-2022-08-03-11-58-11.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-03T14:15:00Z","earningsSummary":null},{"actual":-0.81,"estimate":-0.86,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-11-02T11:22:27Z","audioUrl":"https://files.quartr.com/audio-files/c1e97-2022-11-02-03-39-24.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/b1f64-2022-11-02-01-42-19.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-02T12:00:00Z","earningsSummary":null},{"actual":-0.88,"estimate":-0.8,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-22T11:20:45Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_02_22T13_00_00_00_00_Editas_Medicine_Inc_Earnings_Call_Q4_2022.RFYDFOBRYTV4_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/f1978-2023-02-22-12-06-04.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-22T13:00:00Z","earningsSummary":{"summary":"Editas Medicine's Q4 2022 earnings call highlighted positive clinical data, strong financial positioning, and strategic advancements in genome editing medicines.\nWhile facing challenges in hiring key personnel, regulatory negotiations, and strategic realignment, the company is well-positioned for therapeutic advancements and market growth.\nOpportunities lie in replicating clinical success, strategic partnerships, and advancements in pipeline development, supported by strong collaborations and financial prospects.\nOverall, Editas Medicine's performance, strengths, challenges, and opportunities reflect a company poised for continued growth and innovation in the genome editing space.","headline":"Editas Medicine reports positive clinical data and strategic advancements","lastUpdated":"2024-05-05T22:51:37.401841Z"}},{"actual":-0.71,"estimate":-0.78,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-05-05T11:07:27Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_05_05T12_00_00_00_00_Editas_Medicine_Inc_Q1_2023.ZEUDV41PC9NA_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/f5d7c-2023-05-05-11-22-01.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-05T12:00:00Z","earningsSummary":{"summary":"Editas Medicine's Q1 performance was strong, supported by promising clinical trial data and regulatory advancements.\nThe company's focus on gene editing for hemoglobinopathies and strong IP position are key strengths.\nChallenges include differentiation from competitors and legal uncertainties, while opportunities lie in expansion and regulatory progress.\nOverall, Editas Medicine is well-positioned for growth in the gene editing market.","headline":"Editas Medicine excels in Q1 with promising trials and regulatory progress","lastUpdated":"2024-05-07T02:22:01.285199Z"}},{"actual":-0.56,"estimate":-0.76,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-02T11:15:06Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_08_02T12_00_00_00_00_Editas_Medicine_Inc_Q2_2023.JHA64MTMNG1F_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/7ebfb-2023-08-02-11-10-15.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-02T12:00:00Z","earningsSummary":{"summary":"Editas Medicine shows strong performance with positive clinical data and financial raise\nFacing challenges in pipeline adjustment and FDA discussions for facility planning\nOpportunities lie in expanding trials, partnerships, and enhancing R\u0026D focus","headline":"Editas Medicine reports positive data, raises funds, and faces challenges","lastUpdated":"2024-05-07T04:18:48.780238Z"}},{"actual":-0.55,"estimate":-0.57,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-11-03T11:07:35Z","audioUrl":"https://files.quartr.com/audio-files/dd21a-2023-11-03-01-32-25.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/e1bf1-2024-08-29-07-51-23.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-03T12:00:00Z","earningsSummary":{"summary":"Editas Medicine is making significant progress with EDIT-301, showcasing confidence in their gene editing capabilities and operational readiness.\nWhile facing challenges in safety monitoring and differentiation, the company's strategic hires, strong IP portfolio, and focus on regulatory pathways provide a solid foundation for growth.\nWith a clear roadmap for clinical data presentation, manufacturing scaling, and regulatory submissions, Editas is well-positioned to capitalize on opportunities in gene editing therapies.","headline":"Editas Medicine advances EDIT-301 program, poised for gene therapy leadership","lastUpdated":"2024-05-07T01:13:48.379504Z"}},{"actual":-0.23,"estimate":-0.54,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-28T12:06:31Z","audioUrl":"https://files.quartr.com/audio-files/41059-2024-02-28-02-39-08.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/13d08-2024-02-28-12-19-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-28T13:00:00Z","earningsSummary":{"summary":"Editas Medicine's Q4 2023 Earnings Call showcased strong performance in enrollment, clinical data, and financials. The company's strengths lie in its research capabilities, cash position, and progress in key trials. Challenges include addressing analyst queries and optimizing manufacturing processes.","headline":"Editas Medicine exceeds enrollment goals and showcases promising clinical data","lastUpdated":"2024-05-07T04:19:41.125429Z"}},{"actual":-0.76,"estimate":-0.67,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-05-08T11:45:42Z","audioUrl":"https://files.quartr.com/audio-files/4a8a0-2024-05-08-01-29-13.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/4f965-2024-05-08-11-02-02.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-08T12:00:00Z","earningsSummary":{"summary":"Editas Medicine's Q1 2024 performance reflects solid revenue and strong financial reserves, driven by R\u0026D investments in the Renace program.\nThe company's strengths lie in its financial stability, advancing in vivo capabilities, and fostering strong collaborations for future growth.\nChallenges include legal uncertainties, operational optimizations, and strategic complexities in therapeutic development.\nOpportunities abound in driving Renace, regulatory progress for Reni-cel, and leveraging innovative in vivo approaches for unique indications.","headline":"Editas Medicine reports robust Q1 performance and advances in gene editing","lastUpdated":"2024-05-08T19:19:28.317507Z"}},{"actual":-0.82,"estimate":-0.7,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-08-07T11:17:21Z","audioUrl":"https://files.quartr.com/audio-files/ca9d0-2024-08-07-01-23-02.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/663bc-2024-08-07-11-28-23.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-07T12:00:00Z","earningsSummary":null},{"actual":-0.75,"estimate":-0.78,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-11-04T14:30:42Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/725a8-2024-11-04-12-02-48.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-11-04T12:30:00Z","earningsSummary":null},{"actual":-0.4,"estimate":-0.38,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-03-05T22:39:21Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/295aa-2025-03-05-09-31-15.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-03-05T14:30:00Z","earningsSummary":null},{"actual":-0.43,"estimate":-0.59,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-05-12T21:26:55Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/6760d-2025-05-12-08-47-33.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-12T13:30:00Z","earningsSummary":null},{"actual":null,"estimate":-0.39,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-10T23:31:55Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-06T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-08","title":"Earnings data Q3 2021","quarter":"Q3","hash":"cbc5153c037e76bbd8f7c3d291ea69c194b1bb382f3bd8570f5d95cd4e6bfed2"},{"date":"2022-02-24","title":"Earnings data Q4 2021","quarter":"Q4","hash":"a73a8f371ca04aa8509a7ef3aa69d089e875e3205501a11c43957bd76f19a41c"},{"date":"2022-05-04","title":"Earnings data Q1 2022","quarter":"Q1","hash":"2893231192ef58a9d4c49c18273c6335f60806176483a35c456dcdb4450da8f0"},{"date":"2022-08-03","title":"Earnings data Q2 2022","quarter":"Q2","hash":"a7d229a48374c68880fc7acf8abe22fd1d0a0427aa811d9f0addb158cd333a2d"},{"date":"2022-11-02","title":"Earnings data Q3 2022","quarter":"Q3","hash":"e0b1cf3876508c0ea542b008fa9a3ff19d23999841a5dd2095d9082853130e26"},{"date":"2023-02-22","title":"Earnings data Q4 2022","quarter":"Q4","hash":"6971baca5c244963cf089b20c8511da0769454100a0d0839e070c06c1e7c8b91"},{"date":"2023-05-05","title":"Earnings data Q1 2023","quarter":"Q1","hash":"8f1bc0627ed3d4eab1d7908c6a34c7f4d7b0204674a153f1a54d8308a71891f8"},{"date":"2023-08-02","title":"Earnings data Q2 2023","quarter":"Q2","hash":"9314a4c5860e5d682375d041fb76b1d13906df60366c754c0248fb8f353c8235"},{"date":"2023-11-03","title":"Earnings data Q3 2023","quarter":"Q3","hash":"0084b3c5ede47c8db7b287bfe6a130f28fac447683c89b794091efc966e35d75"},{"date":"2024-02-28","title":"Earnings data Q4 2023","quarter":"Q4","hash":"dc372ae6f64f11a013b6d3542e1a527068b1b089e55da9bec4a470294de57be1"},{"date":"2024-05-08","title":"Earnings data Q1 2024","quarter":"Q1","hash":"9823303fb0decee54c95c304e71c2057f00609526e4b6fc5c046c072be4266bc"},{"date":"2024-08-07","title":"Earnings data Q2 2024","quarter":"Q2","hash":"cfdb766bff66eaad3697c5c312c66fea4f1a74bdfaf082a43605bccd6bd002c2"},{"date":"2024-11-04","title":"Earnings data Q3 2024","quarter":"Q3","hash":"51818b3c63f36d8c50b2125680886f057d112bedb11498e570a59333b74e3a35"},{"date":"2025-03-05","title":"Earnings data Q4 2024","quarter":"Q4","hash":"3bc471c1242cde208289621a0e38a4798ede0a9d8d978d76e1595ad67bebe8bb"},{"date":"2025-05-12","title":"Earnings data Q1 2025","quarter":"Q1","hash":"d705cbacd5f627481a052975832f172bd0a093c4a905eaf38a6e551ecb25abeb"},{"date":"2025-08-06","title":"Earnings data Q2 2025","quarter":"Q2","hash":"dee210be25295fa53cc2a65961038f1da6f4b8c1cffed87d71f0642d6b860916"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Editas Medicine","companyDescription":"Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":4658000,"changePercentage":310.4,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":1917000,"changePercentage":36.05,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":2741000,"changePercentage":1100.36,"valueToRevenueRatio":0.5884499785315586},{"financialKey":"OPERATING_EXPENSES","value":38051000,"changePercentage":-42.97,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":38051000,"changePercentage":-42.97,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":-35310000,"changePercentage":47.29,"valueToRevenueRatio":-7.580506655216832},{"financialKey":"EBITDA","value":-33393000,"changePercentage":49.08,"valueToRevenueRatio":-7.168956633748389},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":1917000,"changePercentage":36.05,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":-76088000,"changePercentage":-22.82,"valueToRevenueRatio":null},{"financialKey":"EPS","value":-0.9161,"changePercentage":-21.18,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":263652000,"changePercentage":-40.13,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":224843000,"changePercentage":-26.41,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":220964000,"changePercentage":-25.39,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":510000,"changePercentage":108.16,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":3369000,"changePercentage":-63.14,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":38809000,"changePercentage":-71.21,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":34611000,"changePercentage":-22.57,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":4198000,"changePercentage":-95.34,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":201232000,"changePercentage":37.88,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":73114000,"changePercentage":9.97,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":13161000,"changePercentage":6.52,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":59953000,"changePercentage":10.76,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":128118000,"changePercentage":61.24,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":17972000,"changePercentage":-17.5,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":110146000,"changePercentage":90.97,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":62420000,"changePercentage":-78.8,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":62420000,"changePercentage":-78.8,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":263652000,"changePercentage":-40.13,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":31133000,"changePercentage":-8.81,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":-189831000,"changePercentage":27.55,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":0.74567,"changePercentage":-79.17,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":-76088000,"changePercentage":-22.82,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":-47799000,"changePercentage":4.16,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":-65414000,"changePercentage":-19.65,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":17615000,"changePercentage":266.98,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":56387000,"changePercentage":1288.35,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":114000,"changePercentage":-93.91,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":56501000,"changePercentage":2065.94,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-228000,"changePercentage":93.91,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-1437000,"changePercentage":-848.44,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":1435000,"changePercentage":647.4,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-2872000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":7151000,"changePercentage":113.14,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":-47913000,"changePercentage":7.4,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:14:17Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-04-24T12:52:02Z","bearsSay":["Editas Medicine Inc is a clinical-stage genome editing company focused on developing CRISPR/Cas9 technology to address serious diseases, yet it faces potential risks that may undermine its financial outlook. The company’s ability to achieve favorable financial projections is heavily contingent on obtaining regulatory approval; failure in this area could result in significant downward revisions to projections. Additionally, if the regulatory pathway is more complex or time-consuming than anticipated, it could materially impact the company's financial projections and overall market performance."],"bullsSay":["Editas Medicine Inc is making notable advancements in genome editing, particularly through its proprietary CRISPR/Cas9 technology, which has shown \"high efficiency editing\" in non-human primate livers during collaborations with Genevant. The company's ongoing efforts to align with environmental, social, and governance (ESG) principles may enhance its long-term growth prospects and sustainability focus, potentially contributing to increased investor confidence. Although competition in the field remains intense, the positive strides Editas has made in both efficacy and safety optimization position it favorably for future developments in treating serious diseases."],"charts":[{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Operating Margin","dataPoints":[{"key":"21 Q2","value":-14617.68},{"key":"21 Q3","value":-633.42},{"key":"21 Q4","value":-333.7},{"key":"22 Q1","value":-749.53},{"key":"22 Q2","value":-852.47},{"key":"22 Q3","value":-136952.39},{"key":"22 Q4","value":-970.72},{"key":"23 Q1","value":-517.32},{"key":"23 Q2","value":-1527.33},{"key":"23 Q3","value":-940.09},{"key":"23 Q4","value":-39.91},{"key":"24 Q1","value":-5902.3},{"key":"24 Q2","value":-14016.18},{"key":"24 Q3","value":-107649.19},{"key":"24 Q4","value":-152.25},{"key":"25 Q1","value":-1635.11}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q2","value":-14579.42},{"key":"21 Q3","value":-630.66},{"key":"21 Q4","value":-332.32},{"key":"22 Q1","value":-746.05},{"key":"22 Q2","value":-840.2},{"key":"22 Q3","value":-132680.96},{"key":"22 Q4","value":-929.29},{"key":"23 Q1","value":-497.78},{"key":"23 Q2","value":-1395.57},{"key":"23 Q3","value":-843.69},{"key":"23 Q4","value":-31.44},{"key":"24 Q1","value":-5458.15},{"key":"24 Q2","value":-13178.76},{"key":"24 Q3","value":-101870.5},{"key":"24 Q4","value":-148.34},{"key":"25 Q1","value":-1633.5}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"R\u0026D","dataPoints":[{"key":"21 Q2","value":33.753},{"key":"21 Q3","value":29.265},{"key":"21 Q4","value":37.552},{"key":"22 Q1","value":37.976},{"key":"22 Q2","value":43.659},{"key":"22 Q3","value":41.326},{"key":"22 Q4","value":51.998},{"key":"23 Q1","value":37.804},{"key":"23 Q2","value":29.779},{"key":"23 Q3","value":40.512},{"key":"23 Q4","value":69.556},{"key":"24 Q1","value":48.787},{"key":"24 Q2","value":54.21},{"key":"24 Q3","value":47.639},{"key":"24 Q4","value":48.611},{"key":"25 Q1","value":26.593}]},{"title":"G\u0026A","dataPoints":[{"key":"21 Q2","value":22.027},{"key":"21 Q3","value":16.185},{"key":"21 Q4","value":16.526},{"key":"22 Q1","value":19.545},{"key":"22 Q2","value":16.937},{"key":"22 Q3","value":16.236},{"key":"22 Q4","value":17.984},{"key":"23 Q1","value":23.008},{"key":"23 Q2","value":17.202},{"key":"23 Q3","value":14.987},{"key":"23 Q4","value":14.455},{"key":"24 Q1","value":19.339},{"key":"24 Q2","value":18.206},{"key":"24 Q3","value":18.088},{"key":"24 Q4","value":16.354},{"key":"25 Q1","value":13.375}]},{"title":"Restructuring charges","dataPoints":[{"key":"24 Q4","value":12.232},{"key":"25 Q1","value":40.853}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q2","value":-96.47},{"key":"21 Q3","value":-90.14},{"key":"21 Q4","value":9.2},{"key":"22 Q1","value":4.19},{"key":"22 Q2","value":1578.63},{"key":"22 Q3","value":-99.32},{"key":"22 Q4","value":-47.58},{"key":"23 Q1","value":45.49},{"key":"23 Q2","value":-54.62},{"key":"23 Q3","value":12604.76},{"key":"23 Q4","value":818.74},{"key":"24 Q1","value":-88.48},{"key":"24 Q2","value":-82.23},{"key":"24 Q3","value":-98.86},{"key":"24 Q4","value":-49.03},{"key":"25 Q1","value":310.4}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q2","value":32.53},{"key":"21 Q3","value":-15.6},{"key":"21 Q4","value":-30.04},{"key":"22 Q1","value":-9.25},{"key":"22 Q2","value":8.63},{"key":"22 Q3","value":26.65},{"key":"22 Q4","value":29.41},{"key":"23 Q1","value":5.72},{"key":"23 Q2","value":-22.47},{"key":"23 Q3","value":-3.58},{"key":"23 Q4","value":20.05},{"key":"24 Q1","value":12.03},{"key":"24 Q2","value":54.14},{"key":"24 Q3","value":18.43},{"key":"24 Q4","value":-8.11},{"key":"25 Q1","value":18.63}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q2","value":67.877},{"key":"21 Q3","value":68.22},{"key":"21 Q4","value":68.356},{"key":"22 Q1","value":68.485},{"key":"22 Q2","value":68.641},{"key":"22 Q3","value":68.736},{"key":"22 Q4","value":68.793},{"key":"23 Q1","value":68.924},{"key":"23 Q2","value":71.377},{"key":"23 Q3","value":81.648},{"key":"23 Q4","value":81.71},{"key":"24 Q1","value":81.939},{"key":"24 Q2","value":82.31},{"key":"24 Q3","value":82.485},{"key":"24 Q4","value":82.614},{"key":"25 Q1","value":83.055}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q2","value":2504.661},{"key":"21 Q3","value":3738.456},{"key":"21 Q4","value":2351.446},{"key":"22 Q1","value":1273.821},{"key":"22 Q2","value":919.789},{"key":"22 Q3","value":1072.282},{"key":"22 Q4","value":756.723},{"key":"23 Q1","value":613.424},{"key":"23 Q2","value":620.98},{"key":"23 Q3","value":702.173},{"key":"23 Q4","value":719.048},{"key":"24 Q1","value":680.094},{"key":"24 Q2","value":460.936},{"key":"24 Q3","value":362.934},{"key":"24 Q4","value":206.535},{"key":"25 Q1","value":124.583}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q2","value":1652.15},{"key":"21 Q3","value":150.82},{"key":"21 Q4","value":47.15},{"key":"22 Q1","value":47.03},{"key":"22 Q2","value":36.14},{"key":"22 Q3","value":6382.63},{"key":"22 Q4","value":28.94},{"key":"23 Q1","value":15.57},{"key":"23 Q2","value":53.77},{"key":"23 Q3","value":32.9},{"key":"23 Q4","value":2.99},{"key":"24 Q1","value":149.8},{"key":"24 Q2","value":224.63},{"key":"24 Q3","value":1487.43},{"key":"24 Q4","value":1.69},{"key":"25 Q1","value":6.69}]}],"overlayChart":null}],"chartsLastUpdated":"2025-05-16T21:46:50Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.4,"sell":0.6,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"VRTX","name":"Vertex Pharmaceuticals","displayName":"Vertex Pharmaceuticals","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"VRTX","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":476.95,"high":480,"low":472.03,"volume":907940,"volumeDate":"2025-07-24","last":472.27,"open":477.14,"gainPercentage":-0.981,"gainValue":-4.68,"ask":477.35,"bid":440,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":121277519200,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":1522147.7097,"highPriceLast52Weeks":519.88,"lowPriceLast52Weeks":377.85,"companyName":"Vertex Pharmaceuticals, Inc.","longBusinessDescription":"Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.","dividendRate":0,"salesOrRevenue":10984400000,"oneYearAnnualRevenueGrowthRate":11.641426974286,"threeYearAnnualRevenueGrowthRate":13.0505,"fiveYearAnnualRevenueGrowthRate":22.3912,"earningsGrowth":-124.4477,"totalDebt":1749500000,"totalAssets":23090600000,"floatAsPercentOfSharesOutstanding":99.7196,"dividendYield":0,"betaTwelveMonth":0.4893,"salesOrRevenueTtm":11043300000,"ebitdaTtm":-129699999.99999999,"debtToEquityRatioQuarterly":9.99678715833248,"totalEnterpriseValue":99487330000,"industry":"PharmaceuticalsMajor","sector":"HealthTechnology","preTaxInterestCoverageRatio":142.460784313725,"fiveYearAverageDebtEquityRatio":7.81,"currentRatio":2.64559103404525,"peratio":-120.4},"recommendation":{"currentConsensusRating":1.8,"recommendationTargetPrice":396.21,"totalRatings":43,"strongSellRatings":0,"sellRatings":0,"holdRatings":10,"buyRatings":13,"strongBuyRatings":20,"lastUpdated":"2025-07-14T16:02:05Z"},"earningEstimates":[{"actual":3.56,"estimate":3.08,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-11-02T20:16:51Z","audioUrl":"https://files.quartr.com/audio-files/1389a-2022-10-19-04-27-24.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/3f175-2021-11-02-12-00-00-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/d9e2e-2023-01-25-10-41-20.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-11-02T00:00:00Z","earningsSummary":null},{"actual":3.37,"estimate":3.29,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-01-26T21:14:17Z","audioUrl":"https://files.quartr.com/audio-files/cc30c-2022-10-19-10-45-00.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/6f47c-2022-01-26-06-42-37-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/fbd6c-2023-01-25-12-11-17.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-01-26T18:37:42Z","earningsSummary":null},{"actual":3.52,"estimate":3.49,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-05-05T21:02:51Z","audioUrl":"https://files.quartr.com/audio-files/2d9f8-2023-01-13-08-45-59.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/5a1cb-2022-05-05-02-36-42-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/065b2-2023-01-25-02-13-34.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-05-05T14:42:36Z","earningsSummary":null},{"actual":3.6,"estimate":3.52,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-08-04T20:39:07Z","audioUrl":"https://files.quartr.com/audio-files/18681-2022-08-05-10-22-57.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/f4ace-2022-10-31-08-05-40.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/3e9c8-2022-08-04-08-10-26.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-03T23:37:00Z","earningsSummary":null},{"actual":4.01,"estimate":3.67,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-10-27T20:11:02Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_10_27T20_30_00_00_00_Vertex_Pharmaceuticals_Inc_Earnings_Call_Q3_2022.LGBJ55WOL5G8_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/d7bde-2022-10-27-08-51-12.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b01c2-2022-10-27-08-46-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-10-27T20:30:00Z","earningsSummary":null},{"actual":3.76,"estimate":3.51,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-07T21:11:02Z","audioUrl":"https://files.quartr.com/audio-files/c4605-2023-02-07-11-09-36.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/reports/fcb83-2023-02-07-09-40-33.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/conference-calls/e50d0-2023-02-07-09-57-10.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-07T21:30:00Z","earningsSummary":{"summary":"Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R\u0026D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.","headline":"Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies","lastUpdated":"2024-05-07T06:46:07.005549Z"}},{"actual":3.05,"estimate":3,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-05-01T20:29:04Z","audioUrl":"https://files.quartr.com/audio-files/09431-2023-05-01-09-12-37.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/8bd37-2023-05-01-08-46-39.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/6a5cf-2023-05-01-08-08-02.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-01T20:30:00Z","earningsSummary":{"summary":"Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.\nThe company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.\nHowever, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.\nOpportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.","headline":"Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline","lastUpdated":"2024-05-07T07:57:38.285811Z"}},{"actual":3.89,"estimate":3.85,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-01T20:03:21Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_08_01T20_30_00_00_00_Vertex_Pharmaceuticals_Inc_Q2_2023.X5APKDTYR7H2_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/5d924-2023-08-02-06-41-31.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/cdfc6-2023-08-01-08-57-04.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-01T20:30:00Z","earningsSummary":{"summary":"Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.\nChallenges include slower uptake for gene therapies and market access.\nOpportunities lie in reimbursement models, new therapy launches, and program advancements.\nOverall, Vertex is strategically positioned for growth and innovation.","headline":"Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements","lastUpdated":"2024-05-07T08:31:32.892384Z"}},{"actual":4.08,"estimate":3.98,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-11-06T21:10:44Z","audioUrl":"https://files.quartr.com/audio-files/e4670-2023-11-06-10-05-48.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/7fb89-2023-11-06-09-13-39.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/a95c8-2023-11-06-09-01-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-06T21:30:00Z","earningsSummary":{"summary":"Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.\nChallenges include navigating patient complexities, regulatory reviews, and market differentiation.\nOpportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.\nOverall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.","headline":"Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism","lastUpdated":"2024-05-07T08:36:37.829126Z"}},{"actual":4.2,"estimate":4.1,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-05T21:20:20Z","audioUrl":"https://files.quartr.com/audio-files/e329d-2024-02-05-10-57-48.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/26c70-2024-02-05-10-35-53.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/37d5a-2024-02-05-09-17-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-05T21:30:00Z","earningsSummary":{"summary":"Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.\nThe company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.\nWhile facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.\nOverall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.","headline":"Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements","lastUpdated":"2024-05-07T09:27:00.890731Z"}},{"actual":4.76,"estimate":4.02,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-05-06T20:07:01Z","audioUrl":"https://files.quartr.com/audio-files/1333c-2024-05-06-09-55-41.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/fd8d7-2024-05-06-08-25-45.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/4fee6-2024-05-06-08-41-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-06T20:30:00Z","earningsSummary":{"summary":"Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.\nWhile facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.\nWith a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.","headline":"Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements","lastUpdated":"2024-05-07T15:00:58.165084Z"}},{"actual":-12.83,"estimate":4.14,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-08-01T20:04:45Z","audioUrl":"https://files.quartr.com/audio-files/8e151-2024-08-01-09-19-41.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/efe09-2024-08-01-08-40-38.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/d6f4a-2024-08-01-08-00-08.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-01T20:30:00Z","earningsSummary":{"summary":"Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.\nThe company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.\nAnticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.","headline":"Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements","lastUpdated":"2024-08-02T00:23:04.300769Z"}},{"actual":4.38,"estimate":4.14,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-11-04T21:02:06Z","audioUrl":"https://files.quartr.com/audio-files/0c7b5-2024-11-04-10-36-42.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/f9b13-2024-11-04-09-48-37.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/bd6f8-2024-11-04-09-29-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-11-04T21:30:00Z","earningsSummary":{"summary":"Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R\u0026D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.","headline":"Vertex Pharmaceuticals excels in Q3, poised for innovative growth","lastUpdated":"2024-11-05T00:12:12.110504Z"}},{"actual":3.98,"estimate":4.02,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-10T21:08:03Z","audioUrl":"https://files.quartr.com/audio-files/2b4a1-2025-02-10-10-16-46.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/3fbe8-2025-02-11-03-17-10.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/dbc95-2025-02-11-03-05-12.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-10T21:30:00Z","earningsSummary":{"summary":"Vertex Pharmaceuticals demonstrated robust financial performance and strategic leadership changes in Q4 2024, setting the stage for continued growth.\nThe company's focus on diversification, global expansion, and patient access underscores its commitment to innovation and market leadership.\nChallenges in IP enforcement, regulatory engagements, and access management require ongoing attention for sustained success.","headline":"Vertex Pharmaceuticals excels in Q4, eyes strong 2025 growth","lastUpdated":"2025-02-11T03:41:34.091004Z"}},{"actual":4.06,"estimate":4.29,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-05-05T20:01:42Z","audioUrl":"https://files.quartr.com/audio-files/d59c6-2025-05-05-09-43-40.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/1358d-2025-05-05-08-06-32.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/6cc0c-2025-05-05-08-21-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-05T20:30:00Z","earningsSummary":{"summary":"Vertex Pharmaceuticals demonstrated solid financial performance and successful product launches in Q1 2025, driving revenue growth and market acceptance. While facing challenges in sustaining momentum and addressing treatment access, Vertex's engagement with policymakers and revenue guidance raise optimism for future prospects. The company's focus on innovation and advocacy, coupled with opportunities for expansion and partnerships, positions Vertex well for continued success and leadership in the biopharmaceutical sector.","headline":"Vertex Pharmaceuticals excels in Q1 2025, raises revenue guidance","lastUpdated":"2025-05-05T23:31:44.504934Z"}},{"actual":null,"estimate":4.04,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-23T23:31:55Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-04T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-02","title":"Earnings data Q3 2021","quarter":"Q3","hash":"d3cd7e5e6fff1a6020e2b58e3445e0054557f27d90f8096ca6e6de311e24f642"},{"date":"2022-01-26","title":"Earnings data Q4 2021","quarter":"Q4","hash":"8ab639e0478e82c67297e7d0b6cdfd96b6d2137a0b725d6336419519a832c17a"},{"date":"2022-05-05","title":"Earnings data Q1 2022","quarter":"Q1","hash":"21db1b10406ffa622eb26a0875ec7128e85822ba2272f7772246ee41d8cb3bd0"},{"date":"2022-08-04","title":"Earnings data Q2 2022","quarter":"Q2","hash":"63aef2a116b7916dafc4e4fe2f6f786549095c61150b6648f5ff19c47a27b914"},{"date":"2022-10-27","title":"Earnings data Q3 2022","quarter":"Q3","hash":"76bab4e867431fcb82301c9472d6aaf938708539e4582e8158142844c54f2e35"},{"date":"2023-02-07","title":"Earnings data Q4 2022","quarter":"Q4","hash":"8b209427ff530119d6163cc3a3cd382f9bc25182b375dd7e71ce2b3ab00c72d2"},{"date":"2023-05-01","title":"Earnings data Q1 2023","quarter":"Q1","hash":"b3717ee1e0219cea563eaab59671e5399acf1aa4e505b3ffe72fdd9c8f32d96c"},{"date":"2023-08-01","title":"Earnings data Q2 2023","quarter":"Q2","hash":"5892ecc7e37ea37078b50c913516a507ea93d37aa7ea8ead1d4eacef088ee584"},{"date":"2023-11-06","title":"Earnings data Q3 2023","quarter":"Q3","hash":"b0c73545bbc5f7f4f0dc0ebc908167f18cd6577bc3d77875c9a5157315ac81d8"},{"date":"2024-02-05","title":"Earnings data Q4 2023","quarter":"Q4","hash":"1d73a5f04193adb4b79102264ed29c7a1f57d84a379bdf84a02c08e5a9920885"},{"date":"2024-05-06","title":"Earnings data Q1 2024","quarter":"Q1","hash":"9d80b9d77b7fcbdc1b103d3120e88d6ddcca8aa998f4d70091dbde7a66eeb80f"},{"date":"2024-08-01","title":"Earnings data Q2 2024","quarter":"Q2","hash":"b5ec4ac3ca7616f3cb0d2629841d6fdf42966e152fa0d6d2e1fd038e848d4f34"},{"date":"2024-11-04","title":"Earnings data Q3 2024","quarter":"Q3","hash":"e6814cbb34aac00ea16a154145abec34101a590d90c6d5bbb59d281e663de2f4"},{"date":"2025-02-10","title":"Earnings data Q4 2024","quarter":"Q4","hash":"941392383bd15ef9ce59eb58b03f64e1989dbbd9107c333052e99e460769df88"},{"date":"2025-05-05","title":"Earnings data Q1 2025","quarter":"Q1","hash":"201b627deedd9f0def8ce4f7b286da9c89cffeffa86db0e3840deb8a9db7daf7"},{"date":"2025-08-04","title":"Earnings data Q2 2025","quarter":"Q2","hash":"0e9c8342589d4a046ff3b213eb46d3d63a073093c213ceb6050d1fae5e5d8d42"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Vertex Pharmaceuticals","companyDescription":"Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":2746100000,"changePercentage":2.19,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":363000000,"changePercentage":5.95,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":2383100000,"changePercentage":1.64,"valueToRevenueRatio":0.8678125341393249},{"financialKey":"OPERATING_EXPENSES","value":1395900000,"changePercentage":15.5,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":1395900000,"changePercentage":15.5,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":987200000,"changePercentage":-13.1,"valueToRevenueRatio":0.3594916426932741},{"financialKey":"EBITDA","value":1035599999.9999999,"changePercentage":-12.94,"valueToRevenueRatio":0.3771166381413641},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":48399999.99999988,"changePercentage":-9.53,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":646300000,"changePercentage":-41.22,"valueToRevenueRatio":null},{"financialKey":"EPS","value":2.4906,"changePercentage":-40.86,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":22880500000,"changePercentage":-4.34,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":10008800000,"changePercentage":-24.68,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":6211900000,"changePercentage":-38.93,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":1805100000,"changePercentage":0.66,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":1359700000,"changePercentage":67.22,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":632100000,"changePercentage":23.67,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":12871700000,"changePercentage":21.1,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":2634400000,"changePercentage":77.32,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":1529200000,"changePercentage":-20.47,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":8708100000,"changePercentage":20.61,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":6384200000,"changePercentage":18.87,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":3783200000,"changePercentage":-0.33,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":3783200000,"changePercentage":-0.33,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":2601000000,"changePercentage":65.15,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":1649100000,"changePercentage":128.63,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":951900000,"changePercentage":11.52,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":16496300000,"changePercentage":-11.05,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":16496300000,"changePercentage":-11.05,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":22880500000,"changePercentage":-4.34,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":1649100000,"changePercentage":128.63,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":-4562800000,"changePercentage":51.72,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":64.19599,"changePercentage":-10.6,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":646300000,"changePercentage":-41.22,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":818900000,"changePercentage":-37.33,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":1087400000,"changePercentage":-7.64,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-268500000,"changePercentage":-307.66,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-55800000,"changePercentage":97.39,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":40700000,"changePercentage":-83.62,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":-9800000.00000018,"changePercentage":99.48,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-86699999.99999982,"changePercentage":82.55,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-680400000,"changePercentage":-90.32,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":-409400000,"changePercentage":-258.18,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":-1300000,"changePercentage":90.15,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-269700000,"changePercentage":-17.26,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":30500000,"changePercentage":295.51,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":113200000,"changePercentage":109.41,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":778200000,"changePercentage":-37.15,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:14:43Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-07-24T08:48:01Z","bearsSay":["Vertex Pharmaceuticals faces several significant risks contributing to a negative outlook on its stock. Key concerns include the potential for lower-than-expected commercial uptake of Kaftrio, ongoing pricing pressure in the cystic fibrosis market, and the threat of increasing competition, all of which could erode long-term market share and pricing power. Additionally, operational challenges related to the launch and adoption of new therapies, such as Journavx, could hinder revenue growth, with projections for 2025 falling substantially short of consensus estimates due to reimbursement and formulary obstacles."],"bullsSay":["Vertex Pharmaceuticals is anticipating significant revenue growth, with projections for its cystic fibrosis (CF) franchise potentially exceeding $11 billion in future years, driven by robust demand among younger patients and successful expansion into new markets. The company reported strong financial performance for 4Q24, exceeding consensus estimates with total revenues of $2.91 billion for the quarter and $11.02 billion for the full year, reflecting solid sales driven by its CF therapies. Furthermore, the 2025 revenue guidance suggests an 8% growth at the midpoint, primarily fueled by U.S. sales of CF treatments, underscoring the strength of Vertex's commercial position and its ongoing investment in innovations such as Alyftrek."],"charts":[{"title":"Revenue Segments","description":"Revenue segments as reported by the company.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Product revenues, net","dataPoints":[{"key":"21 Q2","value":1793.37},{"key":"21 Q3","value":1984.164},{"key":"21 Q4","value":2072.6},{"key":"22 Q1","value":2097.5},{"key":"22 Q2","value":2196.2},{"key":"22 Q3","value":2334.3},{"key":"22 Q4","value":2302.7},{"key":"23 Q1","value":2374.8},{"key":"23 Q2","value":2493.2},{"key":"23 Q3","value":2483.5},{"key":"23 Q4","value":2517.7},{"key":"24 Q1","value":2690.6},{"key":"24 Q2","value":2645.6},{"key":"24 Q3","value":2771.9},{"key":"24 Q4","value":2912},{"key":"25 Q1","value":2760.2}]},{"title":"Other revenues","dataPoints":[{"key":"25 Q1","value":10}]}],"overlayChart":null},{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q2","value":87.28},{"key":"21 Q3","value":88.08},{"key":"21 Q4","value":88.06},{"key":"22 Q1","value":88.28},{"key":"22 Q2","value":88.07},{"key":"22 Q3","value":87.6},{"key":"22 Q4","value":87.69},{"key":"23 Q1","value":88.76},{"key":"23 Q2","value":87.62},{"key":"23 Q3","value":87.16},{"key":"23 Q4","value":85.38},{"key":"24 Q1","value":87.26},{"key":"24 Q2","value":85.94},{"key":"24 Q3","value":85.83},{"key":"24 Q4","value":85.46},{"key":"25 Q1","value":86.89}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q2","value":-2.12},{"key":"21 Q3","value":53.14},{"key":"21 Q4","value":42.34},{"key":"22 Q1","value":49.62},{"key":"22 Q2","value":50.37},{"key":"22 Q3","value":48.26},{"key":"22 Q4","value":44.88},{"key":"23 Q1","value":32.8},{"key":"23 Q2","value":41.16},{"key":"23 Q3","value":41.79},{"key":"23 Q4","value":39.26},{"key":"24 Q1","value":42.35},{"key":"24 Q2","value":-132.86},{"key":"24 Q3","value":40.27},{"key":"24 Q4","value":35.23},{"key":"25 Q1","value":22.74}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q2","value":3.73},{"key":"21 Q3","value":42.93},{"key":"21 Q4","value":37.15},{"key":"22 Q1","value":36.33},{"key":"22 Q2","value":36.9},{"key":"22 Q3","value":39.86},{"key":"22 Q4","value":35.56},{"key":"23 Q1","value":29.46},{"key":"23 Q2","value":36.72},{"key":"23 Q3","value":41.68},{"key":"23 Q4","value":38.47},{"key":"24 Q1","value":40.86},{"key":"24 Q2","value":-135.84},{"key":"24 Q3","value":37.71},{"key":"24 Q4","value":31.35},{"key":"25 Q1","value":23.33}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Research and development expenses","dataPoints":[{"key":"21 Q2","value":1407.09},{"key":"21 Q3","value":493.751},{"key":"21 Q4","value":694.3},{"key":"22 Q1","value":603.1},{"key":"22 Q2","value":600.1},{"key":"22 Q3","value":645},{"key":"22 Q4","value":694.1},{"key":"23 Q1","value":742.6},{"key":"23 Q2","value":785.7},{"key":"23 Q3","value":810},{"key":"23 Q4","value":824.6},{"key":"24 Q1","value":789.1},{"key":"24 Q2","value":966.6},{"key":"24 Q3","value":875.9},{"key":"24 Q4","value":998.7},{"key":"25 Q1","value":979.7}]},{"title":"Acquired in-process research and development expenses","dataPoints":[{"key":"22 Q2","value":61.9},{"key":"22 Q3","value":29},{"key":"22 Q4","value":22.6},{"key":"23 Q1","value":347.1},{"key":"23 Q2","value":110.5},{"key":"23 Q3","value":51.7},{"key":"23 Q4","value":17.8},{"key":"24 Q1","value":76.8},{"key":"24 Q2","value":4449.1},{"key":"24 Q3","value":15},{"key":"24 Q4","value":87.5},{"key":"25 Q1","value":19.8}]},{"title":"Selling, general and administrative expenses","dataPoints":[{"key":"21 Q2","value":194.669},{"key":"21 Q3","value":198.189},{"key":"21 Q4","value":255.2},{"key":"22 Q1","value":215.2},{"key":"22 Q2","value":215.3},{"key":"22 Q3","value":246.8},{"key":"22 Q4","value":267.4},{"key":"23 Q1","value":241.1},{"key":"23 Q2","value":262.6},{"key":"23 Q3","value":263.8},{"key":"23 Q4","value":369.1},{"key":"24 Q1","value":342.7},{"key":"24 Q2","value":372.2},{"key":"24 Q3","value":371.8},{"key":"24 Q4","value":377.6},{"key":"25 Q1","value":396.4}]},{"title":"Change in fair value of contingent consideration","dataPoints":[{"key":"21 Q2","value":1.6},{"key":"21 Q3","value":1.2},{"key":"21 Q4","value":-2},{"key":"22 Q1","value":-7.5},{"key":"22 Q2","value":-49.2},{"key":"22 Q3","value":-2.6},{"key":"22 Q4","value":1.8},{"key":"23 Q1","value":-1.9},{"key":"23 Q2","value":-0.6},{"key":"23 Q3","value":1.2},{"key":"23 Q4","value":-50.3},{"key":"24 Q1","value":-0.1},{"key":"24 Q2","value":0.5},{"key":"24 Q3","value":0.3},{"key":"24 Q4","value":-1.2},{"key":"25 Q1","value":2.2}]},{"title":"Intangible asset impairment charge","dataPoints":[{"key":"25 Q1","value":379}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q2","value":17.64},{"key":"21 Q3","value":28.99},{"key":"21 Q4","value":27.33},{"key":"22 Q1","value":21.64},{"key":"22 Q2","value":22.46},{"key":"22 Q3","value":17.65},{"key":"22 Q4","value":11.1},{"key":"23 Q1","value":13.22},{"key":"23 Q2","value":13.52},{"key":"23 Q3","value":6.39},{"key":"23 Q4","value":9.34},{"key":"24 Q1","value":13.3},{"key":"24 Q2","value":6.11},{"key":"24 Q3","value":11.61},{"key":"24 Q4","value":15.66},{"key":"25 Q1","value":2.96}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q2","value":157.8},{"key":"21 Q3","value":1.96},{"key":"21 Q4","value":39.56},{"key":"22 Q1","value":25.87},{"key":"22 Q2","value":-48.35},{"key":"22 Q3","value":32.47},{"key":"22 Q4","value":4.05},{"key":"23 Q1","value":63.9},{"key":"23 Q2","value":39.86},{"key":"23 Q3","value":22.71},{"key":"23 Q4","value":17.78},{"key":"24 Q1","value":-9.06},{"key":"24 Q2","value":399.78},{"key":"24 Q3","value":12.1},{"key":"24 Q4","value":25.96},{"key":"25 Q1","value":47.05}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q2","value":258.988},{"key":"21 Q3","value":257.876},{"key":"21 Q4","value":254.6},{"key":"22 Q1","value":255.1},{"key":"22 Q2","value":255.9},{"key":"22 Q3","value":256.5},{"key":"22 Q4","value":256.9},{"key":"23 Q1","value":257.4},{"key":"23 Q2","value":257.7},{"key":"23 Q3","value":258},{"key":"23 Q4","value":257.7},{"key":"24 Q1","value":258.2},{"key":"24 Q2","value":258.1},{"key":"24 Q3","value":258},{"key":"24 Q4","value":257.5},{"key":"25 Q1","value":256.9}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q2","value":54172.52},{"key":"21 Q3","value":50349},{"key":"21 Q4","value":49508.243},{"key":"22 Q1","value":60542.373},{"key":"22 Q2","value":68493.426},{"key":"22 Q3","value":73799.667},{"key":"22 Q4","value":78295.413},{"key":"23 Q1","value":77202.497},{"key":"23 Q2","value":86828.149},{"key":"23 Q3","value":90231.372},{"key":"23 Q4","value":95198.503},{"key":"24 Q1","value":109151.468},{"key":"24 Q2","value":112027.273},{"key":"24 Q3","value":123934.428},{"key":"24 Q4","value":119359.49},{"key":"25 Q1","value":119715.4}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q2","value":7.55},{"key":"21 Q3","value":6.34},{"key":"21 Q4","value":5.97},{"key":"22 Q1","value":7.22},{"key":"22 Q2","value":7.8},{"key":"22 Q3","value":7.9},{"key":"22 Q4","value":8.5},{"key":"23 Q1","value":8.13},{"key":"23 Q2","value":8.71},{"key":"23 Q3","value":9.08},{"key":"23 Q4","value":9.45},{"key":"24 Q1","value":10.14},{"key":"24 Q2","value":10.59},{"key":"24 Q3","value":11.18},{"key":"24 Q4","value":10.25},{"key":"25 Q1","value":10.8}]}],"overlayChart":null}],"chartsLastUpdated":"2025-05-05T21:00:12Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.54,"sell":0.46,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"LH","name":"Labcorp Holdings Inc","displayName":"Labcorp Holdings Inc","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":"2024-05-20","untradableReason":null,"newSymbol":"","newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"LH","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":250.51,"high":283.47,"low":259.99,"volume":1,"volumeDate":"2025-07-25","last":267.69,"open":266.63,"gainPercentage":6.858,"gainValue":17.18,"ask":273.69,"bid":240,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":22397247500,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":796553.0161,"highPriceLast52Weeks":283.47,"lowPriceLast52Weeks":209.375,"companyName":"Labcorp Holdings, Inc.","longBusinessDescription":"Labcorp Holdings, Inc. provides laboratory services to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.","dividendRate":2.88,"salesOrRevenue":13008900000,"oneYearAnnualRevenueGrowthRate":6.96701091961583,"threeYearAnnualRevenueGrowthRate":-5.6435,"fiveYearAnnualRevenueGrowthRate":3.8743,"earningsGrowth":72.222,"totalDebt":7272800000,"totalAssets":18379000000,"floatAsPercentOfSharesOutstanding":99.6612,"dividendYield":1.08,"betaTwelveMonth":0.5963,"salesOrRevenueTtm":13483800000,"ebitdaTtm":1903000000,"debtToEquityRatioQuarterly":77.2599053430429,"totalEnterpriseValue":25123008000,"industry":"MedicalOrNursingServices","sector":"HealthServices","preTaxInterestCoverageRatio":5.46327412385982,"fiveYearAverageDebtEquityRatio":63.86,"currentRatio":1.50441696113074,"peratio":29.5},"recommendation":{"currentConsensusRating":1.8,"recommendationTargetPrice":223.5,"totalRatings":31,"strongSellRatings":0,"sellRatings":0,"holdRatings":7,"buyRatings":11,"strongBuyRatings":13,"lastUpdated":"2025-07-18T18:19:50Z"},"earningEstimates":[{"actual":6.77,"estimate":5.79,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-10T12:16:57Z","audioUrl":"https://files.quartr.com/audio-files/7156d-2022-10-19-10-13-57.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/40d2b-2022-02-10-09-44-01-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/bcc1b-2023-01-25-12-18-25.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-10T21:01:44Z","earningsSummary":null},{"actual":6.11,"estimate":5.98,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-04-28T13:43:56Z","audioUrl":"https://files.quartr.com/audio-files/77bd4-2022-10-28-04-17-41.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/54342-2022-04-28-03-09-18-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b02c7-2023-01-25-01-37-18.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-04-28T15:18:09Z","earningsSummary":null},{"actual":4.96,"estimate":4.7,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-07-28T11:54:22Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_07_28_15_00_Q2_2022_Laboratory_Corporation_of_America_Holdings_Earnings_Call.QT7O4AMMSKUC_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/34062-2022-07-28-01-19-04.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/25fb6-2022-07-28-11-25-18.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-07-28T00:23:00Z","earningsSummary":null},{"actual":4.68,"estimate":4.67,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-10-27T11:06:25Z","audioUrl":"https://files.quartr.com/audio-files/a4a0e-2022-10-27-04-38-23.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/386a0-2022-10-27-11-12-43.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/acf10-2022-10-27-11-12-43.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-10-27T13:00:00Z","earningsSummary":null},{"actual":4.14,"estimate":4.11,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-16T12:01:49Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_02_16T14_00_00_00_00_Laboratory_Corporation_of_America_Holdings_Earnings_Call_Q4_2022.D3GJMHF62X9S_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/reports/e9293-2023-02-16-12-35-12.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/conference-calls/63c6e-2023-02-16-12-08-12.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-16T14:00:00Z","earningsSummary":{"summary":"Labcorp's Q4 performance reflects resilience and growth potential in Diagnostics and Drug Development\nStrategic initiatives and spinoff plans position Labcorp for future success and market leadership\nChallenges in cost management and revenue growth require focused strategies for sustainable growth\nOpportunities lie in capital deployment, market expansion, and operational enhancements for Labcorp","headline":"Labcorp posts strong Q4 results, eyes growth amid strategic moves","lastUpdated":"2024-05-08T22:28:12.562088Z"}},{"actual":3.82,"estimate":3.96,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-04-25T10:54:35Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_04_25T13_00_00_00_00_Laboratory_Corporation_of_America_Holdings_Q1_2023.TQA5VP7HY2TP_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/12c9a-2023-04-25-11-44-18.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/14140-2023-04-25-11-29-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-04-25T13:00:00Z","earningsSummary":{"summary":"Labcorp's Q1 2023 performance was strong, driven by Diagnostics base business revenue growth and strategic initiatives.\nWhile facing challenges like margin constraints and revenue declines in Drug Development, Labcorp is focusing on sustained growth and market opportunities.\nThe company's emphasis on digital health, upcoming Investor Days, and robust M\u0026A pipeline showcase a proactive approach to future growth.\nLabcorp's cautious optimism for SALSA approval and continued advocacy for legislation position it well for potential impacts and future developments.","headline":"Labcorp reports strong Q1 results, eyes growth amid challenges","lastUpdated":"2024-05-08T23:11:47.080690Z"}},{"actual":3.42,"estimate":3.47,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-07-27T10:59:32Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_07_27T13_00_00_00_00_Laboratory_Corporation_of_America_Holdings_Q2_2023.MPWEIVOSPBBQ_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/cfc03-2023-07-27-12-14-17.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/812a3-2023-07-27-11-33-15.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-07-27T13:00:00Z","earningsSummary":{"summary":"Labcorp's Q2 performance was strong, with revenue growth and strategic initiatives driving positive results.\nChallenges such as supply constraints and margin expectations were addressed, with a focus on capital allocation and growth opportunities.\nThe company remains optimistic about future prospects, with expansion plans, enhanced disclosures, and consistent guidance for segments.\nInvestor Day scheduled for September to provide more insights, reflecting Labcorp's commitment to transparency and growth.","headline":"Labcorp reports robust Q2 earnings, eyes global expansion opportunities","lastUpdated":"2024-05-08T22:55:24.429203Z"}},{"actual":3.38,"estimate":3.32,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-10-26T11:07:41Z","audioUrl":"https://files.quartr.com/audio-files/a3e79-2023-10-26-02-22-08.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/8d010-2023-10-26-11-32-39.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/92cb6-2023-10-26-11-08-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-10-26T13:00:00Z","earningsSummary":{"summary":"Labcorp's Q3 performance was strong, with a focus on revenue growth, strategic partnerships, and new test introductions. Despite challenges from regulatory impacts, the company remains optimistic about driving substantial shareholder value through growth opportunities and cost-saving initiatives.","headline":"Labcorp reports robust Q3 earnings, eyes growth amid regulatory challenges","lastUpdated":"2024-05-09T01:36:41.666707Z"}},{"actual":3.3,"estimate":3.28,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-15T12:00:27Z","audioUrl":"https://files.quartr.com/audio-files/bdd45-2024-02-15-03-33-20.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/83f81-2024-02-15-12-35-22.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/398cd-2024-02-15-12-44-02.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-15T14:00:00Z","earningsSummary":{"summary":"LabCorp's Q4 call showcased strong financials, strategic partnerships, and innovative offerings. Challenges include pricing issues in Biopharma and COVID impacts on Diagnostics. Opportunities for growth through capital allocation and focus on larger pharma in Biopharma.","headline":"LabCorp reports robust Q4 earnings, eyes growth in strategic areas","lastUpdated":"2024-05-08T22:20:47.499103Z"}},{"actual":3.68,"estimate":3.48,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-04-25T11:03:44Z","audioUrl":"https://files.quartr.com/audio-files/01173-2024-04-25-02-02-10.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/2901a-2024-04-25-11-35-41.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/4f469-2024-04-25-11-23-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-04-25T13:00:00Z","earningsSummary":{"summary":"LabCorp's Q1 2024 earnings call highlighted strong financial performance, strategic acquisitions, and plans for margin improvement. Despite challenges in certain business areas, the company remains focused on profitable growth and innovation in specialty testing.","headline":"LabCorp reports robust Q1 earnings, eyes margin improvement in 2024","lastUpdated":"2024-05-09T02:16:08.972189Z"}},{"actual":3.94,"estimate":3.78,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-08-01T11:00:45Z","audioUrl":"https://files.quartr.com/audio-files/8677f-2024-08-01-02-10-09.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/c6daa-2024-08-01-12-14-04.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/79b12-2024-08-01-11-18-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-01T13:00:00Z","earningsSummary":{"summary":"Labcorp's Q2 2024 earnings reflect a strong performance, marked by revenue growth, strategic acquisitions, and innovation in healthcare solutions.\nWhile facing challenges in certain segments, Labcorp's focus on expansion, new tests, and digital solutions positions it well for future growth and market leadership.\nWith a clear outlook for growth and a commitment to advancing healthcare, Labcorp remains a key player in the diagnostics and biopharma laboratory services industry.","headline":"Labcorp reports robust Q2 earnings, eyes growth through innovation","lastUpdated":"2024-08-01T16:21:42.831958Z"}},{"actual":3.5,"estimate":3.49,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-10-24T10:53:06Z","audioUrl":"https://files.quartr.com/audio-files/ee70a-2024-10-24-02-48-17.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/9c5b6-2024-10-24-11-12-17.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/c99e5-2024-10-24-11-31-00.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-10-24T13:00:00Z","earningsSummary":{"summary":"Labcorp's Q3 2024 performance reflects strong revenue growth and profitability, driven by Diagnostics and Biopharma services.\nDespite challenges such as regulatory delays, the company remains focused on strategic growth initiatives and operational efficiency.\nWith a positive outlook for continued growth, Labcorp's emphasis on partnerships, innovation, and cost-saving measures bodes well for its long-term success.","headline":"Labcorp reports robust Q3 earnings, eyes growth through strategic partnerships","lastUpdated":"2024-10-24T16:37:59.322281Z"}},{"actual":3.45,"estimate":3.39,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-06T11:52:46Z","audioUrl":"https://files.quartr.com/audio-files/3948b-2025-02-06-03-26-06.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/d4f24-2025-02-06-12-12-13.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/3bb6a-2025-02-06-12-27-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-06T14:00:00Z","earningsSummary":{"summary":"Labcorp's solid financial performance in 2024, driven by revenue growth and strategic acquisitions, positions the company well for continued success. While facing regulatory challenges, Labcorp's focus on innovation and expansion offers promising growth prospects in 2025.","headline":"Labcorp reports robust Q4 earnings, eyes strong growth in 2025","lastUpdated":"2025-02-06T15:49:23.854527Z"}},{"actual":3.84,"estimate":4.17,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-06-18T11:00:51Z","audioUrl":"https://files.quartr.com/audio-files/a2cc5-2025-04-29-02-36-09.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/00bc5-2025-04-29-11-26-35.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/de0bd-2025-04-29-10-25-55.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-04-29T13:00:00Z","earningsSummary":{"summary":"Labcorp's Q1 performance reflects steady growth and profitability, supported by strategic initiatives and a focus on innovation. While facing challenges related to external factors and industry competition, the company remains optimistic about its performance and strategic direction. By capitalizing on opportunities in new test offerings and technology utilization, Labcorp is well-positioned for future growth.","headline":"Labcorp reports solid Q1 earnings, focuses on innovation for growth","lastUpdated":"2025-04-29T15:01:22.991201Z"}},{"actual":4.35,"estimate":4.15,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-24T10:51:00Z","audioUrl":"https://files.quartr.com/audio-files/f8cf3-2025-07-24-02-09-11.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/cf2aa-2025-07-24-11-00-18.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/755c1-2025-07-24-10-52-53.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-07-24T13:00:00Z","earningsSummary":{"summary":"Labcorp's Q2 2025 performance reflects robust revenue growth, operational efficiency, and financial strength, supported by strong performance in diagnostics and BLS segments. While facing challenges from potential regulatory impacts, Labcorp's proactive approach and focus on customer experience position it well for sustained growth and resilience. Opportunities lie in leveraging technology, market diversification, and strategic initiatives to drive future growth and enhance competitive positioning in the healthcare sector.","headline":"Labcorp reports strong Q2 earnings, navigates regulatory challenges for growth","lastUpdated":"2025-07-24T15:41:27.628341Z"}},{"actual":null,"estimate":4.15,"period":"Q3 2025","fiscalQuarter":"Q3","fiscalYear":2025,"lastUpdated":"2025-07-24T23:31:14Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-10-23T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2022-02-10","title":"Earnings data Q4 2021","quarter":"Q4","hash":"70e6c9b546ff35115a2b51ebee81c39a46696e1a60bd47eeecd991ce2f996cb2"},{"date":"2022-04-28","title":"Earnings data Q1 2022","quarter":"Q1","hash":"eadd11ccd3f0a1162a6e1195f7b6623a45b0ea9daa76bcd50b25a8cb356c768a"},{"date":"2022-07-28","title":"Earnings data Q2 2022","quarter":"Q2","hash":"7fb068ae06f24ca3fe92bd361440aaec65eed9fd4f4251f2508a5534c8e0746b"},{"date":"2022-10-27","title":"Earnings data Q3 2022","quarter":"Q3","hash":"62e45484ad7b5d2567ae2098f27d60a8b3fc9879303895a468e9587545478d4a"},{"date":"2023-02-16","title":"Earnings data Q4 2022","quarter":"Q4","hash":"45f29de12fd84df598edae628114e69486d2bf4ddf28d8809faf9a12d7372b65"},{"date":"2023-04-25","title":"Earnings data Q1 2023","quarter":"Q1","hash":"08d39d9eb9f4717990bc796abfcd388569a5c414010012d24f652684faa9d3ed"},{"date":"2023-07-27","title":"Earnings data Q2 2023","quarter":"Q2","hash":"51c2e96a6dcbc71d51e66ff17eb401889c9ad81ca64044729ff52965810f348a"},{"date":"2023-10-26","title":"Earnings data Q3 2023","quarter":"Q3","hash":"2f4d47a336523d62769e5206bd6ce64dc9185d76d2a7a9963b695d3377496d38"},{"date":"2024-02-15","title":"Earnings data Q4 2023","quarter":"Q4","hash":"220564f94723f31e2f3df31613224e12fed25b881eabd367f321d13cadfe8fca"},{"date":"2024-04-25","title":"Earnings data Q1 2024","quarter":"Q1","hash":"5644bae66dd2e21fc960c9ee1fe412ebc2a915f14d0f44526cf7a63d7ed49d13"},{"date":"2024-08-01","title":"Earnings data Q2 2024","quarter":"Q2","hash":"80854e69be64f1c1a3b701396a8019069fb43160679f461196f449162f9ecb6c"},{"date":"2024-10-24","title":"Earnings data Q3 2024","quarter":"Q3","hash":"53494cfb382afccdaa125556e1efcecf0f6822501d9902e4503940d94f0b32f2"},{"date":"2025-02-06","title":"Earnings data Q4 2024","quarter":"Q4","hash":"0405656d3055110e9b5e4b78611e072afa85fe40a8164009514431ccc910b6e7"},{"date":"2025-04-29","title":"Earnings data Q1 2025","quarter":"Q1","hash":"8e8872bb1d69689aaaf12bffda1e0f76a5a9980260e794e2b4f36d5502c26ee3"},{"date":"2025-07-24","title":"Earnings data Q2 2025","quarter":"Q2","hash":"a2f7151dd5305078750e70ecdc9186ae538c3ce0fd63503309ea3143607dcd47"},{"date":"2025-10-23","title":"Earnings data Q3 2025","quarter":"Q3","hash":"927df2f3286505af23a8b61152cf9334c11d1f62977b13fd4ca38681d784d4b7"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Laboratory","companyDescription":"Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q2 2025","values":[{"financialKey":"REVENUE","value":3527300000,"changePercentage":9.51,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":2549400000,"changePercentage":8.18,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":977900000,"changePercentage":13.16,"valueToRevenueRatio":0.27723754713236753},{"financialKey":"OPERATING_EXPENSES","value":579300000,"changePercentage":3.85,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":579300000,"changePercentage":3.85,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":398600000,"changePercentage":30.09,"valueToRevenueRatio":0.11300428089473535},{"financialKey":"EBITDA","value":568900000,"changePercentage":22.79,"valueToRevenueRatio":0.16128483542653022},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":170300000,"changePercentage":8.54,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":238300000,"changePercentage":15.9,"valueToRevenueRatio":null},{"financialKey":"EPS","value":2.84,"changePercentage":16.61,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":18059900000,"changePercentage":8.06,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":4087200000,"changePercentage":14.45,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":647300000,"changePercentage":144.17,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":2276700000,"changePercentage":1.35,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":508100000,"changePercentage":15.01,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":655100000,"changePercentage":6,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":13972700000,"changePercentage":6.33,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":3133800000,"changePercentage":6.86,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":10045500000,"changePercentage":5.16,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":793400000,"changePercentage":20.89,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":9570500000,"changePercentage":10.11,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":2716800000,"changePercentage":-33.16,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":690000000,"changePercentage":-68.75,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":2026800000,"changePercentage":9.18,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":6853700000,"changePercentage":48.13,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":5856000000,"changePercentage":55.46,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":997700000,"changePercentage":16.01,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":8489400000,"changePercentage":5.84,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":8472700000.000001,"changePercentage":5.83,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":16700000,"changePercentage":11.33,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":18059900000,"changePercentage":8.06,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":6546000000,"changePercentage":9.55,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":5898700000,"changePercentage":3.3,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":102.20386,"changePercentage":6.98,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":238300000,"changePercentage":15.9,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":620600000,"changePercentage":10.6,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":525400000,"changePercentage":14.77,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":95200000,"changePercentage":-7.84,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-94100000,"changePercentage":49.14,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":77900000,"changePercentage":-39.24,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":-8100000,"changePercentage":64.78,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":11900000,"changePercentage":-65,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-175800000,"changePercentage":45.77,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-267399999.99999997,"changePercentage":-27.33,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":-200000000,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":0,"changePercentage":100,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":59900000,"changePercentage":-0.83,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-7500000,"changePercentage":72.22,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":18800000,"changePercentage":6366.67,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":277900000,"changePercentage":67.61,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":542700000,"changePercentage":25.36,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-25T02:40:46Z"},"dividend":{"dividendType":"CASH","dividendFrequency":"QUARTERLY","dividend":0.72,"priorDividend":0.72,"dividendYieldPercentage":1.11,"announcementDate":"2025-07-10","exDividendDate":"2025-08-28","payableDate":"2025-09-11","recordDate":"2025-08-28","updatedAt":"2025-07-10T11:42:52Z"},"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-01-19T02:08:04Z","bearsSay":["Labcorp Holdings has lowered its revenue guidance for the upcoming fiscal year, projecting a modest growth of only 3.7% to 5.0%, which reflects a concerning trend in the company’s financial health. The impact of pricing cuts under the PAMA regulations and significant challenges in capturing synergies from acquisitions are expected to contribute to downward pressure on profit margins, further complicating the company's growth outlook. Additionally, the company's biopharma revenue growth of 1.1% year-over-year fell short of expectations, highlighting underlying operational difficulties and intensified competition within the market."],"bullsSay":["Laboratory Corp. of America (Labcorp Holdings) is positioned for a strong growth trajectory, with the Diagnostics segment reporting a robust year-over-year revenue growth of 7.9%, culminating in $2.52 billion for the quarter. Additionally, the company has projected revenue growth for 2024 between $12.9 billion to $13.1 billion, representing an increase of 6.4% to 7.5%, which reflects a significant uptick from historical averages. The improved adjusted operating margin of 15.2%, supported by organic growth and efficiencies from LaunchPad, further reinforces the company's operational strength and financial stability."],"charts":[{"title":"Revenue Segments","description":"Revenue segments as reported by the company.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Diagnostics","dataPoints":[{"key":"21 Q3","value":2617.5},{"key":"21 Q4","value":2622.8},{"key":"22 Q1","value":2454.1},{"key":"22 Q2","value":2255.4},{"key":"22 Q3","value":2207.6},{"key":"22 Q4","value":2286.4},{"key":"23 Q1","value":2382.8},{"key":"23 Q2","value":2340.8},{"key":"23 Q3","value":2344.7},{"key":"23 Q4","value":2346.9},{"key":"24 Q1","value":2479.7},{"key":"24 Q2","value":2524.9},{"key":"24 Q3","value":2553.5},{"key":"24 Q4","value":2586.2},{"key":"25 Q1","value":2629.6},{"key":"25 Q2","value":2748.8}]},{"title":"Drug Development","dataPoints":[{"key":"21 Q3","value":1459.5},{"key":"21 Q4","value":1452.6},{"key":"22 Q1","value":1459.3},{"key":"22 Q2","value":1451.9},{"key":"22 Q3","value":1405.8},{"key":"22 Q4","value":1393.2},{"key":"23 Q1","value":1401.3}]},{"title":"Intercompany eliminations and other","dataPoints":[{"key":"21 Q3","value":-14.4},{"key":"21 Q4","value":-19.3},{"key":"22 Q1","value":-13.8},{"key":"22 Q2","value":-10.4},{"key":"22 Q3","value":-7.3},{"key":"22 Q4","value":-5.4},{"key":"23 Q1","value":-6.2},{"key":"23 Q2","value":-6.1},{"key":"23 Q3","value":-7},{"key":"23 Q4","value":-8.4},{"key":"24 Q1","value":-14},{"key":"24 Q2","value":-11},{"key":"24 Q3","value":-9.2},{"key":"24 Q4","value":-23.8},{"key":"25 Q1","value":-5.8},{"key":"25 Q2","value":-6.3}]},{"title":"Biopharma Laboratory Services","dataPoints":[{"key":"23 Q2","value":699},{"key":"23 Q3","value":719.1},{"key":"23 Q4","value":694.8},{"key":"24 Q1","value":710.9},{"key":"24 Q2","value":707},{"key":"24 Q3","value":737.7},{"key":"24 Q4","value":767},{"key":"25 Q1","value":721.3},{"key":"25 Q2","value":784.8}]}],"overlayChart":null},{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q3","value":34.1},{"key":"21 Q4","value":33.89},{"key":"22 Q1","value":31.61},{"key":"22 Q2","value":30.36},{"key":"22 Q3","value":29.38},{"key":"22 Q4","value":26.39},{"key":"23 Q1","value":25.8},{"key":"23 Q2","value":27.76},{"key":"23 Q3","value":27.84},{"key":"23 Q4","value":27.07},{"key":"24 Q1","value":28.24},{"key":"24 Q2","value":28.76},{"key":"24 Q3","value":27.55},{"key":"24 Q4","value":26.92},{"key":"25 Q1","value":28.33},{"key":"25 Q2","value":29.66}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q3","value":18.87},{"key":"21 Q4","value":18.01},{"key":"22 Q1","value":17.64},{"key":"22 Q2","value":14.22},{"key":"22 Q3","value":13.01},{"key":"22 Q4","value":2.46},{"key":"23 Q1","value":9.02},{"key":"23 Q2","value":8.77},{"key":"23 Q3","value":8.25},{"key":"23 Q4","value":-4.05},{"key":"24 Q1","value":10.11},{"key":"24 Q2","value":9.15},{"key":"24 Q3","value":7.74},{"key":"24 Q4","value":6.5},{"key":"25 Q1","value":9.74},{"key":"25 Q2","value":11.18}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q3","value":14.45},{"key":"21 Q4","value":13.63},{"key":"22 Q1","value":12.6},{"key":"22 Q2","value":9.7},{"key":"22 Q3","value":9.78},{"key":"22 Q4","value":2.07},{"key":"23 Q1","value":5.63},{"key":"23 Q2","value":6.22},{"key":"23 Q3","value":5.99},{"key":"23 Q4","value":-5.51},{"key":"24 Q1","value":7.17},{"key":"24 Q2","value":6.37},{"key":"24 Q3","value":5.15},{"key":"24 Q4","value":4.3},{"key":"25 Q1","value":6.36},{"key":"25 Q2","value":6.74}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Selling, general and administrative expenses","dataPoints":[{"key":"21 Q3","value":519.9},{"key":"21 Q4","value":543.7},{"key":"22 Q1","value":464.1},{"key":"22 Q2","value":486},{"key":"22 Q3","value":510},{"key":"22 Q4","value":536.5},{"key":"23 Q1","value":553.6},{"key":"23 Q2","value":505.8},{"key":"23 Q3","value":525.5},{"key":"23 Q4","value":532.9},{"key":"24 Q1","value":508.4},{"key":"24 Q2","value":557.8},{"key":"24 Q3","value":568.6},{"key":"24 Q4","value":595.2},{"key":"25 Q1","value":546},{"key":"25 Q2","value":579.3}]},{"title":"Amortization of intangibles and other assets","dataPoints":[{"key":"21 Q3","value":92.2},{"key":"21 Q4","value":92.9},{"key":"22 Q1","value":67.1},{"key":"22 Q2","value":66.4},{"key":"22 Q3","value":65.2},{"key":"22 Q4","value":60.6},{"key":"23 Q1","value":69.3},{"key":"23 Q2","value":51.5},{"key":"23 Q3","value":55.7},{"key":"23 Q4","value":59.2},{"key":"24 Q1","value":60.1},{"key":"24 Q2","value":62.2},{"key":"24 Q3","value":63.7},{"key":"24 Q4","value":70.4},{"key":"25 Q1","value":69.6},{"key":"25 Q2","value":68.3}]},{"title":"Goodwill and other asset impairments","dataPoints":[{"key":"22 Q1","value":1.2},{"key":"22 Q4","value":270.3},{"key":"23 Q1","value":2.2},{"key":"23 Q2","value":2.8},{"key":"23 Q3","value":10.2},{"key":"23 Q4","value":333.8},{"key":"24 Q1","value":2.5},{"key":"24 Q4","value":2.8}]},{"title":"Restructuring and other charges","dataPoints":[{"key":"21 Q3","value":6.5},{"key":"21 Q4","value":7.8},{"key":"22 Q1","value":12.6},{"key":"22 Q2","value":44.4},{"key":"22 Q3","value":15.1},{"key":"22 Q4","value":11.7},{"key":"23 Q1","value":8.6},{"key":"23 Q2","value":15.8},{"key":"23 Q3","value":7.5},{"key":"23 Q4","value":18.3},{"key":"24 Q1","value":5},{"key":"24 Q2","value":11.6},{"key":"24 Q3","value":18},{"key":"24 Q4","value":11.4},{"key":"25 Q1","value":6.4},{"key":"25 Q2","value":4.1}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q3","value":4.27},{"key":"21 Q4","value":-9.66},{"key":"22 Q1","value":-6.29},{"key":"22 Q2","value":-3.74},{"key":"22 Q3","value":-11.24},{"key":"22 Q4","value":-9.42},{"key":"23 Q1","value":-3.12},{"key":"23 Q2","value":-17.94},{"key":"23 Q3","value":-15.23},{"key":"23 Q4","value":-17.44},{"key":"24 Q1","value":-15.92},{"key":"24 Q2","value":6.17},{"key":"24 Q3","value":7.37},{"key":"24 Q4","value":9.76},{"key":"25 Q1","value":5.3},{"key":"25 Q2","value":9.51}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q3","value":20.75},{"key":"21 Q4","value":5.35},{"key":"22 Q1","value":0.72},{"key":"22 Q2","value":6.44},{"key":"22 Q3","value":-4.57},{"key":"22 Q4","value":36.42},{"key":"23 Q1","value":16.28},{"key":"23 Q2","value":-3.5},{"key":"23 Q3","value":1.46},{"key":"23 Q4","value":7.41},{"key":"24 Q1","value":-9.11},{"key":"24 Q2","value":9.67},{"key":"24 Q3","value":8.58},{"key":"24 Q4","value":-28},{"key":"25 Q1","value":7.99},{"key":"25 Q2","value":3.18}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q3","value":96.3},{"key":"21 Q4","value":95.3},{"key":"22 Q1","value":93.2},{"key":"22 Q2","value":92.3},{"key":"22 Q3","value":90.2},{"key":"22 Q4","value":88.5},{"key":"23 Q1","value":88.4},{"key":"23 Q2","value":88.4},{"key":"23 Q3","value":86.6},{"key":"23 Q4","value":84.9},{"key":"24 Q1","value":84.1},{"key":"24 Q2","value":84.1},{"key":"24 Q3","value":84},{"key":"24 Q4","value":83.6},{"key":"25 Q1","value":83.6},{"key":"25 Q2","value":83.4}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q3","value":28244.79},{"key":"21 Q4","value":27465.46},{"key":"22 Q1","value":25518.16},{"key":"22 Q2","value":22862.71},{"key":"22 Q3","value":21467.6},{"key":"22 Q4","value":20107.2},{"key":"23 Q1","value":21136.44},{"key":"23 Q2","value":17123.08},{"key":"23 Q3","value":18246.62},{"key":"23 Q4","value":17837.49},{"key":"24 Q1","value":18527.23},{"key":"24 Q2","value":17105.94},{"key":"24 Q3","value":18463.2},{"key":"24 Q4","value":19177.84},{"key":"25 Q1","value":20289.72},{"key":"25 Q2","value":20307.9}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q3","value":1.74},{"key":"21 Q4","value":1.69},{"key":"22 Q1","value":1.64},{"key":"22 Q2","value":1.55},{"key":"22 Q3","value":1.49},{"key":"22 Q4","value":1.37},{"key":"23 Q1","value":1.4},{"key":"23 Q2","value":1.41},{"key":"23 Q3","value":1.49},{"key":"23 Q4","value":1.47},{"key":"24 Q1","value":1.46},{"key":"24 Q2","value":1.33},{"key":"24 Q3","value":1.41},{"key":"24 Q4","value":1.44},{"key":"25 Q1","value":1.52},{"key":"25 Q2","value":1.44}]}],"overlayChart":null}],"chartsLastUpdated":"2025-07-24T15:52:45Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":null,"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"DGX","name":"Quest Diagnostics","displayName":"Quest Diagnostics","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"DGX","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":170.48,"high":175.76,"low":170.47,"volume":2114216,"volumeDate":"2025-07-24","last":171.9,"open":172.53,"gainPercentage":0.833,"gainValue":1.42,"ask":273.32,"bid":68.76,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":19190056500,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":1130548.4194,"highPriceLast52Weeks":182.375,"lowPriceLast52Weeks":140.7099,"companyName":"Quest Diagnostics, Inc.","longBusinessDescription":"Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information, and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to physicians, hospitals, patients, and consumers. The All Other segment consists of risk assessment services and healthcare information technology. The company was founded in 1967 and is headquartered in Secaucus, NJ.","dividendRate":3.1,"salesOrRevenue":9872000000,"oneYearAnnualRevenueGrowthRate":6.70125378296585,"threeYearAnnualRevenueGrowthRate":-2.6908,"fiveYearAnnualRevenueGrowthRate":5.6779,"earningsGrowth":12.9978,"totalDebt":7087000000,"totalAssets":16153000000,"floatAsPercentOfSharesOutstanding":99.5011,"dividendYield":1.7999999999999998,"betaTwelveMonth":0.2928,"salesOrRevenueTtm":10522000000,"ebitdaTtm":2059000000,"debtToEquityRatioQuarterly":88.3231876037631,"totalEnterpriseValue":23703180000,"industry":"ServicestotheHealthIndustry","sector":"HealthServices","preTaxInterestCoverageRatio":6.26106194690266,"fiveYearAverageDebtEquityRatio":76.22,"currentRatio":1.08596837944664,"peratio":20.6},"recommendation":{"currentConsensusRating":2.4,"recommendationTargetPrice":150.07,"totalRatings":27,"strongSellRatings":1,"sellRatings":1,"holdRatings":13,"buyRatings":5,"strongBuyRatings":7,"lastUpdated":"2025-07-23T19:07:02Z"},"earningEstimates":[{"actual":3.33,"estimate":3.17,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-03T11:57:44Z","audioUrl":"https://files.quartr.com/audio-files/8a356-2022-10-19-10-48-36.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/6cf59-2023-01-25-12-58-21.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-03T02:39:38Z","earningsSummary":null},{"actual":3.22,"estimate":2.97,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-04-21T10:51:07Z","audioUrl":"https://files.quartr.com/audio-files/23a28-2022-10-28-04-04-14.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/dbbe6-2023-01-25-12-35-58.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-04-21T11:06:10Z","earningsSummary":null},{"actual":2.36,"estimate":2.2,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-07-21T11:38:25Z","audioUrl":"https://files.quartr.com/audio-files/126b2-2022-07-21-02-31-20.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/e3ac1-2022-07-21-11-00-15.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-07-21T01:34:00Z","earningsSummary":null},{"actual":2.36,"estimate":2.17,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-10-20T10:47:35Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_10_20T12_30_00_00_00_Quest_Diagnostics_Inc_Earnings_Call_Q3_2022.DOGPR2MC2JP8_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/468dc-2022-10-20-11-52-36.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-10-20T12:30:00Z","earningsSummary":null},{"actual":1.98,"estimate":1.91,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-02T11:48:09Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_02_02T13_30_00_00_00_Quest_Diagnostics_Inc_Earnings_Call_Q4_2022.LSAW5FD5U95R_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/conference-calls/7d6ab-2023-02-02-12-52-04.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-02T13:30:00Z","earningsSummary":{"summary":"Quest Diagnostics delivered strong financial performance in 2022, with revenue growth and strategic acquisitions driving expansion.\nChallenges include the anticipated decline in COVID-19 testing revenues and regional healthcare recovery disparities post-pandemic.\nOpportunities lie in advanced diagnostics investments, productivity enhancements, and upcoming investor day to showcase growth strategies.\nOverall, Quest Diagnostics remains focused on long-term growth, margin improvement, and shareholder value creation.","headline":"Quest Diagnostics reports robust 2022 performance amidst COVID-19 testing decline","lastUpdated":"2024-05-07T20:43:03.777885Z"}},{"actual":2.04,"estimate":1.97,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-04-27T10:47:24Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_04_27T12_30_00_00_00_Quest_Diagnostics_Inc_Q1_2023.4X19D2WZUXZ4_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/5263f-2023-04-27-10-09-49.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-04-27T12:30:00Z","earningsSummary":{"summary":"Quest Diagnostics' Q1 performance reflects robust revenue growth and strategic acquisitions positioning the company for future success. Challenges in margin progression and market expectations for MRD testing require attention, while opportunities in oncology distribution and consumer testing optimization offer avenues for growth.","headline":"Quest Diagnostics reports strong Q1 earnings, eyes growth opportunities","lastUpdated":"2024-05-07T21:11:34.034894Z"}},{"actual":2.3,"estimate":2.27,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-07-26T10:47:19Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_07_26T12_30_00_00_00_Quest_Diagnostics_Inc_Q2_2023.KX66LPD63DGO_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/057d3-2023-07-26-10-17-51.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-07-26T12:30:00Z","earningsSummary":{"summary":"Quest Diagnostics demonstrated strong financial performance in Q2 2023, with revenue growth, margin improvement, and raised guidance, despite challenges like high turnover and labor costs.\nThe company's strategic focus on innovation, acquisitions, and pricing strategies presents opportunities for sustained growth and market expansion in clinical areas like genomics and oncology.\nNavigating challenges related to employee turnover and cost pressures while leveraging opportunities in M\u0026A, value-based care, and technological advancements will be crucial for Quest Diagnostics' future success.","headline":"Quest Diagnostics reports robust Q2 earnings, raises guidance amid challenges","lastUpdated":"2024-05-07T21:03:14.597979Z"}},{"actual":2.22,"estimate":2.19,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-10-24T10:54:00Z","audioUrl":"https://files.quartr.com/audio-files/a8745-2023-10-24-01-23-25.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/3635e-2023-10-24-10-32-49.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-10-24T12:30:00Z","earningsSummary":{"summary":"Quest Diagnostics delivered strong financial results in Q3, showcasing growth in base business and adjusted EPS. While facing challenges from COVID-19 testing revenue decline and regulatory uncertainties, the company remains focused on leveraging opportunities in growth investments and margin improvements.","headline":"Quest Diagnostics reports robust Q3 earnings amidst COVID challenges","lastUpdated":"2024-05-07T21:44:59.686554Z"}},{"actual":2.15,"estimate":2.11,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-01T11:46:13Z","audioUrl":"https://files.quartr.com/audio-files/6dc30-2024-02-01-02-41-28.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/ec778-2024-02-01-11-54-51.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/69d56-2024-02-01-11-11-51.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-01T13:30:00Z","earningsSummary":{"summary":"Quest Diagnostics delivered strong financial performance in 2023, with revenue growth driven by acquisitions and strategic initiatives.\nThe company's focus on oncology, Alzheimer's offerings, and AI tools deployment positions them for continued growth and innovation.\nWhile facing short-term challenges like regulatory uncertainties and pricing pressures, Quest Diagnostics remains confident in their long-term outlook and growth prospects.\nWith a positive guidance for 2024, including revenue and EPS expectations, the company aims to navigate headwinds and capitalize on opportunities for sustainable growth.","headline":"Quest Diagnostics reports robust 2023 performance and optimistic 2024 outlook","lastUpdated":"2024-05-07T21:27:46.388410Z"}},{"actual":2.04,"estimate":1.85,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-04-23T10:47:28Z","audioUrl":"https://files.quartr.com/audio-files/0cce5-2024-04-23-01-59-20.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/96356-2024-04-23-10-11-50.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-04-23T12:30:00Z","earningsSummary":{"summary":"Quest Diagnostics' Q1 performance showcased strong revenue growth and strategic investments in advanced diagnostics and automation.\nWhile facing challenges like regulatory concerns and pricing pressures, the company's focus on acquisitions and operational efficiency drives growth.\nOpportunities lie in continued automation efforts, market expansion in advanced diagnostics, and the positive outlook for key acquisitions.\nOverall, Quest Diagnostics' solid financial results and raised guidance reflect a resilient business poised for future growth.","headline":"Quest Diagnostics reports robust Q1 results and strategic growth plans","lastUpdated":"2024-05-07T21:19:02.304305Z"}},{"actual":2.35,"estimate":2.34,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-07-23T10:46:01Z","audioUrl":"https://files.quartr.com/audio-files/ba882-2024-07-23-01-08-38.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/79b57-2024-07-23-10-43-48.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-07-23T12:30:00Z","earningsSummary":{"summary":"Quest Diagnostics' Q2 2024 performance reflects solid revenue growth, operational efficiency, and strategic acquisitions driving expansion.\nDespite challenges related to acquisition impact on EPS and industry dynamics, Quest's strong balance sheet and growth strategy position it well for the future.\nThe company's focus on advanced diagnostics, financial stability, and market opportunities underscores its resilience and growth potential in the healthcare sector.","headline":"Quest Diagnostics reports robust Q2 earnings amid strategic acquisitions","lastUpdated":"2024-07-23T16:16:47.000734Z"}},{"actual":2.3,"estimate":2.26,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-10-22T10:45:56Z","audioUrl":"https://files.quartr.com/audio-files/c462b-2024-10-22-01-27-41.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/dff14-2024-10-22-10-54-49.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-10-22T12:30:00Z","earningsSummary":{"summary":"Quest Diagnostics' Q3 2024 performance reflects a robust growth trajectory driven by strategic acquisitions and a focus on advanced diagnostics.\nWhile facing integration challenges and market uncertainties, the company's strong revenue streams and operational initiatives position it well for future growth.\nWith a reaffirmed long-term outlook and proactive acquisition strategy, Quest Diagnostics remains poised for continued success in the healthcare diagnostics sector.","headline":"Quest Diagnostics reports strong Q3 growth driven by acquisitions and advanced diagnostics","lastUpdated":"2024-10-22T16:22:43.913374Z"}},{"actual":2.23,"estimate":2.18,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-01-30T11:45:48Z","audioUrl":"https://files.quartr.com/audio-files/5326f-2025-01-30-02-44-34.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/4a759-2025-01-30-12-05-15.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/729a8-2025-01-30-11-04-49.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-01-30T13:30:00Z","earningsSummary":{"summary":"Quest Diagnostics demonstrated strong financial performance in Q4 2024, driven by revenue growth and strategic acquisitions.\nThe company's focus on core customers, operational improvements, and margin expansion sets a positive trajectory for future growth.\nWhile challenges like integration and margin management exist, opportunities from acquisitions and regulatory support offer avenues for sustained growth.\nOverall, Quest Diagnostics remains well-positioned to capitalize on market opportunities and drive shareholder value.","headline":"Quest Diagnostics reports robust Q4 earnings, eyes growth through acquisitions","lastUpdated":"2025-01-30T16:12:20.798173Z"}},{"actual":2.21,"estimate":2.15,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-04-22T10:45:22Z","audioUrl":"https://files.quartr.com/audio-files/e00fc-2025-04-22-01-32-46.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/acaad-2025-04-22-11-10-10.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/7df6d-2025-04-22-10-36-46.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-04-22T12:30:00Z","earningsSummary":{"summary":"Quest Diagnostics delivered robust financial results in Q1 2025, driven by revenue growth and operational efficiency. The company's strategic focus on core clinical customers and expansion into new growth areas positions it well for future success. While facing challenges in regulatory compliance and operational optimization, Quest Diagnostics remains proactive in addressing industry changes. Investments in technology, collaborations, and strategic initiatives underscore Quest's commitment to innovation and sustainable growth.","headline":"Quest Diagnostics posts strong Q1 results, eyes growth opportunities","lastUpdated":"2025-04-22T15:42:40.835246Z"}},{"actual":2.62,"estimate":2.57,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-22T10:48:14Z","audioUrl":"https://files.quartr.com/audio-files/cebca-2025-07-22-01-00-25.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/89069-2025-07-22-10-04-54.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/ebca3-2025-07-22-10-23-50.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-07-22T12:30:00Z","earningsSummary":{"summary":"Quest Diagnostics delivered impressive Q2 results, showcasing strong financial performance and strategic growth initiatives. While facing regulatory challenges and market dynamics, the company's focus on innovation and operational excellence positions it well for future success. With raised guidance and a strong emphasis on advanced diagnostics and acquisitions, Quest Diagnostics is poised for continued growth and market leadership.","headline":"Quest Diagnostics reports robust Q2 growth and strategic acquisitions","lastUpdated":"2025-07-22T15:41:47.291311Z"}},{"actual":null,"estimate":2.51,"period":"Q3 2025","fiscalQuarter":"Q3","fiscalYear":2025,"lastUpdated":"2025-07-24T23:30:44Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-10-21T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2022-02-03","title":"Earnings data Q4 2021","quarter":"Q4","hash":"4e353eb69fe369fdc6837521fc4228e8feb01b1d5d5c311333b919bb92d58805"},{"date":"2022-04-21","title":"Earnings data Q1 2022","quarter":"Q1","hash":"83a8ef54a024a8928f6dcaf936aed27453abceae1aec292def7f50decf7d3ecf"},{"date":"2022-07-21","title":"Earnings data Q2 2022","quarter":"Q2","hash":"a538bbac58ad0a5f5640d0087ba79770b8b86839dec3d2463a4f7b5f6941486c"},{"date":"2022-10-20","title":"Earnings data Q3 2022","quarter":"Q3","hash":"2812eebba1e08578d4f95f8104a922aadf918cbd4c66a0b3f097bcfc6007abfa"},{"date":"2023-02-02","title":"Earnings data Q4 2022","quarter":"Q4","hash":"8dc0258ea19ac43494116ccd01536aa614d6a38673fd91fb703ad8002ec06d99"},{"date":"2023-04-27","title":"Earnings data Q1 2023","quarter":"Q1","hash":"0a0cf22cc0e132cda836d4273ace2b238082426a647e6543192f9c87a709a676"},{"date":"2023-07-26","title":"Earnings data Q2 2023","quarter":"Q2","hash":"d0989b67305f9647932501d1560a39ad8cafece115694d8e10968cd1a1969a76"},{"date":"2023-10-24","title":"Earnings data Q3 2023","quarter":"Q3","hash":"816600bbdb46d8c4c00ba7dc093de4ed270cbdb760d1da633acbdd3ade2a49ac"},{"date":"2024-02-01","title":"Earnings data Q4 2023","quarter":"Q4","hash":"225eece1e90093721d2da6c1132fca165ed59374eed0e95dfcbeed41ea9d552d"},{"date":"2024-04-23","title":"Earnings data Q1 2024","quarter":"Q1","hash":"93bc1d34e814ae177f0f5e50627cdbe80ec897dfebf485ef39e517beaa59ad15"},{"date":"2024-07-23","title":"Earnings data Q2 2024","quarter":"Q2","hash":"62b1eac52711c722f01d0aac459ca1aa10cf14bf80ecf91ca7308eae7c8b9420"},{"date":"2024-10-22","title":"Earnings data Q3 2024","quarter":"Q3","hash":"785f97dff61fb4265de3a6f1b19ee361730f0783584e95604a70b1d8dc031e60"},{"date":"2025-01-30","title":"Earnings data Q4 2024","quarter":"Q4","hash":"90e32d7d47abf836207b147844ccbf197eb902416cdb0304786a0adfb2abec78"},{"date":"2025-04-22","title":"Earnings data Q1 2025","quarter":"Q1","hash":"62adcdb22cf022a728ae71d2d44ed1d33637a628d0b3e83b1cb77b35286aa810"},{"date":"2025-07-22","title":"Earnings data Q2 2025","quarter":"Q2","hash":"b03f4b688f42b23cd10e5a2b32f157a2555654ebb48cdb6d13df34634f42882c"},{"date":"2025-10-21","title":"Earnings data Q3 2025","quarter":"Q3","hash":"2e7789bcd6eac857f460ffc92a43f676d6f7becfded7b2dfc763a6188b1b88c0"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Quest Diagnostics","companyDescription":"Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q2 2025","values":[{"financialKey":"REVENUE","value":2761000000,"changePercentage":15.19,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":1817000000,"changePercentage":12.09,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":944000000,"changePercentage":21.65,"valueToRevenueRatio":0.34190510684534586},{"financialKey":"OPERATING_EXPENSES","value":519000000,"changePercentage":27.83,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":480000000,"changePercentage":18.23,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":39000000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":425000000,"changePercentage":14.86,"valueToRevenueRatio":0.15392973560304238},{"financialKey":"EBITDA","value":568000000,"changePercentage":16.63,"valueToRevenueRatio":0.20572256428830135},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":143000000,"changePercentage":22.22,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":295000000,"changePercentage":23.43,"valueToRevenueRatio":null},{"financialKey":"EPS","value":2.47,"changePercentage":21.33,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":15969000000,"changePercentage":15.04,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":2198000000,"changePercentage":8.97,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":319000000,"changePercentage":17.71,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":1419000000,"changePercentage":7.58,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":187000000,"changePercentage":2.75,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":273000000,"changePercentage":11.43,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":13771000000,"changePercentage":16.07,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":2775000000,"changePercentage":13.96,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":10589000000,"changePercentage":16.53,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":407000000,"changePercentage":19.01,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":8623000000,"changePercentage":20.67,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":2024000000,"changePercentage":0.6,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":675000000,"changePercentage":-11.76,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":1349000000,"changePercentage":8.18,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":6599000000,"changePercentage":28.54,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":5709000000,"changePercentage":32.06,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":890000000,"changePercentage":9.74,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":7346000000,"changePercentage":9.07,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":7228000000,"changePercentage":9.23,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":118000000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":15969000000,"changePercentage":15.04,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":6384000000,"changePercentage":25.47,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":6065000000,"changePercentage":25.91,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":64.53571,"changePercentage":8.26,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":296000000,"changePercentage":23.33,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":544000000,"changePercentage":51.11,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":489000000,"changePercentage":33.61,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":55000000,"changePercentage":1016.67,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-124000000,"changePercentage":38,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":108000000,"changePercentage":17.39,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":17000000,"changePercentage":-83.96,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-249000000,"changePercentage":37.44,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-293000000,"changePercentage":19.28,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":13000000,"changePercentage":-18.75,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":-401000000,"changePercentage":-33.22,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":90000000,"changePercentage":7.14,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":4000000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":131000000,"changePercentage":164.53,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":436000000,"changePercentage":62.69,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-25T02:40:46Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-07-18T02:15:39Z","bearsSay":["Quest Diagnostics Inc faces notable financial headwinds, including an estimated impact of approximately $0.20 per share due to investments aimed at modernizing its IT infrastructure and compliance with laboratory-developed test (LDT) regulations. Furthermore, the company is experiencing an approximately $0.50 per share increase in year-over-year interest expenses, adding pressure to its profitability. The ongoing mixed hospital backdrop may offer a potential but uncertain tailwind, overshadowed by these significant cost pressures."],"bullsSay":["Quest Diagnostics Inc. demonstrated significant financial growth, with total revenue reaching $2.62 billion for the year, reflecting a 14.5% year-over-year increase and a 5% organic growth rate, driven by robust volume increases of 13.9%. The company's consumer-initiated testing sector, showing remarkable performance, contributed nearly $100 million to revenue, growing nearly 50% in the fourth quarter and approximately 40% for fiscal year 2024. Additionally, improved employee retention and expectations for operating margin expansion, alongside strong cash flow from operations projected at $1.45 billion, support a positive outlook for the firm's future financial stability and growth potential."],"charts":[{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q3","value":39.79},{"key":"21 Q4","value":37.39},{"key":"22 Q1","value":36.95},{"key":"22 Q2","value":34.32},{"key":"22 Q3","value":34.91},{"key":"22 Q4","value":32.49},{"key":"23 Q1","value":33.07},{"key":"23 Q2","value":33.87},{"key":"23 Q3","value":32.85},{"key":"23 Q4","value":32.16},{"key":"24 Q1","value":32.58},{"key":"24 Q2","value":33.54},{"key":"24 Q3","value":32.59},{"key":"24 Q4","value":32.73},{"key":"25 Q1","value":32.54},{"key":"25 Q2","value":34.15}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q3","value":23.5},{"key":"21 Q4","value":19.53},{"key":"22 Q1","value":19.64},{"key":"22 Q2","value":15.81},{"key":"22 Q3","value":15.76},{"key":"22 Q4","value":5.78},{"key":"23 Q1","value":13.08},{"key":"23 Q2","value":14.88},{"key":"23 Q3","value":14.9},{"key":"23 Q4","value":11.66},{"key":"24 Q1","value":12.67},{"key":"24 Q2","value":14.81},{"key":"24 Q3","value":13.26},{"key":"24 Q4","value":13.77},{"key":"25 Q1","value":13.04},{"key":"25 Q2","value":15.86}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q3","value":18.99},{"key":"21 Q4","value":15.05},{"key":"22 Q1","value":14.28},{"key":"22 Q2","value":10.19},{"key":"22 Q3","value":11.1},{"key":"22 Q4","value":4.97},{"key":"23 Q1","value":9.3},{"key":"23 Q2","value":10.65},{"key":"23 Q3","value":10.32},{"key":"23 Q4","value":8.95},{"key":"24 Q1","value":8.79},{"key":"24 Q2","value":10.01},{"key":"24 Q3","value":9.52},{"key":"24 Q4","value":9},{"key":"25 Q1","value":8.86},{"key":"25 Q2","value":10.72}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Selling, general and administrative","dataPoints":[{"key":"21 Q3","value":427},{"key":"21 Q4","value":464},{"key":"22 Q1","value":425},{"key":"22 Q2","value":422},{"key":"22 Q3","value":464},{"key":"22 Q4","value":563},{"key":"23 Q1","value":439},{"key":"23 Q2","value":416},{"key":"23 Q3","value":380},{"key":"23 Q4","value":407},{"key":"24 Q1","value":440},{"key":"24 Q2","value":416},{"key":"24 Q3","value":448},{"key":"24 Q4","value":466},{"key":"25 Q1","value":476},{"key":"25 Q2","value":486}]},{"title":"Amortization of intangible assets","dataPoints":[{"key":"21 Q3","value":25},{"key":"21 Q4","value":26},{"key":"22 Q1","value":27},{"key":"22 Q2","value":27},{"key":"22 Q3","value":27},{"key":"22 Q4","value":39},{"key":"23 Q1","value":26},{"key":"23 Q2","value":28},{"key":"23 Q3","value":27},{"key":"23 Q4","value":27},{"key":"24 Q1","value":29},{"key":"24 Q2","value":29},{"key":"24 Q3","value":32},{"key":"24 Q4","value":37},{"key":"25 Q1","value":39},{"key":"25 Q2","value":39}]},{"title":"Other operating expense (income), net","dataPoints":[{"key":"22 Q2","value":5},{"key":"22 Q3","value":-15},{"key":"22 Q4","value":21},{"key":"23 Q1","value":1},{"key":"23 Q3","value":5},{"key":"23 Q4","value":35},{"key":"24 Q1","value":2},{"key":"24 Q2","value":4},{"key":"24 Q3","value":1},{"key":"24 Q4","value":-6},{"key":"25 Q1","value":2},{"key":"25 Q2","value":-20}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q3","value":-0.43},{"key":"21 Q4","value":-8.59},{"key":"22 Q1","value":-4.01},{"key":"22 Q2","value":-3.8},{"key":"22 Q3","value":-10.38},{"key":"22 Q4","value":-14.98},{"key":"23 Q1","value":-10.72},{"key":"23 Q2","value":-4.69},{"key":"23 Q3","value":-7.68},{"key":"23 Q4","value":-1.93},{"key":"24 Q1","value":1.5},{"key":"24 Q2","value":2.52},{"key":"24 Q3","value":8.41},{"key":"24 Q4","value":14.55},{"key":"25 Q1","value":12.09},{"key":"25 Q2","value":15.19}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q3","value":-7.38},{"key":"21 Q4","value":3.38},{"key":"22 Q1","value":4.15},{"key":"22 Q2","value":0.44},{"key":"22 Q3","value":5.31},{"key":"22 Q4","value":27.14},{"key":"23 Q1","value":3.1},{"key":"23 Q2","value":-2.2},{"key":"23 Q3","value":-13.45},{"key":"23 Q4","value":-24.72},{"key":"24 Q1","value":1.07},{"key":"24 Q2","value":1.13},{"key":"24 Q3","value":16.75},{"key":"24 Q4","value":5.97},{"key":"25 Q1","value":9.77},{"key":"25 Q2","value":12.47}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q3","value":123},{"key":"21 Q4","value":122},{"key":"22 Q1","value":119},{"key":"22 Q2","value":117},{"key":"22 Q3","value":116},{"key":"22 Q4","value":113},{"key":"23 Q1","value":112},{"key":"23 Q2","value":112},{"key":"23 Q3","value":112},{"key":"23 Q4","value":112},{"key":"24 Q1","value":111},{"key":"24 Q2","value":111},{"key":"24 Q3","value":112},{"key":"24 Q4","value":111},{"key":"25 Q1","value":111},{"key":"25 Q2","value":112}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q3","value":17996.991},{"key":"21 Q4","value":18563.032},{"key":"22 Q1","value":16586.577},{"key":"22 Q2","value":15863.328},{"key":"22 Q3","value":15193.1},{"key":"22 Q4","value":16165.78},{"key":"23 Q1","value":15933.344},{"key":"23 Q2","value":15357.44},{"key":"23 Q3","value":14831.152},{"key":"23 Q4","value":14724.528},{"key":"24 Q1","value":14401.806},{"key":"24 Q2","value":15200.673},{"key":"24 Q3","value":16726.64},{"key":"24 Q4","value":17264.274},{"key":"25 Q1","value":18234.525},{"key":"25 Q2","value":19453.616}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q3","value":1.62},{"key":"21 Q4","value":1.69},{"key":"22 Q1","value":1.59},{"key":"22 Q2","value":1.62},{"key":"22 Q3","value":1.53},{"key":"22 Q4","value":1.73},{"key":"23 Q1","value":1.71},{"key":"23 Q2","value":1.64},{"key":"23 Q3","value":1.62},{"key":"23 Q4","value":1.61},{"key":"24 Q1","value":1.52},{"key":"24 Q2","value":1.59},{"key":"24 Q3","value":1.68},{"key":"24 Q4","value":1.65},{"key":"25 Q1","value":1.72},{"key":"25 Q2","value":1.76}]}],"overlayChart":null}],"chartsLastUpdated":"2025-07-22T12:39:32Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":null,"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"BIO","name":"Bio-Rad Laboratories","displayName":"Bio-Rad Laboratories","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"BIO","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":257.07,"high":262.395,"low":256.51,"volume":212512,"volumeDate":"2025-07-24","last":262.06,"open":257.44,"gainPercentage":1.941,"gainValue":4.99,"ask":269,"bid":105.34,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":7131334000,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":352315.3548,"highPriceLast52Weeks":387.99,"lowPriceLast52Weeks":211.43,"companyName":"Bio-Rad Laboratories, Inc.","longBusinessDescription":"Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.","dividendRate":0,"salesOrRevenue":2566500000,"oneYearAnnualRevenueGrowthRate":-3.9218167293212,"threeYearAnnualRevenueGrowthRate":-4.2374,"fiveYearAnnualRevenueGrowthRate":2.4431,"earningsGrowth":-637.1104,"totalDebt":1375100000,"totalAssets":9364100000,"floatAsPercentOfSharesOutstanding":67.7951,"dividendYield":0,"betaTwelveMonth":0.9734,"salesOrRevenueTtm":2541105000,"ebitdaTtm":529562000,"debtToEquityRatioQuarterly":20.5033386232296,"totalEnterpriseValue":8977781422.140001,"industry":"MedicalSpecialties","sector":"HealthTechnology","preTaxInterestCoverageRatio":6.359918200409,"fiveYearAverageDebtEquityRatio":10.7,"currentRatio":5.99407816818002,"peratio":-3.44},"recommendation":{"currentConsensusRating":2,"recommendationTargetPrice":323.67,"totalRatings":12,"strongSellRatings":0,"sellRatings":0,"holdRatings":4,"buyRatings":4,"strongBuyRatings":4,"lastUpdated":"2025-06-09T19:10:19Z"},"earningEstimates":[{"actual":3.71,"estimate":2.44,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-10-28T21:25:40Z","audioUrl":"https://files.quartr.com/audio-files/664eb-2022-10-19-04-46-16.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/ab2da-2024-08-30-09-50-34.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-10-28T00:00:00Z","earningsSummary":null},{"actual":3.21,"estimate":2.85,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-10T22:09:45Z","audioUrl":"https://files.quartr.com/audio-files/f9349-2022-10-19-10-38-51.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://www.bio-rad.com/en-se/corporate/newsroom/bio-rad-reports-fourth-quarter-full-year-2021-financial-results?ID=Bio-Rad-Reports-Four_1644520510\u0026ref=cHVibGljLmNvbQ==","eventDate":"2022-02-10T10:37:00Z","earningsSummary":null},{"actual":4.94,"estimate":3.4,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-04-28T20:54:52Z","audioUrl":"https://files.quartr.com/audio-files/f239e-2022-10-28-04-06-47.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/599e6-2023-01-25-01-41-19.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-04-28T16:49:50Z","earningsSummary":null},{"actual":3.38,"estimate":2.8,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-07-28T20:44:14Z","audioUrl":"https://files.quartr.com/audio-files/828ce-2022-07-28-10-51-46.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/27374-2022-07-28-08-16-26.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-07-29T10:18:00Z","earningsSummary":null},{"actual":2.6,"estimate":2.78,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-10-27T20:14:16Z","audioUrl":"https://files.quartr.com/audio-files/66c29-2022-10-27-10-42-22.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/75288-2022-10-27-08-12-11.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-10-27T21:00:00Z","earningsSummary":null},{"actual":3.31,"estimate":3.45,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-16T21:12:29Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_02_16T22_00_00_00_00_Bio_Rad_Laboratories_Inc_Earnings_Call_Q4_2022.C4CFOGVTX7UC_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/fe255-2023-02-16-09-42-09.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-16T22:00:00Z","earningsSummary":{"summary":"Bio-Rad Laboratories showcased strong financial performance, operational improvements, and strategic initiatives during the Q4 2022 earnings call. Despite challenges like supply chain disruptions and margin impacts, the company remains optimistic about its growth prospects and commitment to long-term targets.","headline":"Bio-Rad Laboratories reports robust earnings, eyes growth through new products","lastUpdated":"2024-05-11T01:54:20.099195Z"}},{"actual":3.34,"estimate":3.54,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-05-04T20:18:08Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_05_04T21_00_00_00_00_Bio_Rad_Laboratories_Inc_Q1_2023.E4E07N239400_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/67f82-2023-05-04-08-45-40.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-04T21:00:00Z","earningsSummary":{"summary":"Bio-Rad Laboratories navigated challenges in Q1 2023 to achieve core sales growth and solid non-GAAP net income, with a revised 2023 outlook projecting 4.5% revenue growth.\nThe impact of Russian sanctions and margin improvement plans were key discussion points, alongside the company's focus on expense management and operational transformation.\nWith a strategic approach to growth, strong performance in key business segments, and a focus on operational efficiency, Bio-Rad aims to capitalize on opportunities for expansion and resilience.","headline":"Bio-Rad reports resilient Q1 performance amidst challenges and opportunities","lastUpdated":"2024-05-11T02:16:30.091079Z"}},{"actual":3,"estimate":2.55,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-03T20:20:00Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_08_03T21_00_00_00_00_Bio_Rad_Laboratories_Inc_Q2_2023.2F894Y3Z3VIK_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/13991-2023-08-03-08-45-20.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-03T21:00:00Z","earningsSummary":{"summary":"Bio-Rad Laboratories faced challenges in BioPharma but showed strengths in Clinical Diagnostics and Life Science segments.\nDespite a decline in net sales, the company reported strong demand for ddPCR and authorized a new share repurchase program.\nAnticipated challenges in BioPharma and China may impact revenue growth, but opportunities exist in expanding ddPCR sales and cost-saving measures.\nThe company maintains a strong cash position, views its valuation favorably, and plans to participate in upcoming healthcare conferences.","headline":"Bio-Rad reports Q2 earnings decline, eyes ddPCR growth opportunities","lastUpdated":"2024-05-11T00:48:15.440694Z"}},{"actual":2.33,"estimate":2.78,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-10-26T20:25:23Z","audioUrl":"https://files.quartr.com/audio-files/e0bd1-2023-10-26-10-46-01.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/cdff2-2023-10-26-08-12-24.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-10-26T21:00:00Z","earningsSummary":{"summary":"Bio-Rad Laboratories faced challenges in Q3 2023 due to biopharma segment issues and economic constraints in China, impacting revenue and forecasting.\nDespite weaknesses, the company saw growth in Clinical Diagnostics revenue and remains focused on operational transformation and strategy execution.\nAnalysts raised concerns about market dynamics and share losses, while Bio-Rad plans to address challenges and capitalize on opportunities in the ddPCR market.\nThe company anticipates a strong Q4 to offset Q3 challenges and is prepared for potential macroeconomic impacts on biotechnology spending.","headline":"Bio-Rad Labs faces Q3 challenges, eyes ddPCR market growth","lastUpdated":"2024-05-11T01:59:03.959545Z"}},{"actual":3.1,"estimate":2.82,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-15T21:16:43Z","audioUrl":"https://files.quartr.com/audio-files/b3a58-2024-02-15-10-37-56.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/e3a78-2024-02-15-09-07-26.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-15T22:00:00Z","earningsSummary":{"summary":"Bio-Rad Laboratories navigated challenges in Q4 2023, with revenue declines but operational resilience in key segments.\nThe company faces headwinds in the China market but sees opportunities in new product launches and market recovery.\nFinancial stability is evident with strong cash reserves, while strategic adjustments are needed to drive future growth.\nGuidance for 2024 hints at a potential turnaround, with a focus on operational efficiency and revenue expansion.","headline":"Bio-Rad Labs reports Q4 revenue decline, eyes growth opportunities","lastUpdated":"2024-05-11T02:39:54.415667Z"}},{"actual":2.29,"estimate":2.15,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-05-07T20:27:07Z","audioUrl":"https://files.quartr.com/audio-files/88ce9-2024-05-07-09-50-45.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/5a348-2024-05-07-08-35-20.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-07T21:00:00Z","earningsSummary":{"summary":"Bio-Rad Laboratories' Q1 2024 earnings call highlighted a mixed performance with declines in Life Science sales but growth in Clinical Diagnostics. Despite challenges in certain segments, the company maintains its full-year outlook and is optimistic about long-term growth strategies and market trends.","headline":"Bio-Rad Laboratories reports mixed Q1 performance, maintains outlook optimism","lastUpdated":"2024-05-08T00:08:57.028359Z"}},{"actual":3.11,"estimate":2.01,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-08-01T20:22:22Z","audioUrl":"https://files.quartr.com/audio-files/61e8e-2024-08-01-09-21-51.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/3076c-2024-08-01-08-09-20.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-01T21:00:00Z","earningsSummary":{"summary":"Bio-Rad Laboratories had a solid quarter but revised full-year outlook due to global spending constraints.\nOperational improvements and successful share repurchases demonstrate resilience and strategic focus.\nChallenges in the Life Science group highlight areas for improvement and strategic decision-making.","headline":"Bio-Rad Laboratories reports solid Q2 performance amidst global spending constraints","lastUpdated":"2024-08-02T00:42:50.820094Z"}},{"actual":2.01,"estimate":1.16,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-10-30T20:26:31Z","audioUrl":"https://files.quartr.com/audio-files/667f9-2024-10-30-09-51-51.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/b0e5e-2024-10-30-08-56-19.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-10-30T21:00:00Z","earningsSummary":{"summary":"Bio-Rad Laboratories reported a strong Q3 performance with revenue surpassing targets driven by product mix and cost efficiencies.\nWhile facing challenges in certain segments, opportunities lie in the expected return to growth in 2025 and the expansion of the Droplet Digital PCR franchise.\nMaintained revenue guidance for 2024 with margin improvements and a focus on corporate transformations and acquisitions for future growth.\nAnalyst questions during the call covered a range of topics including margins, market dynamics, and product pricing.","headline":"Bio-Rad Laboratories exceeds revenue targets in Q3 2024 earnings call","lastUpdated":"2024-10-31T00:23:23.189069Z"}},{"actual":2.9,"estimate":2.88,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-13T22:12:29Z","audioUrl":"https://files.quartr.com/audio-files/8362f-2025-02-13-10-36-57.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/65536-2025-02-13-09-46-30.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-13T22:00:00Z","earningsSummary":{"summary":"Bio-Rad Laboratories navigated challenges in 2024, with a focus on operational efficiency and growth opportunities. The company's acquisition of Stilla Technologies and strategic initiatives aim to drive long-term success. Despite revenue declines in the Life Science segment, Bio-Rad's Clinical Diagnostics segment showed resilience and growth. Investments in innovation and cost management underscore Bio-Rad's commitment to sustainable growth.","headline":"Bio-Rad meets 2024 guidance, eyes growth through acquisitions and efficiency","lastUpdated":"2025-02-14T05:31:25.846647Z"}},{"actual":2.54,"estimate":1.78,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-06-18T09:20:51Z","audioUrl":"https://files.quartr.com/audio-files/b4cb5-2025-05-01-10-36-22.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/4a1a3-2025-05-01-08-12-18.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-01T21:30:00Z","earningsSummary":{"summary":"Bio-Rad Laboratories delivered strong Q1 2025 results, surpassing revenue and margin expectations, driven by robust performance in clinical diagnostics and bioproduction. While facing challenges in the Life Science segment, the company remains focused on innovation, operational efficiency, and mitigating risks from academic research funding reductions and tariff impacts. With a strategic outlook on growth and market adaptability, Bio-Rad is well-positioned to capitalize on opportunities in digital PCR, operational excellence, and customer-centric expansion.","headline":"Bio-Rad Laboratories exceeds Q1 expectations, navigates challenges with strategic focus","lastUpdated":"2025-05-02T05:31:26.093562Z"}},{"actual":null,"estimate":1.82,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-24T23:30:27Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-07-31T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-10-28","title":"Earnings data Q3 2021","quarter":"Q3","hash":"d285aa607a3551c5c4bf832b8dae13d62978a3801f0a10ed6cb0bd5febaf0da1"},{"date":"2022-02-10","title":"Earnings data Q4 2021","quarter":"Q4","hash":"d92297abbd7fde884fa42478827e909fd5ffd3d37b2fffc1337fe9e96d8600ef"},{"date":"2022-04-28","title":"Earnings data Q1 2022","quarter":"Q1","hash":"4bf57b07390b8c5036225ec0f4f46bd0ec5977de64a7bf51f281e88874903538"},{"date":"2022-07-28","title":"Earnings data Q2 2022","quarter":"Q2","hash":"f85837f7abb68271173379ca7ad981d3a8265f14c6fa67f8c14fa5a0c1ade446"},{"date":"2022-10-27","title":"Earnings data Q3 2022","quarter":"Q3","hash":"8159c9c9f14d29dd5116d888cca413a1248e071b21dc13c68bb62a7cf36fede4"},{"date":"2023-02-16","title":"Earnings data Q4 2022","quarter":"Q4","hash":"90dc80dfb62a38a2e2f3eb739ae6300b76e123d20a0046c2402dc03d85664fab"},{"date":"2023-05-04","title":"Earnings data Q1 2023","quarter":"Q1","hash":"3b4008ece41cd6462738cf24934d51b826effd8ddb42a982f5d8a8cb1592fcf0"},{"date":"2023-08-03","title":"Earnings data Q2 2023","quarter":"Q2","hash":"b65a4114d0fee7e9bd300f4ce381541a8d58249162ff9728f55aed01892b8140"},{"date":"2023-10-26","title":"Earnings data Q3 2023","quarter":"Q3","hash":"007056ea4184089a942ba236434abf6b36a8594bfe4db80ad9ad2ce79f8a476e"},{"date":"2024-02-15","title":"Earnings data Q4 2023","quarter":"Q4","hash":"1cfdb08f84a825d2940e96e5253957dca4b0388a213a6d2ae44bbae0af5988fc"},{"date":"2024-05-07","title":"Earnings data Q1 2024","quarter":"Q1","hash":"d45208427e7ef8cabde2239a80a275572c66739da68b8dc0ae332ffe7259c385"},{"date":"2024-08-01","title":"Earnings data Q2 2024","quarter":"Q2","hash":"f8e6e39321e2c23e1e6f8e5708f37d6aed5fc287ca846d664681c278ba8c6f21"},{"date":"2024-10-30","title":"Earnings data Q3 2024","quarter":"Q3","hash":"c5795bcee54af435da59d2173582ddf12043186a2680cbd3904b86b238d9834a"},{"date":"2025-02-13","title":"Earnings data Q4 2024","quarter":"Q4","hash":"1d7309fd00f89d18724268ee764259c4b6b862bf5b67a6eb9feb76d89825e740"},{"date":"2025-05-01","title":"Earnings data Q1 2025","quarter":"Q1","hash":"72286f7cbb5db9f1cd2fa98ac76e1d3a28163994cccb986c4bd11397f830fce6"},{"date":"2025-07-31","title":"Earnings data Q2 2025","quarter":"Q2","hash":"960e31ee43b7faaf8c7b9ff7fad781d6336f5636edd6002eec0f143836f8205f"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Bio-Rad Laboratories","companyDescription":"Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":585400000,"changePercentage":-4.16,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":274800000,"changePercentage":-3.36,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":310600000,"changePercentage":-4.86,"valueToRevenueRatio":0.5305773829859924},{"financialKey":"OPERATING_EXPENSES","value":253700000,"changePercentage":-7.56,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":253700000,"changePercentage":-7.56,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":56900000,"changePercentage":9.41,"valueToRevenueRatio":0.09719849675435599},{"financialKey":"EBITDA","value":105100000,"changePercentage":5.3,"valueToRevenueRatio":0.17953536043730783},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":48200000,"changePercentage":0.84,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":64000000,"changePercentage":-83.33,"valueToRevenueRatio":null},{"financialKey":"EPS","value":2.2894,"changePercentage":-82.98,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":9526900000,"changePercentage":-24.45,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":3036600000,"changePercentage":-0.8,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":1661700000,"changePercentage":0.63,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":438400000,"changePercentage":-4.61,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":790100000,"changePercentage":0.86,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":146400000,"changePercentage":-12.16,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":6490300000,"changePercentage":-32.03,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":681700000,"changePercentage":-4.16,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":710700000,"changePercentage":-2.16,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":5097900000,"changePercentage":-37.15,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":2847500000,"changePercentage":-19.99,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":506600000,"changePercentage":8.68,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":42500000,"changePercentage":4.87,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":37100000,"changePercentage":9.24,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":427000000,"changePercentage":9.02,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":2340900000,"changePercentage":-24.31,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":1327000000,"changePercentage":-2.37,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":1013900000,"changePercentage":-41.51,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":6679400000,"changePercentage":-26.2,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":6679400000,"changePercentage":-26.2,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":9526900000,"changePercentage":-24.45,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":1369500000,"changePercentage":-2.16,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":-292200000,"changePercentage":-16.15,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":241.71638,"changePercentage":-23.82,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":64000000,"changePercentage":-83.33,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":129900000,"changePercentage":87.78,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":96500000,"changePercentage":-1.02,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":33400000,"changePercentage":217.92,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":2900000,"changePercentage":106.73,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":34400000,"changePercentage":-14.38,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":37300000,"changePercentage":1367.41,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-68800000,"changePercentage":14.38,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-97700000,"changePercentage":-15413.48,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":-97600000,"changePercentage":-13010.05,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":-100000,"changePercentage":15.25,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":-1800000,"changePercentage":-167.59,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":33299999.999999996,"changePercentage":13.33,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":95500000,"changePercentage":229.32,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:13:46Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-05-30T08:46:58Z","bearsSay":["Bio-Rad Laboratories faces significant risks that contribute to a negative outlook on its stock, primarily stemming from potentially overstated revenue and earnings estimates due to declining demand for its products. The company continues to experience elevated inventories and reduced equipment sales as a result of ongoing supply chain disruptions that were exacerbated during the pandemic. Furthermore, Bio-Rad's exposure to macroeconomic variables, including foreign currency fluctuations and corporate governance risks associated with its majority shareholders, may further complicate its financial trajectory and limit share price growth."],"bullsSay":["Bio-Rad Laboratories is positioned to grow its revenue and earnings at a faster rate than its peers due to expected improvements in end-markets, which could lead to multiple expansions. The company is also set to benefit from ongoing ERP efficiencies that are anticipated to enhance margins, alongside the expected stabilization and growth of its ddPCR and process chromatography segments. With a current valuation of approximately 7x EBITDA and less than 1.5x sales, Bio-Rad presents an attractive entry point for investors as market pressures are expected to subside and growth trends normalize."],"charts":[{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q2","value":56.09},{"key":"21 Q3","value":58.55},{"key":"21 Q4","value":54.72},{"key":"22 Q1","value":57.64},{"key":"22 Q2","value":57.29},{"key":"22 Q3","value":54.9},{"key":"22 Q4","value":54.37},{"key":"23 Q1","value":53.54},{"key":"23 Q2","value":53.21},{"key":"23 Q3","value":53.1},{"key":"23 Q4","value":53.78},{"key":"24 Q1","value":53.36},{"key":"24 Q2","value":55.61},{"key":"24 Q3","value":54.77},{"key":"24 Q4","value":51.23},{"key":"25 Q1","value":52.27}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q2","value":17.42},{"key":"21 Q3","value":20.98},{"key":"21 Q4","value":14.59},{"key":"22 Q1","value":20.48},{"key":"22 Q2","value":17.39},{"key":"22 Q3","value":13.63},{"key":"22 Q4","value":16.24},{"key":"23 Q1","value":9.14},{"key":"23 Q2","value":13.15},{"key":"23 Q3","value":14.38},{"key":"23 Q4","value":13.99},{"key":"24 Q1","value":7.31},{"key":"24 Q2","value":15.89},{"key":"24 Q3","value":9.92},{"key":"24 Q4","value":8.74},{"key":"25 Q1","value":4.04}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q2","value":127.68},{"key":"21 Q3","value":525.8},{"key":"21 Q4","value":-214.76},{"key":"22 Q1","value":-481.34},{"key":"22 Q2","value":-134.17},{"key":"22 Q3","value":-24.13},{"key":"22 Q4","value":113.34},{"key":"23 Q1","value":10.18},{"key":"23 Q2","value":-170.65},{"key":"23 Q3","value":16.8},{"key":"23 Q4","value":51.33},{"key":"24 Q1","value":62.85},{"key":"24 Q2","value":-339.17},{"key":"24 Q3","value":100.52},{"key":"24 Q4","value":-107.24},{"key":"25 Q1","value":10.93}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Selling, general and administrative","dataPoints":[{"key":"21 Q2","value":213.425},{"key":"21 Q3","value":216.15},{"key":"21 Q4","value":224.146},{"key":"22 Q1","value":197.594},{"key":"22 Q2","value":208.73},{"key":"22 Q3","value":211.047},{"key":"22 Q4","value":212.227},{"key":"23 Q1","value":225.553},{"key":"23 Q2","value":207.824},{"key":"23 Q3","value":201.199},{"key":"23 Q4","value":207.147},{"key":"24 Q1","value":214.883},{"key":"24 Q2","value":194.719},{"key":"24 Q3","value":200.44},{"key":"24 Q4","value":204},{"key":"25 Q1","value":208.8}]},{"title":"Research and development","dataPoints":[{"key":"21 Q2","value":63.391},{"key":"21 Q3","value":64.481},{"key":"21 Q4","value":69.873},{"key":"22 Q1","value":62.543},{"key":"22 Q2","value":67.034},{"key":"22 Q3","value":69.949},{"key":"22 Q4","value":66.2},{"key":"23 Q1","value":74.951},{"key":"23 Q2","value":65.042},{"key":"23 Q3","value":43.535},{"key":"23 Q4","value":63.899},{"key":"24 Q1","value":66.375},{"key":"24 Q2","value":58.904},{"key":"24 Q3","value":90.997},{"key":"24 Q4","value":79.6},{"key":"25 Q1","value":73.5}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q2","value":33.35},{"key":"21 Q3","value":15.42},{"key":"21 Q4","value":-7.23},{"key":"22 Q1","value":-3.68},{"key":"22 Q2","value":-3.47},{"key":"22 Q3","value":-8.87},{"key":"22 Q4","value":-0.34},{"key":"23 Q1","value":-3.32},{"key":"23 Q2","value":-1.45},{"key":"23 Q3","value":-7.15},{"key":"23 Q4","value":-6.72},{"key":"24 Q1","value":-9.75},{"key":"24 Q2","value":-6.26},{"key":"24 Q3","value":2.79},{"key":"24 Q4","value":-2.01},{"key":"25 Q1","value":-4.16}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q2","value":14.74},{"key":"21 Q3","value":8.89},{"key":"21 Q4","value":3.2},{"key":"22 Q1","value":-13.22},{"key":"22 Q2","value":-0.38},{"key":"22 Q3","value":0.13},{"key":"22 Q4","value":-5.3},{"key":"23 Q1","value":15.52},{"key":"23 Q2","value":-1.05},{"key":"23 Q3","value":-12.9},{"key":"23 Q4","value":-2.65},{"key":"24 Q1","value":-6.4},{"key":"24 Q2","value":-7.05},{"key":"24 Q3","value":19.08},{"key":"24 Q4","value":4.63},{"key":"25 Q1","value":0.37}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q2","value":29.764},{"key":"21 Q3","value":29.814},{"key":"21 Q4","value":29.922},{"key":"22 Q1","value":29.933},{"key":"22 Q2","value":29.794},{"key":"22 Q3","value":29.733},{"key":"22 Q4","value":29.683},{"key":"23 Q1","value":29.596},{"key":"23 Q2","value":29.355},{"key":"23 Q3","value":29.102},{"key":"23 Q4","value":28.792},{"key":"24 Q1","value":28.518},{"key":"24 Q2","value":28.395},{"key":"24 Q3","value":27.949},{"key":"24 Q4","value":27.997},{"key":"25 Q1","value":27.941}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q2","value":18114.876},{"key":"21 Q3","value":22333.727},{"key":"21 Q4","value":22392.518},{"key":"22 Q1","value":18044.002},{"key":"22 Q2","value":15517.073},{"key":"22 Q3","value":14824.012},{"key":"22 Q4","value":11980.979},{"key":"23 Q1","value":13854.361},{"key":"23 Q2","value":11945.87},{"key":"23 Q3","value":11228.425},{"key":"23 Q4","value":9024.334},{"key":"24 Q1","value":9377.774},{"key":"24 Q2","value":8258.714},{"key":"24 Q3","value":8876.826},{"key":"24 Q4","value":9502.994},{"key":"25 Q1","value":8405.575}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q2","value":6.33},{"key":"21 Q3","value":7.47},{"key":"21 Q4","value":7.64},{"key":"22 Q1","value":6.44},{"key":"22 Q2","value":5.61},{"key":"22 Q3","value":5.44},{"key":"22 Q4","value":4.1},{"key":"23 Q1","value":5.12},{"key":"23 Q2","value":4.38},{"key":"23 Q3","value":4.44},{"key":"23 Q4","value":3.31},{"key":"24 Q1","value":3.84},{"key":"24 Q2","value":3.23},{"key":"24 Q3","value":3.42},{"key":"24 Q4","value":3.56},{"key":"25 Q1","value":3.59}]}],"overlayChart":null}],"chartsLastUpdated":"2025-05-01T22:37:27Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":null,"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"LLY","name":"Eli Lilly","displayName":"Eli Lilly","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"LLY","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":798.89,"high":810.14,"low":797.65,"volume":728,"volumeDate":"2025-07-25","last":805.43,"open":801.36,"gainPercentage":0.819,"gainValue":6.54,"ask":807.2,"bid":802.4,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":763335006500,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":3779783.3387,"highPriceLast52Weeks":972.53,"lowPriceLast52Weeks":677.0912,"companyName":"Eli Lilly \u0026 Co.","longBusinessDescription":"Eli Lilly \u0026 Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.","dividendRate":5.6,"salesOrRevenue":45042700000,"oneYearAnnualRevenueGrowthRate":31.9967413059978,"threeYearAnnualRevenueGrowthRate":17.4481,"fiveYearAnnualRevenueGrowthRate":15.538,"earningsGrowth":80.7268,"totalDebt":33644199999.999996,"totalAssets":78714900000,"floatAsPercentOfSharesOutstanding":89.6518,"dividendYield":0.7000000000000001,"betaTwelveMonth":0.7942,"salesOrRevenueTtm":49003200000,"ebitdaTtm":21551100000,"debtToEquityRatioQuarterly":244.315817517507,"totalEnterpriseValue":728234048000,"industry":"PharmaceuticalsMajor","sector":"HealthTechnology","preTaxInterestCoverageRatio":21.8293620292083,"fiveYearAverageDebtEquityRatio":194.88,"currentRatio":1.3722583069765,"peratio":66.72},"recommendation":{"currentConsensusRating":1.9,"recommendationTargetPrice":691.5,"totalRatings":36,"strongSellRatings":2,"sellRatings":1,"holdRatings":3,"buyRatings":17,"strongBuyRatings":13,"lastUpdated":"2025-07-11T12:32:59Z"},"earningEstimates":[{"actual":1.94,"estimate":1.68,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-10-26T10:35:10Z","audioUrl":"https://files.quartr.com/audio-files/04d0e-2022-10-19-04-32-06.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/906e4-2021-10-26-12-00-00-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f4ea3-2023-01-25-10-38-17.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-10-26T00:00:00Z","earningsSummary":null},{"actual":2.49,"estimate":2.19,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-03T14:22:12Z","audioUrl":"https://files.quartr.com/audio-files/97c8d-2022-10-19-10-16-36.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/9d451-2023-01-25-12-51-21.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-03T02:34:14Z","earningsSummary":null},{"actual":2.62,"estimate":2.13,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-04-28T10:50:43Z","audioUrl":"https://files.quartr.com/audio-files/71960-2022-10-28-04-27-41.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/a66bc-2022-04-28-03-05-19-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/29f29-2023-01-25-01-38-18.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-04-28T15:19:05Z","earningsSummary":null},{"actual":1.25,"estimate":1.69,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-08-04T10:42:38Z","audioUrl":"https://files.quartr.com/audio-files/d07ea-2022-08-04-06-31-25.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/d6a24-2022-08-04-11-33-07.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/204f9-2022-08-04-11-22-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-04T01:10:00Z","earningsSummary":null},{"actual":1.98,"estimate":1.92,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-11-01T10:28:26Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_11_01T13_00_00_00_00_Eli_Lilly_and_Co_Earnings_Call_Q3_2022.4RMDVWN3A7M4_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/48eeb-2022-11-01-11-41-47.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/607f3-2022-11-01-11-38-47.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-01T13:00:00Z","earningsSummary":null},{"actual":2.09,"estimate":1.78,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-02T11:47:26Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_02_02T15_00_00_00_00_Eli_Lilly_and_Co_Earnings_Call_Q4_2022.F190RBWVOKPT_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/reports/36d28-2023-02-02-12-39-12.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/conference-calls/277cd-2023-02-02-12-18-12.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-02T15:00:00Z","earningsSummary":{"summary":"Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.\nThe company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.\nChallenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.\nOpportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.","headline":"Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies","lastUpdated":"2024-05-05T20:12:24.168598Z"}},{"actual":1.62,"estimate":1.73,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-04-27T10:47:10Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_04_27T14_00_00_00_00_Eli_Lilly_and_Company_Q1_2023.4Q46R9ANHXV0_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/34006-2023-04-27-10-29-51.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/063e9-2023-04-27-10-23-51.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-04-27T14:00:00Z","earningsSummary":{"summary":"Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.\nWhile facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.\nOpportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.\nOverall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.","headline":"Eli Lilly reports robust Q1 growth amidst capacity challenges","lastUpdated":"2024-05-05T20:49:38.351360Z"}},{"actual":2.11,"estimate":1.99,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-08T10:48:25Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_08_08T13_00_00_00_00_Eli_Lilly_and_Company_Q2_2023.M3DRMXC9JBO9_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/f3d4f-2023-08-08-11-02-11.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f665e-2023-08-08-11-48-02.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-08T13:00:00Z","earningsSummary":{"summary":"Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.\nThe company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.\nOpportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.\nOverall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.","headline":"Eli Lilly reports robust Q2 earnings, eyes growth through innovation","lastUpdated":"2024-05-06T21:52:30.799537Z"}},{"actual":0.1,"estimate":-0.15,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-11-02T10:47:24Z","audioUrl":"https://files.quartr.com/audio-files/0d3ec-2023-11-02-05-23-48.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/dcd25-2023-11-02-12-56-13.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/95606-2023-11-02-11-32-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-02T13:00:00Z","earningsSummary":{"summary":"Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.\nChallenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.\nInvestors advised to focus on guidance range for insights into 2024 expectations.","headline":"Eli Lilly posts robust Q3 results, eyes expansion and commercial growth","lastUpdated":"2024-05-06T20:39:28.344626Z"}},{"actual":2.49,"estimate":2.19,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-06T11:46:04Z","audioUrl":"https://files.quartr.com/audio-files/ad4dd-2024-02-06-04-32-30.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/ae7e1-2024-02-06-12-06-12.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b5882-2024-02-06-12-11-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-06T15:00:00Z","earningsSummary":{"summary":"Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.\nThe company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.\nChallenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.\nOverall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.","headline":"Eli Lilly posts robust Q4 results, eyes global expansion opportunities","lastUpdated":"2024-05-05T19:45:11.746779Z"}},{"actual":2.58,"estimate":2.46,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-04-30T10:49:22Z","audioUrl":"https://files.quartr.com/audio-files/47147-2024-04-30-03-45-13.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/415d6-2024-04-30-10-33-55.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/ceb03-2024-04-30-10-12-55.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-04-30T14:00:00Z","earningsSummary":{"summary":"Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.\nWhile facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.\nOpportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.\nOverall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.","headline":"Eli Lilly reports robust Q1 growth, eyes pipeline opportunities","lastUpdated":"2024-05-07T03:46:51.597393Z"}},{"actual":3.92,"estimate":2.7,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-08-08T10:51:15Z","audioUrl":"https://files.quartr.com/audio-files/97d59-2024-08-08-03-43-13.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/eef1a-2024-08-08-11-12-12.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/5e779-2024-08-08-11-51-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-08T14:00:00Z","earningsSummary":null},{"actual":1.18,"estimate":1.45,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-10-30T10:48:00Z","audioUrl":"https://files.quartr.com/audio-files/a2426-2024-10-30-03-30-20.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/51a29-2024-10-30-11-59-06.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/4156d-2024-10-30-11-47-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-10-30T14:00:00Z","earningsSummary":{"summary":"Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.\nKey pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.\nChallenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.","headline":"Eli Lilly reports stellar Q3 results, eyes global expansion opportunities","lastUpdated":"2024-10-30T19:13:26.111190Z"}},{"actual":5.32,"estimate":5.08,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-06T11:47:17Z","audioUrl":"https://files.quartr.com/audio-files/e2714-2025-02-06-04-54-18.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/c0e8c-2025-02-06-12-14-04.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b7ff0-2025-02-06-12-55-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-06T15:00:00Z","earningsSummary":{"summary":"Eli Lilly's strong performance in Q4 2024 sets a positive tone for 2025.\nBalancing challenges like pricing pressures with growth opportunities is key.\nInvestors can expect continued focus on R\u0026D and shareholder returns.\nStrategic acquisitions and product launches drive future revenue growth.","headline":"Eli Lilly reports robust Q4 results, eyes growth amidst challenges","lastUpdated":"2025-02-06T17:42:20.124312Z"}},{"actual":3.34,"estimate":3.02,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-05-01T10:46:06Z","audioUrl":"https://files.quartr.com/audio-files/e22c5-2025-05-01-03-37-13.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/a1c5f-2025-05-01-11-58-22.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f4a9c-2025-05-01-11-55-04.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-01T14:00:00Z","earningsSummary":{"summary":"Eli Lilly's Q1 2025 showcased strong financial performance, promising pipeline developments, and strategic initiatives to drive growth. Despite challenges in trade dynamics and pricing reforms, the company remains focused on innovation and market expansion to sustain its growth trajectory.","headline":"Eli Lilly (LLY) reports stellar Q1 results, eyes global expansion","lastUpdated":"2025-05-01T17:43:57.264355Z"}},{"actual":null,"estimate":5.58,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-24T23:31:15Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-07T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-10-26","title":"Earnings data Q3 2021","quarter":"Q3","hash":"7f8ef586d04d5bb74cc79c76625d5d4926e26405ad682409092c4d02ca32f7d5"},{"date":"2022-02-03","title":"Earnings data Q4 2021","quarter":"Q4","hash":"b59e0c6777ab8aa2c1fbcf612d33086098d38defb4401f317e0e11169d3f19ac"},{"date":"2022-04-28","title":"Earnings data Q1 2022","quarter":"Q1","hash":"d25c4f773b9b09aa21cea6126331b6e9fa115f344b2455928aec5ae908d1d0f8"},{"date":"2022-08-04","title":"Earnings data Q2 2022","quarter":"Q2","hash":"d14a4bdce2da877f80c4a16e4839c6fed82e2a19a725eb0bf0b1dde3b382c560"},{"date":"2022-11-01","title":"Earnings data Q3 2022","quarter":"Q3","hash":"a5540fa9addca16dfab76cebb2cb1994bbbd7bae872214eabe71d04eefc55c14"},{"date":"2023-02-02","title":"Earnings data Q4 2022","quarter":"Q4","hash":"c740e6acb1f333b51d1decc40ebef2150cd3290e689a4e0598047f5d1efa7fb7"},{"date":"2023-04-27","title":"Earnings data Q1 2023","quarter":"Q1","hash":"363ebfb8573a1ed7174fdbed57199060b1cf801251e53f8e1418c98f0e131be2"},{"date":"2023-08-08","title":"Earnings data Q2 2023","quarter":"Q2","hash":"65a38ab51d1d4adfd5cabc80acff84f3930659a62b07eb0fd750e49adf24415b"},{"date":"2023-11-02","title":"Earnings data Q3 2023","quarter":"Q3","hash":"10a1aba78b28d893ce6212fac9f3800655a20304bea6b8e99973dcddc2e48f52"},{"date":"2024-02-06","title":"Earnings data Q4 2023","quarter":"Q4","hash":"1ec4886040d2ea965fc2f84166ebeaedfedb467faa0653393f600be8e529d685"},{"date":"2024-04-30","title":"Earnings data Q1 2024","quarter":"Q1","hash":"375ff4db6181aae2a928745e020a0e3f9b2137d9a287edd6f2e5df1452703e39"},{"date":"2024-08-08","title":"Earnings data Q2 2024","quarter":"Q2","hash":"1271123d5ef93a6a6d4a72633a115c525ed2a48e13768d47adf4b8bf6fa379c7"},{"date":"2024-10-30","title":"Earnings data Q3 2024","quarter":"Q3","hash":"c06499151c959d3d165480d843ccbd40215c65362c9e2462a839f296e017b206"},{"date":"2025-02-06","title":"Earnings data Q4 2024","quarter":"Q4","hash":"1ab968f5eab722e7c1c06a313655c674e949cc766857222e81fb568d3be95605"},{"date":"2025-05-01","title":"Earnings data Q1 2025","quarter":"Q1","hash":"e9958cb317ed372159cf0e7d4b098edb8adc1c467d9e43503963e7a8f315ffc9"},{"date":"2025-08-07","title":"Earnings data Q2 2025","quarter":"Q2","hash":"bf9c7cec88224825e57552974f6f0c133f22f882540fd3da585758584c3af6b0"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Eli Lilly","companyDescription":"Eli Lilly \u0026 Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.","executives":null,"brands":[{"id":"ec3556ba-e79c-48e8-9ed1-e77000e792af","name":"Cialis","description":"Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/NE3e8MaGRpWGaIVfh2dyOA-thumbnail-300x300.png"},{"id":"f0b9c23d-1faf-48ed-b14b-278aaf2be224","name":"Cymbalta","description":"Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/W4Hje2KxTJSKQx2cWRmXCw-thumbnail-300x300.png"},{"id":"8bfcfab4-31f4-48ce-9850-ae6cf2e67793","name":"Gemzar","description":"Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/sdJ66TnJSuSW_ZR8LtCOPA-thumbnail-300x300.png"},{"id":"ef47a1fc-917d-485e-92c7-29179d2d2b2a","name":"Methadone","description":"Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/hNwNMQUTReeWrrzWD4Gw6Q-thumbnail-300x300.png"},{"id":"e7579738-4aea-491d-8933-ab78dd6af1d4","name":"Prozac","description":"Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/xMWfDQuxRLqCugqvTgLeGQ-thumbnail-300x300.png"}]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":12728500000,"changePercentage":45.17,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":2224200000,"changePercentage":32.91,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":10504300000,"changePercentage":48.06,"valueToRevenueRatio":0.8252582786659858},{"financialKey":"OPERATING_EXPENSES","value":5202500000,"changePercentage":16.26,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":5202500000,"changePercentage":16.26,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":5301800000,"changePercentage":102.4,"valueToRevenueRatio":0.4165298346230899},{"financialKey":"EBITDA","value":5764600000,"changePercentage":90.87,"valueToRevenueRatio":0.45288918568566605},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":462800000,"changePercentage":15.53,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":2759300000,"changePercentage":23.02,"valueToRevenueRatio":null},{"financialKey":"EPS","value":3.0638,"changePercentage":23.46,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":89388800000,"changePercentage":39.79,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":41261200000,"changePercentage":63.81,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":3220700000,"changePercentage":24.53,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":14003200000,"changePercentage":39.84,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":9311000000,"changePercentage":52.59,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":14726300000,"changePercentage":127.01,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":48127600000,"changePercentage":24.19,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":18474100000,"changePercentage":35.6,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":11782700000,"changePercentage":0.69,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":17870800000,"changePercentage":33.08,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":73542000000,"changePercentage":44.07,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":30068100000,"changePercentage":61.67,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":4016400000,"changePercentage":143.2,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":6175700000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":19876000000,"changePercentage":17.29,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":43473900000,"changePercentage":33.98,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":34499500000,"changePercentage":40.47,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":8974400000,"changePercentage":13.77,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":15846800000,"changePercentage":22.87,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":15764800000,"changePercentage":23.05,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":82000000,"changePercentage":-3.76,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":89388800000,"changePercentage":39.79,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":38515900000,"changePercentage":46.94,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":35295200000,"changePercentage":49.4,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":16.62787,"changePercentage":23.34,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":2759300000,"changePercentage":23.02,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":1665600000,"changePercentage":42.85,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":5029800000,"changePercentage":72.42,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-3364200000,"changePercentage":-92.11,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-3352300000,"changePercentage":-184.67,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":3266500000,"changePercentage":201.67,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":-125100000,"changePercentage":-322.64,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-6493700000,"changePercentage":-191.09,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":1379700000,"changePercentage":543.21,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":-1200000000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":6461000000,"changePercentage":0.13,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":1346300000,"changePercentage":15.15,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-686300000,"changePercentage":-76.06,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":131900000,"changePercentage":471.55,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-175100000,"changePercentage":51.14,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":156100000,"changePercentage":-13.13,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:14:27Z"},"dividend":{"dividendType":"CASH","dividendFrequency":"QUARTERLY","dividend":1.5,"priorDividend":1.3,"dividendYieldPercentage":0.79,"announcementDate":"2025-06-23","exDividendDate":"2025-08-15","payableDate":"2025-09-10","recordDate":"2025-08-15","updatedAt":"2025-06-23T16:01:36Z"},"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2024-12-14T06:31:40Z","bearsSay":["Eli Lilly faces significant revenue risks due to the impending loss of exclusivity for several of its key products, which may lead to increased generic competition and a rapid decline in sales, particularly in the U.S. The company is also vulnerable to heightened pricing pressures and potential setbacks in its drug pipeline, which could further impede growth prospects and negatively impact future revenues and net income. Additionally, unforeseen quality and manufacturing issues could exacerbate these challenges, creating a compounded threat to the firm's financial stability."],"bullsSay":["Eli Lilly has demonstrated substantial growth in its top-line revenue and operational efficiencies, supported by a capable leadership team navigating the company’s strategic initiatives. The company’s robust pipeline, featuring promising developments such as orforglipron, retatrutide, and donanemab, showcases significant potential for further revenue expansion and market penetration, particularly in light of favorable trial results and regulatory support. Revenue projections for 2024, 2025, and 2026 have been positively adjusted to $42.6 billion, $51.0 billion, and $59.7 billion, respectively, indicating sustained growth momentum for the firm."],"charts":[{"title":"Revenue Segments","description":"Revenue segments as reported by the company.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Diabetes","dataPoints":[{"key":"21 Q2","value":3175.5},{"key":"21 Q3","value":3274.1},{"key":"21 Q4","value":3627.5},{"key":"22 Q1","value":3388.2},{"key":"22 Q2","value":3438.2},{"key":"22 Q3","value":3662.6},{"key":"22 Q4","value":3975.9},{"key":"23 Q1","value":4190.4},{"key":"23 Q2","value":5010.9},{"key":"23 Q3","value":4720.4},{"key":"23 Q4","value":5745.9},{"key":"24 Q1","value":5493},{"key":"24 Q2","value":7514.6},{"key":"24 Q3","value":7407},{"key":"24 Q4","value":9106.3},{"key":"25 Q1","value":9208.1}]},{"title":"Oncology","dataPoints":[{"key":"21 Q2","value":1554},{"key":"21 Q3","value":1406.1},{"key":"21 Q4","value":1408.9},{"key":"22 Q1","value":1353},{"key":"22 Q2","value":1368.7},{"key":"22 Q3","value":1293.3},{"key":"22 Q4","value":1651.1},{"key":"23 Q1","value":1356},{"key":"23 Q2","value":1671},{"key":"23 Q3","value":1747.1},{"key":"23 Q4","value":1884.2},{"key":"24 Q1","value":1810},{"key":"24 Q2","value":2158.7},{"key":"24 Q3","value":2231.8},{"key":"24 Q4","value":2551.9},{"key":"25 Q1","value":1947.5}]},{"title":"Immunology","dataPoints":[{"key":"21 Q2","value":785.4},{"key":"21 Q3","value":1004.9},{"key":"21 Q4","value":956.5},{"key":"22 Q1","value":748.1},{"key":"22 Q2","value":796.5},{"key":"22 Q3","value":866.4},{"key":"22 Q4","value":933.6},{"key":"23 Q1","value":777.8},{"key":"23 Q2","value":928.5},{"key":"23 Q3","value":986.9},{"key":"23 Q4","value":1104.4},{"key":"24 Q1","value":834},{"key":"24 Q2","value":1082.4},{"key":"24 Q3","value":1185.7},{"key":"24 Q4","value":1290.9},{"key":"25 Q1","value":1088}]},{"title":"Neuroscience","dataPoints":[{"key":"21 Q2","value":512.2},{"key":"21 Q3","value":450.2},{"key":"21 Q4","value":470.6},{"key":"22 Q1","value":397.7},{"key":"22 Q2","value":389.9},{"key":"22 Q3","value":373.2},{"key":"22 Q4","value":385.3},{"key":"23 Q1","value":360.5},{"key":"23 Q2","value":387.2},{"key":"23 Q3","value":1768.1},{"key":"23 Q4","value":362.8},{"key":"24 Q1","value":389.1},{"key":"24 Q2","value":339.5},{"key":"24 Q3","value":351.8},{"key":"24 Q4","value":393.1},{"key":"25 Q1","value":272.1}]},{"title":"Other","dataPoints":[{"key":"21 Q2","value":712.9},{"key":"21 Q3","value":637.7},{"key":"21 Q4","value":1536.3},{"key":"22 Q1","value":1923},{"key":"22 Q2","value":494.7},{"key":"22 Q3","value":746},{"key":"22 Q4","value":355.9},{"key":"23 Q1","value":275.3},{"key":"23 Q2","value":314.6},{"key":"23 Q3","value":276.1},{"key":"23 Q4","value":256.2},{"key":"24 Q1","value":241.9},{"key":"24 Q2","value":207.6},{"key":"24 Q3","value":262.8},{"key":"24 Q4","value":190.6},{"key":"25 Q1","value":212.9}]}],"overlayChart":null},{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q2","value":71.02},{"key":"21 Q3","value":78.87},{"key":"21 Q4","value":74.37},{"key":"22 Q1","value":73.46},{"key":"22 Q2","value":77.95},{"key":"22 Q3","value":77.25},{"key":"22 Q4","value":78.79},{"key":"23 Q1","value":76.62},{"key":"23 Q2","value":78.25},{"key":"23 Q3","value":80.41},{"key":"23 Q4","value":80.88},{"key":"24 Q1","value":80.91},{"key":"24 Q2","value":80.79},{"key":"24 Q3","value":81.02},{"key":"24 Q4","value":82.23},{"key":"25 Q1","value":82.52}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q2","value":20.82},{"key":"21 Q3","value":27.77},{"key":"21 Q4","value":23.96},{"key":"22 Q1","value":30.78},{"key":"22 Q2","value":18.65},{"key":"22 Q3","value":24.15},{"key":"22 Q4","value":25.14},{"key":"23 Q1","value":21.46},{"key":"23 Q2","value":25.57},{"key":"23 Q3","value":4.74},{"key":"23 Q4","value":25.52},{"key":"24 Q1","value":28.61},{"key":"24 Q2","value":32.86},{"key":"24 Q3","value":13.34},{"key":"24 Q4","value":38.04},{"key":"25 Q1","value":29.03}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q2","value":20.62},{"key":"21 Q3","value":16.39},{"key":"21 Q4","value":21.57},{"key":"22 Q1","value":24.36},{"key":"22 Q2","value":14.68},{"key":"22 Q3","value":20.91},{"key":"22 Q4","value":26.53},{"key":"23 Q1","value":19.32},{"key":"23 Q2","value":21.21},{"key":"23 Q3","value":-0.61},{"key":"23 Q4","value":23.4},{"key":"24 Q1","value":25.58},{"key":"24 Q2","value":26.25},{"key":"24 Q3","value":8.48},{"key":"24 Q4","value":32.58},{"key":"25 Q1","value":21.67}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Research and development","dataPoints":[{"key":"21 Q2","value":1672.8},{"key":"21 Q3","value":1708.9},{"key":"21 Q4","value":1959.4},{"key":"22 Q1","value":1610.1},{"key":"22 Q2","value":1781.9},{"key":"22 Q3","value":1802.9},{"key":"22 Q4","value":1995.9},{"key":"23 Q1","value":1985.1},{"key":"23 Q2","value":2356.5},{"key":"23 Q3","value":2409.1},{"key":"23 Q4","value":2562.7},{"key":"24 Q1","value":2522.8},{"key":"24 Q2","value":2711.2},{"key":"24 Q3","value":2734.1},{"key":"24 Q4","value":3022.5},{"key":"25 Q1","value":2733.7}]},{"title":"Marketing, selling and administrative","dataPoints":[{"key":"21 Q2","value":1685.7},{"key":"21 Q3","value":1577.9},{"key":"21 Q4","value":1592},{"key":"22 Q1","value":1557.9},{"key":"22 Q2","value":1625.1},{"key":"22 Q3","value":1614.2},{"key":"22 Q4","value":1643.2},{"key":"23 Q1","value":1749.2},{"key":"23 Q2","value":1925.4},{"key":"23 Q3","value":1803.9},{"key":"23 Q4","value":1924.6},{"key":"24 Q1","value":1952.2},{"key":"24 Q2","value":2117.3},{"key":"24 Q3","value":2099.8},{"key":"24 Q4","value":2424.5},{"key":"25 Q1","value":2468.8}]},{"title":"Acquired in-process research and development","dataPoints":[{"key":"21 Q2","value":25},{"key":"21 Q3","value":174},{"key":"21 Q4","value":376.6},{"key":"22 Q1","value":165.6},{"key":"22 Q2","value":440.4},{"key":"22 Q3","value":62.4},{"key":"22 Q4","value":240.1},{"key":"23 Q1","value":105},{"key":"23 Q2","value":97.1},{"key":"23 Q3","value":2975.1},{"key":"23 Q4","value":622.6},{"key":"24 Q1","value":110.5},{"key":"24 Q2","value":154.3},{"key":"24 Q3","value":2826.4},{"key":"24 Q4","value":189.2},{"key":"25 Q1","value":1571.7}]},{"title":"Asset impairment, restructuring and other special charges","dataPoints":[{"key":"21 Q4","value":104.5},{"key":"22 Q3","value":206.5},{"key":"22 Q4","value":38.1},{"key":"23 Q4","value":67.7},{"key":"24 Q2","value":435},{"key":"24 Q3","value":81.6},{"key":"24 Q4","value":344},{"key":"25 Q1","value":35}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q2","value":22.56},{"key":"21 Q3","value":17.98},{"key":"21 Q4","value":7.53},{"key":"22 Q1","value":14.76},{"key":"22 Q2","value":-3.74},{"key":"22 Q3","value":2.49},{"key":"22 Q4","value":-8.73},{"key":"23 Q1","value":-10.88},{"key":"23 Q2","value":28.12},{"key":"23 Q3","value":36.84},{"key":"23 Q4","value":28.1},{"key":"24 Q1","value":25.98},{"key":"24 Q2","value":35.98},{"key":"24 Q3","value":20.43},{"key":"24 Q4","value":44.68},{"key":"25 Q1","value":45.17}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q2","value":9.83},{"key":"21 Q3","value":10.36},{"key":"21 Q4","value":8.17},{"key":"22 Q1","value":-11.62},{"key":"22 Q2","value":13.71},{"key":"22 Q3","value":6.51},{"key":"22 Q4","value":-2.86},{"key":"23 Q1","value":15.17},{"key":"23 Q2","value":13.82},{"key":"23 Q3","value":95.01},{"key":"23 Q4","value":32.17},{"key":"24 Q1","value":19.44},{"key":"24 Q2","value":23.72},{"key":"24 Q3","value":7.7},{"key":"24 Q4","value":15.5},{"key":"25 Q1","value":48.49}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q2","value":907.3},{"key":"21 Q3","value":906.7},{"key":"21 Q4","value":909.555},{"key":"22 Q1","value":906.35},{"key":"22 Q2","value":902.94},{"key":"22 Q3","value":903.782},{"key":"22 Q4","value":904.732},{"key":"23 Q1","value":903.283},{"key":"23 Q2","value":902.699},{"key":"23 Q3","value":899.838},{"key":"23 Q4","value":903.98},{"key":"24 Q1","value":903.802},{"key":"24 Q2","value":904.248},{"key":"24 Q3","value":905.027},{"key":"24 Q4","value":903.158},{"key":"25 Q1","value":900.604}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q2","value":182251.166},{"key":"21 Q3","value":223783.534},{"key":"21 Q4","value":230574.012},{"key":"22 Q1","value":233256.423},{"key":"22 Q2","value":270617.439},{"key":"22 Q3","value":285920.474},{"key":"22 Q4","value":320366.506},{"key":"23 Q1","value":304164.291},{"key":"23 Q2","value":378152.346},{"key":"23 Q3","value":463270.796},{"key":"23 Q4","value":527654.03},{"key":"24 Q1","value":643207.866},{"key":"24 Q2","value":723325.156},{"key":"24 Q3","value":813663.619},{"key":"24 Q4","value":747820.243},{"key":"25 Q1","value":749384.483}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q2","value":6.76},{"key":"21 Q3","value":8.26},{"key":"21 Q4","value":7.21},{"key":"22 Q1","value":7.47},{"key":"22 Q2","value":10.43},{"key":"22 Q3","value":10.3},{"key":"22 Q4","value":10.97},{"key":"23 Q1","value":10.93},{"key":"23 Q2","value":11.37},{"key":"23 Q3","value":12.19},{"key":"23 Q4","value":14.1},{"key":"24 Q1","value":18.34},{"key":"24 Q2","value":16},{"key":"24 Q3","value":17.78},{"key":"24 Q4","value":13.81},{"key":"25 Q1","value":14.72}]}],"overlayChart":null}],"chartsLastUpdated":"2025-05-01T13:19:13Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.49,"sell":0.51,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"GSK","name":"GlaxoSmithKline","displayName":"GlaxoSmithKline","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"DEPOSITORY_RECEIPT","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"GSK","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":38.03,"high":38.315,"low":37.77,"volume":3902,"volumeDate":"2025-07-25","last":38.23,"open":37.93,"gainPercentage":0.526,"gainValue":0.2,"ask":37.83,"bid":37.81,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":77233010600,"instrumentClass":"DEPOSITORY_RECEIPT","averageDailyVolumeLast3Months":5462827.8548,"highPriceLast52Weeks":44.67,"lowPriceLast52Weeks":31.715,"companyName":"GSK Plc","longBusinessDescription":"GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.","dividendRate":1.612,"salesOrRevenue":40092639068.8499,"oneYearAnnualRevenueGrowthRate":6.34856431843739,"threeYearAnnualRevenueGrowthRate":5.6891,"fiveYearAnnualRevenueGrowthRate":-0.7426,"earningsGrowth":-29.9569,"totalDebt":21273266400,"totalAssets":74471461200,"floatAsPercentOfSharesOutstanding":100,"dividendYield":4.22,"betaTwelveMonth":0.2439,"salesOrRevenueTtm":40230878751.2834,"ebitdaTtm":11411756430,"debtToEquityRatioQuarterly":130.197075651621,"totalEnterpriseValue":85708744000,"industry":"PharmaceuticalsMajor","sector":"HealthTechnology","preTaxInterestCoverageRatio":8.79192546014409,"fiveYearAverageDebtEquityRatio":135.79,"currentRatio":0.868177235850415,"peratio":19.61},"recommendation":{"currentConsensusRating":2.2,"recommendationTargetPrice":48.5,"totalRatings":6,"strongSellRatings":0,"sellRatings":0,"holdRatings":3,"buyRatings":1,"strongBuyRatings":2,"lastUpdated":"2024-07-02T17:58:38Z"},"earningEstimates":[{"actual":1.26,"estimate":1.01,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2022-09-16T12:51:33Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2021-10-27T00:00:00Z","earningsSummary":null},{"actual":0.86,"estimate":0.81,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-09-16T12:51:37Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-02-09T00:00:00Z","earningsSummary":null},{"actual":1.1,"estimate":0.95,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-09-16T12:51:33Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-04-27T00:00:00Z","earningsSummary":null},{"actual":0.87,"estimate":0.89,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-09-16T12:51:34Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-07-27T00:00:00Z","earningsSummary":null},{"actual":1.11,"estimate":0.96,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-11-02T09:01:31Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-11-02T00:00:00Z","earningsSummary":null},{"actual":0.61,"estimate":0.5,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-01T11:06:54Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2023-02-01T00:00:00Z","earningsSummary":null},{"actual":0.9,"estimate":0.82,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-04-26T09:00:04Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2023-04-26T00:00:00Z","earningsSummary":null},{"actual":0.97,"estimate":0.87,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-07-26T07:44:18Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2023-07-26T00:00:00Z","earningsSummary":null},{"actual":1.27,"estimate":1.07,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-11-01T07:59:04Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2023-11-01T00:00:00Z","earningsSummary":null},{"actual":0.718,"estimate":0.75,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-01-31T10:03:47Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2024-01-31T00:00:00Z","earningsSummary":null},{"actual":1.093,"estimate":0.91,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-05-01T10:10:08Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2024-05-01T00:00:00Z","earningsSummary":null},{"actual":1.1,"estimate":0.99,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-07-31T07:56:53Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2024-07-31T00:00:00Z","earningsSummary":null},{"actual":1.29,"estimate":1.23,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-10-30T10:07:31Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2024-10-30T00:00:00Z","earningsSummary":null},{"actual":0.58,"estimate":0.43,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-05T11:18:19Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-02-05T00:00:00Z","earningsSummary":null},{"actual":1.13,"estimate":1.04,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-04-30T08:33:59Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-04-30T00:00:00Z","earningsSummary":null},{"actual":null,"estimate":1.12,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-24T23:30:59Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-07-30T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-10-27","title":"Earnings data Q3 2021","quarter":"Q3","hash":"96023271dfb30db04a8aafb54c75efad70746cd7abae330ae8f01cef69128187"},{"date":"2022-02-09","title":"Earnings data Q4 2021","quarter":"Q4","hash":"584db14e2eda6a5a3163f58512cf1e2caae2d9398500cd529638d48f059bf3ee"},{"date":"2022-04-27","title":"Earnings data Q1 2022","quarter":"Q1","hash":"28c5deee53922f15739bc6243e745c7eda7e316f6307ed8e43775b28dc95eaf7"},{"date":"2022-07-27","title":"Earnings data Q2 2022","quarter":"Q2","hash":"0934db7bb4acf13b77155ef6ee8334e802ef213dbb7c495920f83e166da499a3"},{"date":"2022-11-02","title":"Earnings data Q3 2022","quarter":"Q3","hash":"f6cc40060d49529ccbac3ca12544bdc44a9110dfe02d79060c3191128cc10300"},{"date":"2023-02-01","title":"Earnings data Q4 2022","quarter":"Q4","hash":"f92a07a859d1922e120051fa7eb89988bd860ad9f5370c08c4ee6cf7a00a654f"},{"date":"2023-04-26","title":"Earnings data Q1 2023","quarter":"Q1","hash":"f0ed3ffaff294056c87baea114888816c870376edee80027e705ad937a0e0329"},{"date":"2023-07-26","title":"Earnings data Q2 2023","quarter":"Q2","hash":"e2e3d1866437573df80474338c24ee56402d09c8991bd7d8657c69758ac85228"},{"date":"2023-11-01","title":"Earnings data Q3 2023","quarter":"Q3","hash":"b7290f7c4ef0377a75022f64db4668b64965cffb06f90c0a0d44742262052581"},{"date":"2024-01-31","title":"Earnings data Q4 2023","quarter":"Q4","hash":"4654a06a7c96c58719d627f8bf8f91b61d1f2029e2a5377eaac33b66259e7576"},{"date":"2024-05-01","title":"Earnings data Q1 2024","quarter":"Q1","hash":"9decbe1cf54f2be7d3c0783500e1013e9ab7ea5fa696878960759411d0ab173a"},{"date":"2024-07-31","title":"Earnings data Q2 2024","quarter":"Q2","hash":"348fb43fb4f52006aa589c74a492952c16aa12f335c9e3bcae05723840d6bd70"},{"date":"2024-10-30","title":"Earnings data Q3 2024","quarter":"Q3","hash":"7a7f392da67b6ebd2f4b4a353c6a99d1ca58e4731383039b2424554e11dada34"},{"date":"2025-02-05","title":"Earnings data Q4 2024","quarter":"Q4","hash":"c5bb742435dda5d58461265803309fa6033c6be5ea1a893a67bce9ed66f47989"},{"date":"2025-04-30","title":"Earnings data Q1 2025","quarter":"Q1","hash":"423c21132b5e117fa99276a9acbe589caf5acb02396a65d929b9ad26a46d6204"},{"date":"2025-07-30","title":"Earnings data Q2 2025","quarter":"Q2","hash":"48daeb2a7996d79a90302830e11578bb40f6423332775c0ef8c5925ec8684e85"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"GlaxoSmithKline","companyDescription":"GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R\u0026D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R\u0026D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":9465010901.52599,"changePercentage":1.38,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":2425440526.38892,"changePercentage":-1.24,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":7039570375.137071,"changePercentage":2.32,"valueToRevenueRatio":0.7437466737626389},{"financialKey":"OPERATING_EXPENSES","value":4345895771.84223,"changePercentage":-0.45,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":4345895771.84223,"changePercentage":-0.45,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":2693674600,"changePercentage":7.13,"valueToRevenueRatio":0.2845928681989911},{"financialKey":"EBITDA","value":3730090780,"changePercentage":16.19,"valueToRevenueRatio":0.3940926026190439},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":1036416180,"changePercentage":48.89,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":2231506029.471,"changePercentage":62.81,"valueToRevenueRatio":null},{"financialKey":"EPS","value":1.0006,"changePercentage":53.49,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":78354978750,"changePercentage":6.01,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":23343213750,"changePercentage":7.4,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":5789013750,"changePercentage":11.91,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":9681915750,"changePercentage":5.12,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":7744500000,"changePercentage":7.52,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":127784250,"changePercentage":-13.54,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":55011765000,"changePercentage":5.43,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":12870068250,"changePercentage":3.25,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":29924748000,"changePercentage":4.61,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":12216948750,"changePercentage":9.97,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":60731078250,"changePercentage":6.17,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":26887613250,"changePercentage":7.25,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":2527288500,"changePercentage":-23.52,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":810591000,"changePercentage":-10.88,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":23549733750,"changePercentage":12.91,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":33843465000,"changePercentage":5.33,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":21263815500,"changePercentage":11.06,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":12579649500,"changePercentage":-3.13,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":17623900500,"changePercentage":5.46,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":18273147750,"changePercentage":4.52,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":-649247250,"changePercentage":15.88,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":78354978750,"changePercentage":6.01,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":23791104000,"changePercentage":5.97,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":18002090250,"changePercentage":4.19,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":8.94646,"changePercentage":4.34,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":2231506029.471,"changePercentage":62.81,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":1421766539.0929801,"changePercentage":19.42,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":2414106692.15345,"changePercentage":52.32,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-992340153.060468,"changePercentage":-151.65,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-1580440218.3894498,"changePercentage":-520.13,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":564173081.943007,"changePercentage":-20.97,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":-27704928.1311298,"changePercentage":-102.06,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":1083010826.9441614,"changePercentage":18.14,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-3199919199.1454887,"changePercentage":0.88,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":1240425191.3255901,"changePercentage":198.92,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":-295939005.037069,"changePercentage":-1396.67,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":2541297498.57364,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":770700728.01143,"changePercentage":7.01,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-36520132.5364893,"changePercentage":51.18,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":-13852464.0655649,"changePercentage":42.5,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":1067899047.96355,"changePercentage":411.94,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":1159829040,"changePercentage":32.38,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:14:24Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":false},"advancedInfo":{"updateDate":"2024-05-30T00:00:00Z","bearsSay":[],"bullsSay":[],"charts":[],"chartsLastUpdated":"1970-01-01T00:00:00Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.59,"sell":0.41,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"REGN","name":"Regeneron Pharmaceuticals","displayName":"Regeneron Pharmaceuticals","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"REGN","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":572.39,"high":577.7299,"low":563.67,"volume":12,"volumeDate":"2025-07-25","last":564.64,"open":572.54,"gainPercentage":-1.354,"gainValue":-7.75,"ask":591.84,"bid":546,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":60961357600,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":1304015.871,"highPriceLast52Weeks":1211.1999,"lowPriceLast52Weeks":476.4869,"companyName":"Regeneron Pharmaceuticals, Inc.","longBusinessDescription":"Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.","dividendRate":0.88,"salesOrRevenue":14202000000,"oneYearAnnualRevenueGrowthRate":8.27005763425121,"threeYearAnnualRevenueGrowthRate":-2.7438,"fiveYearAnnualRevenueGrowthRate":22.0977,"earningsGrowth":15.6547,"totalDebt":2938800000,"totalAssets":37852400000,"floatAsPercentOfSharesOutstanding":96.3933,"dividendYield":0.16,"betaTwelveMonth":0.7139,"salesOrRevenueTtm":14085700000,"ebitdaTtm":4455500000,"debtToEquityRatioQuarterly":9.20388190937675,"totalEnterpriseValue":75915483000,"industry":"PharmaceuticalsMajor","sector":"HealthTechnology","preTaxInterestCoverageRatio":75.6123188405797,"fiveYearAverageDebtEquityRatio":13.45,"currentRatio":4.92673694835418,"peratio":14.37},"recommendation":{"currentConsensusRating":1.8,"recommendationTargetPrice":783.15,"totalRatings":40,"strongSellRatings":0,"sellRatings":1,"holdRatings":6,"buyRatings":17,"strongBuyRatings":16,"lastUpdated":"2025-07-23T13:09:28Z"},"earningEstimates":[{"actual":15.37,"estimate":9.49,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-11-04T10:37:51Z","audioUrl":"https://files.quartr.com/audio-files/2161d-2022-10-19-04-55-35.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/93592-2023-01-25-10-20-22.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-11-04T00:00:00Z","earningsSummary":null},{"actual":23.72,"estimate":18.11,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-04T11:43:01Z","audioUrl":"https://files.quartr.com/audio-files/8985b-2022-10-19-10-28-24.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/58817-2023-01-25-12-19-20.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-04T02:54:15Z","earningsSummary":null},{"actual":11.49,"estimate":10.04,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-05-04T10:39:45Z","audioUrl":"https://files.quartr.com/audio-files/c8e56-2022-10-28-05-10-04.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/53164-2022-05-04-09-16-12-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/ca18c-2023-01-25-01-02-23.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-05-04T09:12:16Z","earningsSummary":null},{"actual":9.77,"estimate":9.54,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-08-03T10:36:28Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_08_03_14_30_Q2_2022_Regeneron_Pharmaceuticals_Inc_Earnings_Call.8QKH4B59NJAO_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/9c0d1-2022-08-03-05-40-32.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/eff6c-2022-08-03-11-07-23.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-03T01:06:00Z","earningsSummary":null},{"actual":11.14,"estimate":9.52,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-11-03T10:32:55Z","audioUrl":"https://files.quartr.com/audio-files/a8b82-2022-11-03-03-53-50.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/057ac-2022-11-03-02-54-30.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f942c-2022-11-03-11-55-58.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-03T12:30:00Z","earningsSummary":null},{"actual":12.56,"estimate":10.03,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-03T11:39:13Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_02_03T13_30_00_00_00_Regeneron_Pharmaceuticals_Inc_Earnings_Call_Q4_2022.CN8O9BB2MDF1_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/reports/f9ba5-2023-02-03-01-09-31.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/conference-calls/1657e-2023-02-03-12-49-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-03T13:30:00Z","earningsSummary":{"summary":"Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.\nThe company's focus on safety, efficacy, and strategic imperatives positions it for future growth.\nChallenges include competitive positioning, trial data anticipation, and managing uncertainties.\nOpportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.","headline":"Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations","lastUpdated":"2024-05-04T03:19:35.084482Z"}},{"actual":10.09,"estimate":9.6,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-05-04T10:32:19Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_05_04T12_30_00_00_00_Regeneron_Pharmaceuticals_Inc_Q1_2023.T6BO2WGPKQWI_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/9725b-2023-05-04-01-26-48.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/2d369-2023-05-04-11-40-09.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-04T12:30:00Z","earningsSummary":{"summary":"Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.\nDespite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.\nWith a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.\nNavigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.","headline":"Regeneron excels in Q1 with strong revenue growth and pipeline advancements","lastUpdated":"2024-05-04T01:28:49.860354Z"}},{"actual":10.24,"estimate":9.92,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-03T10:31:04Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_08_03T12_30_00_00_00_Regeneron_Pharmaceuticals_Inc_Q2_2023.S1JTF5F8M0FM_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/ff1f3-2023-08-03-02-56-46.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/cfb47-2023-08-03-10-27-49.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-03T12:30:00Z","earningsSummary":{"summary":"Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.\nWhile facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.\nBalancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.\nRobust cash position and focus on patient well-being position Regeneron for continued success and market expansion.","headline":"Regeneron reports strong Q2 earnings, eyes aflibercept launch","lastUpdated":"2024-05-04T01:24:39.684032Z"}},{"actual":11.59,"estimate":10.77,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-11-02T10:35:42Z","audioUrl":"https://files.quartr.com/audio-files/4522f-2023-11-02-01-08-54.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/b5ca5-2023-11-02-12-32-29.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/9a1b1-2023-11-02-11-53-11.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-02T12:30:00Z","earningsSummary":{"summary":"Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.\nWhile facing legal challenges and competitive pressures, the company's strategic focus on innovation, R\u0026D, and shareholder value management positions it for long-term success.\nWith a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.","headline":"Regeneron posts robust Q3 results, eyes innovation and market growth","lastUpdated":"2024-05-04T02:51:08.005413Z"}},{"actual":11.86,"estimate":10.77,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-02T11:31:21Z","audioUrl":"https://files.quartr.com/audio-files/cb154-2024-02-02-02-14-52.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/3d54d-2024-02-02-01-24-34.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/ba766-2024-02-02-12-16-02.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-02T13:30:00Z","earningsSummary":{"summary":"Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.\nThe company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.\nWhile facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.\nOverall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.","headline":"Regeneron posts strong Q4 results, eyes growth through innovation","lastUpdated":"2024-05-03T15:52:43.207068Z"}},{"actual":9.55,"estimate":10.1,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-05-02T10:31:43Z","audioUrl":"https://files.quartr.com/audio-files/31cf1-2024-05-02-01-14-41.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/90684-2024-05-02-12-39-33.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/4f4fa-2024-05-02-10-15-32.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-02T12:30:00Z","earningsSummary":{"summary":"Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.\nThe company's robust pipeline and focus on innovation position it well for future growth.\nChallenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.\nOpportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.","headline":"Regeneron posts solid Q1 results, faces FDA request challenges","lastUpdated":"2024-05-03T16:36:27.013190Z"}},{"actual":11.56,"estimate":10.53,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-08-01T10:30:46Z","audioUrl":"https://files.quartr.com/audio-files/63cf9-2024-08-01-01-30-40.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/9adbc-2024-08-01-12-49-37.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/be877-2024-08-01-11-15-09.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-01T12:30:00Z","earningsSummary":{"summary":"Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.\nWhile facing regulatory challenges, the company's pipeline and market position remain robust.\nOpportunities for expansion and innovation present avenues for future growth.\nOverall, Regeneron's Q2 results reflect resilience and strategic focus.","headline":"Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities","lastUpdated":"2024-08-01T16:08:26.153917Z"}},{"actual":12.46,"estimate":11.69,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-10-31T10:30:36Z","audioUrl":"https://files.quartr.com/audio-files/576d8-2024-10-31-02-37-26.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/6c8f2-2024-10-31-12-16-37.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/75254-2024-10-31-11-17-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-10-31T12:30:00Z","earningsSummary":{"summary":"Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.","headline":"Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth","lastUpdated":"2024-10-31T16:33:08.315795Z"}},{"actual":12.07,"estimate":11.19,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-04T11:32:08Z","audioUrl":"https://files.quartr.com/audio-files/a8f68-2025-02-04-02-29-56.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/2b884-2025-02-04-01-55-25.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/c0966-2025-02-04-12-17-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-04T13:30:00Z","earningsSummary":null},{"actual":8.22,"estimate":8.82,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-04-29T10:30:33Z","audioUrl":"https://files.quartr.com/audio-files/255a7-2025-04-29-01-47-43.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/adfed-2025-04-29-12-43-32.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/c65c3-2025-04-29-10-38-39.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-04-29T12:30:00Z","earningsSummary":{"summary":"Regeneron Pharmaceuticals navigated mixed performance in Q1 2025, with strong sales growth for DUPIXENT and Libtayo but challenges with EYLEA sales and FDA interactions. The company's financials remain robust, with total revenues of $3 billion and an updated gross margin guidance. Strategic investments in manufacturing facilities and pipeline advancements present growth potential amidst regulatory challenges.","headline":"Regeneron reports mixed Q1 performance, plans U.S. manufacturing investments","lastUpdated":"2025-04-29T15:31:28.799001Z"}},{"actual":null,"estimate":7.55,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-24T23:31:36Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-01T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-04","title":"Earnings data Q3 2021","quarter":"Q3","hash":"6514eb0c74aac5656bf2d6c329b32c557a3810d76793d52969d6c3ee7fcc5b6e"},{"date":"2022-02-04","title":"Earnings data Q4 2021","quarter":"Q4","hash":"86e60734e6ef4bfe0c752e8145584a0aa9e2530c22a0aaccf652098ae8dfa7de"},{"date":"2022-05-04","title":"Earnings data Q1 2022","quarter":"Q1","hash":"10f8132875b0e6f057e152d5e0803a6e89e8d0d301819ec10277955b952e8b36"},{"date":"2022-08-03","title":"Earnings data Q2 2022","quarter":"Q2","hash":"068bbb9ac1c2db3b6bc7d2a99c056832b83d9a131f5bc22c3f1049cf1e3a46f9"},{"date":"2022-11-03","title":"Earnings data Q3 2022","quarter":"Q3","hash":"cf91839225fb4ac0f624e046a58e696f6ce362c81342b708e5bd26bdfe18be6e"},{"date":"2023-02-03","title":"Earnings data Q4 2022","quarter":"Q4","hash":"bb9f727a0597d7a3548447c05aed6c625803c6a2a448764b6fbfc2cfd7cbe29c"},{"date":"2023-05-04","title":"Earnings data Q1 2023","quarter":"Q1","hash":"e0ac74ee6473c0186ab671482622034d780facf6ae986ad4bea203c01975cf34"},{"date":"2023-08-03","title":"Earnings data Q2 2023","quarter":"Q2","hash":"d55cc49bc2f39837a9e699326a41c85b327acaf7515fad266b5f5cadc75eafdc"},{"date":"2023-11-02","title":"Earnings data Q3 2023","quarter":"Q3","hash":"095ff751f339599e12ed885eb8a0d0beeebd4f0708823c3dd824ee512b832587"},{"date":"2024-02-02","title":"Earnings data Q4 2023","quarter":"Q4","hash":"bf03b589bd788a694b1b90ae52cf4cb47dd87bcbb30588dac9c2ed8fb83b9185"},{"date":"2024-05-02","title":"Earnings data Q1 2024","quarter":"Q1","hash":"8fb65ab5c16812e3efc9edfe094ff10188854ec058f3d7bc3bd1d49c66ddfb5a"},{"date":"2024-08-01","title":"Earnings data Q2 2024","quarter":"Q2","hash":"fdef64c360f17c42f1dcb70c09c63d614f732322a1cf36a0932e38e572e5f97e"},{"date":"2024-10-31","title":"Earnings data Q3 2024","quarter":"Q3","hash":"bd0d04334aad00ef2d368267c753d1dcc32b34e382cee4fbbfc32d885c3c7ead"},{"date":"2025-02-04","title":"Earnings data Q4 2024","quarter":"Q4","hash":"519bd5e00572dd7d40ef6c33cd736b9a4b946d6430519d853239149f016c9979"},{"date":"2025-04-29","title":"Earnings data Q1 2025","quarter":"Q1","hash":"515f26c440a221ea7368d4ef29483c6500b837c01c954f0eb34d485162ae61dc"},{"date":"2025-08-01","title":"Earnings data Q2 2025","quarter":"Q2","hash":"aa8f1c616f54487d65667e29de27888dc7a6e72b308f65d5b716854605c15d16"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Regeneron Pharmaceuticals","companyDescription":"Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":3028700000,"changePercentage":-3.7,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":591200000,"changePercentage":7.9,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":2437500000,"changePercentage":-6.15,"valueToRevenueRatio":0.8048007395912438},{"financialKey":"OPERATING_EXPENSES","value":1833500000,"changePercentage":-0.28,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":1833500000,"changePercentage":0.56,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":604000000,"changePercentage":-20.37,"valueToRevenueRatio":0.19942549608743024},{"financialKey":"EBITDA","value":730900000,"changePercentage":-16.24,"valueToRevenueRatio":0.24132466074553438},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":126900000,"changePercentage":11.22,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":808700000,"changePercentage":12.01,"valueToRevenueRatio":null},{"financialKey":"EPS","value":7.2725,"changePercentage":15.94,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":37545200000,"changePercentage":9.24,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":17571700000,"changePercentage":-6.89,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":8349400000,"changePercentage":-20.63,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":5561000000,"changePercentage":6.49,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":3192400000,"changePercentage":17.59,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":468900000,"changePercentage":13.02,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":19973500000,"changePercentage":28.88,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":4694200000,"changePercentage":11.09,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":1167000000,"changePercentage":10.23,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":14112300000,"changePercentage":38.17,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":8157600000,"changePercentage":10.56,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":3566600000,"changePercentage":-0.4,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":3566600000,"changePercentage":-0.4,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":4591000000,"changePercentage":20.89,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":2704800000,"changePercentage":0.06,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":1886200000,"changePercentage":72.37,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":29387600000,"changePercentage":8.88,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":29387600000,"changePercentage":8.88,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":37545200000,"changePercentage":9.24,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":2704800000,"changePercentage":0.06,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":-5644600000,"changePercentage":27.78,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":271.60444,"changePercentage":10.89,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":808700000,"changePercentage":12.01,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":1045099999.9999999,"changePercentage":-30.9,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":915500000,"changePercentage":-14.6,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":129600000,"changePercentage":-70.58,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":647500000,"changePercentage":138.38,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":271500000,"changePercentage":67.8,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":919000000,"changePercentage":160.25,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-543000000,"changePercentage":-67.8,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-1089200000,"changePercentage":-2412.53,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":-980800000,"changePercentage":-350.97,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":93800000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-14600000,"changePercentage":95.75,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":600000,"changePercentage":220,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":604000000,"changePercentage":571.88,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":815800000,"changePercentage":-40.82,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:14:32Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-04-24T13:11:30Z","bearsSay":["The negative outlook on Regeneron Pharmaceuticals's stock is primarily driven by potential significant erosion in Eylea sales, projected at a decline of 30%, which would also adversely affect revenue from collaborations with Bayer and Sanofi. This anticipated decline is attributed to competitive pressures from biosimilars and new market entrants, as well as slower uptake and growth rates for both Eylea and Dupixent. Additionally, risks are compounded by potential clinical setbacks in the oncology pipeline, contributing to downward adjustments in total revenue projections for the Eylea franchise over the upcoming fiscal years."],"bullsSay":["Regeneron Pharmaceuticals demonstrates a positive outlook driven by growing demand for its existing therapies, particularly Dupixent, which is expected to maintain its momentum due to its established long-term efficacy in treating type 2 inflammatory diseases. The company is poised for continued revenue growth linked to strategic collaborations with Bayer and Sanofi, as well as new drug developments that could enhance its market position and expand its product pipeline. Furthermore, manufacturing efficiencies are projected to bolster profit margins, solidifying Regeneron's financial outlook as it navigates patent protection and potential market share increases from high-dose Eylea and other emerging therapies."],"charts":[{"title":"Revenue Segments","description":"Revenue segments as reported by the company.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Net product sales","dataPoints":[{"key":"21 Q2","value":4137.8},{"key":"21 Q3","value":2279.9},{"key":"21 Q4","value":3975.2},{"key":"22 Q1","value":1638.6},{"key":"22 Q2","value":1754.4},{"key":"22 Q3","value":1801.4},{"key":"22 Q4","value":1699.3},{"key":"23 Q1","value":1668},{"key":"23 Q2","value":1772.1},{"key":"23 Q3","value":1786.1},{"key":"23 Q4","value":1851.8},{"key":"24 Q1","value":1761.3},{"key":"24 Q2","value":1918.6},{"key":"24 Q3","value":1946.4},{"key":"24 Q4","value":2002.9},{"key":"25 Q1","value":1415.6}]},{"title":"Collaboration revenue","dataPoints":[{"key":"21 Q2","value":954.7},{"key":"21 Q3","value":1073.9},{"key":"21 Q4","value":890.3},{"key":"22 Q1","value":1232.5},{"key":"22 Q2","value":1043.6},{"key":"22 Q3","value":1050.6},{"key":"22 Q4","value":1587.4},{"key":"23 Q1","value":1378.1},{"key":"23 Q2","value":1316.7},{"key":"23 Q3","value":1438.3},{"key":"23 Q4","value":1370},{"key":"24 Q1","value":1266.8},{"key":"24 Q2","value":1524},{"key":"24 Q3","value":1660.1},{"key":"24 Q4","value":1606.9},{"key":"25 Q1","value":1531.2}]},{"title":"Other revenue","dataPoints":[{"key":"21 Q2","value":46},{"key":"21 Q3","value":99},{"key":"21 Q4","value":86.2},{"key":"22 Q1","value":94},{"key":"22 Q2","value":59.2},{"key":"22 Q3","value":84.2},{"key":"22 Q4","value":127.7},{"key":"23 Q1","value":116},{"key":"23 Q2","value":69.3},{"key":"23 Q3","value":138.3},{"key":"23 Q4","value":212.5},{"key":"24 Q1","value":116.9},{"key":"24 Q2","value":104.5},{"key":"24 Q3","value":114.2},{"key":"24 Q4","value":179.4},{"key":"25 Q1","value":81.9}]}],"overlayChart":null},{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q2","value":86.49},{"key":"21 Q3","value":86.87},{"key":"21 Q4","value":80.15},{"key":"22 Q1","value":86.34},{"key":"22 Q2","value":89.6},{"key":"22 Q3","value":89.17},{"key":"22 Q4","value":84.16},{"key":"23 Q1","value":85.53},{"key":"23 Q2","value":87.17},{"key":"23 Q3","value":87.02},{"key":"23 Q4","value":84.94},{"key":"24 Q1","value":86.2},{"key":"24 Q2","value":86.46},{"key":"24 Q3","value":86.8},{"key":"24 Q4","value":85.07},{"key":"25 Q1","value":84.66}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q2","value":65.13},{"key":"21 Q3","value":53.49},{"key":"21 Q4","value":53.3},{"key":"22 Q1","value":42.44},{"key":"22 Q2","value":38.84},{"key":"22 Q3","value":41.67},{"key":"22 Q4","value":33.58},{"key":"23 Q1","value":29.93},{"key":"23 Q2","value":32.18},{"key":"23 Q3","value":33.03},{"key":"23 Q4","value":28.32},{"key":"24 Q1","value":23.89},{"key":"24 Q2","value":30.15},{"key":"24 Q3","value":31.7},{"key":"24 Q4","value":26.13},{"key":"25 Q1","value":19.53}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q2","value":60.3},{"key":"21 Q3","value":47.27},{"key":"21 Q4","value":45.01},{"key":"22 Q1","value":32.83},{"key":"22 Q2","value":29.82},{"key":"22 Q3","value":44.8},{"key":"22 Q4","value":35.06},{"key":"23 Q1","value":25.86},{"key":"23 Q2","value":30.66},{"key":"23 Q3","value":29.96},{"key":"23 Q4","value":33.76},{"key":"24 Q1","value":22.95},{"key":"24 Q2","value":40.37},{"key":"24 Q3","value":36.03},{"key":"24 Q4","value":24.21},{"key":"25 Q1","value":26.7}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Research and development","dataPoints":[{"key":"21 Q2","value":714.2},{"key":"21 Q3","value":665.4},{"key":"21 Q4","value":785.6},{"key":"22 Q1","value":843.8},{"key":"22 Q2","value":794.3},{"key":"22 Q3","value":911.3},{"key":"22 Q4","value":1043.1},{"key":"23 Q1","value":1101.2},{"key":"23 Q2","value":1085.3},{"key":"23 Q3","value":1075.3},{"key":"23 Q4","value":1177.2},{"key":"24 Q1","value":1248.4},{"key":"24 Q2","value":1200},{"key":"24 Q3","value":1271.5},{"key":"24 Q4","value":1412.1},{"key":"25 Q1","value":1327.4}]},{"title":"Selling, general, and administrative","dataPoints":[{"key":"21 Q2","value":414.7},{"key":"21 Q3","value":445},{"key":"21 Q4","value":559.6},{"key":"22 Q1","value":450},{"key":"22 Q2","value":476.3},{"key":"22 Q3","value":529.1},{"key":"22 Q4","value":660.5},{"key":"23 Q1","value":601.1},{"key":"23 Q2","value":652},{"key":"23 Q3","value":640.5},{"key":"23 Q4","value":737.7},{"key":"24 Q1","value":689},{"key":"24 Q2","value":758.8},{"key":"24 Q3","value":714.4},{"key":"24 Q4","value":792.2},{"key":"25 Q1","value":633}]},{"title":"Other operating (income) expense, net","dataPoints":[{"key":"21 Q2","value":-31.3},{"key":"21 Q3","value":42},{"key":"21 Q4","value":-15.8},{"key":"22 Q1","value":-20.2},{"key":"22 Q2","value":-17.4},{"key":"22 Q3","value":-45.7},{"key":"22 Q4","value":-6.6},{"key":"23 Q1","value":-0.5},{"key":"23 Q2","value":-0.6},{"key":"23 Q3","value":-0.5},{"key":"23 Q4","value":-0.5},{"key":"24 Q1","value":15.3},{"key":"24 Q2","value":14.6},{"key":"24 Q3","value":8},{"key":"24 Q4","value":15.5}]},{"title":"Acquired in-process research and development","dataPoints":[{"key":"22 Q1","value":28.1},{"key":"22 Q2","value":197},{"key":"22 Q4","value":30},{"key":"23 Q1","value":56.1},{"key":"23 Q3","value":100},{"key":"23 Q4","value":30},{"key":"24 Q1","value":7.1},{"key":"24 Q2","value":23.9},{"key":"24 Q3","value":56.2},{"key":"24 Q4","value":13.8},{"key":"25 Q1","value":12.3}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q2","value":163.24},{"key":"21 Q3","value":50.51},{"key":"21 Q4","value":104.37},{"key":"22 Q1","value":17.26},{"key":"22 Q2","value":-44.4},{"key":"22 Q3","value":-14.96},{"key":"22 Q4","value":-31.05},{"key":"23 Q1","value":6.64},{"key":"23 Q2","value":10.53},{"key":"23 Q3","value":14.53},{"key":"23 Q4","value":0.58},{"key":"24 Q1","value":-0.54},{"key":"24 Q2","value":12.32},{"key":"24 Q3","value":10.65},{"key":"24 Q4","value":10.33},{"key":"25 Q1","value":-3.7}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q2","value":7.6},{"key":"21 Q3","value":19.19},{"key":"21 Q4","value":47.25},{"key":"22 Q1","value":17.48},{"key":"22 Q2","value":32.12},{"key":"22 Q3","value":21.03},{"key":"22 Q4","value":29.91},{"key":"23 Q1","value":35.05},{"key":"23 Q2","value":19.76},{"key":"23 Q3","value":30.16},{"key":"23 Q4","value":12.59},{"key":"24 Q1","value":11.49},{"key":"24 Q2","value":15.01},{"key":"24 Q3","value":12.93},{"key":"24 Q4","value":14.87},{"key":"25 Q1","value":0.66}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q2","value":105},{"key":"21 Q3","value":106.2},{"key":"21 Q4","value":106.2},{"key":"22 Q1","value":106.8},{"key":"22 Q2","value":107.9},{"key":"22 Q3","value":106.9},{"key":"22 Q4","value":107},{"key":"23 Q1","value":107.1},{"key":"23 Q2","value":107},{"key":"23 Q3","value":106.3},{"key":"23 Q4","value":106.6},{"key":"24 Q1","value":107.8},{"key":"24 Q2","value":108.1},{"key":"24 Q3","value":108.1},{"key":"24 Q4","value":107.6},{"key":"25 Q1","value":106.7}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q2","value":53193},{"key":"21 Q3","value":65928.96},{"key":"21 Q4","value":65291.76},{"key":"22 Q1","value":67572.36},{"key":"22 Q2","value":70135},{"key":"22 Q3","value":67282.86},{"key":"22 Q4","value":78955.3},{"key":"23 Q1","value":80774.82},{"key":"23 Q2","value":82497},{"key":"23 Q3","value":83541.17},{"key":"23 Q4","value":87785.1},{"key":"24 Q1","value":102507.02},{"key":"24 Q2","value":104792.14},{"key":"24 Q3","value":120304.49},{"key":"24 Q4","value":90297.92},{"key":"25 Q1","value":73388.26}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q2","value":2.59},{"key":"21 Q3","value":4.77},{"key":"21 Q4","value":3.3},{"key":"22 Q1","value":5.7},{"key":"22 Q2","value":6.14},{"key":"22 Q3","value":5.73},{"key":"22 Q4","value":5.78},{"key":"23 Q1","value":6.39},{"key":"23 Q2","value":6.53},{"key":"23 Q3","value":6.21},{"key":"23 Q4","value":6.39},{"key":"24 Q1","value":8.15},{"key":"24 Q2","value":7.39},{"key":"24 Q3","value":8.08},{"key":"24 Q4","value":5.96},{"key":"25 Q1","value":6.06}]}],"overlayChart":null}],"chartsLastUpdated":"2025-04-29T14:44:59Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.48,"sell":0.52,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"TMO","name":"Thermo Fisher Scientific","displayName":"Thermo Fisher Scientific","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"TMO","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":466.71,"high":484.6,"low":465.035,"volume":147,"volumeDate":"2025-07-25","last":475.03,"open":466.67,"gainPercentage":1.783,"gainValue":8.32,"ask":485.09,"bid":470.01,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":179320974800,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":2882557.8871,"highPriceLast52Weeks":627.88,"lowPriceLast52Weeks":385.46,"companyName":"Thermo Fisher Scientific, Inc.","longBusinessDescription":"Thermo Fisher Scientific Inc. serves the scientific community through a broad offering of innovative products and services. Thermo Fisher Scientific serves customers working in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial, research and development, quality and process control settings. The company’s global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through its brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. The company continuously increases its depth of capabilities across its broad portfolio of innovative products and services and leverages its extensive global channels to address customers’ needs. The company does this through organic investments in research and development, capacity and capabilities and through acquisitions. The company’s goal is to enable its customers to be more productive in an increasingly competitive business environment, enable them to accelerate innovation, solve their challenges and advance their important work. The company’s history roots back to the year 1956 when the business was first established. Thermo Fisher Scientific was formed in 2006 from the merger of Thermo Electron and Fisher Scientific and is headquartered in Waltham, MA.","dividendRate":1.64,"salesOrRevenue":42879000000,"oneYearAnnualRevenueGrowthRate":0.0513335044450148,"threeYearAnnualRevenueGrowthRate":3.3388,"fiveYearAnnualRevenueGrowthRate":11.5718,"earningsGrowth":7.0349,"totalDebt":32775000000,"totalAssets":97321000000,"floatAsPercentOfSharesOutstanding":99.8331,"dividendYield":0.35000000000000003,"betaTwelveMonth":0.7899,"salesOrRevenueTtm":43212000000,"ebitdaTtm":10813000000,"debtToEquityRatioQuarterly":69.7935652587368,"totalEnterpriseValue":226530082340,"industry":"MedicalSpecialties","sector":"HealthTechnology","preTaxInterestCoverageRatio":4.63240628778718,"fiveYearAverageDebtEquityRatio":67.78,"currentRatio":1.93300833464381,"peratio":27.5},"recommendation":{"currentConsensusRating":1.8,"recommendationTargetPrice":517.53,"totalRatings":36,"strongSellRatings":0,"sellRatings":0,"holdRatings":5,"buyRatings":17,"strongBuyRatings":14,"lastUpdated":"2025-07-24T18:37:51Z"},"earningEstimates":[{"actual":6.54,"estimate":5.26,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-02T11:10:39Z","audioUrl":"https://files.quartr.com/audio-files/ee68d-2022-10-19-10-30-33.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/ed433-2025-03-03-02-01-00.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-02T01:50:00Z","earningsSummary":null},{"actual":7.25,"estimate":6.18,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-04-28T10:14:32Z","audioUrl":"https://files.quartr.com/audio-files/99f56-2022-10-28-04-39-40.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/dd026-2024-08-29-06-10-21.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-04-28T14:35:36Z","earningsSummary":null},{"actual":5.51,"estimate":4.99,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-07-28T10:13:47Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_07_28_14_30_Q2_2022_Thermo_Fisher_Scientific_Inc_Earnings_Call.Y8KL0V6PYVYZ_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/b0817-2024-08-29-06-59-20.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-07-28T00:06:00Z","earningsSummary":null},{"actual":5.08,"estimate":4.82,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-10-26T10:06:19Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_10_26T12_30_00_00_00_Thermo_Fisher_Scientific_Inc_Earnings_Call_Q3_2022.I4V5WSWRA6MS_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/9d29b-2024-08-29-06-53-20.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-10-26T12:30:00Z","earningsSummary":null},{"actual":5.4,"estimate":5.19,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-01T11:02:54Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_02_01T13_30_00_00_00_Thermo_Fisher_Scientific_Inc_Earnings_Call_Q4_2022.PVLVVL5A2ZWA_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/d8bd7-2025-03-03-02-46-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-01T13:30:00Z","earningsSummary":{"summary":"Thermo Fisher Scientific delivered exceptional 2022 results with strong Q4 performance and robust full-year revenue. Growth strategy and segment strengths position the company well for continued success in 2023.\nChallenges such as normalization of growth, margin influences, and market dynamics require strategic management. Opportunities in high-growth markets and next-gen technologies offer avenues for further expansion and value creation.\nMaintaining a focus on innovation, sustainability, and operational efficiency will be key to navigating challenges and capitalizing on growth opportunities in 2023.\nOverall, Thermo Fisher Scientific's solid financial performance, strategic focus, and market positioning set a positive trajectory for continued success and value creation in the coming year.","headline":"Thermo Fisher excels in 2022, eyes growth amid challenges","lastUpdated":"2024-05-07T05:21:45.250622Z"}},{"actual":5.03,"estimate":5.03,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-04-26T10:01:52Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_04_26T12_30_00_00_00_Thermo_Fisher_Scientific_Inc_Q1_2023.61LQI4CZXW1L_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/0e368-2023-04-28-08-12-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-04-26T12:30:00Z","earningsSummary":{"summary":"Thermo Fisher Scientific's Q1 2023 showcased resilience amid challenges, driven by innovation and strategic initiatives. While facing short-term headwinds, the company remains well-positioned for long-term growth through market opportunities and operational strengths.","headline":"Thermo Fisher excels in Q1 despite COVID challenges, eyes growth","lastUpdated":"2024-05-07T09:25:37.115931Z"}},{"actual":5.15,"estimate":5.42,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-07-26T10:03:01Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_07_26T12_30_00_00_00_Thermo_Fisher_Scientific_Inc_Q2_2023.06RRZ4D0UU9T_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/1a0dc-2023-07-26-10-46-04.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-07-26T12:30:00Z","earningsSummary":{"summary":"Thermo Fisher Scientific navigated a challenging macroeconomic environment in Q2 2023, with varied performance across end markets. The company is focused on managing costs, driving productivity, and pursuing strategic acquisitions to enhance capabilities. Despite challenges, Thermo Fisher remains committed to ESG priorities and market outperformance.","headline":"Thermo Fisher faces market challenges, focuses on cost management and acquisitions","lastUpdated":"2024-05-07T01:43:49.847921Z"}},{"actual":5.69,"estimate":5.61,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-10-25T10:03:12Z","audioUrl":"https://files.quartr.com/audio-files/acd9d-2023-10-25-01-18-31.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/86b8a-2023-10-25-10-04-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-10-25T12:30:00Z","earningsSummary":{"summary":"Thermo Fisher Scientific's Q3 performance was solid, with revenue growth and strategic acquisitions driving market position strengthening.\nWhile facing challenges like revenue impact in Q4 and customer caution, the company remains optimistic about industry outlook and growth opportunities.\nThe company's focus on innovation, ESG priorities, and operational efficiency positions it well for future growth and success.\nManagement's insights into 2024 outlook indicate a balanced approach to growth through strategic investments and operational improvements.","headline":"Thermo Fisher reports solid Q3 earnings, eyes growth opportunities","lastUpdated":"2024-05-06T22:28:41.767395Z"}},{"actual":5.67,"estimate":5.64,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-01-31T11:01:03Z","audioUrl":"https://files.quartr.com/audio-files/b16a3-2024-01-31-02-56-38.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/1c14f-2024-02-01-07-31-17.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-01-31T13:30:00Z","earningsSummary":{"summary":"Thermo Fisher Scientific delivered strong financial performance in Q4 2023 and full-year 2023, driven by innovation and customer focus.\nWhile facing challenges in certain segments and markets, the company remains optimistic about growth opportunities and market outpacing.\nStrategic acquisitions, focus on sustainability, and operational excellence position Thermo Fisher for continued success in 2024 and beyond.\nGuidance for 2024 indicates a focus on organic growth, stable segment margins, and a commitment to long-term market outperformance.","headline":"Thermo Fisher posts solid earnings, eyes growth amid market challenges","lastUpdated":"2024-05-06T11:28:03.341339Z"}},{"actual":5.11,"estimate":4.71,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-04-24T10:09:45Z","audioUrl":"https://files.quartr.com/audio-files/8a582-2024-04-24-01-58-36.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/02b12-2024-04-24-10-56-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-04-24T12:30:00Z","earningsSummary":{"summary":"Thermo Fisher Scientific's Q1 2024 earnings call highlighted strong financial performance driven by a proven growth strategy and disciplined capital deployment. While facing challenges in certain end markets and regulatory uncertainties, the company remains optimistic about future growth opportunities. Key strengths include innovation, strategic partnerships, and a focus on corporate social responsibility.","headline":"Thermo Fisher reports strong Q1 earnings, eyes growth opportunities","lastUpdated":"2024-05-07T05:23:04.026874Z"}},{"actual":5.37,"estimate":5.12,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-07-24T10:00:39Z","audioUrl":"https://files.quartr.com/audio-files/4ba55-2024-07-24-01-48-29.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/fe729-2024-07-24-10-12-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-07-24T12:30:00Z","earningsSummary":{"summary":"Thermo Fisher Scientific's Q2 performance reflects resilience and strategic focus amidst market challenges. The company's emphasis on innovation, operational efficiency, and customer relationships positions it well for sustained growth. With a positive outlook for 2024 and a commitment to long-term success, Thermo Fisher remains a strong player in the industry.","headline":"Thermo Fisher excels in Q2, raises 2024 guidance amid market challenges","lastUpdated":"2024-07-24T16:27:01.559253Z"}},{"actual":5.28,"estimate":5.24,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-10-23T10:01:09Z","audioUrl":"https://files.quartr.com/audio-files/4877a-2024-10-23-01-01-40.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/08344-2024-10-23-10-06-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-10-23T12:30:00Z","earningsSummary":{"summary":"Thermo Fisher Scientific's Q3 2024 earnings call showcased strong financial performance, strategic innovations, and growth opportunities.\nWhile facing challenges in certain market segments, the company's focus on innovation, partnerships, and financial strength positions it well for future growth.\nWith raised EPS guidance and revenue expectations, Thermo Fisher is poised for continued success through market expansion and strategic initiatives.","headline":"Thermo Fisher excels in Q3 earnings, eyes growth opportunities","lastUpdated":"2024-10-23T16:16:23.603773Z"}},{"actual":6.1,"estimate":5.94,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-01-30T11:09:27Z","audioUrl":"https://files.quartr.com/audio-files/35a46-2025-01-30-02-48-56.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/5a7f1-2025-01-30-11-17-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-01-30T13:30:00Z","earningsSummary":{"summary":"Thermo Fisher Scientific's strong financial performance, strategic pillars, and customer-centric approach underscore its market leadership and growth potential.\nWhile challenges exist in a dynamic market environment, the company's focus on innovation, operational excellence, and partnerships positions it well for future success.\nWith a clear roadmap for growth, robust financials, and a commitment to shareholder value, Thermo Fisher is well-positioned to capitalize on market opportunities and drive continued success.","headline":"Thermo Fisher excels in Q4 2024, poised for sustained growth","lastUpdated":"2025-01-30T16:05:56.931181Z"}},{"actual":5.15,"estimate":5.1,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-04-23T10:00:46Z","audioUrl":"https://files.quartr.com/audio-files/4586c-2025-04-23-01-57-39.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/ae3ec-2025-04-23-10-01-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-04-23T12:30:00Z","earningsSummary":{"summary":"Thermo Fisher Scientific's Q1 performance showcased strength in revenue and innovation, with opportunities for growth in specific segments. Challenges lie in managing sector-specific declines and macroeconomic uncertainties, but strategic actions are in place to address them.","headline":"Thermo Fisher excels in Q1 with strong revenue and innovation","lastUpdated":"2025-04-23T15:41:44.421938Z"}},{"actual":5.36,"estimate":5.23,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-23T10:01:19Z","audioUrl":"https://files.quartr.com/audio-files/3d331-2025-07-23-01-32-49.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/8c51b-2025-07-23-10-58-04.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-07-23T12:30:00Z","earningsSummary":{"summary":"Thermo Fisher Scientific delivered steady revenue growth and increased guidance for the full year. While facing challenges from market declines and policy impacts, the company's strategic focus on innovation and partnerships remains strong. Opportunities exist to navigate challenges, drive growth, and enhance shareholder value through strategic initiatives.","headline":"Thermo Fisher Scientific reports Q2 growth, raises full-year guidance","lastUpdated":"2025-07-23T15:41:43.975638Z"}},{"actual":null,"estimate":5.5,"period":"Q3 2025","fiscalQuarter":"Q3","fiscalYear":2025,"lastUpdated":"2025-07-24T23:31:48Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-10-22T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2022-02-02","title":"Earnings data Q4 2021","quarter":"Q4","hash":"c3bebc4bcf39bdc52a3152b5c3b90714bee67246fc25e2c5fe644539165906af"},{"date":"2022-04-28","title":"Earnings data Q1 2022","quarter":"Q1","hash":"d30c59daecb898f5b5fa3e440210710fd751b2d29b263f30af4ac6a163e93c3a"},{"date":"2022-07-28","title":"Earnings data Q2 2022","quarter":"Q2","hash":"01af1630717324e34a5ae0d84142740ba2217c58b0c5fa5a09e01e8dda620d4a"},{"date":"2022-10-26","title":"Earnings data Q3 2022","quarter":"Q3","hash":"11feaaf4fae11ffc86809bc80fe90b8e9d4d8e388430592c73ab28561dee1826"},{"date":"2023-02-01","title":"Earnings data Q4 2022","quarter":"Q4","hash":"100dd856f45080b1e64afc2387229461564defdccb63b33894dd43781343fa4b"},{"date":"2023-04-26","title":"Earnings data Q1 2023","quarter":"Q1","hash":"aed976f9fcfc170a96188e7cebdc8c448b44729712cc376207d2c8d5f5f7df6a"},{"date":"2023-07-26","title":"Earnings data Q2 2023","quarter":"Q2","hash":"429ffc7e24b78ccc27378dda9499aecdbc33c59022ca10813afd7b2b50f36220"},{"date":"2023-10-25","title":"Earnings data Q3 2023","quarter":"Q3","hash":"bdb52815cc44a5034d84cbcfa85fbdc23ee53592beb4be0b04f0678ca959d0b9"},{"date":"2024-01-31","title":"Earnings data Q4 2023","quarter":"Q4","hash":"017f1d1f0edcecc647394646f1fc1f9960cfe5818784056bc43059d316faf579"},{"date":"2024-04-24","title":"Earnings data Q1 2024","quarter":"Q1","hash":"99029c7b8d3f72d79e567746ced85fd31a7aaabed032e84f774b99326ee8622c"},{"date":"2024-07-24","title":"Earnings data Q2 2024","quarter":"Q2","hash":"b9ec41ce298bea3aeea9b5c967080bc93843015d96cdb12fa74c74dbdbd6cf95"},{"date":"2024-10-23","title":"Earnings data Q3 2024","quarter":"Q3","hash":"47754742309d7c7878d1acc46b9e38d568af411cf503b40beef3c4197697e36c"},{"date":"2025-01-30","title":"Earnings data Q4 2024","quarter":"Q4","hash":"4e5754ebcd3916c34b2ff386b4cdfd66a6cea875a7ff06c167695a9d92b007bc"},{"date":"2025-04-23","title":"Earnings data Q1 2025","quarter":"Q1","hash":"20d0fd218181f3f894b5e5006b9fb73a80ec5d8138a83365572ff9a12716dce7"},{"date":"2025-07-23","title":"Earnings data Q2 2025","quarter":"Q2","hash":"1bfe35a5ddc42a891379f3c08ec27343433e1828d5e1db51e6c698eb33921eef"},{"date":"2025-10-22","title":"Earnings data Q3 2025","quarter":"Q3","hash":"bdb486ec3a9eb143bb173cbdcfcc6a95f20f2309f676a2630c1212bd9f2e5c36"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Thermo Fisher Scientific","companyDescription":"Thermo Fisher Scientific Inc. serves the scientific community through a broad offering of innovative products and services. Thermo Fisher Scientific serves customers working in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial, research and development, quality and process control settings. The company’s global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through its brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. The company continuously increases its depth of capabilities across its broad portfolio of innovative products and services and leverages its extensive global channels to address customers’ needs. The company does this through organic investments in research and development, capacity and capabilities and through acquisitions. The company’s goal is to enable its customers to be more productive in an increasingly competitive business environment, enable them to accelerate innovation, solve their challenges and advance their important work. The company’s history roots back to the year 1956 when the business was first established. Thermo Fisher Scientific was formed in 2006 from the merger of Thermo Electron and Fisher Scientific and is headquartered in Waltham, MA.","executives":null,"brands":[{"id":"8a5ae0b7-82f6-43db-aa1d-ae7ba3b6e245","name":"Life Technologies","description":"Life Technologies was a biotech company founded in November 2008 through a US$6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees, and owned more than 3,600 licenses and patents.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/7DV38FkIQcuO-acrTnksxA-thumbnail-300x300.png"}]},"etfFundamental":null,"financials":{"periodKey":"Q2 2025","values":[{"financialKey":"REVENUE","value":10855000000,"changePercentage":2.98,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":6807000000,"changePercentage":9.84,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":4048000000,"changePercentage":-6.81,"valueToRevenueRatio":0.3729157070474436},{"financialKey":"OPERATING_EXPENSES","value":2131000000,"changePercentage":-17.59,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":2131000000,"changePercentage":-17.59,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":1917000000,"changePercentage":9.04,"valueToRevenueRatio":0.17660064486411792},{"financialKey":"EBITDA","value":2602000000,"changePercentage":2.12,"valueToRevenueRatio":0.23970520497466605},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":685000000,"changePercentage":-13.29,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":1623000000,"changePercentage":4.44,"valueToRevenueRatio":null},{"financialKey":"EPS","value":4.2778,"changePercentage":5.84,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":101230000000,"changePercentage":2.78,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":24584000000,"changePercentage":-3.5,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":6390000000,"changePercentage":-27.67,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":8594000000,"changePercentage":-8.87,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":5559000000,"changePercentage":6.94,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":4040000000,"changePercentage":100.6,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":76646000000,"changePercentage":4.97,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":9635000000,"changePercentage":3.8,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":62397000000,"changePercentage":5.11,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":4615000000,"changePercentage":5.44,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":50627000000,"changePercentage":-0.66,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":12718000000,"changePercentage":-13.9,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":2214000000,"changePercentage":-56.77,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":10504000000,"changePercentage":8.84,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":37909000000,"changePercentage":4.75,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":33015000000,"changePercentage":9.02,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":4894000000,"changePercentage":-17.15,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":50602000000,"changePercentage":6.45,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":50476000000,"changePercentage":6.42,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":126000000,"changePercentage":22.33,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":101230000000,"changePercentage":2.77,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":35229000000,"changePercentage":-0.5,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":28839000000,"changePercentage":8.54,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":1619000000,"changePercentage":4.18,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":1400000000,"changePercentage":-28.57,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":2126000000,"changePercentage":-2.3,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-726000000,"changePercentage":-236.11,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-288000000,"changePercentage":-13.83,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":294000000,"changePercentage":-2.33,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":-47000000,"changePercentage":-135,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":1000000,"changePercentage":-93.75,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-536000000,"changePercentage":2.55,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-991000000,"changePercentage":-769.3,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":-787000000,"changePercentage":-78600,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":162000000,"changePercentage":8.72,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-42000000,"changePercentage":-220,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":310000000,"changePercentage":2166.67,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":431000000,"changePercentage":-72.69,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":1106000000,"changePercentage":-33.33,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-24T18:40:48Z"},"dividend":{"dividendType":"CASH","dividendFrequency":"QUARTERLY","dividend":0.43,"priorDividend":0.39,"dividendYieldPercentage":0.41,"announcementDate":"2025-07-10","exDividendDate":"2025-09-15","payableDate":"2025-10-15","recordDate":"2025-09-15","updatedAt":"2025-07-10T20:59:09Z"},"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-04-10T09:50:28Z","bearsSay":["Thermo Fisher Scientific is experiencing a concerning decline in adjusted operating margins, which fell by 50 basis points to 35.4%, largely due to unfavorable volume mix and increased retention costs, indicating challenges in maintaining profitability amidst strategic investments. The company is now forecasting an organic revenue decline of 0.5% for 2024, alongside a slight adjustment in estimated adjusted EPS, reflecting a downward trend in organic growth, particularly in its Life Science Solutions segment which posted a 4% decline. Additionally, with operating margins across key segments deteriorating—specifically a notable drop of 180 basis points to 24.9%—the financial outlook suggests ongoing pressures that may hinder future performance."],"bullsSay":["Thermo Fisher Scientific is experiencing notable growth across its business segments, particularly driven by strong performance in the healthcare market and research channels, contributing to a resilient outlook for the company. The firm has demonstrated improved organic growth potential, with management forecasting total revenues of $42.4 billion to $43.3 billion for 2024, reflecting stability even as it navigates industry challenges. Furthermore, the company benefits from a favorable cost environment and strategic execution on operational improvements and mergers and acquisitions, enhancing its competitive positioning within the life sciences and diagnostics sectors."],"charts":[{"title":"Revenue Segments","description":"Revenue segments as reported by the company.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Life Sciences Solutions","dataPoints":[{"key":"21 Q3","value":3721},{"key":"21 Q4","value":4150},{"key":"22 Q1","value":4231},{"key":"22 Q2","value":3292},{"key":"22 Q3","value":2962},{"key":"22 Q4","value":3046},{"key":"23 Q1","value":2612},{"key":"23 Q2","value":2463},{"key":"23 Q3","value":2433},{"key":"23 Q4","value":2469},{"key":"24 Q1","value":2285},{"key":"24 Q2","value":2355},{"key":"24 Q3","value":2387},{"key":"24 Q4","value":2604},{"key":"25 Q1","value":2341},{"key":"25 Q2","value":2499}]},{"title":"Analytical Instruments","dataPoints":[{"key":"21 Q3","value":1476},{"key":"21 Q4","value":1725},{"key":"22 Q1","value":1518},{"key":"22 Q2","value":1607},{"key":"22 Q3","value":1621},{"key":"22 Q4","value":1878},{"key":"23 Q1","value":1723},{"key":"23 Q2","value":1749},{"key":"23 Q3","value":1754},{"key":"23 Q4","value":2037},{"key":"24 Q1","value":1687},{"key":"24 Q2","value":1782},{"key":"24 Q3","value":1808},{"key":"24 Q4","value":2186},{"key":"25 Q1","value":1718},{"key":"25 Q2","value":1728}]},{"title":"Specialty Diagnostics","dataPoints":[{"key":"21 Q3","value":1362},{"key":"21 Q4","value":1447},{"key":"22 Q1","value":1482},{"key":"22 Q2","value":1101},{"key":"22 Q3","value":1065},{"key":"22 Q4","value":1115},{"key":"23 Q1","value":1108},{"key":"23 Q2","value":1109},{"key":"23 Q3","value":1083},{"key":"23 Q4","value":1105},{"key":"24 Q1","value":1109},{"key":"24 Q2","value":1117},{"key":"24 Q3","value":1129},{"key":"24 Q4","value":1157},{"key":"25 Q1","value":1148},{"key":"25 Q2","value":1134}]},{"title":"Laboratory Products and Services","dataPoints":[{"key":"21 Q3","value":3487},{"key":"21 Q4","value":4195},{"key":"22 Q1","value":5442},{"key":"22 Q2","value":5537},{"key":"22 Q3","value":5585},{"key":"22 Q4","value":5947},{"key":"23 Q1","value":5763},{"key":"23 Q2","value":5831},{"key":"23 Q3","value":5728},{"key":"23 Q4","value":5719},{"key":"24 Q1","value":5723},{"key":"24 Q2","value":5758},{"key":"24 Q3","value":5740},{"key":"24 Q4","value":5936},{"key":"25 Q1","value":5640},{"key":"25 Q2","value":5995}]},{"title":"Eliminations","dataPoints":[{"key":"21 Q3","value":-716},{"key":"21 Q4","value":-815},{"key":"22 Q1","value":-855},{"key":"22 Q2","value":-567},{"key":"22 Q3","value":-556},{"key":"22 Q4","value":-536},{"key":"23 Q1","value":-496},{"key":"23 Q2","value":-465},{"key":"23 Q3","value":-424},{"key":"23 Q4","value":-444},{"key":"24 Q1","value":-460},{"key":"24 Q2","value":-470},{"key":"24 Q3","value":-467},{"key":"24 Q4","value":-487},{"key":"25 Q1","value":-482},{"key":"25 Q2","value":-501}]}],"overlayChart":null},{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q3","value":51.41},{"key":"21 Q4","value":50.45},{"key":"22 Q1","value":47.41},{"key":"22 Q2","value":43.11},{"key":"22 Q3","value":41.5},{"key":"22 Q4","value":41.35},{"key":"23 Q1","value":39.89},{"key":"23 Q2","value":40.83},{"key":"23 Q3","value":41.88},{"key":"23 Q4","value":41.3},{"key":"24 Q1","value":41.6},{"key":"24 Q2","value":42.07},{"key":"24 Q3","value":41.68},{"key":"24 Q4","value":43.03},{"key":"25 Q1","value":41.57},{"key":"25 Q2","value":41.24}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q3","value":24.41},{"key":"21 Q4","value":23.71},{"key":"22 Q1","value":23.87},{"key":"22 Q2","value":18.24},{"key":"22 Q3","value":16.01},{"key":"22 Q4","value":16.25},{"key":"23 Q1","value":14.59},{"key":"23 Q2","value":14.76},{"key":"23 Q3","value":17.62},{"key":"23 Q4","value":17.03},{"key":"24 Q1","value":16.06},{"key":"24 Q2","value":17.26},{"key":"24 Q3","value":17.33},{"key":"24 Q4","value":17.7},{"key":"25 Q1","value":16.58},{"key":"25 Q2","value":16.9}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q3","value":20.38},{"key":"21 Q4","value":15.49},{"key":"22 Q1","value":18.74},{"key":"22 Q2","value":15.16},{"key":"22 Q3","value":14},{"key":"22 Q4","value":13.76},{"key":"23 Q1","value":12.03},{"key":"23 Q2","value":12.73},{"key":"23 Q3","value":16.21},{"key":"23 Q4","value":14.97},{"key":"24 Q1","value":12.83},{"key":"24 Q2","value":14.68},{"key":"24 Q3","value":15.38},{"key":"24 Q4","value":16.05},{"key":"25 Q1","value":14.53},{"key":"25 Q2","value":14.89}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Selling, general and administrative","dataPoints":[{"key":"21 Q3","value":1727},{"key":"21 Q4","value":1958},{"key":"22 Q1","value":1808},{"key":"22 Q2","value":1740},{"key":"22 Q3","value":1743},{"key":"22 Q4","value":1836},{"key":"23 Q1","value":1646},{"key":"23 Q2","value":1673},{"key":"23 Q3","value":1578},{"key":"23 Q4","value":1672},{"key":"24 Q1","value":1731},{"key":"24 Q2","value":1687},{"key":"24 Q3","value":1739},{"key":"24 Q4","value":1846},{"key":"25 Q1","value":1721},{"key":"25 Q2","value":1779}]},{"title":"Amortization of acquisition-related intangible assets","dataPoints":[{"key":"21 Q3","value":423},{"key":"21 Q4","value":466},{"key":"22 Q1","value":609},{"key":"22 Q2","value":600},{"key":"22 Q3","value":594},{"key":"22 Q4","value":592},{"key":"23 Q1","value":606},{"key":"23 Q2","value":585},{"key":"23 Q3","value":584},{"key":"23 Q4","value":563},{"key":"24 Q1","value":551},{"key":"24 Q2","value":513},{"key":"24 Q3","value":450},{"key":"24 Q4","value":438},{"key":"25 Q1","value":429},{"key":"25 Q2","value":429}]},{"title":"Research and development","dataPoints":[{"key":"21 Q3","value":351},{"key":"21 Q4","value":392},{"key":"22 Q1","value":364},{"key":"22 Q2","value":365},{"key":"22 Q3","value":351},{"key":"22 Q4","value":391},{"key":"23 Q1","value":346},{"key":"23 Q2","value":345},{"key":"23 Q3","value":319},{"key":"23 Q4","value":327},{"key":"24 Q1","value":331},{"key":"24 Q2","value":339},{"key":"24 Q3","value":346},{"key":"24 Q4","value":374},{"key":"25 Q1","value":342},{"key":"25 Q2","value":352}]},{"title":"Restructuring and other costs","dataPoints":[{"key":"21 Q3","value":18},{"key":"21 Q4","value":46},{"key":"22 Q1","value":2},{"key":"22 Q2","value":24},{"key":"22 Q3","value":33},{"key":"22 Q4","value":55},{"key":"23 Q1","value":112},{"key":"23 Q2","value":183},{"key":"23 Q3","value":84},{"key":"23 Q4","value":80},{"key":"24 Q1","value":29},{"key":"24 Q2","value":77},{"key":"24 Q3","value":45},{"key":"24 Q4","value":228},{"key":"25 Q1","value":98},{"key":"25 Q2","value":82}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q3","value":9.49},{"key":"21 Q4","value":1.44},{"key":"22 Q1","value":19.3},{"key":"22 Q2","value":18.3},{"key":"22 Q3","value":14.44},{"key":"22 Q4","value":6.99},{"key":"23 Q1","value":-9.38},{"key":"23 Q2","value":-2.58},{"key":"23 Q3","value":-0.96},{"key":"23 Q4","value":-4.93},{"key":"24 Q1","value":-3.42},{"key":"24 Q2","value":-1.36},{"key":"24 Q3","value":0.22},{"key":"24 Q4","value":4.68},{"key":"25 Q1","value":0.2},{"key":"25 Q2","value":2.97}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q3","value":24.09},{"key":"21 Q4","value":9.57},{"key":"22 Q1","value":21},{"key":"22 Q2","value":8.08},{"key":"22 Q3","value":8.02},{"key":"22 Q4","value":0.42},{"key":"23 Q1","value":-2.62},{"key":"23 Q2","value":2.09},{"key":"23 Q3","value":-5.73},{"key":"23 Q4","value":-8.07},{"key":"24 Q1","value":-2.51},{"key":"24 Q2","value":-6.1},{"key":"24 Q3","value":0.58},{"key":"24 Q4","value":9.24},{"key":"25 Q1","value":-1.97},{"key":"25 Q2","value":0.99}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q3","value":394},{"key":"21 Q4","value":394},{"key":"22 Q1","value":392},{"key":"22 Q2","value":392},{"key":"22 Q3","value":392},{"key":"22 Q4","value":391},{"key":"23 Q1","value":386},{"key":"23 Q2","value":386},{"key":"23 Q3","value":386},{"key":"23 Q4","value":387},{"key":"24 Q1","value":382},{"key":"24 Q2","value":382},{"key":"24 Q3","value":382},{"key":"24 Q4","value":382},{"key":"25 Q1","value":378},{"key":"25 Q2","value":378}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q3","value":216266.6},{"key":"21 Q4","value":246013.6},{"key":"22 Q1","value":225164.8},{"key":"22 Q2","value":215678.4},{"key":"22 Q3","value":219284.8},{"key":"22 Q4","value":207112.7},{"key":"23 Q1","value":217433.8},{"key":"23 Q2","value":208169.8},{"key":"23 Q3","value":205583.6},{"key":"23 Q4","value":187308},{"key":"24 Q1","value":214340.2},{"key":"24 Q2","value":218847.8},{"key":"24 Q3","value":226144},{"key":"24 Q4","value":210023.6},{"key":"25 Q1","value":204724.8},{"key":"25 Q2","value":158041.8}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q3","value":5.79},{"key":"21 Q4","value":5.75},{"key":"22 Q1","value":4.76},{"key":"22 Q2","value":4.92},{"key":"22 Q3","value":5.13},{"key":"22 Q4","value":4.52},{"key":"23 Q1","value":5.08},{"key":"23 Q2","value":4.87},{"key":"23 Q3","value":4.86},{"key":"23 Q4","value":4.3},{"key":"24 Q1","value":5.18},{"key":"24 Q2","value":5.19},{"key":"24 Q3","value":5.34},{"key":"24 Q4","value":4.61},{"key":"25 Q1","value":4.94},{"key":"25 Q2","value":3.64}]}],"overlayChart":null}],"chartsLastUpdated":"2025-07-23T16:49:59Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.57,"sell":0.43,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false}],"quotes":[{"symbol":"A","last":"120.35","lastUpdated":"2025-07-24T20:00:00Z","ask":"125","bid":"110","gainPercentage":"0.737","gainValue":"0.88","rawJson":{"symbol":"A","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":119.47,"high":122.75,"low":119.43,"volume":426,"last":120.35,"open":119.43,"gainPercentage":0.737,"gainValue":0.88,"ask":125,"bid":110,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:26:07Z","last":121.25,"gainValue":0.9,"gainPercentage":0.748}}},{"symbol":"VRTX","last":"472.27","lastUpdated":"2025-07-24T20:00:00Z","ask":"477.35","bid":"440","gainPercentage":"-0.981","gainValue":"-4.68","rawJson":{"symbol":"VRTX","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":476.95,"high":480,"low":472.03,"volume":907940,"last":472.27,"open":477.14,"gainPercentage":-0.981,"gainValue":-4.68,"ask":477.35,"bid":440,"extendedHours":{"type":"PostMarket","timestamp":"2025-07-24T23:56:51Z","last":472.54,"gainValue":0.27,"gainPercentage":0.057}}},{"symbol":"ALNY","last":"328","lastUpdated":"2025-07-24T20:00:00Z","ask":"521.52","bid":"131.84","gainPercentage":"0.725","gainValue":"2.36","rawJson":{"symbol":"ALNY","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":325.64,"high":332.19,"low":324.3,"volume":677122,"last":328,"open":326.35,"gainPercentage":0.725,"gainValue":2.36,"ask":521.52,"bid":131.84,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:42:52Z","last":326.59,"gainValue":-1.41,"gainPercentage":-0.43}}},{"symbol":"BIO","last":"262.06","lastUpdated":"2025-07-24T20:00:00Z","ask":"269","bid":"105.34","gainPercentage":"1.94","gainValue":"4.99","rawJson":{"symbol":"BIO","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":257.07,"high":262.39,"low":256.51,"volume":212512,"last":262.06,"open":257.44,"gainPercentage":1.94,"gainValue":4.99,"ask":269,"bid":105.34,"extendedHours":{"type":"PostMarket","timestamp":"2025-07-24T23:47:14Z","last":261,"gainValue":-1.06,"gainPercentage":-0.404}}},{"symbol":"EDIT","last":"3.26","lastUpdated":"2025-07-24T20:00:00Z","ask":"3.26","bid":"3.24","gainPercentage":"-5.78","gainValue":"-0.2","rawJson":{"symbol":"EDIT","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":3.46,"high":3.58,"low":3.18,"volume":3013,"last":3.26,"open":3.46,"gainPercentage":-5.78,"gainValue":-0.2,"ask":3.26,"bid":3.24,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T08:20:07Z","last":3.25,"gainValue":-0.01,"gainPercentage":-0.307}}},{"symbol":"WAT","last":"298.47","lastUpdated":"2025-07-24T20:00:00Z","ask":"305","bid":"297.16","gainPercentage":"0.961","gainValue":"2.84","rawJson":{"symbol":"WAT","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":295.63,"high":305,"low":294.19,"volume":24,"last":298.47,"open":294.33,"gainPercentage":0.961,"gainValue":2.84,"ask":305,"bid":297.16,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T08:22:02Z","last":298,"gainValue":-0.47,"gainPercentage":-0.157}}},{"symbol":"AMGN","last":"308.55","lastUpdated":"2025-07-24T20:00:00Z","ask":"310","bid":"301.2","gainPercentage":"-0.217","gainValue":"-0.67","rawJson":{"symbol":"AMGN","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":309.22,"high":311.28,"low":307.35,"volume":1,"last":308.55,"open":309.23,"gainPercentage":-0.217,"gainValue":-0.67,"ask":310,"bid":301.2,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:11:54Z","last":309,"gainValue":0.45,"gainPercentage":0.146}}},{"symbol":"IQV","last":"200.82","lastUpdated":"2025-07-24T20:00:00Z","ask":"208.91","bid":"197.1","gainPercentage":"3.39","gainValue":"6.58","rawJson":{"symbol":"IQV","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":194.24,"high":206.78,"low":196.29,"volume":3,"last":200.82,"open":197.1,"gainPercentage":3.39,"gainValue":6.58,"ask":208.91,"bid":197.1,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T08:53:03Z","last":200.83,"gainValue":0.01,"gainPercentage":0.005}}},{"symbol":"DHR","last":"202.81","lastUpdated":"2025-07-24T20:00:00Z","ask":"204.8","bid":"202.81","gainPercentage":"2.49","gainValue":"4.92","rawJson":{"symbol":"DHR","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":197.89,"high":204.68,"low":198.01,"volume":1,"last":202.81,"open":198.01,"gainPercentage":2.49,"gainValue":4.92,"ask":204.8,"bid":202.81,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T08:57:14Z","last":202.84,"gainValue":0.03,"gainPercentage":0.015}}},{"symbol":"CLLS","last":"2","lastUpdated":"2025-07-24T20:00:00Z","ask":"2.3","bid":"2.25","gainPercentage":"-14.163","gainValue":"-0.33","rawJson":{"symbol":"CLLS","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":2.33,"high":2.4,"low":2,"volume":4552,"last":2,"open":2.32,"gainPercentage":-14.163,"gainValue":-0.33,"ask":2.3,"bid":2.25,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:33:12Z","last":2.26,"gainValue":0.26,"gainPercentage":13}}},{"symbol":"CRSP","last":"66.06","lastUpdated":"2025-07-24T20:00:00Z","ask":"66.48","bid":"66.08","gainPercentage":"-3.053","gainValue":"-2.08","rawJson":{"symbol":"CRSP","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":68.14,"high":69.57,"low":65.34,"volume":1639,"last":66.06,"open":68.55,"gainPercentage":-3.053,"gainValue":-2.08,"ask":66.48,"bid":66.08,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:32:31Z","last":66.2,"gainValue":0.14,"gainPercentage":0.212}}},{"symbol":"DGX","last":"171.9","lastUpdated":"2025-07-24T20:00:00Z","ask":"273.32","bid":"68.76","gainPercentage":"0.833","gainValue":"1.42","rawJson":{"symbol":"DGX","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":170.48,"high":175.76,"low":170.47,"volume":2114216,"last":171.9,"open":172.53,"gainPercentage":0.833,"gainValue":1.42,"ask":273.32,"bid":68.76,"extendedHours":{"type":"PostMarket","timestamp":"2025-07-24T23:53:48Z","last":175,"gainValue":3.1,"gainPercentage":1.8}}},{"symbol":"TMO","last":"475.03","lastUpdated":"2025-07-24T20:00:00Z","ask":"485.09","bid":"470.01","gainPercentage":"1.78","gainValue":"8.32","rawJson":{"symbol":"TMO","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":466.71,"high":484.6,"low":465.04,"volume":147,"last":475.03,"open":466.67,"gainPercentage":1.78,"gainValue":8.32,"ask":485.09,"bid":470.01,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T08:58:12Z","last":475,"gainValue":-0.03,"gainPercentage":-0.006}}},{"symbol":"LLY","last":"805.43","lastUpdated":"2025-07-24T20:00:00Z","ask":"807.2","bid":"802.4","gainPercentage":"0.819","gainValue":"6.54","rawJson":{"symbol":"LLY","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":798.89,"high":810.14,"low":797.65,"volume":728,"last":805.43,"open":801.36,"gainPercentage":0.819,"gainValue":6.54,"ask":807.2,"bid":802.4,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:38:18Z","last":805.1,"gainValue":-0.33,"gainPercentage":-0.041}}},{"symbol":"IDXX","last":"549.97","lastUpdated":"2025-07-24T20:00:00Z","ask":"874.45","bid":"392","gainPercentage":"1.72","gainValue":"9.29","rawJson":{"symbol":"IDXX","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":540.68,"high":551.1,"low":537.52,"volume":625362,"last":549.97,"open":537.81,"gainPercentage":1.72,"gainValue":9.29,"ask":874.45,"bid":392,"extendedHours":{"type":"PostMarket","timestamp":"2025-07-24T22:44:20Z","last":550.33,"gainValue":0.36,"gainPercentage":0.065}}},{"symbol":"GILD","last":"113.2","lastUpdated":"2025-07-24T20:00:00Z","ask":"113.64","bid":"113.08","gainPercentage":"-0.317","gainValue":"-0.36","rawJson":{"symbol":"GILD","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":113.56,"high":113.7,"low":112.51,"volume":310,"last":113.2,"open":113.58,"gainPercentage":-0.317,"gainValue":-0.36,"ask":113.64,"bid":113.08,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T08:36:57Z","last":113.63,"gainValue":0.43,"gainPercentage":0.38}}},{"symbol":"LH","last":"267.69","lastUpdated":"2025-07-24T20:00:00Z","ask":"273.69","bid":"240","gainPercentage":"6.86","gainValue":"17.18","rawJson":{"symbol":"LH","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":250.51,"high":283.47,"low":259.99,"volume":1,"last":267.69,"open":266.63,"gainPercentage":6.86,"gainValue":17.18,"ask":273.69,"bid":240,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:02:03Z","last":267.69,"gainValue":0,"gainPercentage":0}}},{"symbol":"REGN","last":"564.64","lastUpdated":"2025-07-24T20:00:00Z","ask":"591.84","bid":"546","gainPercentage":"-1.354","gainValue":"-7.75","rawJson":{"symbol":"REGN","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":572.39,"high":577.73,"low":563.67,"volume":12,"last":564.64,"open":572.54,"gainPercentage":-1.354,"gainValue":-7.75,"ask":591.84,"bid":546,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:04:48Z","last":591.86,"gainValue":27.22,"gainPercentage":4.82}}},{"symbol":"CRL","last":"177.1","lastUpdated":"2025-07-24T20:00:00Z","ask":"184","bid":"107","gainPercentage":"5.45","gainValue":"9.15","rawJson":{"symbol":"CRL","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":167.95,"high":184.17,"low":173.5,"volume":1744443,"last":177.1,"open":173.5,"gainPercentage":5.45,"gainValue":9.15,"ask":184,"bid":107,"extendedHours":{"type":"PostMarket","timestamp":"2025-07-24T23:23:49Z","last":177.1,"gainValue":0,"gainPercentage":0}}},{"symbol":"GSK","last":"38.23","lastUpdated":"2025-07-24T20:00:00Z","ask":"37.83","bid":"37.81","gainPercentage":"0.526","gainValue":"0.2","rawJson":{"symbol":"GSK","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":38.03,"high":38.31,"low":37.77,"volume":3902,"last":38.23,"open":37.93,"gainPercentage":0.526,"gainValue":0.2,"ask":37.83,"bid":37.81,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:36:10Z","last":37.87,"gainValue":-0.36,"gainPercentage":-0.942}}},{"symbol":"BIIB","last":"132.59","lastUpdated":"2025-07-24T20:00:00Z","ask":"133.21","bid":"132","gainPercentage":"1.23","gainValue":"1.61","rawJson":{"symbol":"BIIB","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":130.98,"high":132.65,"low":130,"volume":3,"last":132.59,"open":130.78,"gainPercentage":1.23,"gainValue":1.61,"ask":133.21,"bid":132,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:23:09Z","last":132.7,"gainValue":0.11,"gainPercentage":0.083}}}]},"__N_SSG":true},"page":"/themes/[name]","query":{"name":"genetic-engineering"},"buildId":"vtCYKp0Ai9E1UhSXnGgkP","assetPrefix":"https://public.com","isFallback":false,"gsp":true,"customServer":true,"scriptLoader":[]}</script></body></html>